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Malaria is a global health burden, killing more than 400,000 people each year. The 
disease, which mostly affects children under 5 years, is caused by the Plasmodium 
falciparum parasite.  When inside the mammalian host, P. falciparum parasites invade 
red blood cells, where they mature and multiply in numbers. To ensure their continued 
survival, they express a protein on the surface of the red blood cell, which allows them 
to stick to cells lining the walls of small blood vessels in host tissues. This affords the 
parasite a means to escape destruction by the spleen, but has devastating 
consequences for the host by leading to the obstruction of blood flow and causing 
damage to vital organs. During infection in non-immune individuals, P. falciparum 
parasites are predicted to express a specific sub-set of these proteins. These so called 
group-“A” and/ or “B/A” proteins have been associated with severe disease outcome, 
whereas other subtypes have been linked to mild/uncomplicated infection. This 
suggests that during first exposure to P. falciparum, clinical outcome may be 
determined by the parasite. Yet, severe disease has also been linked to actions of the 
host immune system. Upon sensing the invading P. falciparum parasite, innate immune 
cells respond to target and destroy parasite-infected red blood cells. This results in the 
activation of pro-inflammatory responses thought to be crucial for the early control of 
parasite growth. However, when inflammatory responses persist or become 
dysregulated they can also contribute to pathological disease. 
 
It is likely that both parasite and host-mediated factors contribute to severe disease 
pathology at later stages of infection but their influence at the early stages, as drivers 
of this response, has not been defined. This study aimed to investigate the early 
interactions between the P. falciparum parasite and the non-immune human host, 
using controlled human malaria infection (deliberate infection of adult volunteers). Data 
presented in this thesis highlight an inter-individual variability in host immune 
responses to primary P. falciparum infection. Whereas most volunteers demonstrated a 
classic inflammatory-type response and reported symptoms of malaria, some 
suppressed inflammation, and others failed to elicit a response in the time frame 
assessed. Parasites isolated from these volunteers were not found to express the 
group-A, B/A disease-associated gene/protein subtypes, nor appeared to have any 
influence on the diversity of host immune responses observed. These findings suggest 
that it is most likely early decisions of the innate immune response that determine 
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clinical outcome during primary infection, and that host genetics and/or environmental 





















Severe malaria infections cause over 400,000 deaths annually, mostly among African 
children under 5 years of age. In order to reduce the burden of this disease, focus must 
be placed on understanding what drives pathogenesis in those at greatest risk. It is 
increasingly appreciated that early immune responses such as inflammation and 
phagocytosis, although important for host defense, can also contribute to pathogenesis 
when unrestrained. However, most studies of human malaria have been conducted at 
the terminal stages of infection, making it difficult to identify the early immune events 
that may be dictating clinical outcome. The expression of Plasmodium falciparum 
erythrocyte membrane 1 (PfEMP1), along with other variant surface antigens (VSAs), 
is also thought to influence disease severity, by mediating parasite-host interactions 
that lead to obstruction of blood flow and organ dysfunction in the non-immune host. 
Yet, whether these parasite proteins actually drive pathology has been difficult to 
assess. It is likely that a contribution of both parasite genetics and host immune 
responses is involved in the progression to severe disease, but how the two might 
interact to drive this outcome has not yet been explored. Using controlled human 
malaria infection (CHMI), this study aimed to: (1) characterise the early immune 
response to P. falciparum during primary infection and investigate inter-individual 
variability within the cohort, (2) assess patterns of parasite VSA expression during 
infection in the malaria-naïve host and (3) determine the influence of parasite VSA 
expression on the developing immune response, and vice versa.   
 
Microarray analysis of the host (whole blood) response to P. falciparum revealed a 
dichotomous pattern of gene expression, with volunteers demonstrating either up-
regulation or down-regulation of genes associated with the innate inflammatory 
response, cell signaling and metabolism. This inter-individual variability correlated with 
chemokine levels in the plasma and clinical adverse events, but not with parasite 
growth in the circulation. RNA-sequencing of parasites, isolated from the blood of these 
individuals, demonstrated broad-level expression of PfEMP1-encoding var genes. 
However, expression was dominated by variants out-with those that have been 
associated with severe disease, and was remarkably similar across samples from all 
volunteers despite the observed diversity in host responses. Although we cannot 
speculate as to the severity of outcome in the volunteers, these findings challenge 
some key concepts in the field, for instance: (1) expression of group-A (disease-
 VII 
associated) PfEMP1 is not driving, nor is required for early disease outcome in malaria-
naïve individuals and (2) the host immune response is not directed by parasite gene 
expression, and vice versa; the type of host immune response elicited has little 
influence of parasite VSA expression early in infection. Focus should now be placed on 
understanding the diversity of host immune responses produced during primary            
P. falciparum infection, the clinical outcome(s) associated with these responses and 
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This chapter includes a general introduction to malaria and the thesis topic. A specific 
introduction is provided for each results chapter. 
 
1.1 Malaria- a general background 
1.1.1 The burden of malaria 
Malaria is a global health burden with over 3 billion people at risk of the disease, and 
estimated annual cases of over 400 million (Hay et al. 2004) (WHO malaria report, 
2017). Over the course of the previous century, malaria has been successfully 
eliminated from developed countries with temperate and sub-tropical climates, 
including North America and Europe. Today, people at greatest risk are those living in 
tropical countries of Africa, Asia and South America, with sub-Saharan Africa and India 
accounting for approximately 90% of cases worldwide (figure 1.1). Efforts made by the 
Roll Back Malaria partnership and other public health coalitions have contributed to an 
estimated 60% decline in global malaria mortality rates since 2000. Between 2000 and 
2015, approximately 6.2 million lives were saved as a result of scaled-up interventions 
(http://www.rollbackmalaria.org/index.html.). In 2016, the global tally of malaria-
associated deaths reached 445,000, similar to that observed in 2015. Furthermore, the 
number of reported cases increased by 5 million. Therefore, although the incidence of 
malaria has fallen globally over the past two decades, the rate of decline appears to 
have now stalled (WHO malaria report, 2017).  
 
In addition to its impact on human disease and mortality, malaria also has significant 
socio-economic consequences. Poverty is concentrated in the same geographical 
areas that frame malaria transmission, and the extent of the correlation suggests the 
two are closely related (Sachs and Malaney 2002). Furthermore, malaria-endemic 
countries demonstrate lower rates of economic growth compared to non-malarious 
countries (Sachs and Malaney 2002, Orem et al. 2012). Data collected from 62 
independent businesses in Greater Accra, Ashanti and Western Regions of Ghana, 
from 2012 to 2014, revealed an estimated loss of approximately US$6.58 million to 
malaria, 90% of which were costs directly related to staff absenteeism and 
treatment/prevention of malaria in staff and their dependents (Nonvignon et al. 2016). 
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Thus, in order to help eradicate poverty in these areas, there is a need for greater 
private sector investment in malaria control.  
 
Figure 1.1 | Map of countries and territories with indigenous cases of malaria in 2000 and their status by 2016. 
Countries with zero indigenous cases over (at least) the past 3 consecutive years are eligible to request certification of 
malaria-free status from the World Health Organization (WHO). All countries within the WHO European Region reported 
zero indigenous cases in 2016. In 2016, the greatest number of malaria cases (90%) were reported across sub-Saharan 
Africa and India. Data source: WHO database. Figure was directly taken from the World Malaria Report 2017.  
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A combination of interventions including timely diagnosis, treatment with effective 
drugs, and the use of protective measures such as bed nets and insecticides have 
aided the decline in malaria incidence and vector control (Goodman et al. 1999). 
However, the emergence of drug and insecticide-resistant parasite strains continues to 
pose a major threat to current preventative/curative therapies. The leading malaria 
vaccine candidate, RTS,S, provides around 25 - 35% protection in in those at greatest 
risk of severe disease (Rts 2015). Although this represents a major advance in malaria 
vaccine development, these levels of protection are far from sufficient. Greater 
investment therefore needs to be placed in understanding the more basic aspects of 
the immune response to the parasite, in order to keep reducing (and eventually 
eliminate) the global malaria burden. 
 
1.1.2 The malaria parasite 
Malaria is caused by the apicomplexan parasite Plasmodium. The Plasmodium 
parasite has co-evolved with the mosquito vector and its host for millions of years, 
demonstrating an ability to infect many vertebrates including birds, reptiles and 
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mammals. In humans, malaria can be caused by five Plasmodium species; namely    
P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi, which have diverse 
geographical distributions and infection characteristics (Table 1.1). P. falciparum is 
common across the tropics, but is most prevalent in sub-Saharan Africa. It causes the 
most life-threatening forms of malaria disease and is responsible for the greatest 
mortality of the five human-infectious species. P. vivax, once prevalent in temperate 
areas of Europe and North America, now occurs most commonly in South America and 
Asia. Infections with P. vivax have been known to cause febrile illness and, in some 
reported cases, severe disease (Manning et al. 2011, Rahimi et al. 2014, Barber et al. 
2015), however this remains controversial. Microscopically confirmed P. ovale is rare 
outside of West Africa, but a major characteristic of this species, along with P. vivax is 
its ability to form hypnozoites (dormant stages of the parasite residing in the liver), 
which can lead to relapse of infections for up to 1 year after the initial mosquito-bite 
(White 2011, White and Imwong 2012). P. malariae is geographically wide-spread but 
is associated with infrequent and mild infections, thus having little impact on the public 
health burden. A major concern with this species however, is its tendency to remain 
undetected in asymptomatic individuals, therefore serving as reservoirs for ongoing 
transmission to the mosquito vector. The zoonotic species P. knowlesi was first 
described in 1931, in a long-tail macaque (Maccaca fascicularis) and has since been 
found responsible for over half of all human malaria cases reported in the Malaysian 
part of Borneo, (Singh et al. 2004). Infections with this species are concentrated in 
Malaysia, where severe disease and death have been reported (Cox-Singh et al. 2010, 
Fatih et al. 2012, Willmann et al. 2012). Moreover, reports of emerging resistance of   
P. knowlesi to chloroquine and mefloquine are of growing concern (Fatih et al. 2013). 
 





1.1.3 The life-cycle of Plasmodium  
Our understanding of malaria transmission can be largely credited to Alphonse 
Laveran and Ronald Ross, whose contributions to the field of malaria research cannot 
be overestimated. Ross was awarded the Nobel Prize in 1902, for his discovery of 
Plasmodium parasites in the salivary glands of tropical mosquitoes (Nobel Media AB 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1902). Recognition was 
later given to Laveran (in 1907), for his detection of Plasmodium gametocytes in the 
blood of infected individuals, and linking this to malaria disease (Nobel Media AB 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1907).  
 
Malaria is a vector-borne disease that is transmitted to humans by Plasmodium-
infected female Anopheles mosquitoes. As a consequence, the distribution of malaria 
is restricted to geographical areas where the Anopheles mosquito can thrive. High 
temperatures, rainfall and humidity are ideal breeding conditions for the 25 
anthropophilic species that can transmit malaria to humans (Sinka et al. 2012). 
Transmission relies on a complex interplay between the parasite, mosquito and human 
host (figure 1.2).  Following sexual reproduction in the midgut of the female Anopheles 
mosquito, haploid sporozoites accumulate in the salivary glands of the vector and are 
injected into the skin of the human host during a blood meal. Experimental models 
have shown that typically few (as little as 1 to 100) motile sporozoites are released 
during one infectious bite (Beier et al. 1991). Sporozoites migrate to the liver and 
replicate within hepatocytes for the next ~5 - 15 days (depending on the Plasmodium 
species), to form schizonts, containing 10,000 to 30,000 merozoites, which are then 
released back into the blood stream (Prudencio et al. 2006). Some species of malaria 
(P. vivax and P. ovale) are able to form hypnozoites, dormant stages of liver-stage 
parasites which can be re-activated to resume replication at a later time (Shanks and 
White 2013). Once in the blood stream, each merozoite is able to invade one 
erythrocyte, initiating the asexual intra-erythrocytic stage of the cycle. Within the 
erythrocyte, merozoites form rings that mature into pigmented trophozoites, which then 
undergo schizogony to form schizonts containing up to 32 new daughter merozoites. 
These merozoites can in turn multiply, leading to exponential growth in non-immune 
individuals (Simpson et al. 2002). Some blood-stage parasites differentiate into the 
sexual form of the parasite termed gametocytes, which can then be ingested by the 
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mosquito vector during feeding to re-start the cycle (Silvestrini et al. 2000, Buchholz et 
al. 2011, Dantzler et al. 2015, Tiburcio et al. 2015). 
 
Figure 1.2 | The life-cycle of Plasmodium. An illustration of the various developmental stages of Plasmodium 
(from infection to transmission) within the mosquito vector and human host. A) A female anopheles mosquito 
inoculates approximately 10 sporozoites into the dermis, some of which reach the liver and establish an infection 
of hepatocytes. B) Inside hepatocytes the parasite undergoes a period of asexual replication lasting 5 – 15 days 
(depending on Plasmodium species), giving rise to between 1x104 – 3x104 merozoites, per infected liver cell. C) 
After release into the blood-stream, they invade erythrocytes and mature (from rings, to trophozoites, to 
schizonts) and replicate asexually so each blood-stage schizont can give rise to up to 20 new daughter 
merozoites. It is this exponential blood-stage replication phase that gives rise to all of the morbidity and mortality 
associated with malaria disease. D) Some blood-stage parasites develop into male or female gametocytes: the 
transmissible forms of the parasite. After being ingested by a feeding mosquito, the gametes fuse to form a 
zygote, which become motile ookinetes able to traverse the midgut wall of the mosquito where they reside as 
oocysts. Oocysts can give rise to 5x104 haploid sporozoites after replication, which migrate to the salivary glands 
where they can then be inoculated into a new host upon the next feed. Figure was reproduced from White et al., 
2014. 
 
Figure 1.2 | The life-cycle of Plasmodium. An illustration of the various developmental stages of Plasmodium (from 
infection to transmission) within the mosquito vector and human host. A) A female anopheles mosquito inoculates 
approximately 10 sporozoites into the dermis, some of which reach the liver and establish an infection of hepatocytes. 
B) Inside hepatocytes the parasite undergoes a period of asexual replication lasting 5 – 15 days (depending on 
Plasmodium species), giving rise to between 1x104 – 3x104 merozoites, per infected liver cell. C) After release into the 
blood-stream, the merozoites invade erythrocytes and mature (from rings, to trophozoites, to schizonts) and replicate 
asexually. Thus, each blood-stage schizont can give rise to up to ~32 new daughter merozoites. It is this exponential 
blood-stage replication phase that gives rise to the morbidity and mortality associated with malaria disease. D) Some 
blood-stage parasites develop into male or female gametocytes: the transmissible forms of the parasite. After being 
ingested by a feeding mosquito, the gametes fuse to form a zygote, which become motile ookinetes with the ability to 
traverse the midgut wall of the mosquito where they reside as oocysts. Oocysts can give rise to 5x104 haploid 
sporozoites after replication, which migrate to the salivary glands wh re they can th n be introduced into a new host 
upon the next feed. Figure was reproduced from White et al. 2014. 
 
Infections with malaria parasites remain asymptomatic during the liver-stage replication 
phase, whereas all morbidity and mortality associated with malaria disease is attributed 
to the blood-stage of the parasite life cycle.  
 
1.1.4 Manifestations of disease 
In human malaria infection, disease can present in differing degrees: 
mild/uncomplicated, and severe. Most malaria infections are uncomplicated, whereby 
patients experience non-specific symptoms such as fever, chills and myalgia. These 
are normally observed about 7 to 14 days post-infection (White et al. 2014), and are 
easily resolved with appropriate treatment. If left untreated however, uncomplicated 
malaria can rapidly progress to severe disease. The clinical features of severe malaria 
are characteristically diverse, and are influenced by both age and transmission 
intensity. In sub-Saharan Africa, where P. falciparum predominates, inoculation rates 
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can be as high as 1,000 (bites) per year. In such settings, morbidity and mortality from 
malaria are pronounced during early childhood, but by adulthood infections are mostly 
asymptomatic (Dondorp et al. 2008, von Seidlein et al. 2012). In areas where 
transmission is low and erratic (termed unstable), symptomatic disease is observed at 
all ages, as protective immunity is often not acquired. Severe anemia (haemoglobin 
concentration <5g/dl) is the main manifestation of malaria disease in young children 
living in areas of high transmission (Calis et al. 2008) (figure 1.3), and is thought to be 
a combined result of accelerated splenic removal of un-parasitised red blood cells, 
erythrocyte destruction during parasite schizogeny and ineffective erythropoiesis 
(Graham 2008). Metabolic acidosis and hypoglycemia are also features commonly 
linked to fatal outcome in children (English et al. 1996, Mackintosh et al. 2004, Maitland 
and Marsh 2004), resulting from the accumulation of organic acids such as lactic acid, 
in tissues where sequestered parasites obstruct microcirculatory flow (Day 2000, Day 
et al. 2000). In adults, acute respiratory distress (breathing difficulties) is a major 
complication in those with severe falciparum malaria. It often manifests after the start of 
antimalarial treatment and its pathogenesis is not fully understood, although is likely 
due to acidosis (Taylor et al. 2012, Hanson et al. 2013).  Renal failure, as a result of 
acute kidney injury, is also common in adult patients, and is frequently accompanied by 
the dysfunction of other vital organs- leading to high mortality (Nguansangiam et al. 
2007). Severe jaundice, resulting from hepatocyte injury, haemolyisis and cholestasis 
is also more common in adults than in children (figure 1.3). The most striking 
manifestation of severe disease however is cerebral malaria (CM), characterised by 
seizures, coma and death (Grau and Craig 2012, Ponsford et al. 2012). In fatal cases 
of CM, capillaries and venules in the brain become clogged with parasitised 
erythrocytes, leading to extensive microvascular obstruction and impaired perfusion, 
which is thought to be the crucial pathophysiological process involved (Beare et al. 
2009, Maude et al. 2009). CM has been shown to occur in all age groups, but may 
have slightly different pathogenic features between children and adults; cerebral 
oedema is frequently reported in children, but less so in the majority of adult cases 
(Idro et al. 2005, Medana et al. 2011, Potchen et al. 2012, Seydel et al. 2015, Mohanty 
et al. 2017). CM has a 15 - 25% case-fatality rate, even with appropriate medical 
intervention (Marsh et al. 1995, Murphy and Breman 2001). Many of the syndromes 
cause rapid deterioration, and 50-80% of malaria deaths in hospital occur within 24 
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hours of admission, (Marsh et al. 1995, Schellenberg et al. 1999, Ranque et al. 2008), 
highlighting the importance of prompt triage and treatment.  
 
 
Figure 1.3 | Manifestations of severe P. falciparum malaria by age. Graph shows the proportion of patients (%) (y-
axis) with observed symptoms of each of the listed clinical manifestations of severe P. falciparum, as a relation to 




1.2 Naturally Acquired Immunity to Malaria 
In areas where malaria is endemic, severe disease is associated almost exclusively 
with the very young, whereas older children and adults develop naturally acquired 
immunity with continued exposure to the Plasmodium parasite (Gupta et al. 1999, 
Barry and Hansen 2016) (figure 1.4). Naturally acquired immunity is compromised 
however, in pregnant women, especially in primigravidae, and in adults who return to 
malaria-endemic regions after a period of absence (Doolan et al. 2009). Thus, 
interventions that reduce exposure below a level capable of maintaining immunity may 
compromise protection against severe malaria in the majority, and risk increased 






Figure 1.4. | Naturally acquired immunity as a relation between age and malaria severity. All infants are initially 
susceptible to severe malaria (red line), but clinical immunity is acquired with repeated exposure, which makes 
symptoms of malaria milder (blue line), while parasites are still present in the blood-stream of almost every child. 
Parasitological immunity is slow to develop and many people harbour microscopically-detectable blood-stage parasites 
well into adulthood (green line). The here shown timings for the development of clinical and parasitological immunity are 
typical for areas of moderate transmission. Figure reproduced from Marsh et al. 2006 and Langhorne et al. 2008. 
 
 
Despite decades of research, the underlying mechanisms of naturally acquired 
immunity to malaria are not fully understood. The protection associated with the very 
gradual acquisition of anti-parasite immunity (figure 1.4) appears largely dependent on 
antibodies capable of recognising blood-stage antigens (Garraud et al. 2003, Duah et 
al. 2010). Transfer of immunoglobulin (Ig) from clinically immune adults to children with 
high-density infections is able to reduce parasite numbers, and attenuate clinical 
symptoms (Cohen et al. 1961). Moreover, immune IgG inhibits P. falciparum growth in 
vitro (Mitchell et al. 1976). It is therefore likely that protection against high density 
infection requires the induction of antibodies capable of recognising multiple antigens, 
and in malaria endemic areas, the breadth and magnitude of the malaria-specific 
antibody response correlates with increasing age and exposure (Dorfman et al. 2005, 
Weiss et al. 2010). Conversely, immunity to (severe) clinical disease develops much 
more quickly (figure 1.4). In areas of high transmission, it is estimated that 10 – 20% of 
all children will suffer an episode of severe malaria before the onset of partial immunity 
but once suffered, will likely be protected from subsequent severe infections (Gupta et 
al. 1999, Goncalves et al. 2014). In an important study by Goncalves et al, the 
incidence of P. falciparum infection and associated disease was documented in a large 
cohort of (882) Tanzanian children, by monitoring the children from birth, for up to 4 
years of age. Of these 882 children, 102 (~11%) experienced an episode(s) of severe 
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malaria which, in the majority of cases, was restricted to the first, second or third 
infection. As is consistent with the schematic shown in figure 1.4, the incidence of 
severe malaria decreased considerable after infancy, whereas the incidence of high-
density parasitaemia was similar among all age groups of children (Goncalves et al. 
2014). These data suggest that the rapid development of immunity to severe (life-
threatening) disease is not associated with better control of parasite growth, and 
occurs early in life at a time where limited exposure to the parasite has not yet afforded 
an accumulation of protective antibodies. It is therefore speculated that innate immune 
responses play a crucial role in shaping outcome of infection in the malaria-naive 
(Langhorne et al. 2008, Liehl and Mota 2012, Wu et al. 2014), however it is not yet 
clear why some children are more susceptible to severe malaria than others.  
 
 
1.3 The innate immune response to malaria 
Innate responses are the major forces combating infection in non-immune individuals, 
and thus are predicted to influence clinical outcome during primary infection with         
P. falciparum. Over recent years, various strategies have been employed to investigate 
innate host responses to malaria infection. Cross-sectional and longitudinal studies of 
malaria-endemic populations have afforded the analysis of genetic and/or 
immunological features associated with disease severity. Studies of controlled human 
malaria infection in non-immune volunteers have been useful for examining the early 
stages of infection, although the ethical necessity to treat (most often) before the onset 
of clinical symptoms precludes the correlation of variables with disease outcome. 
Autopsy studies of fatal malaria have yielded some important insights, but studies are 
small and likely confounded by artifacts of death and/or co-morbidities.  
 
In vitro model systems have been widely utilised to study the response of primary host 
cells, such as peripheral blood mononuclear cells (PBMCs) and endothelial cells, or 
cell lines upon exposure to Plasmodium. These experiments are easily manipulated 
and permit controlled exposure of host cells to parasite, but are reductionist in nature. 
Murine models have also been used to investigate the host response to malaria, as a 
variety of Plasmodium strains naturally infect rodents. These models have to be 
considered carefully however, as the combination of parasite strain and genetic 
background of the host greatly influences the course and outcome of infection. While 
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no single model fully recapitulates P. falciparum malaria, various aspects of human 
malaria infection can be probed using the appropriate model.  
 
Research suggests that host innate responses to malaria can mediate both protection 
and pathology, evidence for which will be discussed in the following sections.  
 
1.3.1 Phagocytic clearance of parasitised erythrocytes 
Phagocytosis of parasitised erythrocytes (PEs) and merozoites by myeloid cells is 
thought to be a primary mechanism for controlling parasite growth in non-immune 
individuals. This is underlined by evidence from in vitro studies confirming the ability of 
monocytes, macrophages and neutrophils to phagocytose PEs, independently of 
malaria-specific antibodies (Trubowitz and Masek 1968, Su et al. 2002). The non-
opsonic uptake of mature-stage PEs by macrophages is largely mediated by 
scavenger receptor CD36 (McGilvray et al. 2000, Serghides et al. 2003, Patel et al. 
2004), likely through the engagement of parasite proteins such as P. falciparum 
erythrocyte membrane protein-1 (PfEMP1), exposed on the surface of the red blood 
cell (RBC) (Baruch et al. 1996). There is also evidence to suggest that ring-stage PEs 
can be opsonised by complement proteins and natural IgG, and thus targeted for 
destruction via complement and Fc receptor-dependent pathways (Turrini et al. 1992, 
Ayi et al. 2004). In support of this, a loss of function mutation in the Fc gamma receptor 
IIb, which normally inhibits IgG-mediated phagocytosis, has been shown to enhance 
the opsonic PE internalisation by macrophages in vitro and reduced parasitaemia in 
the Plasmodium chabaudi mouse model (Clatworthy et al. 2007). Although, this 
association has not been upheld in a more recent, and much larger, genetic study on 
human malaria infection (Rockett et al. 2014). During infection in the RBC, parasites 
break down haemoglobin, producing haemozoin as a by-product. Haemozoin is 
insoluble in the phagolysosome, and thus persists in the cell following phagocytosis of 
PEs. In malaria infected humans and mice, haemozoin-laden myeloid cells are found 
abundant in the blood and particularly the spleen- the primary site of PE clearance 
(Coban et al. 2010). In vitro studies of dendritic cell (DC) activation, in response to 
Plasmodium, have demonstrated the efficient phagocytosis and phagosomal 
maturation of infected erythrocytes (Bettiol et al. 2010). Yet, results also suggest for a 
dose-dependent inhibition of DC maturation (Elliott et al. 2007) that occurs at high 
concentrations of infected erythrocytes. This is characterised by a failure of DCs to up-
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regulate the co-stimulatory molecules required for full effector function (Urban et al. 
1999). In line with this, DCs extracted from malaria-infected humans show an impaired 
capacity to mature, produce pro-inflammatory cytokines and present antigens to T cells 
(Woodberry et al. 2012, Loughland et al. 2016, Gotz et al. 2017, Loughland et al. 
2017). Thus, it appears that malaria does not induce classical activation of DCs. 
However, it is important to note that human studies are limited to assessment of 
circulating cells, and it is possible that fully functioning DCs are migrating into tissues 
where they exert their effects as mediators of innate host defense.  
 
Based on these data, myeloid cells, particularly monocytes (given their location in the 
blood and capacity to phagocytose) are speculated to play a crucial role in the innate 
response to malaria. In a study of controlled human malaria infection with P. vivax, 
volunteers were found to have elevated levels of the (CD16+CD14+) monocyte subset 
at diagnosis, compared to baseline. Moreover, these cells displayed enhanced 
phagocytic activity in response to infection (Antonelli et al. 2014). Parasite clearance by 
monocytes/macrophages has also been explored using the P. chabaudi mouse model, 
where resolution of infection has been shown to be dependent on recruitment of a 
CD11bhiLy6C+ monocyte population from the bone marrow to the spleen. These cells 
demonstrated extensive phagocytic activity towards PEs in vitro and in vivo (Sponaas 
et al. 2009). Macrophages have also been shown to control parasitaemia during non-
lethal P. yoelii infection (Couper et al. 2007). 
 
The phagocytosis of parasitised erythrocytes therefore appears to correlate with better 
control of malaria infection in humans and mice. However phagocytosis is tightly linked 
to inflammation, which also plays an important role in the innate response.  
 
1.3.2 The systemic inflammatory response to malaria infection 
In studies of semi-immune populations and experimental vaccine trials, robust T-helper 
cell-1 (TH1) responses, in particular IFNγ production, has been associated with 
protection. While memory T cells are the major source of IFNγ (Schoenborn and 
Wilson 2007), it can also be produced by innate immune cells, and has been shown to 
exert effector functions relevant for non-immune individuals, such as enhanced 
phagocytosis of PEs (Su et al. 2002, Horowitz et al. 2010). In line with this, exposure of 
malaria-naïve PBMCs to P. falciparum induces production of IFNγ in NK cells, gamma 
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delta (γδ) T cells and (cross-reactive) alpha beta (αβ) T cells in an IL-12 dependent 
manner (Hensmann and Kwiatkowski 2001, Horowitz et al. 2010). In controlled human 
malaria infection, early IFNγ responses correlate with lower parasite densities, 
suggesting better control of parasite growth. However, there is considerable inter-
individual variation in this response (Walther et al. 2006). In African children, severe 
malaria syndromes have been associated with promoter variants that reduce 
transcription of IFNγ and/or IL-12p40 (Cabantous et al. 2005, Marquet et al. 2008). Yet, 
this finding has been contested by a more recent genetic screening in a large cohort of 
individuals, where almost all protective mutations were found to be associated 
exclusively with red cell genes (Rockett et al. 2014). In P. chabaudi-resistant mice, 
deficiency in the IL-12p40 subunit reduces IFNγ induction and increases mortality (Su 
and Stevenson 2002), suggesting a key role of this cytokine in host defense. However, 
evidence is controversial across the different models of infection, and its protective 
capacity may be context and species dependent. More recently, studies in both mice 
and humans have identified production of Type I IFNs (IFNα/β) among the earliest of 
host cytokine responses during Plasmodium infection, however the extent to which 
they mediate protection remains to be defined (Rocha et al. 2015, Montes de Oca et al. 
2016, Yu et al. 2016, Zander et al. 2016).  
 
Tumour Necrosis Factor (TNF), produced early in infection by 
monocytes/macrophages, is another cytokine thought to be critical for the control of 
parasite replication. In a prospective study of children in Papua New Guinea, ex vivo 
stimulation of PBMCs with P. falciparum revealed patterns of TNF production that 
correlated with protection (Robinson et al. 2009). The protective functions of TNF are 
thought to be induced through the generation of nitric oxide (NO) (Rockett et al. 1992). 
Moreover, TNF has been shown to enhance killing of parasitised erythrocytes in vitro, 
and administration of exogenous TNF reduces parasitaemia in both P. chabaudi and   
P. yoelii- infected mice (Clark et al. 1987, Taverne et al. 1987). Importantly, high levels 
of TNF correlated with a rapid parasitological cure in patients, supporting a protective 
role of this cytokine in the clearance of P. falciparum parasites (Kremsner et al. 1995). 
However, elevated levels of TNF have also been associated with severe malaria 
disease (Kwiatkowski et al. 1990, Awandare et al. 2006, Boeuf et al. 2012). 
It is likely that anti-inflammatory responses, such as interleukin-10 (IL-10) and 
transforming growth factor-β (TGFβ) production, play an important role in the resolution 
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of infection by preventing malaria-associated immunopathology (Linke et al. 1996, 
Omer and Riley 1998).  However, the timing of these responses appears to be a 
critical.  Data from models of lethal P. yoelii and P. chabaudi infections suggests an 
association between early production of transforming growth factor-β (TGFβ), low IFNγ 
and uncontrolled parasitaemia. In these infection settings, inhibition of TGFβ enhanced 
pro-inflammatory responses, reduced parasitaemia and improved survival (Tsutsui and 
Kamiyama 1999, Omer et al. 2003). Furthermore, in studies of controlled human 
malaria infection, early production TGFβ coinciding with parasites entering the 
circulation, correlated with reduced plasma levels of pro-inflammatory cytokines and 
increased rates of parasite replication, although this response was not observed in all 
volunteers (Walther et al. 2005). Additionally, blood-stage P. falciparum infection was 
found to promote the development of parasite-specific IL-10 producing TH1 cells in 
malaria-naïve volunteers. This parasite-induced IL-10 suppressed inflammatory 
cytokine responses and was associated with higher parasite burdens (Montes de Oca 
et al. 2016).  
Thus, data from both human and mouse models suggest an important role of the 
systemic inflammatory response in host protection from malaria. However, 
contradictory evidence from the field underscores the complexity involved in 
mechanisms of host defense against Plasmodium. For instance, whereas tumor 
necrosis factor alpha (TNFα), Interferon gamma (IFNγ), Interleukin (IL)- 1β, IL-2, IL-6, 
IL-8, IL-10 and IL-12 have been reported in children and adults with symptomatic         
P. falciparum malaria, compared to asymptomatic and healthy controls (Day et al. 
1999, Lyke et al. 2004, Walther et al. 2006, Mirghani et al. 2011), higher levels of the 
same pro-inflammatory cytokines have been observed in non-severe P. vivax 
infections (Zeyrek et al. 2006, Jain et al. 2010, Goncalves et al. 2012, Scherer et al. 
2016).  
Strategies used to contain pathogens are harsh by nature, and if responses are 
excessive or dysregulated, they can often become detrimental to the host. The 
pathology associated with severe malaria anemia (SMA) is a prime example of this. 
Low plasma IL-10 or high TNF/IL-10 ratios have been consistently observed in children 
with SMA compared to mild malaria (Kurtzhals et al. 1998, Othoro et al. 1999, May et 
al. 2000, Perkins et al. 2000, Awandare et al. 2006, Thuma et al. 2011). The ability of 
IL-10 to suppress pro-inflammatory cytokine production by PBMCs in response to        
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P. falciparum (Ho et al. 1998) has given rise to the hypothesis that unrestrained 
inflammatory responses contribute to the pathology of SMA. Impaired erythropoiesis is 
one of the hallmark characteristics associated with SMA, as is the destruction of 
unparasitised RBCs (Graham 2008). TNF has been shown to suppress erythropoiesis 
in vitro (Broxmeyer et al. 1986) and in chronically exposed mice (Johnson et al. 1989). 
Furthermore, pro-inflammatory cytokines are predicted to enhance phagocytosis of 
RBCs via activation of macrophages (Burchard et al. 1995, Salmon et al. 1997), 
although evidence is indirect in murine models of infection.  
An ability to keep inflammatory responses in check may therefore protect children 
against severe malaria, at time when they are yet to develop protective antibodies 
(Portugal et al. 2013). However, there is an increasing need to identify the key 
parasite-host interactions that induce inflammation so that interventions can be better 
targeted to downstream events. 
 
1.3.3 Innate sensing of malaria parasites  
In contrast to viral and bacterial infections, for which many pattern recognition 
receptors and signaling pathways are well defined, our understanding of the parasite-
associated molecular patterns (PAMPs) and reciprocal host receptors involved in the 
response to Plasmodium, is still limited. In the context of human malaria infection,       
P. falciparum presents itself in many different forms. Thus, it is of considerable interest 
to define the Plasmodium parasite molecules being recognised by the host. Evidence 
from a large body of studies in both mouse models and human infection has 
highlighted a role of key parasite recognition receptors (PRRs), including toll-like 
receptors (TLRs), retinoic acid-inducible gene-I-like receptors (RLRs), cytosolic DNA 
sensors and nucleotide-binding oligomerisation domain-like receptors (NLRs) in host 
defense against Plasmodium parasites (Gazzinelli and Denkers 2006, Liehl and Mota 
2012, Gazzinelli et al. 2014, Oviedo-Boyso et al. 2014, Wu et al. 2014). However, the 
significance of each has been much debated. 
 
1.3.3.1 Toll-like receptors (TLR) 
TLRs are widely expressed in a cell-type specific manner, and each recognises a 
distinct set of ligands. TLR 1, 2, 4, 5 and 6 are detected on the cell surface, and in 
 16 
intracellular compartments. TLR4 senses lipopolysaccharide (LPS), and other microbial 
products, as well as “danger signals” released from dead or dying cells. TLR2 forms 
heterodimers with TLR1 or TLR6 to recognise ligands such as lipoproteins and yeast 
cell wall, whereas TLR5 detects flagellin. TLR3, 7, 8 and 9 sense nucleic acids; TLR9 
recognises CpG DNA, while TLR3, TLR7 and TLR8 detect RNA (Akira et al. 2006, 
Kawai and Akira 2006, Kawai and Akira 2010). Ligand binding interactions induce TLR 
dimerisation and recruitment of adaptor proteins (such as Myeloid differentiation factor 
88 (MyD88) and TIR domain-containing adaptor inducing IFN-β (TRIF)), to initiate 
signaling cascades. Signalling via MyD88 leads to activation of MAPKs and NF-κB, 
transcription of pro-inflammatory cytokines and chemokines, and generation of anti-
microbial effectors such as Nitric Oxide (NO) (Yamamoto et al. 2004, Akira et al. 2006, 
Coban et al. 2007, Litvak et al. 2009). The TRIF-dependent pathway is unique to TLR3 
and TLR4, and results in activation of IRF3 and transcription of Type I Interferons 
(IFNs)- important for the control of viral infection (Akira et al. 2006).  
 
TLRs have been shown to be important for innate and adaptive immune responses in a 
variety of infectious disease models, as has been previously reviewed (Trinchieri and 
Sher 2007, Palm and Medzhitov 2009). In the Plasmodium berghei ANKA model, mice 
deficient of MyD88 demonstrate impaired production of pro-inflammatory cytokines, 
and mutations in TLR9, TLR2 and TLR2/4 were shown to provide protection against 
cerebral malaria (Coban et al. 2007, Griffith et al. 2007). In human studies, 
Plasmodium-mediated enhancement of TLR responsiveness in immune cells has been 
described. In a study comparing PBMC expression profiles isolated from volunteers 
experimentally infected (pre-symptomatic), with those from individuals naturally 
infected in the field (symptomatic), common to both was an up-regulation of toll-like 
receptor signaling through NF-κB pathways (TLR1, TLR2, TLR4 and TLR8), as well as 
expression of genes such as TNFα, IFNγ and IL-1β (Ockenhouse et al. 2006). A similar 
observation was documented in PBMCs which had been isolated from individuals, in a 
subsequent study of controlled human malaria infection (CHMI) (McCall et al. 2007). 
Moreover, acute infection in Ghanaian school children and a Brazilian cohort has been 
shown to present with augmented reactivity to TLR stimulation (Hartgers et al. 2008, 
Franklin et al. 2009). Thus, evidence suggests that TLRs play an important role during 
initiation of the host inflammatory response to Plasmodium infection, but the extent of 
their involvement remains to be defined. 
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1.3.3.2 Nod-like receptors (NLR) 
NLRs are cytosolic PRRs, implicated in inflammatory responses to pathogens and 
environmental hazards. Their protein structure consists of a C-terminal Leucine Rich 
Repeat (LRR) domain involved in ligand sensing; a central nucleotide-binding domain, 
which mediates oligomerization; and a variable N-terminal domain. NLR proteins Nod1 
and Nod2 recognise components of bacterial peptidoglycan, and activate NF-κB for 
downstream transcription of pro-inflammatory cytokines (Girardin et al. 2003, Girardin 
et al. 2003). Nod proteins have also been shown to induce activation of Type I IFNs in 
response to bacteria and viruses (Herskovits et al. 2007, Sabbah et al. 2009). Other 
NLRs, such as NLRP3, self-assemble to form inflammasome complexes when 
activated. This leads to the auto-activation of Caspase-1, driving the maturation and 
secretion of IL-1β and IL-18 (Lee et al. 2009, Latz 2010).  
 
Like TLRs, NLRs have been shown to contribute to both innate and adaptive immune 
responses, and to a variety of pathogens. Moreover, dysregulated NLR signaling has 
been implicated in the pathogenesis of diseases such as atherosclerosis, inflammatory 
bowel disease, asthma and gout (Davis et al. 2011, Magalhaes et al. 2011). 
Interestingly, activation of the NLRP3 inflammasome, and resulting IL-1β production, 
has recently been associated with malaria infection in both mouse and human models 
of the disease (Ataide et al. 2014, Kalantari et al. 2014). In the second study, NLRP3 
inflammasome activation was found to be dependent on the initial activation of TLR9, 
highlighting the cooperative and synergistic nature of PRRs during the innate host 
response (Kalantari et al. 2014). 
 
1.3.3.3 Other pattern recognition receptors (PRRs) 
Among other PRRs implicated in the induction of inflammation are the C-type lectin 
receptors (CLRs), which detect pathogen carbohydrate components, and the Rig-like 
receptors (RLRs), which recognise double-stranded RNA in the cytoplasm (Takeuchi 
and Akira 2010, Goubau et al. 2013, McNab et al. 2015). When activated, RLRs induce 
Type-I IFN responses, and so far have been linked to host defense against RNA 
viruses; DNA viruses; intracellular bacteria (due to reverse transcription of microbial 
DNA) (Chiu et al. 2009) and extracellular bacteria (by an unknown mechanism)(Kong 
et al. 2009). Given that Type-I IFN induction is observed during malaria infection in 
both mouse and human models (Rocha et al. 2015, Montes de Oca et al. 2016, 
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Spaulding et al. 2016, Yu et al. 2016, Zander et al. 2016), RLRs are also predicted to 
be involved in the host response to Plasmodium, although precise mechanisms of 
interactions are yet to be defined. Other PRRs are responsible for the detection of 
cytoplasmic DNA, such as the AIM2 inflammasome, as has been implicated during 
Plasmodium infection (Kalantari et al. 2014) and DAI receptor (Takaoka et al. 2007, 
Hornung et al. 2009, Hornung and Latz 2010, Sharma et al. 2011, Roers et al. 2016, 
Sisquella et al. 2017). Thus, every pathogen type is sensed by multiple host receptors 
during infection.  
 
 
1.3.3.4 Parasite-associated molecular patterns (PAMPs) 
Extensive attempts have been made to define the “malaria toxin” that induces 
inflammatory responses. Previous efforts were complicated by a lack of understanding 
of innate immunity, but with recent advances in PRR discovery, interest in this field has 
been revived. 
 
Of the PAMPs that have been implicated in driving the host inflammatory response, 
glycosylphosphatidylinositol (GPI) has been studied most comprehensively. Protozoa 
make extensive use of GPIs to anchor membrane proteins (Gowda et al. 1997), and 
are thus thought to be essential for parasite viability (Naik et al. 2000). Both free and 
membrane-associated PfGPIs are thought to be released upon schizont rupture, 
triggering the production of pro-inflammatory cytokines, such as TNF (Schofield and 
Hackett 1993, Tachado et al. 1996, Naik et al. 2000). This process is thought to be 
dependent on TLR2 (Zhu et al. 2005, Durai et al. 2013). However, GPI has also been 
shown to act as a ligand for TLR4, albeit to a lesser extent (Krishnegowda et al. 2005). 
In support of these findings, SNPs related to TLR2 and TLR4 pathways have been 
associated with human malaria disease, suggesting that recognition of PfGPI is a 
crucial step in preventing pathology (Mockenhaupt et al. 2006, Mockenhaupt et al. 
2006, Ferwerda et al. 2007, Leoratti et al. 2008, Hamann et al. 2010). However, the 
effects of these TLR variants are not fully understood, and it is important to consider 
the complex role of inflammation in severe malaria disease. Interestingly, human 
studies have shown a correlation between levels of anti-GPI antibodies with increasing 
age in malaria-endemic regions (Naik et al. 2000, Boutlis et al. 2002, de Souza et al. 
2002), suggesting that GPI neutralisation may contribute to protection from severe 
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malaria. This is consistent with data from mouse models of P. berghei infection, 
whereby immunisation with the PfGPI glycan core prevented cerebral, pulmonary and 
systemic manifestations compared to un-immunised controls (Schofield et al. 2002). 
Overall, these data implicate PfGPI, through interactions with TLR2 and TLR4, as an 
important PAMP during initiation of the inflammatory response to the malaria parasite. 
 
Haemoglobin degradation is an obligate process for the survival of P. falciparum 
parasites. This process takes place during the asexual cycle in the blood, and results in 
the production of malarial haemozoin. Upon lysis of infected RBCs, the release of 
haemozoin into the blood, along with other parasite components, coincides with 
induction of pro-inflammatory cytokines (Liehl and Mota 2012). Thus, it has been 
implicated in the induction of malaria-associated fever. Haemozoin-loaded 
macrophages can induce expression of pro-inflammatory cytokine genes (Shio et al. 
2009), and dendritic cells (DCs) have also been found responsive to stimulation 
(Parroche et al. 2007). Studies have shown that haemozoin purified from P. falciparum 
is a ligand for TLR9 (Coban et al. 2005, Coban et al. 2010). However, this finding has 
been contested by others showing that only natural haemozoin contaminated with 
Plasmodium DNA is able to trigger activation of the immune response (Parroche et al. 
2007). Others provide evidence for the interaction being TLR-independent (Togbe et al. 
2007). In line with this, nucleotide-binding oligomerization domain-like receptors 
(NLRs) have also been implicated in haemozoin-induced inflammation. Activation of 
the NLRP3 inflammasome drives production of pyrogenic IL-1β, and has been 
associated with disease severity in various mouse models of malaria infection (Dostert 
et al. 2009, Shio et al. 2009, Kalantari et al. 2014). Thus, irrespective of the 
mechanism, there is robust evidence implicating haemozoin, either alone, or in 
complex with other parasite molecules, as a potent activator of the innate immune 
response during Plasmodium infection. 
 
There is also evidence for a role of Plasmodium nucleic acids (DNA and RNA) in the 
initiation of inflammation during infection. When delivered into the cytosol of various 
cell types, Plasmodium-derived AT-rich genomic DNA triggers the induction of Type I 
IFN responses via a pathway involving Interferon regulator factor 3-7 (IRF3/IRF7), 
TANK-binding kinase 1 (TBK1), stimulator of interferon genes (STING) and cGAS 
(Sharma et al. 2011, Wu et al. 2013). In line with this, Plasmodium RNA has also been 
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linked to induction of Type I IFN responses following recognition by retinoic acid-
inducible gene-I-like receptors, RIG-I and/or melanoma-differentiation-associated 
protein 5 (MDA5), as has been reviewed (Goubau et al. 2013, McNab et al. 2015). The 
mechanisms of such interactions are still unclear, but have been discussed in recent 
literature (Kalantari et al. 2014, Sisquella et al. 2017).  
 
1.3.3.5 Linking the innate immune response to protection and/or pathology 
Despite recent advances in our understanding of the innate immune response to 
Plasmodium, many questions still remain regarding the initiation and propagation of 
responses that lead to severe malaria disease in human infection. What is the relative 
importance of the different parasite stimuli and host sensors, and how do they interact? 
What are the key cell types and signaling pathways involved? Do these pathways 
contribute to protection and/or development of severe disease?  
 
In order to fully understand the key parasite-host interactions responsible for onset of 
disease, it is important to consider the parasite and host factors predicted to influence 
clinical outcome.  
 
 
1.4 Factors influencing disease outcome 
A range of host polymorphisms have been associated with protection from severe 
malaria (de Mendonca et al. 2012). The best characterised of these include: blood 
group O (Rowe et al. 2007), sickle cell (HbS) (Aidoo et al. 2002), α+ thalassemia 
(Wambua et al. 2006, Opi et al. 2014) and glucose-6-phosphate dehydrogenase 
deficiency (Ruwende et al. 1995, Rockett et al. 2014). These polymorphisms are 
common in Africa, and thus may protect the majority of children, whereas those lacking 
these polymorphisms could be at greater risk of severe disease. Certain environmental 
factors have also been shown to influence differences in disease susceptibility. The 
use of bed nets, the level of fitness, co-infections, past infection history and nutritional 
status are factors contributing to variability in clinical outcome (Bartoloni and 
Zammarchi 2012, Goncalves et al. 2014).  
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Parasite specific factors such as parasite multiplication rates (PMR) and choice of 
invasion pathway have also been linked to disease outcome, although evidence is 
controversial. Whereas higher PMRs have been associated with severe disease in 
adults (Chotivanich et al. 2000), no such correlation was observed in African children 
with severe versus uncomplicated malaria (Deans et al. 2006). Furthermore, 
differences in clinical outcome have been documented when comparing infections 
involving sialic acid-dependent and sialic acid-independent invasion pathways (Bowyer 
et al. 2015, Mensah-Brown et al. 2015), although these data are contradictory to earlier 
studies of clinical isolates (Deans et al. 2007, Gomez-Escobar et al. 2010). 
 
There is substantial evidence that the parasite-encoded variant surface antigens 
(VSAs), on the surface of PEs, are the decisive determinants of clinical outcome during 
P. falciparum malaria (Hviid 2010). There are several VSAs expressed by                    
P. falciparum, the best characterised of which is P. falciparum Erythrocyte Membrane 
Protein 1 (PfEMP1), encoded by var genes. Expression of PfEMP1 gives rise to the 
ability of infected erythrocytes to agglutinate, rosette and adhere to endothelial cells, 
enabling them to sequester out of the circulation and avoid clearance by the spleen 
(Pain et al. 2001, Doumbo et al. 2009, Rowe et al. 2009). Switching between PfEMP1 
variants correlates with changes in the antigenic and adhesion phenotype of the 
parasite, and the expression of specific PfEMP1 types has been associated with 
severe malaria (Bull et al. 2000, Jensen et al. 2004, Bull et al. 2005, Kyriacou et al. 
2006, Lavstsen et al. 2012). An overview of var genes, PfEMP1, and their associated 
virulence is discussed in the following section.  
 
 
1.5 Var Genes, PfEMP1 and Parasite Virulence 
1.5.1 PfEMP1 variant surface antigens 
Each parasite genome has approximately 60 var genes encoding 60 variants of 
PfEMP1 (Smith et al. 1995). Var genes are activated in a mutually exclusive fashion 
whereby just one is expressed at any given time, while all others are transcriptionally 
silenced (Dzikowski et al. 2006). During infection, P. falciparum parasites are able to 
switch expression between different var genes as a means to evade the developing 
host immune response. This, in turn, gives rise to variable expression of PfEMP1 
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types. The global var gene repertoire present in the parasite population is highly 
diverse. However, recent evidence suggests that every parasite var gene repertoire is 
organised similarly (Kraemer and Smith 2003, Lavstsen et al. 2003, Kraemer et al. 
2007). The majority of var genes (and hence PfEMP1) can be classified into groups (A, 
B, C or E) on the basis of various structural features: upstream sequence, 
chromosome location and direction of transcription. Both group-A and B var genes are 
located in the sub-telomeric regions near the chromosome ends, but have an opposing 
direction of transcription; group-A towards the telomeres and group-B towards the 
centromere. Group-C var genes are located at chromosome internal clusters (Gardner 
et al. 2002). Var genes are made up of two exons; the hypervariable exon 1, encoding 
for the extracellular region involved in adhesion interactions and the transmembrane, 
conserved exon 2, which encodes the acid terminal segment (ATS). The extracellular 
region of the PfEMP1 is made up of the N-terminal segment (NTS), Duffy binding-like 
domains (DBL) and cysteine rich interdomain regions (CIDR) (figure 1.5). The DBL 
domains can be classified into six types (α, β, γ, δ, ε and ζ) and the CIDR into four 
groups (α, β, δ and γ). Furthermore, 23 functionally conserved tandem domains of 
DBL-CIDR, termed ‘domain cassettes’ (DC) have also been described (Rask et al. 
2010). Each molecule of PfEMP1 contains a number of functional cytoadhesive 
domains, and depending on domain composition, demonstrate diverse cytoadhesive 
functions (Kraemer and Smith 2006, Hviid and Jensen 2015, Bull and Abdi 2016). The 
DBLβ domains of group-A and B PfEMP1, for instance, have been implicated in the 
binding of the host receptor ICAM-1 (Bengtsson et al. 2013, Gullingsrud et al. 2013), 
whereas the CIDRα2-6 domains of group-B and C PfEMP1 have been shown to 
interact with CD36 (Miller et al. 2002, Robinson et al. 2003).  
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Figure 1.4 | Schematic representation of a parasite-derived PfEMP1 protein variant on the surface of an 
infected erythrocyte. The extracellular region of the PfEMP1 is involved in adhesion interactions with host 
cell receptors and is made up of the N-terminal segment (NTS), Duffy binding-like domains (DBL) and cysteine 
rich interdomain regions (CIDR). The DBL domains can be classified into six types (α, β, γ, δ, ε and ζ) and the 
CIDR into four groups (α, β, δ and γ). Only one PfEMP1 variant is expressed per cell at any given time. The 
number, location and type of DBL and CIDR domains vary among PfEMP1 variants, giving rise to variable 
domain compositions and diversity in adhesion specificities. This schematic shows a hypothetical model of a 
PfEMP1 variant. TM, transmembrane region. Figure was taken from Rowe at al., 2009. 
 
Figure 1.5 | Schematic representation of a parasite-derived PfEMP1 protein variant on the surface of an infected 
erythro yte. The extrac llular region of the PfEMP1 is involved in adhesion interactions with host cell recep ors and is 
made up of the N-terminal s gment (NTS), Duffy binding-like domains (DBL) and cysteine rich interdomain regions 
(CIDR). Th  DBL domains can be classified into six types (α, β, γ, δ, ε and ζ) and the CIDR into four groups (α, β, δ and 
γ). Only one PfEMP1 variant is expressed per cell at any given time. The number, location and type of DBL and CIDR 
domains vary among PfEMP1 variants, giving rise to variable domain compositions and diversity in adhesion 
specificities. This schematic shows a hypothetical model of a PfEMP1 variant. TM, transmembrane region. Figure was 
taken from Rowe at al. 2009. 
 
 
1.5.2 PfEMP1-associated virulence 
The interaction of PfEMP1 proteins with endothelial and circulating cells causes 
obstruction of blood flow and tissue perfusion, contributing to organ failure in the non-
immune host (Dondorp et al. 2000, Dondorp et al. 2004, Dondorp et al. 2008). 
However, the vast majority of P. falciparum infections do not lead to severe disease 
and only certain types of PfEMP1, with specific adhesion specificities, have been 
implicated in pathology (Hviid and Jensen 2015, Bull and Abdi 2016). Group-A PfEMP1 
proteins have a structure consisting of a DBLα1 and a CIDRα1/β/γ/δ (non-CD36 
binding) domain and their pattern of expression has been linked to severe disease 
outcome in numerous studies (Kirchgatter and Portillo Hdel 2002, Bull et al. 2005, 
Kaestli et al. 2006, Kyriacou et al. 2006, Rottmann et al. 2006, Normark et al. 2007, 
Falk et al. 2009, Warimwe et al. 2009, Kalmbach et al. 2010, Lavstsen et al. 2012, 
Warimwe et al. 2012, Bertin et al. 2013, Almelli et al. 2014, Abdi et al. 2015, Bertin et 
al. 2016, Jespersen et al. 2016, Mkumbaye et al. 2017, Shabani et al. 2017, Tonkin-Hill 
et al. 2018). However, data on the host cell receptors associated with these parasite-
host interactions are largely inconclusive (Rowe et al. 2009, Craig et al. 2012). 
Sequestration of mature infected erythrocytes in the microvasculature of the brain is 
one of the key features of cerebral malaria pathology and parasites that transcribe a 
subset of group-A and B/A var genes encoding ‘Domain cassette (DC) 8 and 13’ type 
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PfEMP1 have been associated with this pathology, in children specifically 
(MacPherson et al. 1985, Bertin et al. 2013, Almelli et al. 2014, Milner et al. 2014). 
Infected erythrocytes that express these variants have been reported to bind EPCR, 
expressed on human brain endothelial cells (HBEC), implicating this host receptor in 
the interaction (Turner et al. 2013). Owing to the difficulty of performing the relevant 
experiments however, there is yet limited evidence for a direct association between 
EPCR binding and cerebral malaria, and the host receptor ICAM-1 has also been 
implicated with various degrees of controversy (Ockenhouse et al. 1991, Turner et al. 
1994, Newbold et al. 1997). Most B- and C-type PfEMP1 have a 4-domain extracellular 
structure including a CD36-binding head consisting of a DBLα0 and a CIDRα2–6, plus 
another DBL and CIDR domain (Kraemer and Smith 2003). The expression of group-B 
PfEMP1 has been associated with both severe and mild malaria (Kaestli et al. 2006, 
Rottmann et al. 2006, Merrick et al. 2012, Almelli et al. 2014), whereas group-C 
PfEMP1 have only been found expressed in parasites causing asymptomatic infections 
and in long-term in vitro cultivated parasites (Jensen et al. 2004, Sharp et al. 2006, 
Frank et al. 2007, Enderes et al. 2011).  
 
 
1.5.3 PfEMP1 selection in the human host 
Because of their exposure on the surface of infected erythrocytes during blood-stage 
infection, VSAs such as PfEMP1 are targets of naturally acquired immunity (Bull et al. 
1998, Bull et al. 2000, Chan et al. 2012). This is thought to impose a selection pressure 
on the infecting parasite population, causing them to switch expression between 
different PfEMP1 variants in order to evade the host immune system and establish 
chronic infection (Smith et al. 1995, Bull et al. 1998, Chan et al. 2012). Interestingly, 
healthy individuals (having experienced previous episodes of malaria), asymptomatic 
individuals and those recovering from disease demonstrate high levels of antibodies to 
a broad repertoire of PfEMP1 (Bull et al. 1998, Ofori et al. 2002, Hviid 2005). Thus 
production of antibodies, capable of neutralising binding of PfEMP1s to host cell 
receptors, may be important in the development of immunity to severe disease (Marsh 
et al. 1989, Dobbs and Dent 2016).   
 
As previously discussed, in areas of high malaria transmission, immunity to severe 
disease develops rapidly (Langhorne et al. 2008, Goncalves et al. 2014). One popular 
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explanation for this in the scientific community is that restricted subtypes of disease-
causing PfEMP1 variants are specialised for infection in malaria-naïve hosts, and upon 
development of antibodies to these variants, children are subsequently protected from 
severe infection (Bull et al. 1999, Bull et al. 2000, Nielsen et al. 2002, Staalsoe et al. 
2003, Jensen et al. 2004, Abdi et al. 2017). In line with this, it is predicted that PfEMP1 
of the group-A, B/A subclass confer a growth advantage in the immunologically naïve 
host through mechanisms that allow them to adhere to a more diverse range of 
endothelial cells, and thus more efficiently escape clearance from the spleen (Abdi et 
al. 2017). However, this has been extremely difficult to test in the field, owing to the 
difficulty in controlling for current and past infection history. In one recent study, 
controlled human malaria infection (CHMI) of 28 Kenyan adults was used to investigate 
an association between pre-existing antibodies against infected erythrocytes, and 
parasite expression of group-A and DC-8-like PfEMP1 (Abdi et al. 2017). The study 
reports that in individuals with high levels of pre-existing antibodies, lower levels of 
group-A var transcripts are detected in parasites that go on to establish blood-stage 
infection, compared to volunteers with low levels of pre-existing antibodies. Based on 
these data, the authors propose a model whereby group-A and DC8-and 13-type 
PfEMP1 confer a fitness advantage in the naïve host, and suggest for dominant 
expression of these variants in all cases of primary infection with P. falciparum (Abdi et 
al. 2017). However, alternative models of var gene/PfEMP1 selection have been 
proposed (Peters et al. 2002, Lavstsen et al. 2005, Wang et al. 2009, Bachmann et al. 
2011, Bachmann et al. 2016). In another study of CHMI, parasite var gene expression 
was assessed following sporozoite infection of non-immune volunteers. Analysis was 
limited to just one blood sample containing mRNA material sufficient for qPCR, but 
reported the detection of 90% of all var gene transcripts (Wang et al. 2009), suggesting 
a theory whereby at the onset of blood-stage infection, P. falciparum (3D7-strain) gene 
expression is based on a strategy that allows all or most PfEMP1 variants to be 
expressed. Similar broad-level detection of var gene variants has since been 
documented by Bachmann et al, although there appeared dominant expression of 
group-B variants in this cohort of 18 volunteers (Bachmann et al. 2016). In contrast, 
studies of P. falciparum in vitro cultures established from parasites isolated from non-
immune individuals, display a dominant group-A transcript pattern (Lavstsen et al. 
2005, Bachmann et al. 2011). However results from these studies are confounded by a 
possible bias in transcription profile due to var gene switching of cultured parasites; a 
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well-documented phenomenon (Roberts et al. 1992, Horrocks et al. 2004, Peters et al. 
2007, Bachmann et al. 2011). Therefore, in order to understand what drives severe 
disease in the malaria-naïve, it is important to investigate this parasite-host interaction 
further.  
 
1.5.4 Other variant surface antigens 
The P. falciparum genome consists of other multi-gene families with a potential 
influence on parasite virulence. These include the repetitive interspersed family (rif), 
which encode RIFINS, and sub-telomeric variable open reading frame (stevor), which 
encode STEVORS (Kyes et al. 1999, Lavazec et al. 2007, Joannin et al. 2008). These 
proteins are expressed on the surface of infected erythrocytes (Bachmann et al. 2015), 
however their role in malaria is unclear due to the limited studies available (Abdel-Latif 
et al. 2003, Niang et al. 2009, Chan et al. 2014, Niang et al. 2014). RIFINS have been 
implicated in severe malaria given their ability to form rosettes upon binding to 
uninfected red cells (Goel et al. 2015). Whereas, in another study they have been 
shown to interact with the host inhibitory receptors; leucocyte immunoglobulin-like 
receptor B1 (LILRB1) and leucocyte-associated immunoglobulin-like receptor 1 
(LAIR1), in a process thought to inhibit activation of LILRB1-expressing B cells and 
natural killer cells (Saito et al. 2017). Thus, P. falciparum-derived RIFINs may utilise 
immune inhibitory receptors to achieve immune evasion. The role of these VSAs, and 
their interaction with the human host, also warrants further exploration. 
 
1.5.5 Understanding the innate immune response to P. falciparum  
Malaria is a complex disease, not least in part due to the heterogeneity between, and 
within, the clinically-defined syndromes. Interpreting how immunity develops is further 
complicated by the various host and parasite factors influencing susceptibility and 
protection. Most observations of the innate immune responses to human malaria are 
derived either from in vitro studies or from cross-sectional epidemiological studies 
conducted at a time when the infection has already led to disease. Furthermore, in the 
setting of natural infection: previous exposure, infective dose, age, genetic diversity 
and co-infections are all confounding factors. Therefore, in order to better delineate the 
innate immune response to P. falciparum infection in the human host, we need to 
consider a model that limits the introduction of variability.  
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Controlled Human Malaria Infection (CHMI) offers a unique opportunity to study the 
earliest immune events during P. falciparum infection in the human host, in a setting 
where many of the above-listed variables can be excluded. CHMI, and its applications 
will be discussed in the following section.  
 
1.6 Controlled Human Malaria Infection 
The deliberate infection of human volunteers with malaria is not a recent practice. 
During the early twentieth century, artificial induction of malaria-fever, termed 
“malariatherapy” served as the most effective treatment for neurosyphillis in the pre-
penicillin era; a discovery which earned Julius Wagner Von Jauregg the 1927 Nobel 
Prize in Medicine (figure 1.6). During the 1920s to 1950s, thousands of patients were 
infected with Plasmodium, providing the largest body of data on the human response to 
controlled malaria infection. These data are still very much relevant today (Austin et al. 
1992, Collins and Jeffery 1999, Molineaux et al. 2002, Collins et al. 2004). Although the 
aim of these studies was not to assess the early immune events during malaria, they 
provide the first evidence for inter-individual variation in response to controlled malaria 
infection, as well as detailed information on parasite growth kinetics within the human 
host (McKenzie et al. 2001, McKenzie et al. 2002, Molineaux et al. 2002). Many 
fundamental insights can be attributed to these historical studies of malariatherapy and 
their significance to the field of malaria research must not be overlooked. 
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Figure 1.5 | Malariatherapy in the early 20th century. Julius Wagner-Jauregg (black suit, 
facing camera) oversees the transfusion of blood from a malaria patient to a psychiatric patient 
suffering from neurosyphilis (center) for induction of malaria-fever at Horton Hospital, Epsom, 
in 1934. (Photograph sourced from the Institut für Gescjocjte der Medizin Vienna, Austria and 
reproduced in Raju, T.N., 2006). Figure taken directly from Raju, T.N., 2006. 
 
Figure 1.6 | Malariatherapy in the early 20th century. Julius Wagner-Jauregg (black suit, facing camera) oversees 
the transfusion of bl od from a malaria patient to a psychiatric patient suffering from neurosyphilis (center) for induction 
of malaria-fever at H r n Hospital, Epsom, in 1934. (Photograph sourced from the Institut für Gescjocjte der Medizin 




Controlled Human Malaria infection (CHMI), is now the most practiced controlled 
human infection model worldwide, and is a critical tool for the assessment of new 
malaria vaccine candidates. Field studies are often complex and expensive to 
organise, requiring large numbers of participants to allow for variables such as genetic 
heterogeneity and co-infections, whereas CHMI requires relatively small numbers of 
healthy volunteers per trial. To date, over 3,000 human volunteers have been safely 
exposed to P. falciparum infection across four specialised centres, namely the Walter 
Reed Army Institute, Silver Spring, Maryland (USA), the University of Oxford (UK), the 
Radbound University Nijmegen Medical Centre (RUMC, The Netherlands) and the 
Queensland Institute of Medical Research (QIMR), Brisbane, Australia (Roestenberg et 
al. 2017).  
Traditionally, malaria vaccines are designed to target different life cycle stages of the 
parasite, using antigens expressed at either the pre-erythrocytic or blood-stages. 
Depending on the type of vaccine being tested, different models of CHMI are routinely 
used to infect volunteers.  
 
1.6.1 Mosquito-bite challenge model  
Exposure to five infectious mosquito bites, via the mosquito-bite challenge model, 
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mimics the natural route of infection leading to detection of blood-stage parasites by 
thick blood film approximately 9 - 11 days later, at which point drug treatment is 
initiated (Roestenberg et al. 2012). Most volunteers undergoing the mosquito-bite 
challenge experience non-specific symptoms of uncomplicated malaria, with fever and 
headaches being most common. The prepatent period (time from exposure to positive 
thick smear) is used to estimate efficacy of the vaccine, and is supplemented by exact 
measurements of parasite numbers in the blood using quantitative RealTime (qRT) 
PCR (Hermsen et al. 2001), allowing for calculation of parasite multiplication rates 
within the human host. Pooled data from clinical trials at RUMC have shown that an 
estimated 23 to 5,273 (mean 500) merozoites per mL are released within the first 
erythrocytic cycle, approximately 6.5 days after mosquito bite (Roestenberg et al. 
2012), however this number is likely highly variable between volunteers. Once in the 
circulation, P. falciparum parasites follow a pattern of synchronous replication, 
multiplying approximately 10.8-fold every 48 hours  (Roestenberg et al. 2012). Due to 
the nature of CHMI diagnosis criteria, volunteer infections are terminated after just 2 - 3 
erythrocytic replication cycles following mosquito-bite challenge. This short time frame 
has been deemed inappropriate for the assessment of partially effective blood-stage 
vaccines, which may demonstrate effects only after several replication cycles in the 
blood (Sanderson et al. 2008, Sheehy et al. 2013). In this instance, volunteers are 
instead infected by intravenous (iv) injection of PEs (blood-stage challenge model).  
 
1.6.2 Blood-stage challenge model  
All blood inoculum used in recent trials of blood-stage vaccines has come from one of 
two donors experimentally infected with the 3D7 reference strain of P. falciparum 
(Cheng et al. 1997). Injection of 1,800 parasitised erythrocytes iv leads to blood-stage 
parasitaemia that can be detected by qRT PCR after 3.5 days, reaching thick-film 
positivity (diagnosis) at 8 days post-infection. Thus, a greater number of erythrocytic 
cycles in which to monitor the effects of vaccines targeting blood-stage parasites are 
afforded (Sanderson et al. 2008). However, inoculum dose has varied greatly between 
different trials using this model: from 30 to 6,000 parasitised erythrocytes (Cheng et al. 
1997, Pombo et al. 2002). One major advantage of the blood-stage challenge model is 
that every volunteer within the same trial can be guaranteed an identical immune 
challenge, whereby the dose and timing of parasites entering circulation is stringently 
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controlled (Duncan and Draper 2012, Payne et al. 2016). Moreover, given that the 
number of PEs being used to initiate infection is known, it allows for much more 
accurate modelling of parasite growth with each 48-hour cycle of replication in the 
blood (Douglas et al. 2013). However, individuals undergoing P. falciparum infection by 
blood-stage challenge experience fewer symptoms compared to those following 
mosquito-bite, for reasons that are not understood (Duncan and Draper 2012). This 
precludes the (already difficult) correlation of host responses variables with clinical 
outcome.  
 
1.6.3 Sporozoite infection model 
The recent availability of cryopreserved parasites from Sanaria Inc. provides an 
appealing alternative to current models of CHMI, whereby volunteers are infected by 
intravenous inoculation of cryopreserved sporozoites (PfSPZ challenge) (Lyke et al. 
2015, Mordmuller et al. 2015). Here, the number of sporozoites injected can be 
controlled, minimising inter-individual variation and strengthening statistical power 
compared to the mosquito-bite model. Its use has already been shown to be safe, well 
tolerated and infectious for a large proportion of tested individuals (Roestenberg et al. 
2013, Shekalaghe et al. 2014).  
 
1.6.4 Standardisation of CHMI 
The advance of molecular technology for fast and accurate parasite detection is 
beginning to diversify the design of CHMI and there has been recent discussion over 
how best to standardise studies (Roestenberg et al. 2017). At some trial sites, qRT 
PCR is replacing microscopy for diagnosis, as a more sensitive method for detecting 
blood-stage parasites. In this instance, drug treatment is initiated when parasite 
densities (p/mL) surpass a predefined threshold (Burel et al. 2016). This approach is 
thought to improve safety, reducing the clinical burden without compromising the 
evaluation of protective efficacy (Walk et al. 2016, Stanisic et al. 2018). In other 
studies, infections have been allowed to continue beyond the thick film threshold if 
clinical symptoms are absent (Roestenberg et al. 2017). Most CHMI trials have been 
performed using the 3D7 or parental NF54 strain of P. falciparum, however, the long-
term culture of this strain has sparked concerns over its likely divergence from field 
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strains. The introduction of a more diverse range of Plasmodium genotypes has 
therefore been proposed, to bridge the gap between strain-specific P. falciparum 
developed for CHMI, and strains found in the natural endemic setting (Roestenberg et 
al. 2017). The general design of CHMI in current trials, however, is similar and results 
are highly reproducible across sites, highlighting the robustness of this model 
(Roestenberg et al. 2012). 
 
1.6.5 CHMI for studying host and parasite immunobiology 
Over recent years, the CHMI model has been exploited beyond its use anti-malaria 
vaccine screening, and is being increasingly applied to more basic research questions. 
Many sub-studies undertaken within the frame-work of drug or vaccine evaluation have 
already provided some valuable insights, as summarised in table 1.2 (Peters et al. 
2002, Lavstsen et al. 2005, Walther et al. 2005, Ockenhouse et al. 2006, Walther et al. 
2006, Wang et al. 2009, Teirlinck et al. 2011, Turner et al. 2011, Woodberry et al. 
2012, Arevalo-Herrera et al. 2014, Scholzen et al. 2014, Rojas-Pena et al. 2015, 
Teirlinck et al. 2015, Arevalo-Herrera et al. 2016, Bachmann et al. 2016, Burel et al. 
2016, Loughland et al. 2016, Montes de Oca et al. 2016, Stanisic et al. 2016, Tran et 
al. 2016, Burel et al. 2017, Loughland et al. 2017, Gardinassi et al. 2018, Rothen et al. 
2018). Importantly, CHMI has provided evidence which supports the inter-individual 
variability in host responses to controlled Plasmodium infection, first documented in 
early studies of malariatherapy (Molineaux et al. 2002). Following mosquito-bite 
challenge with P. falciparum (3D7 strain), Walther et al were able to group volunteers 
according to their cytokine response profiles, which ranged from anti-inflammatory 
(associated with the upregulation of TGF-β), to pro-inflammatory (characterised by 
detectable IL-12p70, and high levels of IFNγ). Moreover, pro-inflammatory responses 
in these individuals were associated with better control of parasite growth, and 
development of clinical symptoms (Walther et al. 2006). In a more recent study, Burel 
et al report a dichotomy in volunteer miRNA expression patterns following direct blood 
inoculation of P. falciparum-infected erythrocytes (Burel et al. 2017). Thus, inter-
individual variability in the host immune response to controlled P. falciparum infection 
has been reported at both the transcript and protein level, highlighting an important gap 
in our understanding of human malaria infection.  
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Table 1.2 | CHMI for studying host/ parasite immunobiology: a summary 
Publication reference Study site Plasmodium species Study type CHMI model Focus of study Cohort size Volunteer immune status
WRAIR, US Mosquito-bite Comparison of transcriptional immune events during P. faclaiprum infection 22 malaria-naïve 
Cameroon, West Africa Natural infection in pre-symtomatic (malaria-naïve CHMI) vs symptomatic (naturally-infected, Cameroon) 15 previously exposed (Cameroonian adults)
Blood-stage or
PfSPZ challenge
Malaria Vaccine and Drug Development Centre 7 malaria-naïve adults (Cali, Columbia)
(CECIV, Cali, Columbia) 9 semi-immune (adults) (Beunaventura, Columbia)
cryopreserved sporozoites The dynamics of BAFF induction and B cell subset
(PfSPZ challenge)  acivation and composition in the blood
Malaria Vaccine and Drug Development Centre Comparison of (whole blood) transcriptional profiles in naïve versus semi-immune 7 malaria-naïve adults (Cali, Columbia)
(CECIV, Cali, Columbia) volunteers experimentally infected with P. vivax 9 semi-immune (adults) (Beunaventura, Columbia)
Malaria Vaccine and Drug Development Centre 7 malaria-naïve adults (Cali, Columbia)
(CECIV, Cali, Columbia) 9 semi-immune (adults) (Beunaventura, Columbia)
The Institute of Tropical Medicine 
(Tubingen, Germany)
P. falciparum & Profiling the host cellular response during 19 (Pf)
P. vivax infection with P. falcairum, compred to P. vivax 8 (Pv)
Characterisation of P. falciparum parasite strains (NF54, 3D7B and 7G8) 
for assessment of in vivo infectivity in the malaria naïve host
RUMC, Nijmegen, Netherlands Mosquito-bite Comparison of (whole-blood) RNA-seq profiles in adults who are naturally exposed 5 malaria-naïve (Dutch adults)
Kalifabougou, Mali Natural infection and i) asymptomatc or ii) febrile, to those who were previoulsy malaria-naïve 8 previously exposed (Malian adults)
Assessment of early immune events (miRNA expression profiles) 
and evidence for inter-individual variation in host responses
The activation and cytokine production of plasmacytoid dendritic cells (pDCs)
during P. falciaprum infection 
Malaria Vaccine and Drug Development Centre 7 malaria-naïve adults (Cali, Columbia)






In primary infection, loss of dendritic cell numbers and function occurs early during the prepatent period.
Plasmacytoid DCs (pDCs) appear inactive during sub-microscopic P. falciparum blood-stage infection,
yet retain their ability to respond to TLR stimulation
Mccall et al. 2007 RUMC, Nijmegen, Netherlands P. falciparum Mosquito-biteHost immunology 15 malaria-naïve TLR responses during acute-phase P. falciparum infection in the malaria-naïve
TLR4 responses were characterised by the up-regulation of proinflammatory cytokines during infection, compared to baseline. 
TLR2/TLR1 responses demonstrated increases in both pro- and anti-inflammatory cytokine production. 
develop classic malaria-associated  symptoms, whereas semi-immune voluneers display minor or no symptoms at the day of diagnosis. 
Higher serological (antibody) responses were detected in semi-immune volunteers, compared to malaria-naive volunteers, although malaria-naïve 
volunteers also had pre-existing antibodies. Semi-immune volunteers without fever displayed a lower response to challenge.
BAFF and BAFF receptor levels correlate with B cell subset activation and redistribution in CHMI
Whole-blood transcriptome analysis revealed a strong interferon response, and down-regulation of transcripts linked to inflammation  
and innate immunity in response to P. vivax infection, in both naïve and semi-immune volunteers.
P. falciparum activation induces activation of monocytes and CD16+ dendritic cells (DCs) 
and induces up-regulation of CD16 and CD1c expression 
Malaria-naïve individuals demonstrate much higher activation of pathways downstream of pro-inflammatory cytokines, compared to malaria-experienced
Infectivity of P. falciparum in malaria-naïve individuals is associated with knob expression and cytoadherence of the parasite
CCVTM, Oxford/ LSHTM, London





The maturation status of (CD1c+) myeloid DCs and their associated cytokine production
Key finding(s)
The composition and frequency of var transcript expression differs markedly between parasites isolated 
after infection in the human host and the parasite population used to infect
P. falciparum
P. falciparum Blood-stage
P. vivax Host immunology Mosquito-bite Antibody profiling in naïve and semi-immune volunteers experimentally infected with P. vivax
P. vivax Host immunology Mosquito-bite Parasitaemia levels, clincial manifestations and immune responses duing infection with P. vivax
Parasites isolated form volunteers (2nd and 3rd generation parasites, following hepatic release) 
Cellular responses to both PfSPZ and PfRBCs are induced and remain undiminished for up to 14 months after a single infection.

























Woodberry et al. 2012 Host immunology The kinetics of Dendritic Cell (DC) apoptosis/loss during P. falciparum infection 10
RUMC, Nijmegen, Netherlands
P. falciparum
 have dominant expression of group-A and B var gene variants
Cells with the characteristics of Treg cells are rapidly induced following blood-stage infection and are associated with a burst 
 of TGFβ production, decreased proinflammatory cytokine production, and decreased antigen-specific immune responses
TLR signalling is upregulated in both pre-symptomatic and symptomatic individuals, as well as genes that function in phagocytosis and inflammation.
Differences between pre-symptomatic and symptomatic volunteers were linked to genes that regulate the induction of apoptosis.
Volunteers infected by CHMI have diverse cytokine responses to P. falciparum. 
Proinflammatroy responses are associated with better control of paraiste growth and adverse clinical events
At the onset of blood-stage infection in the naïve host, all (or most) parasite var gene variants are expressed
Both innate and adaptive lymphocyte subsets contribute to the increased IFNγ response (αβT cells, γδT cells and NK cells).
Antibodies against PfEMP1, RIFIN, MSP3 and GLURP are aquired after a single, low density 
P. falciparum infection in malaria-naïve individuals 
Longevity and composition of host cellular immune responses 15 malaria-naïve 
malaria-naïve
malaria-naïve 
Peters et al. 2002 Parasite genetics Parasite var gene profiling malaria-naïve 2
Turner et al. 2011 Host immunology Screening for anti-VSA antibodies in volunteer plasma 44 malaria-naïve 
Teirlinck et al. 2011 Host immunology 
Walther et al. 2005
Ockenhouse et al. 2006 Host immunology
Lavstsen et al. 2005 Parasite genetics Parasite var gene profiling 10
Walther et al. 2006 18
Host immunology The host regulatory T cell (Treg) response 26
Remaining DCs demonstrated a reduced ability to uptake particulate antigen.
Host immunology
Scholzen et al. 2014 Host immunology 18
QIMR, Brisbane, Australia
QIMR, Brisbane, Australia 
QIMR, Brisbane, Australia
QIMR, Brisbane, Australia





Host immunology 21 malaria-naïve
Burel et al. 2016
Arevalo-Herrera et al. 2016
Bachmann et al. 2016 Parasite genetics Parasite var gene profiling 18 malaria-naïve
Broad-level detetcion of paraiste var gene variants after ~3 replication cycles in the blood
Var gene expression dominated by those of the group-B and, to a lesser extent, group-A sub-types
P. vivax but not P. falciparum blood-stage infection in the human host is associated
with the expansion of a CD8+ T cell population with cytotoxic potential
P. falciparum infection is associated with reduced CD1c+ myeloid dendritic cell HLA-DR
and CD86 expression, but enhanced TNF production
Type I IFNs suppress innate immune cell function and parasite-specifc CD4+ T cell IFNγ production,
Burel et al. 2017
with distinct kinetics after infection. Metabolomics data highlighted differences in amino acid pathways and lipid metabolism between the two groups. 
Host immunology malaria-naïve
Tran et al. 2016 Host immunology
Stanisic et al. 2016 Parasite immunobiology 3 malaria-naïve
and promote the development of parasite-specific IL-10 producing Th1 (Tr1) cells.
Gardinassi  et al. 2018
 Malawian volunteers. Febrile and asymptomatic profiles were indistinguishable, with the exception of genes activated by pro-inflammatory cytokines.
Volunteers displayed a dichotomous pattern of high or low expression of a defined set of micro-RNAs (miRNAs), which correlated
 variation in parasite growth rate. High miRNA responders had higher numbers of activated cD4+ T cells and enhanced antimalarial antibody responses
Montes de Oca et al. 2016 Host immunology  Immuno-regulatory networks during the host response to P. falciparum 65 malaria-naïve
previously exposed (Tanzanian adults)
Loughland et al. 2017
Rothen et al. 2018
Host immunology 59 malaria-naïve
Ifakara Health Institute, Bagamoyo, Tanzania
P. vivax Mosquito-biteHost immunology Integrative metabolomics and transcriptomics signatures of clinical tolerance to P. vivax
P. falciparum
Grouping volunteers based  on prepatent period identified 265 genes whose expression levels were linked to time of blood-stage parasitaemia detection.
Modules associated with these 265 genes were linked to regulation of transcription, cell cycle and erythrocyte development.
At baseline, naïve and semi-immune volunteers differed in the expression of interferon-related genes, neutrophil and B cell signatures that progressed
malaria-naïve 
Loughland et al. 2016 Host immunology 62 malaria niave
Wang et al. 2009 Parasite genetics Parasite var gene profiling 1 malaria-naïve 
Teirlinck et al. 2015 Host immunology Composition and activation status of monocytes and dedritic cells in the blood 18 malaria-naïve 
Rojas-Pena et al. 2015
Arevalo-Herrera et al. 2014
Malaria-naïve and semi-immune individuas demonstrate comparable prepatent periods during infection with P. vivax. Malaria-naïve volunteers
Host immunology Transcriptional analysis of early host immune events (whole blood) 10
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Publication reference Study site Plasmodium species Study type CHMI model Focus of study Cohort size Volunteer immune status
WRAIR, US Mosquito-bite Comparison of transcriptional immune events during P. faclaiprum infection 22 malaria-naïve 
Cameroon, West Africa Natural infection in pre-symtomatic (malaria-naïve CHMI) vs symptomatic (naturally-infected, Cameroon) 15 previously exposed (Cameroonian adults)
Blood-stage or
PfSPZ challenge
Malaria Vaccine and Drug Development Centre 7 malaria-naïve adults (Cali, Columbia)
(CECIV, Cali, Columbia) 9 semi-immune (adults) (Beunaventura, Columbia)
cryopreserved sporozoites The dynamics of BAFF induction and B cell subset
(PfSPZ challenge)  acivation and composition in the blood
Malaria Vaccine and Drug Development Centre Comparison of (whole blood) transcriptional profiles in naïve versus semi-immune 7 malaria-naïve adults (Cali, Columbia)
(CECIV, Cali, Columbia) volunteers experimentally infected with P. vivax 9 semi-immune (adults) (Beunaventura, Columbia)
Malaria Vaccine and Drug Development Centre 7 malaria-naïve adults (Cali, Columbia)
(CECIV, Cali, Columbia) 9 semi-immune (adults) (Beunaventura, Columbia)
The Institute of Tropical Medicine 
(Tubingen, Germany)
P. falciparum & Profiling the host cellular response during 19 (Pf)
P. vivax infection with P. falcairum, compred to P. vivax 8 (Pv)
Characterisation of P. falciparum parasite strains (NF54, 3D7B and 7G8) 
for assessment of in vivo infectivity in the malaria naïve host
RUMC, Nijmegen, Netherlands Mosquito-bite Comparison of (whole-blood) RNA-seq profiles in adults who are naturally exposed 5 malaria-naïve (Dutch adults)
Kalifabougou, Mali Natural infection and i) asymptomatc or ii) febrile, to those who were previoulsy malaria-naïve 8 previously exposed (Malian adults)
Assessment of early immune events (miRNA expression profiles) 
and evidence for inter-individual variation in host responses
The activation and cytokine production of plasmacytoid dendritic cells (pDCs)
during P. falciaprum infection 
Malaria Vaccine and Drug Development Centre 7 malaria-naïve adults (Cali, Columbia)






In primary infection, loss of dendritic cell numbers and function occurs early during the prepatent period.
Plasmacytoid DCs (pDCs) appear inactive during sub-microscopic P. falciparum blood-stage infection,
yet retain their ability to respond to TLR stimulation
Mccall et al. 2007 RUMC, Nijmegen, Netherlands P. falciparum Mosquito-biteHost immunology 15 malaria-naïve TLR responses during acute-phase P. falciparum infection in the malaria-naïve
TLR4 responses were characterised by the up-regulation of proinflammatory cytokines during infection, compared to baseline. 
TLR2/TLR1 responses demonstrated increases in both pro- and anti-inflammatory cytokine production. 
develop classic malaria-associated  symptoms, whereas semi-immune voluneers display minor or no symptoms at the day of diagnosis. 
Higher serological (antibody) responses were detected in semi-immune volunteers, compared to malaria-naive volunteers, although malaria-naïve 
volunteers also had pre-existing antibodies. Semi-immune volunteers without fever displayed a lower response to challenge.
BAFF and BAFF receptor levels correlate with B cell subset activation and redistribution in CHMI
Whole-blood transcriptome analysis revealed a strong interferon response, and down-regulation of transcripts linked to inflammation  
and innate immunity in response to P. vivax infection, in both naïve and semi-immune volunteers.
P. falciparum activation induces activation of monocytes and CD16+ dendritic cells (DCs) 
and induces up-regulation of CD16 and CD1c expression 
Malaria-naïve individuals demonstrate much higher activation of pathways downstream of pro-inflammatory cytokines, compared to malaria-experienced
Infectivity of P. falciparum in malaria-naïve individuals is associated with knob expression and cytoadherence of the parasite
CCVTM, Oxford/ LSHTM, London





The maturation status of (CD1c+) myeloid DCs and their associated cytokine production
Key finding(s)
The composition and frequency of var transcript expression differs markedly between parasites isolated 
after infection in the human host and the parasite population used to infect
P. falciparum
P. falciparum Blood-stage
P. vivax Host immunology Mosquito-bite Antibody profiling in naïve and semi-immune volunteers experimentally infected with P. vivax
P. vivax Host immunology Mosquito-bite Parasitaemia levels, clincial manifestations and immune responses duing infection with P. vivax
Parasites isolated form volunteers (2nd and 3rd generation parasites, following hepatic release) 
Cellular responses to both PfSPZ and PfRBCs are induced and remain undiminished for up to 14 months after a single infection.

























Woodberry et al. 2012 Host immunology The kinetics of Dendritic Cell (DC) apoptosis/loss during P. falciparum infection 10
RUMC, Nijmegen, Netherlands
P. falciparum
 have dominant expression of group-A and B var gene variants
Cells with the characteristics of Treg cells are rapidly induced following blood-stage infection and are associated with a burst 
 of TGFβ production, decreased proinflammatory cytokine production, and decreased antigen-specific immune responses
TLR signalling is upregulated in both pre-symptomatic and symptomatic individuals, as well as genes that function in phagocytosis and inflammation.
Differences between pre-symptomatic and symptomatic volunteers were linked to genes that regulate the induction of apoptosis.
Volunteers infected by CHMI have diverse cytokine responses to P. falciparum. 
Proinflammatroy responses are associated with better control of paraiste growth and adverse clinical events
At the onset of blood-stage infection in the naïve host, all (or most) parasite var gene variants are expressed
Both innate and adaptive lymphocyte subsets contribute to the increased IFNγ response (αβT cells, γδT cells and NK cells).
Antibodies against PfEMP1, RIFIN, MSP3 and GLURP are aquired after a single, low density 
P. falciparum infection in malaria-naïve individuals 
Longevity and composition of host cellular immune responses 15 malaria-naïve 
malaria-naïve
malaria-naïve 
Peters et al. 2002 Parasite genetics Parasite var gene profiling malaria-naïve 2
Turner et al. 2011 Host immunology Screening for anti-VSA antibodies in volunteer plasma 44 malaria-naïve 
Teirlinck et al. 2011 Host immunology 
Walther et al. 2005
Ockenhouse et al. 2006 Host immunology
Lavstsen et al. 2005 Parasite genetics Parasite var gene profiling 10
Walther et al. 2006 18
Host immunology The host regulatory T cell (Treg) response 26
Remaining DCs demonstrated a reduced ability to uptake particulate antigen.
Host immunology
Scholzen et al. 2014 Host immunology 18
QIMR, Brisbane, Australia
QIMR, Brisbane, Australia 
QIMR, Brisbane, Australia
QIMR, Brisbane, Australia





Host immunology 21 malaria-naïve
Burel et al. 2016
Arevalo-Herrera et al. 2016
Bachmann et al. 2016 Parasite genetics Parasite var gene profiling 18 malaria-naïve
Broad-level detetcion of paraiste var gene variants after ~3 replication cycles in the blood
Var gene expression dominated by those of the group-B and, to a lesser extent, group-A sub-types
P. vivax but not P. falciparum blood-stage infection in the human host is associated
with the expansion of a CD8+ T cell population with cytotoxic potential
P. falciparum infection is associated with reduced CD1c+ myeloid dendritic cell HLA-DR
and CD86 expression, but enhanced TNF production
Type I IFNs suppress innate immune cell function and parasite-specifc CD4+ T cell IFNγ production,
Burel et al. 2017
with distinct kinetics after infection. Metabolomics data highlighted differences in amino acid pathways and lipid metabolism between the two groups. 
Host immunology malaria-naïve
Tran et al. 2016 Host immunology
Stanisic et al. 2016 Parasite immunobiology 3 malaria-naïve
and promote the development of parasite-specific IL-10 producing Th1 (Tr1) cells.
Gardinassi  et al. 2018
 Malawian volunteers. Febrile and asymptomatic profiles were indistinguishable, with the exception of genes activated by pro-inflammatory cytokines.
Volunteers displayed a dichotomous pattern of high or low expression of a defined set of micro-RNAs (miRNAs), which correlated
 variation in parasite growth rate. High miRNA responders had higher numbers of activated cD4+ T cells and enhanced antimalarial antibody responses
Montes de Oca et al. 2016 Host immunology  Immuno-regulatory networks during the host response to P. falciparum 65 malaria-naïve
previously exposed (Tanzanian adults)
Loughland et al. 2017
Rothen et al. 2018
Host immunology 59 malaria-naïve
Ifakara Health Institute, Bagamoyo, Tanzania
P. vivax Mosquito-biteHost immunology Integrative metabolomics and transcriptomics signatures of clinical tolerance to P. vivax
P. falciparum
Grouping volunteers based  on prepatent period identified 265 genes whose expression levels were linked to time of blood-stage parasitaemia detection.
Modules associated with these 265 genes were linked to regulation of transcription, cell cycle and erythrocyte development.
At baseline, naïve and semi-immune volunteers differed in the expression of interferon-related genes, neutrophil and B cell signatures that progressed
malaria-naïve 
Loughland et al. 2016 Host immunology 62 malaria niave
Wang et al. 2009 Parasite genetics Parasite var gene profiling 1 malaria-naïve 
Teirlinck et al. 2015 Host immunology Composition and activation status of monocytes and dedritic cells in the blood 18 malaria-naïve 
Rojas-Pena et al. 2015
Arevalo-Herrera et al. 2014
Malaria-naïve and semi-immune individuas demonstrate comparable prepatent periods during infection with P. vivax. Malaria-naïve volunteers
Host immunology Transcriptional analysis of early host immune events (whole blood) 10
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1.7 Scope of this thesis 
The development of effective preventative/curative therapies for malaria requires a 
better understanding of what constitutes protection in those at greatest risk of 
severe disease. In children with limited immunity to P. falciparum, most episodes of 
severe disease appear restricted to the 1st, 2nd or 3rd malaria infection, suggesting 
an important role of the innate immune response in determining outcome of 
infection. Therefore, investigation into the earliest immune events during infection in 
the malaria-naive is essential. When it comes to anti-malaria vaccine design, there 
are important practical implications in understanding diversity in host immune 
responses. Yet, the host and/or parasite factors driving inter-individual variation 
remain undefined. One potential source is differential expression of parasite VSAs, 
however little work has been done to investigate their influence on the developing 
host immune response in the malaria-naïve. Furthermore, although the expression 
of particular PfEMP1 variants has been associated with different clinical outcomes, 
little is known about their expression at the onset of infection. This is also true for 
other multi-gene family members such as the RIFINS and STEVORS, whereby 
research into their role as VSAs is limited to just a handful of studies.  
The CHMI model offers a unique opportunity to investigate the earliest immune 
events taking place during primary infection with P. falciparum. Yet most studies to 
date have been limited to the assessment of host immune responses in isolation, 
without considering the influence of parasite gene expression on developing host 
immunities and associated clinical outcome(s). With this in mind, this project 
explores the hypothesis that inter-individual variability in the immune response to 
primary P. falciparum infection is driven by parasite VSA expression, and has three 








Chapter 3 objectives: To characterise the earliest immune events during                 
P. falciparum infection in the malaria-naïve host, and assess inter-individual 
variation within the cohort. 
 
Chapter 4 objectives: To investigate parasite multi-gene family expression (var, rif 
and stevor), and determine their influence on the developing host immune response, 
and vice versa. 
  
Chapter 5 objectives: To optimise a method for direct ex vivo RNA-sequencing of 
parasites isolated at the onset of infection, and at multiple time points throughout, 
































2 Materials and Methods 
Samples used for investigating early parasite-host interactions in Controlled Human 
Malaria Infection were collected from volunteers enrolled in a phase I/IIa vaccine 
study that took place from March to December 2014 at the Centre for Clinical 
Vaccinology and Tropical Medicine (CCVTM), Oxford (Clinical/ Trials.gov i.d: 
NCT02044198). The trial was designed and conduced by a team lead by Dr Simon 
Draper at the Jenner Institute, University of Oxford. This chapter describes the 
protocol for CHMI, and gives details of the host/parasite sample collection used for 
my sub-study. Sections marked (*) indicate the sample processing steps performed 
by me. Specific materials and methods have been included in subsequent chapters.  
 
2.1 Controlled Human Malaria Infection (CHMI) 
2.1.1 Study Design and Ethical Approvals 
The study was designed to assess the safety, immunogenicity and efficacy of the 
AMA1 FMP2.1/AS01B asexual blood-stage candidate as a vaccine for P. falciparum 
malaria. To assess vaccine efficacy, all volunteers underwent blood-stage challenge 
with P. falciparum (3D7 strain) - infected erythrocytes, results from which have been 
previously published (Payne et al. 2016).  
 
Ethical approval for this study was given by the United Kingdom National Health 
Service (NHS) Research Ethics Service (Oxfordshire Research Ethics Committee A, 
reference 13/SC/0596) and the Western Institutional Review Board in the United 
States (reference 20131985). The study was approved by the United Kingdom 
Medicines and Healthcare Products Regulatory Agency (reference 21584/0326/001-
0001) and was conducted in full concordance with the Declaration of Helsinki 2008. 
 
2.1.2 Volunteer Cohort and Inclusion/Exclusion Criteria 
Volunteers were recruited at multiple trial sites across the UK: the Centre for Clinical 
Vaccinology and Tropical Medicine (CCVTM), Oxford; the Hammersmith National 
Institute for Health Research (NIHR)/Wellcome Trust Clinical Research Facility 
(WTCRF), London; and the NIHR WTCRF, Southampton. The original vaccine study 
recruited 30 volunteers in total: 15 to receive the candidate vaccine and 15 to act as 
unvaccinated, infectivity controls (Payne et al. 2016). Given my interest in the host 
 38 
response to P. falciparum infection during primary exposure to the parasite, the 
volunteer cohort for my sub-study included 14 (unvaccinated) controls only. All 
volunteers gave written informed consent prior to participation. Recruited volunteers 
were healthy, malaria-naïve male or non-pregnant females aged 18 – 45 years. 
Table 3.1 (chapter 3) provides more detailed information on the 14 participants in 
this study. A full list of volunteer inclusion and exclusion criteria is provided in 
Appendix 1. 
 
2.1.3 Blood-stage CHMI 
The inoculum used for CHMI was prepared and cryopreserved at the QIMR in 
Brisbane, Australia, in 1994 and consisted of P. falciparum (3D7-strain) infected 
erythrocytes taken from a single donor. Details of inoculum production have been 
previously published (Cheng et al. 1997).  
 
The inoculum was prepared for use in this blood-stage CHMI, as has been 
described previously (Payne et al. 2016). In brief, a single vial of inoculum was 
thawed, washed and diluted under aseptic conditions in a derogated containment 
level III laboratory area, using solutions licensed for clinical use and single-use 
disposable consumables. Inoculum was administered intravenously (iv) in a 5 mL 
volume of 0.9% saline, at an estimated dose of 1,000 parasitised erythrocytes (PEs) 
per volunteer. A limiting dilution assay for assessment of inoculum viability later 
confirmed this dose to be 690 ring-stage PEs. All volunteers were inoculated at the 
CCVTM, within 2 hours and 13 minutes of inoculum preparation. Following CHMI, 
blood was collected from each volunteer the day after inoculum challenge (C +1), 
and twice daily from C +2. Thick blood films were evaluated by experienced 
microscopists and qPCR was performed for quantification of parasites/ mL of blood 
(p/mL). qPCR confirmed that all volunteers in the study were successfully infected. 
Treatment with the combination drug Riamet® was prescribed to volunteers when 
two out of three diagnosis criteria were met: a positive thick blood film and/or qPCR 
≥500 parasites/mL and/or symptoms consistent with malaria infection All volunteers 
were monitored for at least two days following their initial course of drug-therapy.  
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2.1.4 Parasite qPCR  
Parasite qPCR was performed on C +1, and twice daily from C +2, by staff at the 
Jenner Institute. Details of the protocol have been previously published (Sheehy et 
al. 2012). Briefly, blood was depleted of white cells and the DNA extracted from a 
0.5 mL volume using the Qiagen Blood Mini Kit. 10% of each extraction was then 
run in triplicate for qPCR (equating to 150 μL of blood directly assessed). Previously 
published primers with TaqManTM probe (5′ FAM-AAC AAT TGG AGG GCA AG-
NFQ-MGB 3′) were used to amplify the P. falciparum 18s ribosomal region (Applied 
Biosystems, Foster City, CA). Parasites per mL equivalent mean values were 
generated by a standard TaqManTM absolute quantitation, against a defined plasmid 
standard curve with an ABI StepOne Plus machine and v2.3 software. Results 
obtained using a dilution series of microscopically-counted cultured parasites 
suggested that this method has a lower limit of quantification (LLQ, defined as 
%CV<20%) of around 20 p/mL blood. Thus, mean parasite equivalent values below 
20 p/mL or with only one positive replicate of three tested were classed as negative. 
Raw qPCR data is provided in Appendix 2. 
 
2.1.5 Modelling of Parasite Multiplication Rate (PMR) 
Parasite Multiplication Rate (PMR) was modeled by Dr Alexander Douglas, using a 
linear model fitted to log10-transformed qPCR data as previously published (Douglas 
et al. 2013). PMR was calculated for all volunteers that underwent blood-stage 
CHMI, given they all had ≥ 5 data points above the lower limit of quantification (the 
criterion for modeling PMR using this method).  
 
2.1.6 Full blood counts 
Full blood counts (FBCs) were carried out by NHS staff in the haematology 
department at either one of the Churchill or John Radcliffe Hospitals in Oxford, at 
baseline (C -1), C +6 and day of diagnosis (DoD) for each volunteer. These data 
provide an accurate measurement of total red and white cell counts per mL of blood, 
as well as a break-down of the contribution from individual leukocyte subsets; 
neutrophils, lymphocytes, monocytes, eosinophils and basophils. 
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2.1.7 Volunteer clinical assessments 
Measurements of temperature, heart rate and blood pressure were recorded for 
every volunteer, at each clinic visit during CHMI and as a follow-up during their 
course of drug-therapy. Adverse Events (AEs) were also monitored at each visit, 
with volunteers being asked to grade any symptoms likely related to their malaria 
infection as mild, moderate or severe according to the below specifications: 
• Grade 0: None 
• Grade 1: Transient or mild discomfort (<48 hours); no medical 
intervention/therapy required 
• Grade 2: Mild to moderate limitation in activity - some assistance may be 
needed; no or minimal medical intervention/therapy required 
• Grade 3: Marked limitation in activity, some assistance usually required; 
may require medical intervention/therapy 
 
Solicited AEs included symptoms such as nausea, headaches, diarrhoea and rigors. 
Samples for biochemistry analysis were taken at baseline (C -1), C +6 and day of 
diagnosis and were processed by NHS staff in the biochemistry department at either 
the Churchill or John Radcliffe hospital in Oxford. Biochemistry analyses included 
the quantitative assessment of electrolytes, urea, creatinine, bilirubin, alanine 















2.2 Sample collection and processing* 
All venipuncture was carried out by trained medical staff at the CCVTM in Oxford. 
2.2.1.1 List of Materials 
Reagent Supplier Catalog Number
1.5 mL Eppendorf® tubes Sigma-Aldrich T9661-1000EA
2 mL K3 EDTA  Vacuette tubes Becton Dickinson (BD) 367836
2 mL Lithiam Heparin Vacuette tubes Grenier Bio-One 454089
6 mL Lithiam Heparin Vacuette tubes Grenier Bio-One 456084
9 mL Lithiam Heparin Vacuette tubes Grenier Bio-One 455084
Casyton counting buffer Sedna Scientific 43003
Casyton tubes Sedna Scientific 43001
FCS (heat-inactivated, filtered and batch tested) Biosera S1810
L-Glutamine Gibco 25030-24
Leucosep tubes Grenier Bio-One 227209
Lymphoprep Axis Shield 1114545
Penicillin/Streptomycin Gibco BRL/Invitrogen 15140-122
RPMI Sigma-Aldrich R0883
Tempus™ Blood RNA Tubes Applied Biosystems 4342792






days post challenge  
Host + Parasite 
Sample collection 
2 1 3 4 5 6 7 8 9 10 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5 
Day of diagnosis 
(7.5 – 10.5 days post-challenge) 
0 
Host sample collection 
 
Figure 2.1 | CHMI Sample Collection and Schedule. Grey arrows represent the blood collection schedule for 
qPCR analysis. Red arrows represent bleeds taken for analysis of the host response to P. falciparum infection. 
Thick red arrow at diagnosis (ranging 7.5 – 10.5 days post-challenge) represents a larger (67 mL) blood volume 
collected for host and parasite analysis. 
 
 
A 2 mL volume of blood was collected in EDTA tubes (Beckton Dickinson) for 
routine qPCR on the morning of C +1, and twice daily from C +2 (represented by 
grey arrows in figure 2.1). 
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An additional (17 mL) volume of blood was collected at each volunteer’s baseline (C 
-1), and at 48 hour intervals post infection (C +2, C +4, C +6, C +8…) up to (and 
including) day of diagnosis for analysis of the host response to P. falciparum 
infection (red arrows in figure 2.1). This blood volume was divided as per sample 
processing requirements: 
 
2.2.1.2 Samples for whole-blood transcriptome analysis 
3 mL was collected directly into 6 mL TempusTM reagent (TempusTM Blood RNA 
Tube, Applied Biosystems) for whole-blood transcriptome analysis. Immediately 
following blood-draw, tempus tubes were shaken for 10 seconds to ensure thorough 
mixing, as per manufacturer’s guidelines. Tubes were frozen and stored at -70oC 
prior to RNA extraction.  
 
2.2.1.3 Isolation of plasma and Peripheral Blood Mononuclear Cells (PBMCs) 
14 mL of blood was collected in lithium heparin tubes (Grenier Bio-One) for isolation 
of plasma and PBMCs. Following collection, blood was transferred to a pre-
prepared 50 mL Leucosep tube (Grenier Bio-One) containing 15 mL lymphoprep 
(Axis Shields) for centrifugation at 1,000g, for 13 minutes at room temperature. 
Following centrifugation, 2 mL was collected from the plasma fraction and 
transferred to 4x 1.5 mL Eppendorf tubes (Sigma) for snap-freezing on dry ice and 
storage at -70oC. The remaining supernatant from the Leucosep tube (containing 
the PBMC fraction) was then transferred to a fresh 50 mL falcon tube and 
centrifuged at 18,000 rpm (Thermo Scientific, Heraeus Megafuge 40R) for 5 minutes 
before 2x washes in 20 mL RPMI wash media (500 mL RPMI, 1% 
Penicillin/Streptomycin, 1% L-glutamine). PBMCs were resuspended in a 10 mL 
volume of culture media (500 mL RPMI, 1% Pen/Strep, 1% L-glutamine, 10% FCS) 
and counted on an automated CASY® Counter (TTC model), using a programme 
set to measure a cell diameter range of 5.75 M – 15 M. PBMCs were 
resuspended at a final concentration of 1x107/mL and split into 2x 1.5 mL Eppendorf 
tubes for pelleting by centrifugation at 3,000 rpm (Thermo Scientific, Heraeus 
Megafuge 40R) for 5 minutes. PBMCs were then resuspended in 1 mL TRIzolTM 
reagent (Ambion), mixed and incubated for 5 minutes at 37oC before being snap-
frozen on dry ice and stored at -70oC. 
 43 
2.2.1.4 Samples for ex vivo Parasite RNA-sequencing 
At day of diagnosis (ranging C +7.5 – C +10.5), a 50 mL volume of blood was 
collected into lithium heparin tubes (Grenier Bio-One) for isolation/purification of     
P. falciparum parasites (see chapter 4, section 4.4.2). 
 
On the day of challenge, 2 mL of (surplus) blood-inoculum used to infect the 
volunteers were collected and transferred in to 2x 1.5 mL Eppendorf tubes. Samples 
were centrifuged at 3,000 rpm (Beckman Coulter, Allegra x-12 R) for 5 minutes 
before aspirating the supernatant and resuspension of the pellets in 1 mL TRIzolTM 
reagent. Resuspended samples were mixed by pipetting and then incubated at 37oC 
for 5 minutes, to ensure thorough homogenisation. Samples were snap-frozen on 
dry ice and stored at -70oC prior to RNA extraction (see chapter 4, section 4.4.3).  
 
2.3 Statistical Analysis* 
Unless otherwise stated, statistical analyses were performed using GraphPad Prism 
(software version 7.0b). For comparisons between different time-points within the 
same group of volunteers, a Wilcoxon signed-rank test was used. For comparisons 
between different volunteer groups, a non-parametric, unpaired U-test was used 
(Mann-Whitney). Pairwise comparisons (correlation analyses) were performed using 











































3 Diversity in the Host Response to P. falciparum Infection 
3.1 Abstract  
In areas where malaria is endemic, severe disease is associated almost exclusively 
with children under the age of five, having had little or no previous exposure to the 
Plasmodium parasite. A better understanding of the earliest immune responses to 
P. falciparum in the malaria-naïve is thus of great importance. Herein, controlled 
human malaria infection was used to investigate the early immune events following 
primary infection of 14 healthy volunteers with blood-stage Plasmodium falciparum. 
Furthermore, responses were compared among individuals to assess diversity in the 
host response. By day 8 of infection, a dichotomous pattern of gene expression was 
detected in the blood, with volunteers responding by up-regulation of genes 
classically associated with the innate inflammatory response, or by down-regulation 
of genes linked to inflammation, cell signaling and metabolism. Four volunteers in 
the cohort failed to elicit an immune response in the time frame assessed. The 
observed inter-individual variability in host transcriptional responses correlated with 
chemokine levels in the plasma, but not with parasite growth kinetics in the blood. 
These results highlight the need for further investigation into factors driving diversity 
in the human response to Plasmodium falciparum.  
 
3.2 Introduction 
Malaria has an associated pattern of disease that ranges from asymptomatic, to 
death, with children under the age of five, living in sub-Saharan Africa, being at 
greatest risk of severe disease (WHO malaria report, 2017). Recent evidence has 
suggested that immunity to severe (life-threatening) disease occurs rapidly in areas 
where transmission rates are high, and often within the first few years of life 
(Goncalves et al. 2014). This paradigm suggests for an essential role of the innate 
immune response, at a time where limited exposure to the parasite has not yet 
afforded a build-up of protective antibodies (Molineaux et al. 2002, Langhorne et al. 
2008). However, it is not yet clear why certain children respond more adversely to 
infection than others, and the molecular mechanisms that underpin such inter-
individual variability are not well understood. The ability to mount an effective 
immune response to infection is determined by a combination of factors including 
environmental exposure, and host genetics (Oosting et al. 2016, Ter Horst et al. 
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2016). Thus, interpreting how immunity to Plasmodium infection develops is 
complex. Most observations of the human response to P. falciparum have been 
made in the setting of natural infection where previous exposure, infective dose, 
developing immunity, genetic variability and co-infections are confounding factors. 
Moreover, the short time-window in which to monitor the earliest of immune 
responses is extremely limiting in this setting. 
Studies of malariatherapy, dating back to the early twentieth century, provided the 
first evidence for inter-individual variation in host responses to controlled 
Plasmodium infection. In a setting where parasite strain, dose and level of previous 
exposure was controlled for, individuals displayed marked differences in their ability 
to control parasite growth, and in the severity of symptoms presented (Collins and 
Jeffery 1999, Collins et al. 2004). Concordant with this, heterogeneity in innate 
immune responses has been reported in individuals experimentally infected with    
P. falciparum sporozoites (Walther et al. 2006) and more recently, in volunteers 
infected by direct blood inoculation of P. falciparum-infected erythrocytes (Burel et 
al. 2017). Therefore, the diversity in the human response to controlled P. falciparum 
infection, and the immune mechanisms underpinning such diversity, warrants further 
investigation.  
Controlled Human Malaria Infection (CHMI) offers a unique opportunity to study the 
earliest molecular events following primary exposure of the human immune system 
to P. falciparum; the species responsible for the most severe forms of malaria 
disease. Infecting volunteers by direct blood inoculation (blood-stage model) 
ensures that every individual receives an identical immune challenge, whereby the 
dose and timing of parasites entering circulation is stringently controlled (Duncan 
and Draper 2012, Payne et al. 2016). By sampling volunteers over a time-course of 
infection, we can begin to investigate the order and timing of key immune events, 






3.3  Hypotheses and specific aims 
This chapter investigates the hypotheses that individuals demonstrate variability in 
response to controlled P. falciparum infection, and that the type of immune response 
produced will influence parasite growth in the circulation, or vice versa.  
 
 Specific aims 
 
1. To characterise the earliest immune events in response to primary infection 
with P. falciparum, and assess inter-individual variation within the cohort. 
2. To investigate a relationship between host immune response(s) and parasite 
growth in the circulation. 
3. To predict the associated clinical outcome(s) in volunteers, using biomarkers 
of severe disease. 
 
3.4 Methods 
3.4.1 List of Materials 
Reagent Supplier Catalog Number
1.5 mL DNA LoBind Eppendorf® tubes Eppendorf 22431021
50 mL Falcon tubes Becton Dickinson (BD) 352098
Sterile D10 ST pipette tips Gilson F171101
Sterile D200 ST pipette tips Gilson F171301
Sterile D1000 ST pipette tips Gilson F171501
Tempus™ Blood RNA Tubes Applied Biosystems 4342792
TempusTM  Spin RNA Isolation Kit Applied Biosystems 4380204
AbsoluteRNA wash solution Applied Biosystems 4305545
RNA 6000 Nano Chip Bioanalyzer Kit Agilent 5067-1511
Ultrapure DEPC H20 Thermo Fisher Scientific 750024
Anti-PfHRP2 IgM Abcam ab9206
Anti-PfHRP2-HRP IgG Abcam MPFG-55P
Casein in PBS blocking reagent Thermo Fisher Scientific 37528
NUNC MaxiSorp 96 well, flat-bottom ELISA plates (uncoated) BioLegend 423501
1x PBS Gibco 20012-019
Recombinant PfHRP2 protein Gifted from Dr david Sullivan, John Hopkins University -
Sulfuric acid (1-2M) Sigma-Aldrich 339741-100ML
TMB Substrate Sigma-Aldrich T0440-100ML
Angiopoietin-2 Quantikine ELISA Kit R&D Systems DANG20
LEGENDplex™ custom-panel kit for 13 analytes (Human) BioLegend ® 92919
MultiScreen® HTS Vacuum Manifold (Merk) Millipore MSVMHTS00
Nunc 96-well v-bottom Microwell plates Scientific Laboartoy Supplies 249570
Sterile, Low protein Binding 96-well plates with 1.2 µm filter wells (Merk) Millipore MSBVS1210
Anti-CMV IgG Human ELISA Kit Abcam ab108724  
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3.4.2 Volunteer Sample Collection 
For analysis of the host transcriptional response to infection with P. falciparum, 
volunteers were bled (3 mL into TempusTM Blood RNA Tubes, Applied biosystems) 
the day before challenge (C -1), and at 48 hour intervals post infection (C +2, C +4, 
C +6, C +8…) up to (and including) day of diagnosis (see figure 2.1). Immediately 
following blood-draw, tempus tubes were shaken for 10 seconds to ensure thorough 
mixing, as per manufacturer’s guidelines. Tubes were frozen and stored at -70oC 
prior to RNA extraction.  
 
3.4.3 Baseline Controls Bleeds 
To control for every-day fluctuations in host gene expression, four volunteers were 
recruited at the University of Edinburgh to act as uninfected (baseline) controls. 
Volunteers were bled (3 mL into TempusTM Blood RNA Tubes, Applied biosystems) 
over a time course matched with that of the infected volunteers during CHMI (every 
48 hours, over a period of 12 days). The uninfected volunteers (2 male, 2 female) 
were white Caucasian, had a mean age of 24 years (22 – 25 years), with no 
previous history of malaria infection.   
 
3.4.4 RNA Extraction 
RNA extraction was done using the TempusTM Spin RNA Isolation Kit (Applied 
Biosystems). Note that this kit is not compatible for the isolation of small RNAs 
(<200 nt in length), due to the low molecular weight cut-off from the columns 
provided (approximately 200 bp). In brief, samples were thawed at room 
temperature, topped up to 12 mL volumes with 1x PBS (TempusTM Spin RNA 
Isolation Kit) and mixed before centrifugation at 3,000g at 4oC for 30 minutes. The 
supernatant was discarded, and the pellet resuspended in 400 μl of “RNA 
Resuspension Solution” for transferal to a spin filter for a series of 30 second 
centrifugation spins at 16,000g and 4oC, using the wash solutions provided. A 
DNAse treatment step using “AbsoluteRNA wash solution” (Applied Biosystems), for 
20 minutes at room temperature, was included for the removal of genomic DNA. 
The purified RNA was incubated in 100 μl “Nucleic Acid Purification Elution Solution” 
for 2 minutes at 70oC before being eluted off the filter.  
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3.4.5 RNA Quantification and QC 
Samples were quantified by nanodrop (ND-1000, software version 3.5.2) and 
normalised to a final concentration of 50 ng/μl in DEPC H20 (Thermo Fisher 
Scientific), where possible. The ratios of absorbance at A260nm/280nm and 
A260nm/230nm were used to assess sample purity, with an A260/280 ratio of ~2.0 
and an A260/230 ratio of 2.0-2.2 generally accepted as “pure” for RNA. The Agilent 
2100 Bioanalyzer, RNA 6000 Nano chip assay for total eukaryotic RNA (RNA 
concentration range of 25 ng/μl -500 ng/μl) was used to assess the RNA integrity 
number (RIN), as per the manufacturer’s instructions. A RIN value of  7.0 is 
generally accepted as being indicative of high quality RNA for use in downstream 
molecular applications.  
 
3.4.6 Microarray for Whole-blood Transcriptome Analysis 
Preparation of RNA samples for microarray analysis, and running of the microarray 
itself was performed by Dr Robert Holt, and others, at Hologic (Tepnel Pharma 
Services, West Lothian, UK). Data acquisition and sample QC was performed by Dr 
Alasdair Ivens at the University of Edinburgh. 
 
3.4.6.1 Sample Randomisation and Microarray 
RNA samples were randomized and assigned a sample code before shipment to 
Hologic, blinding them to sample identity. This measure was taken to ensure 
unbiased sample-chip positioning, and provides confidence that any differential 
intensity observed is more likely to reflect true differential expression. Samples were 
assessed using the Affymetrix GeneChip® human Transcriptome Array (HTA, 
version 2.0: www.affymetrix.com); designed for improved detection of transcript 
isoforms, compared to previous chip versions. 70% of probes comprising the HTA 
v2.0 are designed to cover exons for coding transcripts, and the remaining 30%, to 
cover exon-exon splice junctions and non-coding transcripts.  
 
3.4.6.2 Data Acquisition and Sample QC  
Data was acquired using the function rma (robust multi-array average) from the 
package affy (Gautier et al. 2004), for background correction and probeset 
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summarisation. Samples were QC analysed using the arrayQualityMetrics package 
in Bioconductor (Kauffmann and Huber 2010). The package utilises three 
visualisation tools to score arrays and identify outliers, namely: the MA plot, the 
boxplot and heatmap. An array was classed as an outlier if it was detected as such 
for two or more of these matrices.  
 
3.4.7 Gene expression analysis 
All steps involved in the conceptual/biological analyses of the host transcriptional 
response were derived from myself, with contribution from my two supervisors. All 
statistical analyses and graphical presentations of the microarray data, were done in 
collaboration with Dr Alasdair Ivens (University of Edinburgh), using R-Bioconductor.  
Samples collected the day before challenge (C -1) served as internal baseline 
controls for the corresponding volunteers, whereas expression values from the four 
uninfected volunteers provided a background cut-off for the level of variance 
expected due to everyday fluctuations in gene expression. Analysis was performed 
on transcripts of known protein-coding function only, and excluded all small RNAs of 
< 200 nt in length (see section 3.4.4). 
 
3.4.7.1 Top 100 most variably expressed genes through time 
In order to determine potential diversity within the cohort, patterns of differential 
gene expression unique to each individual were first assessed. To ensure that even 
the earliest of events would be detected, a list of the top 100 most variably 
expressed genes through time (C -1 through to day of diagnosis) was composed for 
each volunteer. Top 100 gene lists were created by 1) calculating the within-gene 
median expression through the patient time-course (for every gene in the dataset) 2) 
calculating the difference from that median at each time-point in the patient time-
course 3) calculating the variance of these differences, to give one value per gene 
4) sorting genes based on this variance value (high – low), and selecting the top 
100. Volunteer gene lists were selected independently and thus are unique to each 




3.4.7.2 Global gene set analysis 
The global gene set was used for determining overlapping expression profiles within 
the cohort. The gene set was composed by pooling the ‘top 100’ genes for each of 
the 14 volunteers (n = 1,400 genes), and then removing any shared (redundant) 
genes from the list. This resulted in a set of 517 genes for analysis, which was 
applied to all 14 infected, and the 4 uninfected controls. Principle component 
analysis (PCA) was performed on the 517 gene set for 1) all infected, all time-points 
(82 samples) and 2) all infected, diagnosis time-point only (14 samples). PCA plots 
were created in 3 dimensions, using the PCA-prcomp software package (R-
Bioconductor).  
 
3.4.7.3 Analysis of within-volunteer “distance travelled” 
For assessment of the within-volunteer “distance travelled”, Principle Component 
Analysis was performed on each individual, using expression data restricted to the 
517 global gene set. Data was plotted in 2-dimensions: PC1 against PC2, covering 
the largest proportion of variance observed within the volunteer dataset. Once 
plotted, the distance travelled between each sequential time-point in the volunteer 
time-course was calculated using Pythagoras Theorem (a2 + b2 = c2). “Total 
distance” was taken as the sum of each sequential distance travelled, and “final 
distance”, calculated by drawing a direct line between the first time-point and the 
last.  
 
3.4.8 Ingenuity Pathway Analysis 
Ingenuity pathway analysis (IPA) core analysis (IPA®, QIAGEN Redwood City 
www.qiagen.com/ingenuity) was utilised to investigate the canonical pathways 
significantly perturbed during primary P. falciparum infection. IPA utilises the 
Ingenuity knowledge base; built upon a wide range of published information 
including textbooks, reviews, biomedical literature and a variety of public databases 
to provide insight into molecular and chemical interactions in the context of human 
disease and infection.  
 
So as to extend analysis beyond the 517 global gene set, and to give more 
statistical power to the software, all gene features on the array were considered for 
IPA. Genes without annotation, and those encoding small RNAs (< 200 nt in length) 
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were excluded. To investigate pathways associated with the variability in host 
response, analysis was performed on genes differentially expressed between the 
“classical” and “non-classical” responder groups at diagnosis, using an adjusted p-
value cut-off of 0.05. To investigate the pathways associated specifically with 
members of the “classical” and “non-classical” responder groups, individual analysis 
was performed on volunteers 16 and 19, respectively. In this instance, genes 
demonstrating a ≥ 1.5 fold change at diagnosis (relative to median expression) were 
considered. IPA was also used to predict the upstream regulators responsible for 
the gene expression patterns observed in the dataset. The analysis examines the 
known targets of each upstream regulator, and compares the targets’ direction of 
change to expectations derived from the literature. The software then issues a 
prediction of downstream activation or inhibition (z-score). IPA does not make an 
activation or inhibition prediction for the upstream regulator itself, but provides a 
value of significant overlap (Fisher’s Exact p-value), based on known interactions 
from published data. 
 
3.4.9 PfHRPII ELISA 
An ELISA was set up to quantify levels of P. falciparum Histidine Rich Protein II 
(PfHRPII) in the plasma of volunteers. The protocol was modified from that used 
with the commercially available ‘Anti-HRP2 ELISA kit’ (Celllabs), and from that 
previously published (Martin et al. 2009).  In brief, wells of a 96-well ELISA plate 
(BioLegend) were coated with 100 μl anti-HRP2 IgM antibody (1 μg /mL), overnight 
at 4oC and then blocked using 200 μl/ well of Casein buffer (1% w/v casein in PBS, 
Thermo Fisher Scientific) for 2 hours at room temperature. Supernatant was 
removed and wells of the plate washed x3 in 200 μl/ well Casein buffer. 50 μl of 
plasma samples were diluted in an equal volume of Casein buffer before addition to 
the plate. The standard curve was prepared by diluting recombinant PfHRPII protein 
(Dr David Sullivan, John Hopkins University) to 125 ng/mL in PBS and making 1:2 
serial dilutions to cover the range; 125 ng/mL – 0.061 ng/mL. “Blank” wells of PBS 
served as negative controls. Plasma samples, controls and standards were added 
to the plate (in duplicate), and the plate sealed for incubation at room temperature 
for 1 hour. Supernatants were discarded and the plate washed x3 in Casein buffer 
before addition of 100 μl anti-HRPII IgG-HRP conjugate antibody (0.05 μg /mL) to 
each well. The plate was then incubated for 1 hour at room temperature before 3x 
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washes with PBS (200 μl/well). 100 μl of 3,3’,5,5’-tetramethylbenzidine (TMB) 
substrate was then added to each well of the plate, and plate incubated for 5 - 10 
minutes, whilst protected from light. The reaction was stopped with use of 1M 
Sulfuric acid (50 μl/well) and optical densities determined by use of a microplate 
reader (Multiskan Ascent, Lab systems) with wavelength set to 405 nm. Standard 
curves were constructed by plotting mean absorbance of each standard (y-axis) 
against (log10) concentration (ng/mL) on the x-axis and interpolating using the 
Sigmoidal, 4 PL function in GraphPad Prism.  
 
3.4.10 LEGENDplex™ for Quantification of Cytokines/Chemokines in 
Volunteer Plasma 
A chosen set of 12 analytes; CCL2 (MCP1), CXCL9 (MIG) CXCL10 (IP-10), 
Interferon alpha (IFNα), Interferon gamma (IFNγ), Interleukin-1β (IL-1β), Interleukin- 
6 (IL-6), Interleukin-8 (IL-8), Interleukin-10 (IL-10), Interleukin-17 (IL-17), Interleukin 
18 (IL-18) and Tumour necrosis factor alpha (TNFα), were quantified in the plasma 
of volunteers using a custom-designed multiplex assay from BioLegend® 
(www.biolegend.com/legendplex). Plasma collected at time-points spanning the full 
infection time course (including baseline), for 13 of the 14 volunteers was screened. 
These samples, run in duplicate (and with the inclusion of standard and control 
samples) reached maximum kit capacity and hence one volunteer (volunteer #20) 
was excluded. Plasma sample were not collected for the 4 uninfected (baseline) 
controls.  
 
Plasma samples were diluted 1:2, and standard prepared by making 1:4 serial 
dilutions of stock (8-point standard curve). The assay was performed as per the 
manufacturer’s guidelines in 2x 96-well, low protein-binding filter-bottom plates 
(Merck). In brief, wells were wetted with 100 μl of 1x “wash buffer”, plates incubated 
at room temperature for 1 minute, and then placed on a vacuum manifold 
(MultiScreen® HTS, Merck) (≤ 10 Hg applied for 5-10 seconds) for removal of 
residual liquid from the wells. 25 μl of “matrix B” and “assay buffer” was added to the 
standard and test sample wells, respectively, before addition of 25 μl standard and 
plasma to the appropriate wells. The aliquot of mixed beads was vortexed before 
addition to each well on the plate, in 25 μl volumes. Plates were then sealed, 
covered to protect from light and incubated at room temperature for 2 hours, on a 
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plate shaker set to 500 rpm (ThermoMixer C, Eppendorf®).  Following incubation, 
supernatant was filtered from the wells using the vacuum manifold, as before and 
then plate washed x2 with 200 μl/ well of “wash buffer”. 25 μl of detection antibodies 
were added to each well, plate sealed, covered and then incubated for 1 hour before 
the addition of 25 μl of Streptavidin-Phycoerythrin (SA-PE) to each well. Plates were 
incubated for 30 minutes at room temperature, supernatant filtered, and the plate 
washed x2 using 200 μl/well of “wash buffer”. Beads were resuspended in 150 μl 
“wash buffer” using the plate shaker and then transferred, as appropriate, to 2x 
Nunc 96 well v-bottom plates (Scientific Laboratory Supplies) for running on the flow 
cytometer. Fluorescence was measured using an automated plate counter and 
BD™ LSRFortessa™ flow cytometer running FACSDiva™. The PE (575 – 585 nm) 
and APC (660 nm) channels were used for bead classification, according to PMT 
voltages that had been set up in advance, using the “Setup Beads-3” provided with 
the kit.  Samples were read in the order prescribed by a template containing details 
of sample/plate layout, and data analysed using the LEGENDplex™ data analysis 
software provided with the kit. Data is presented as the raw concentrations (pg/mL) 
through time, and as fold-change from baseline, at each subsequent time-point in 
the infection time course. Fold-change was calculated by dividing the concentration 
measured at C +2, C +4, C +6 etc, by the concentration as measured the day before 
challenge (C -1) for each corresponding volunteer. In the event where analytes were 
undetectable, samples were assigned the largest integer below the limit of detection 
for that particular analyte (details of which were provided in the kit manual).  
 
3.4.11 Angiopoietin-2 ELISA 
Levels of Angiopoietin-2 (ANG-2) in volunteer plasma were quantified using the 
Human Angiopoietin-2 Quantikine ELISA kit from R&D Systems, as per the 
manufacturer’s instructions. Plasma collected at baseline (C -1) and day of 
diagnosis for each of the 14 volunteers was assayed in duplicate (n = 56 samples). 
In brief, plasma samples were diluted five-fold using the “Calibrator Diluent” 
provided with the kit, and standard prepared by 2-fold serial dilutions of the standard 
stock (final range; 3,000 pg/mL – 46.9 pg/mL). 100 μl of “Assay Diluent” was added 
to each well of the plate followed by 50 μl of standard, control or sample (to 
appropriate wells) for a 2-hour incubation at room temperature, using a microplate 
shaker (ThermoMixer C, Eppendorf®) set to 500 rpm. Wells were aspirated and 
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washed x4 in 400 μl “Wash Buffer”, ensuring complete removal of liquid after each 
wash. 200 μl of the “Human Angiopoietin-2 Conjugate” was added to each well and 
the plate incubated as before. The plate was washed x4 and then 200 μl of 
“Substrate Solution” was added to each well for 30 minutes incubation at room 
temperature. 50 μl of “Stop Solution” was then added to each well and within 30 
minutes, the optical densities (O.D) were determined with use of a microplate reader 
(Multiskan Ascent, Lab systems), by subtracting readings measured at 570 nm 
wavelength from readings measured at 450 nm wavelength. Sample and standard 
readings were background-corrected by subtracting the mean O.D reading taken 
from duplicate “blank” wells containing 150 μl of “Assay Diluent”. A standard curve 
was constructed by plotting the mean absorbance of each standard (y-axis) against 
concentration (pg/mL) on the x-axis and drawing a line of best fit (R2value = 0.998). 
Levels of ANG-2 in the plasma were read off the curve and multiplied five-fold to 
correct for the original 1:5 dilution made. Data is presented as the mean of duplicate 
samples. 
 
3.4.12 Anti-Cytomegalovirus (CMV) IgG ELISA 
Qualitative assessment of Anti-CMV IgG antibodies in volunteer plasma was done 
using the Anti-CMV IgG Human ELISA Kit from Abcam, as per the manufacturer’s 
guidelines. In brief, plasma samples collected at baseline (C -1) from the 14 infected 
were diluted 1:100 with “IgG Sample Diluent”, and added (in duplicate) in 100 ul 
volumes to wells of the pre-coated plate. 100 μl of the “CMV IgG positive control”, 
“negative control” and “CMV IgG cut-off” solutions were then added, in duplicate and 
two wells of 100 μl PBS served as the substrate “blank”. Wells were covered in foil, 
and incubated for 1 hour at 37oC before aspiration of supernatant and 3x washes 
with 300 μl of 1x “Wash Solution”. Wells were then inverted and blotted to ensure 
removal of residual liquid before addition of 100 μl “CMV anti-IgG HRP conjugate”, 
for incubation at room temperature for 30 minutes. After another 3x washes with 1x 
“Wash Solution”, 100 μl “TMB Substrate Solution” was added to each well, and plate 
incubated for exactly 15 minutes at room temperature, protected from light. “Stop 
Solution” was then added (100 μl/ well) and optical densities read by measuring 
absorbance at both 450 nm and 620 nm on a microplate reader (Multiskan Ascent, 
Lab systems). The mean, background-subtracted absorbance was calculated for 
each sample, and compared to the mean absorbance value of the “CMV IgG Cut-off 
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control”. The “CMV IgG Cut-off control” is a titration of the purified human anti-CMV 
IgG, used for the positive control. Samples were considered positive if their 
absorbance value was >10% over the cut-off value, by converting O.D values to 
Standard Units using the following equation: (mean) absorbance value [x10] / 
(mean) absorbance value for the cut-off control. The cut-off control = 10 standard 
units, samples with < 9 standard units are defined as CMV-negative, and samples 
with > 11 standard units are defined as CMV-positive.  
 
3.5 Results 
3.5.1 Volunteer Characteristics 
Infected volunteers had a mean age of 24 years (ranging 19 – 34 years) and were 
71% Male (table 3.1). Mean time to qPCR detection and thick smear positivity 
(prepatent period) was 5 days (5 – 7 days) and 9 days (7.5 – 10.5 days), 
respectively. Parasitaemia (p/mL) at diagnosis ranged 1,440/mL - 273,247/mL and 
parasite multiplication rates (mean; 10.0 and range; 6.7 – 12.8) were comparable 
with that of previous CHMI studies using P. falciparum 3D7-strain (Roestenberg et 
al. 2012, Sheehy et al. 2013).  
 
Table 3.1 | Volunteer characteristics 
Age Time to qPCR detection Parasite Multiplication Rate Prepatent period
(years) (days) (PMR/48 hours) (days)
12 20 M UK 5.0 12.8 7.5 1,645
13 27 M Belgium 5.0 8.9 10.5 70,368
16 21 M UK 5.0 11.9 10.0 273,247
17 34 M Albania 6.5 6.7 10.5 16,911
18 23 F Switzerland 5.0 11.3 8.5 19,670
19 20 M UK 5.0 9.7 8.5 6,932
20 27 M UK 5.0 12.8 8.5 15,025
22 19 F UK 7.0 6.8 10.0 8,865
24 20 M UK 5.0 9.4 10.0 43,707
26 24 F UK 5.0 9.9 9.0 9,133
27 19 M UK 5.0 11.2 9.0 13,421
106 22 F UK 5.0 11.3 8.5 16,162
206 29 M Kenya 5.0 9.9 10.0 185,576
208 34 M Pakistan 5.5 7.1 9.0 1,440




3.5.2 RNA quality  
The Agilent bioanalyzer software tool calculates RIN scores based on the ratio of 
the ribosomal bands as well as the presence or absence of degradation products. 
RIN values ranged from 6.5 - 9.9 (figure 3.1), with 98% of samples having RIN 
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Figure 3.1 | Bioanalyzer electropherograms of total RNA from two representative samples of highest (A) and lowest (B) achieved RNA 
integrity. Y-axis shows fluorescence units (FU) versus time in seconds (s) on the x-axis. Peaks represent; marker, mRNA, 18s subunit and 
28s subunit ribosomal RNA. ((Plots generated through the bioanalyzer (Agilent Technologies)). 
	
 
Figure 3.1 | Bioanalyzer electropherograms of total RNA from two representative samples of highest (A) and 
lowest (B) achieved RNA integrity. Y-axis shows fluorescence units (FU) against time in seconds (s) on the x-axis. 
Peaks represent; marker, mRNA, 18s subunit and 28s subunit ribosomal RNA. (Plots generated through the 
bioanalyzer (Agilent Technologies)). 
 
3.5.3 Sample Exclusion  
Based on the QC criteria, 7 samples in the microarray dataset were identified as 
outliers. Failed samples included; C -1 and C +4 for volunteer #26, C +2 for 
volunteer #27, C +4 for volunteer #208, C -1 and C +6 for baseline control number 3 
(BC.3) and C +12 for BC.4, resulting in incomplete time-courses for these 
volunteers.  
 
3.5.4 The Host (Whole Blood) Transcriptional Response to P. falciparum 
Infection  
3.5.4.1 Diversity in the host (whole blood) transcriptional response to blood-
stage P. falciparum 
To assess diversity in the host response to P. falciparum infection, a list of the top 
100 most variably expressed genes through time (C -1 through to day of diagnosis) 
was composed for each individual, and thus patterns of gene expression compared. 
Top 100 gene lists are provided for the 14 infected and 4 uninfected volunteers, in 
Appendix 3. In figure 3.2, top 100 genes are presented as heatmaps of the log-2 
fold change (deviation from median expression), through time (positive fold-
changes in red and negative fold-changes in blue).  
 58 
-1 +2 +4 +6 +8 +10 
vol 016 
-1 +4 +6 +8 +10 +10.5 +2 
vol 017 
-1 +4 +6 +8 +10 +10.5 +2 
vol 013 
-1 +4 +6 +8 +9 
vol 027* 
+2 +6 +8 +9 
vol 026* 






















-1 +2 +6 +8 +10 -1 +2 +6 +8 +10 
A 
-7 -6 -5 -4 -3 -2 -1 0  1 2 3 4 5 6 7 
Figure 3.2 (Part A) | Diversity in the host transcriptional response to P. falciparum infection (legend continues on next page)  
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Figure 3 .2 | D ivers i ty in the host 
transcriptional response to P. falciparum 
infection. Heatmaps showing log-2 fold-change 
(deviation from median) of the top 100 most 
variably-expressed genes (rows) through time 
(columns). Infected volunteers are grouped 
based on similarities in expression profile; A) n 
= 8, B) n = 4 and C) n = 2. Also shown are 
heatmaps for the 4 uninfected controls (D). 
Shown in purple is the mean variation (and 
range) of the top 25th percentile of genes for 
each volunteer gene list.  (*) represents 
volunteers who have incomplete time-courses 
due to the exclusion of failed QC samples.  
	
 
                               Figure 3.2  (Parts B, C &D) | Diversity in the host transcriptional response to P. falciparum infection
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Based on these data, 8 of the 14 volunteers responded to P. falciparum malaria 
infection by up-regulating genes typically associated with the innate inflammatory 
response, namely: Interferon-stimulated genes (ISGs), members of the 
inflammasome activation pathway, complement receptors and pattern recognition 
receptors, as has been previously documented in studies of CHMI (Montes de Oca 
et al. 2016, Loughland et al. 2017). Of the most variably expressed genes in this set 
of volunteers, the most strongly up-regulated included CXCL10, a chemokine 
produced by many cells of the immune system in response to stimulation with IFNγ, 
and a biomarker associated with increased risk of cerebral malaria and death in 
infected humans (Jain et al. 2008, Wilson et al. 2011, Gotz et al. 2017). Also among 
the most variably expressed genes were FCγR1 (high affinity IgG Fc receptor); 
SERPING 1, involved in regulation of complement activation; CARD17, a regulator 
of IL-1β production; RSAD2, which encodes a protein of known anti-viral function 
and acts to promote production of Type1 interferons (IFNs) in plasmacytoid DCs, 
and STAT1/STAT2, the signal transducers and transcription activators that mediate 
cell response to IFNs. Interestingly, among the top 12 most variable genes for all 8 
volunteers was CD274 (PDL-1), which encodes an inhibitory ligand which when 
bound to its PD1 receptor, acts to block T cell activation and cytokine production. 
On the other hand, 2 of the 14 volunteers in the cohort had a very different type of 
response, whereby a large proportion of their top 100 genes were suppressed in 
response to infection (figure 3.2, panel C). Genes down-regulated in these 
volunteers included the c-type lectins CLEC4E and CLEC7A, glycoproteins with cell 
signaling properties as well as functions in pattern recognition of mycobacteria and 
pathogenic fungi; ALAS2 and FECH, enzymes involved in the heme biosynthesis 
pathway; GYPA, the major intrinsic membrane protein of the erythrocyte, bearing 
receptors for the MN blood-group antigens, and a range of genes associated with 
cell signaling and metabolism eg LRRK2, MBOAT2 and RGS18. Four of the 
fourteen volunteers did not produce a detectable response in the time frame 
assessed (figure 3.2, panel B). When considering the variance levels for the top 25th 
percentile of “variable” genes (figure 3.2), these 4 individuals had levels comparable 
to that of the uninfected controls (mean variance of the top 25th percentile of genes 
in the 4 uninfected controls = 0.27). Notably, of the volunteers who did respond, 
their responses were undetectable in the blood until 8 days post-infection (C +8). 
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This was a surprising finding, and can perhaps be explained by the 
uncharacteristically low-dose inoculum given to volunteers in this CHMI study (~690 
PEs). Inoculum dose has been shown to be inversely correlated with pre-patent 
period (Glynn and Bradley 1995).  It is difficult to speculate how the 4 unresponsive 
volunteers would have gone on to respond if given more time before initiation of 
drug treatment. Based on their top 100 gene list, volunteer #20 had 54% of genes 
shared with those belonging to larger responder group, and looked as if they were 
trending towards up-regulation of said genes towards the end of their infection time 
course. However, based on variance levels, volunteer #20 was responding no more 
than the uninfected controls. The stringent cut-offs used for diagnosis in studies of 
CHMI (first microscopic detection of parasites), means that volunteer infections are 
terminated when parasitaemias are still magnitudes lower than would be observed 
in the field. Nevertheless, analysis of gene expression patterns, at multiple time-
points in individuals receiving identical immune challenge, has revealed diversity in 
the host response to primary infection with P. falciparum. 
 
3.5.4.2 Dichotomy in the host transcriptional response to blood-stage             
P. falciparum infection 
Having established inter-individual variation in the host response to blood-stage 
infection with P. falciparum, volunteer profiles were compared using a global gene-
set to determine potential groupings within the cohort. For this analysis, the top 100 
genes for each volunteer were pooled to comprise a list of 1,400 genes. Given that 
many of the genes were shared between volunteers however, the final set of (non-
redundant) genes used for analysis totaled just 517. A list of the 517 genes is 
provided in Appendix 4. Based on this global gene set, a heatmap displaying the 
raw expression data for each of the 14 infected, and 4 uninfected volunteers was 
created, allowing for direct comparison between volunteers (figure 3.3, part A). 
Visualising the data this way highlighted a dichotomy in the host response, whereby 
volunteers could be grouped as either “classical responders”: up-regulating clusters 
of genes linked to the onset of inflammation and Interferon responses (n = 8), or as 
“non-classical responders”: suppressing a completely different set of genes (n = 2). 
For the purpose of classification, volunteers that failed to elicit a response in the 
time frame assessed are hereon referred to as “unknowns” (n = 4). Based on their 
top 100 most variable gene lists, the 8 “classical” responders showed a significant 
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overlap in expression profiles, with the two most diverse volunteers in the group 
sharing 79% of genes. These 8 volunteers continued to demonstrate similar 
patterns of expression when the comparison was extended to the global gene set of 
517, as clusters of genes being up- or down-regulated were consistent across all in 
the group. Another two of the volunteers could be also grouped based on a high 
percentage of overlapping genes in the global gene set (volunteer 22 had 59% of 
genes shared with volunteer 19). Importantly, the genes shared between these 
individuals were distinct from those of the 8 “classical” responders and were mostly 
down-regulated in response to infection. For confirmation of groupings by statistical 
means, Principle Component Analysis was performed on the (82) samples 
comprising the infection time courses for each of the 14 infected volunteers (figure 
3.3, part B), as well as the (14) samples taken at the last, day of diagnosis time-
point only (figure 3.3, part C). In PCA plot B a clear divergence is observed, with all 
8 volunteers (in red) grouping separately from the rest of the volunteers at day of 
diagnosis. A similar observation was noted for the two “non-classical” responders (in 
blue) at day of diagnosis, but in the opposite direction along PC1; the Principle 
Component encoding the largest percentage of variance in the dataset. This 
confirmed the two groups to be distinct from one another in their transcriptional 
response to infection with P. falciparum, and thus established the use of the 517 
global gene set for determining host responder status.  
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Figure 3.3 | Dichotomy in the host response to blood-stage P. falciparum infection. A) Heatmap of raw expression data for the 517 genes 
(ordered by variance along the y-axis) through time (x-axis). Volunteers are grouped by similarities in expression profile and colour-coded as 
such; uninfected controls (black), “unknowns” (yellow), “classical” responders (red) and “non-classical” responders (blue). Volunteer I.Ds are 
shown along the top and end-points (diagnosis) for each volunteer are marked by coloured dots along the bottom. B) Principle Component 
Analysis of the same 517 genes for the 82 samples comprising all time-points, for all infected volunteers and C) the 14 samples comprising day 
of diagnosis only (volunteer I.Ds are marked). The variation encoded by each principle component (1, 2 and 3) is presented along each axis, as 
a percentage of the total variation in the dataset.  
 
Figure 3.3 | Dichotomy in the host transcriptional response to blood-stage P. falciparum infection.               
A) Heatmap of raw expression data for th  517 genes (order d by v riance along the y-axis) through time (x-axis). 
Volunteers are grouped by similarities in expression profile and colour-coded as such; uninfected controls (black), 
“unknowns” (yellow), “classical” responders (red) and “non-classical” responders (blue). Volunteer I.Ds are shown 
along the top, and end-po nts (diagnosis) for each volunteer are marked by coloured dots along the bottom.             
B) Principle Component Analysis of the same 517 genes for the 82 samples comprising all time-points, for all 
infected volunteers and C) the 14 samples comprising day of diagnosis only (volunteer I.Ds are marked). The 
variation encoded by each principle component (1, 2 and 3) is presented along each axis, as a percentage of the 
total variation in the dataset.  
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3.5.4.3 Within-volunteer distance travelled  
Another way to distinguish the responder volunteers from the “unknowns” was to 
consider the within-volunteer “distance travelled”, or movement from baseline (C -1), 
through to day of diagnosis. Thus, Principle Component Analysis was performed to 
assess within-volunteer variation, and data plotted in two-dimensions: Principle 
Component 1 (PC1) against Principle Component 2 (PC2), accounting the majority 
of all variation encoded within the volunteer’s dataset. The scaling of each PCA plot 
was set to match, and “distance travelled” between each time point calculated using 
“Pythagoras’ Theorem” as previously described (section 3.4.7.3). Four individual 
PCA plots (one volunteer representative from each transcriptional group) are shown 
in figure 3.4; uninfected control BC.2, “unknown” responder 018, “classical” 
responder 016 and “non-classical” responder 022. Data presented highlights a far 
reduced “distance travelled” in the baseline control (BC.2) and the “unknown” 
responder (018) when compared to that of responder volunteers 16 and 22. This 
analysis was consistent with the classification of the “unknowns” based on their 
levels of gene variance (figure 3.2). A break-down of “distance travelled” and “final 
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Figure 3.4 | Within-volunteer di tance travelled. Analysis was performed using the 517 global gene s t. Data is 
presented in 2- dimensions (PC1 on the x-axis against PC2 on the y-axis). Percentage (%) variance encoded by 
each PC is shown. Plots for one representative volunteer from each response group, plus one baseline control are 
shown; baseline control no. 2 (black), “unknown” volunteer 18 (yellow), “classical” responder volunteer 16 (red) and 
“non-classical” responder volunteer 22 (blue). Distance travelled is scaled as in the key shown above. 
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3.5.5 Hematological perturbations during acute-phase P. falciparum infection  
When investigating inter-individual variation in gene expression patterns in 
peripheral blood, it is important to consider the relative proportions of specific blood 
cell subsets within each individual. Full blood counts (FBCs) were carried out by 
NHS staff in the haematology department at either one of the Churchill or John 
Radcliffe Hospitals in Oxford, at baseline (C -1), C +6 and day of diagnosis (DoD) 
for each volunteer. Measurements of total red and white cell counts per mL of blood, 
as well as a break-down of the contribution from individual leukocyte subsets; 
neutrophils, lymphocytes, monocytes, eosinophils and basophils were provided for 
each volunteer (Table 3.2). 
 
Figure 3.5 (parts A – C) displays mean absolute cell counts within each responder 
group, at baseline, C +6 and day of diagnosis. Within the group of 8 “classical” 
responders; neutrophils, monocytes, eosinophils and basophils were within the 
healthy reference range, and showed little fluctuation in numbers throughout the 
course of infection. A significant drop in lymphocyte numbers (from 2.17x106/mL to 
1.01x106/mL, p = 0.0078) was observed at diagnosis in these volunteers, however 
(figure 3.5, part A). This effect was due to a decrease in lymphocyte counts across 
all volunteers in the group, but was most marked in 3 out of the 8 individuals (16, 17 
and 26), who became lymphopenic at diagnosis (<1x106 lymphocytes/mL of whole 
blood, figure 3.5 part D). Comparison of lymphocyte counts between groups did not 
reveal any significant differences, at any of the three time-points (table 3.2). Within 
the group of 2 “non-classical” responders, mean neutrophil counts were slightly 
below the healthy reference range at baseline and C +6: 1.77x106/mL and 
1.57x106/mL, respectively, but increased at diagnosis (2.76x106/mL, not significant). 
Low neutrophil counts were observed in volunteer 22, specifically. A similar pattern 
was observed for lymphocyte numbers, whereas monocytes, eosinophils and 
basophils showed little fluctuation throughout the course of infection. In the case of 
the 4 “unknown” volunteers, all cell types were within the healthy reference range 
throughout, and showed little fluctuation in numbers. Thus, the only significant 
perturbation observed in response to blood-stage P. falciparum infection was a drop 
in lymphocyte counts at diagnosis, in the 8 “classical” responder volunteers. This 
was also evident when considering the relative blood cell proportions in each 
individual, at diagnosis compared to baseline (figure 3.5, part E and F). Given that 
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lymphopenia is a key feature of inflammatory disease, these data support transcript-
level inflammation in the 8 “classical” responders. However, data also suggest a 
potential influence of differing cell proportions on the transcript-level variation 
observed within the cohort. Thus, in order to validate the diversity in host responses 
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Figure 3.5 | Hematological perturbations during acute-phase P. falciparum malaria infection. Top panel graphs 
show the absolute cell counts for neutrophils, lymphocytes, monocytes, eosinophils and basophils as measured at 
baseline (circles), C +6 (squares) and day of diagnosis (triangles) in the 8 “classical” responders (A), the 2 “non-
classical” responders (B) and the 4 “unknown” volunteers (C). Data is presented as the mean and standard deviation. 
Coloured (horizontal) lines denote the lower cut-off of the healthy reference range for each corresponding cell subset. 
Statistical analysis was done using Wilcoxon signed rank test (** = significant drop in lymphocyte count at diagnosis in 
the “classical” responders, p-value = 0.0078). D) Lymphocyte counts at baseline    (C -1) and day of diagnosis, 
presented for each volunteer in the; “unknowns” (yellow); “classical” responders (red) and “non-classical” responders 
(blue). Green line denotes lymphopenia at <1x106 cells/mL. Volunteer I.Ds for the three “classical” responders who 
became lymphopenic at diagnosis are shown. Bottom panel graphs show the percentage (%) of each cell subset 
contributing to total white cell count (y-axis) for each volunteer (x-axis) at baseline (E) and diagnosis (F). Numbers on 


























































































































Figure 3.5 | Hae atological perturbations during blood-stage P. falciparu  infection. T p panel graphs show 
the absolute cell counts for neutrophils, lymphocytes, mon cytes, eosinophils and basophils r d at 
baseline (circles), C +6 (squar    f i i  t i l ) i  t   l ical” responders (A), the 2 “non-
clas ical” r  (B) and the 4 “unknown” volunteers (C). Data is presented as the me  nd standard 
deviation. Coloured (horizontal) lines denote the lower cut-off of the h althy ref renc  range for each corr sponding 
cell subset. Statistical analysis was done usin  Wilcoxon signed rank test (** = significant drop in lymphocyte cou t 
at diagno is in the “classical” responders, p-value = 0.0078). D) Lymphocyt  counts at baseli e (C -1) and day of 
diagnosis, presented for each volunteer i  the; “unkn ns” (yellow); “classical” responders (red) and “non-classical” 
responders (blue). Green line denotes lymphopenia at <1x106 c lls/mL. Voluntee  I.Ds for the three “classical” 
responders who became lymphopenic at diagnosis are shown. Bottom panel graphs show the p rcentage (%) of 
each cell subset contributing to total white c ll count (y-axis) for each volunteer (x-axis) at baseline (E) a d 
diagnosis (F). Numbers on bars (or attached to bars) denote t e % of cells attribut d to each c ll type. A colour key 
for cell type is provided. 
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Table 3.2 | Full blood count analysis 
 69 
 
3.5.6 Quantification of plasma cytokines and chemokines for validation of 
the host transcriptional response 
A chosen set of 12 analytes; CCL2 (MCP-1), CXCL9 (MIG) CXCL10 (IP-10), IFNα, 
IFNγ, IL-1β, IL- 6, IL-8, IL-10, IL-17, IL-18 and TNFα, were quantified in the plasma 
of volunteers. Analytes selected for analysis were chosen based on their known 
association with inflammation and/or predefined role in human malaria infection and 
thus were used not only to validate the diversity in host transcriptional responses, 
but to try to predict severity of outcome. High levels of the cytokines; TNFα, IFNγ, 
IL-1β, IL-6, IL-8 IL-10 and IL-18 have been reported in both children and adults with 
symptomatic P. falciparum (Day et al. 1999, Lyke et al. 2004, Walther et al. 2006, 
Mirghani et al. 2011), whereas CXCL9, CXCL10 and CCL2 are considered robust 
biomarkers of severe disease (Abrams et al. 2003, Armah et al. 2007, Jain et al. 
2008, Ayimba et al. 2011, Wilson et al. 2011). Plasma samples from 13 of the 14 
infected (volunteer ♯20 excluded due to limited kit capacity) were screened using 
the (custom-designed) LegendPlexTM assay from BioLegend®. Analysis included all 
infection time-points, with samples collected the day before challenge (C -1) 
providing a baseline read-out for each corresponding volunteer. The normalised 
concentrations as measured for all 12 analytes tested, through each individual’s 
time-course of infection can be found in Appendix 6. 
 
Results from this analysis confirmed the diversity in host responses observed at the 
transcript level, with CXCL10 and CXCL9 found elevated (> 1.5-fold from baseline) 
in 8 and 6 of the 8 “classical” responders, respectively (figure 3.6). CCL2 looked to 
be following a similar trend, however this response was less marked (Appendix 6). 
Importantly, CXCL10 was found as the gene most strongly up-regulated in response 
to P. falciparum infection in 6 of the 8 “classical” responders, and was within the top 
4 most strongly up-regulated genes for the group as a whole. The biggest fold-
change observed above baseline for CXCL10 and CXCL9 was in volunteer ♯16; the 
most inflammatory volunteer in the cohort (35-fold and 38-fold, respectively). These 
chemokines are considered robust biomarkers of severe malaria disease, and thus 
results suggest that if left untreated, these 8 volunteers would have likely gone on to 
become seriously ill. IFNγ is thought to be one of the key mediators of the immune 
effector mechanisms essential for initial control of malaria infections in the non-
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immune, but there is also evidence that IFNγ levels need to be carefully balanced to 
avoid immune pathology (Good and Doolan 1999, Plebanski and Hill 2000). 
Interestingly, IFNγ (Type II IFN) was only detected in three of the most inflammatory 
volunteers of the same group (♯16, ♯17 and ♯13), and not until the end of their 
infection time-course (C +10 onwards). The biggest fold-change observed above 
baseline was in volunteer ♯16 (63-fold), followed by volunteer ♯17 (25-fold) and 
volunteer ♯13 (4-fold). INFα (Type I IFN), was detectable in 11 of the 13 volunteers 
screened in this analysis, but demonstrated no trend. Levels of INFα varied little 
throughout infection, and concentrations were observed within a similar range for all 
volunteers (Appendix 6).  
 
Figure 3.6 | Cytokine and Chemokine production during blood-stage P. falciparum infection. 
Levels of CXCL9, CXCL10, IFNα and IFNγ were quantified in volunteer plasma, by multiplex assay 
(BioLegend®). Data is presented as fold-change from baseline (y-axis), at each time-point in infection 
(x-axis) for 13 of the 14 infected volunteers. Volunteers are colour-coded as per transcriptional 
response group: ”unknown” volunteers: 12, 18 and 208 (yellow), “classical” responders: 13, 16, 17, 24, 
26, 27, 106 and 206 (red) and “non-classical” responders: 19 and 22 (blue). Green lines indicate 2-fold 
increase or decrease in concentration relative to baseline (unique to each volunteer). For IFNγ plots, 
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Figure 3.6 | Cytokine and chemokine production during blood-stage P. falciparum infection 
Levels of CXCL9, CXCL10, IFNα and IFNγ were quantified in volunteer plasma, by multiplex assay (BioLegend®). 
Data is presented as fold change from baseline (y-axis), at ach time-point in infection (x-axis) for 13 of the 14 
infected volunteer . Volunteers are colour-coded as per transcriptional response group; ‘unknown” volunteers 12, 
18 and 208 (yellow); “cl ssical” responders 13, 16, 17, 24, 26, 7, 106 and 206 (red); and “non-classical” 
responders 19 and 22 (blue). Green line indicates a 1.5-fold increase in concentration relative to baseline. For the 
IFNγ plot, the volunteer I.Ds for which elevated levels were found, are shown. 
 
 
Figure 3.7 displays the concentrations of CXCL10, CXCL9, CCL2, IFNγ, IFNα, 
TNFα, IL-10, and IL-6 as measured throughout the course of each individual’s 
infection time-course. In volunteers of the “unknown” group (♯18, ♯12, and ♯208), 
the kinetics of cytokine and chemokine production appear to reflect their 
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transcriptional profile whereby no obvious fluctuation in response to infection is 
observed. Where IL-10 appears to be dropping from baseline at certain time-points, 
this is likely explained by concentrations being below or very close to the limit of 
detection (0.8 pg/mL). Observations within the group of 8 “classical” responders 
suggest a kinetic whereby levels of CXCL10, CXCL9, and CCL2 can be found 
elevated from C +8 onwards in the majority of individuals. The response of these 
chemokines occurs in advance of a spike in INFγ as observed in three volunteers, 
suggesting that the early transcript-level IFN-stimulated responses detected from C 
+8 onwards is not being driven by IFNγ in the circulation. When considering that 
levels of IFNα appear similar to the “unknown” volunteers, and that little fluctuation 
is observed throughout infection, results suggest that the whole-blood IFN-signature 
observed in these 8 “classical” responders, is instead being driven by IFNβ (not 
tested), or by IFNs (INFα and/or IFNβ and/or IFNγ) stimulation in host tissue(s). In 
three of the “classical” responders, an increase in IL-10 production (> 2-fold above 
baseline) was also observed for volunteers: ♯16 (19-fold) and ♯27 (3-fold) from C 
+8, and in volunteer ♯17 (4-fold) from C +10. Interestingly, 2 out of 3 of these IL-10 
producers (♯16 and ♯17) were also shown to produce INFγ (figure 3.6). This 
observation is consistent with data showing the two cytokines to be co-regulated 
during the host response to P. falciparum infection (Brustoski et al. 2005, 
Jagannathan et al. 2014, Villegas-Mendez et al. 2016), and may be indicative of 
immune-regulatory mechanisms at play in these inflammatory volunteers. The 
cytokine/chemokine profile for volunteer ♯16 validates transcriptional data 
highlighting this individual as the most inflammatory in the cohort. This volunteer 
demonstrated elevated plasma levels of CCL2, CXCL10, CXCL9, INFγ, IL-10 and 
IL-6; all of which have been associated with symptomatic malaria infection (Day et 
al. 1999, Lyke et al. 2004, Walther et al. 2006, Mirghani et al. 2011). In vivo, IL-6 
and TNFα production has been associated with cerebral malaria (Kwiatkowski et al. 
1990, Wenisch et al. 1999, Lyke et al. 2004). However, elevated levels of TNFα has 
also been linked to parasite clearance and resolution of fever (Kremsner et al. 
1995). TNFα was detected in 11 of the 13 volunteers tested, but at a limited number 
of time-points for each. Its concentration did not appear to fluctuate in response to 
P. falciparum infection, with the exception of volunteer ♯22 of the “non-classical” 
responders whereby a 2.6-fold increase in concentration was observed at their day 
of diagnosis time-point (C +10). It has been suggested that IL-18, along with IL-12, 
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plays an important role in initiating the inflammatory cytokine cascade during acute-
phase infection with P. falciparum, and associations have been reported between 
circulating levels of these cytokines and risk of severe Plasmodium falciparum 
malaria (Malaguarnera et al. 2002). IL-18 was detected at similar concentrations for 
all 13 volunteers screened in this cohort, and concentrations varied little in response 
to P. falciparum infection during the time frame assessed (Appendix 6). 
 
IL-1β was largely undetectable (limit of detection = 0.9 pg/mL) with the exception of 
volunteers ♯12, ♯13, ♯19, ♯22 and ♯208, and no obvious fluctuations in 
concentration were observed throughout infection in these individuals (Appendix 6). 
This was also true for IL-17 (limit of detection = 1.9 pg/mL). Importantly, IL-1β is 
highly unstable (degrades very quickly) ex vivo, which may have affected the ability 
to detect it in volunteer plasma. IL-8 was detectable in just three volunteers, and at a 
maximum of just two time-points for each (limit of detection = 1.0 pg/mL). Thus, due 
to issues of assay sensitivity and/or cytokine instability, I was unable to compare 
levels of these inflammatory mediators in volunteer plasma. Nevertheless, results 
from this analysis validate the diversity in host responses observed at the transcript 
level and confirm, at the protein level, the inflammatory gene signature observed in 
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Figure 3.7 | Kinetics of cytokine and chemokine production during blood-stage P. falciparum infection. Concentrations of CXCL10, CXCL9, CCL2, INFγ, TNFα, IL-10, IFNα and IL-6 were 
quantified in volunteer plasma, by muliplex assay (BioLegend®). Graphs show concentration (pg/mL) of each cytokine (y-axis) through time (x-axis). Plots are shown for three of the four individuals 
in the “unknown” group (panel A), the eight “classical” responder group (panel B) and the two “non-classical” responder group (panel C). Black vertical line denotes day of diagnosis. A colour-key for 
each analyte is provided. 
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3.5.7 Biological pathways affected during P. falciparum blood-stage infection 
Ingenuity pathway analysis (IPA) core analysis was utilised to investigate the 
canonical pathways significantly perturbed during primary P. falciparum infection. 
For this analysis, all gene features on the array (with the exception of those without 
annotation, and those encoding small RNAs <200 nt) were considered. 
3.5.7.1 In the “classical” relative to “non-classical” responders 
In order to investigate the immune signaling pathways associated with the variability 
in host responses, differentially expressed genes (DEGs) between the “classical” 
responders (n = 8), and the “non-classical” responders (n = 2) were considered for 
pathway analysis. Using a p-value < 0.05 (adjusted for multiple comparisons using 
the Benjamini-Hochberg method) resulted in 882 genes differentially expressed 
between the two groups at diagnosis (560 up and 322 down in the “classical” 
responders). Figure 3.8, part A shows the top 20 pathways significantly associated 
with these genes. IFN signalling and activation of the innate inflammatory response 
(Fcγ receptor-mediated phagocytosis, dendritic cell maturation, toll-like receptor 
signaling and activation of the inflammasome) were found enriched within the 
response of the “classical” responder group. Figure 3.8, part B displays the top 20 
upstream regulators associated with the genes differentially expressed between the 
two groups. IFNα (3.9x10-20), STAT1 (9.7x10-19) and IFNγ (9.7x10-16) were predicted 
with greatest significance, acting upstream of 47, 32 and 49 genes in the dataset, 
respectively.  
 
To further dissect the biological pathways associated with the “classical” responder 
group, or the “non-classical” responders specifically, analysis was performed on a 
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Upstream Regulator Molecule Type Predicted Activation State Activation z-score p-value of overlap Number of Target Molecules
Interferon alpha group Activated 3.869 3.93x10 -20 47
STAT1 transcription regulator Activated 4.887 9.74x10 -19 32
IFNG cytokine Activated 5.934 9.73x10 -16 49
TGM2 enzyme Activated 4.61 4.68x10 -11 32
IRF1 transcription regulator Activated 2.598 8.53x10 -10 14
CEBPA transcription regulator Activated 2.706 1.07x10 -9 23
TNF cytokine Activated 5.076 3.07x10 -9 48
RELA transcription regulator Activated 3.517 4.47x10 -9 26
MAPK1 kinase Inhibited -4.191 1.75x10 -8 26
CD40LG cytokine Activated 2.193 4.15x10 -8 17
TLR7/8 group Activated 3.317 3.91x10 -7 11
IL1B cytokine Activated 3.939 5.76x10 -7 25
IRF4 transcription regulator Inhibited -2.491 1.15x10 -6 12
IFNL1 cytokine Activated 3.44 4.64x10 -6 12
PRL cytokine Activated 3.672 4.69x10 -6 14
TLR9 transmembrane receptor Activated 2.164 5.33x10 -6 11
SAFB other Inhibited -2.111 5.33x10 -6 11
NFkB (complex) complex Activated 2.155 5.82x10 -6 26
IRF9 transcription regulator Activated 2.186 6.16x10 -6 6





Figure 3.8 | Canonical Pathways and Upstream Regulators significantly associated with genes 
differentially expressed between the “classical” and “non-classical” responder groups. A) The top 20 most 
significantly-enriched pathways are presented. Bars represent the –log p-value for the statistical test of the 
probability of molecules within the dataset being associated with the canonical pathway by random chance alone 
(Fisher’s exact right-tailed test). Threshold (black vertical line) indicates significance at p = 0.05 (-log p = 1.3). Bar 
shading represents predicted pathway activation (orange), pathway inhibition (blue) or an equal chance of 
activation or inhibition (white), based on the calculated z-score. The ratio of genes differentially expressed in the 
dataset to total number of genes associated with the pathway is shown on the right. B) Top 20 most significantly-
associated molecules predicted to be regulating differential gene expression observed in the dataset (p- value of 
overlap, Fisher’s exact right-tailed test). Predicted activation status, as based on the calculated z-score is shown 
for each, as is as the number of target molecules in the dataset predicted to be affected. (Analysis was generated 




Figure 3.8 | Canonical pathways and upstream regulators significantly associated with gene differentially 
expressed between the "classical" and "non-classical" responder groups. A) The top 20 most significantly-
enriched pathways are presented. Bars represent the –log p-value for the statistical test of the probability of 
molecules within he datase  being a s ciated with the canonical pathway by random chance alone (Fisher’s exact 
right-tailed test). Threshold (black vertical line) indicates significance at p = 0.05 (-log p = 1.3). Bar shading 
represents predicted pathway activation (orange), pathway inhibition (blue) or an equal chance of activation or 
inhibition (white), based on the calculated z-score. The ratio of genes differentially expressed in the dataset to total 
number of genes associated with the pathway is shown on the right. B) Top 20 most significantly-associated 
molecules predicted to be regulating differential gene expression observed in the dataset (p- value of overlap, 
Fisher’s exact right-tailed test). Predicted activation status, as based on the calculated z-score is shown for each, as 
is as the mber of target molecules in the dataset predicted to be affected. (Analysis was generated through use of 




3.5.7.2 In the “classical” responder volunteer ♯16 
Genes demonstrating a ≥ 1.5 fold increase over median expression at diagnosis, in 
volunteer ♯16 were considered for analysis. Using this fold-change cut-off resulted 
in 762 genes (531 up and 231 down) differentially expressed in this volunteer. 
Figure 3.9 shows the top 20 most significantly enriched pathways associated with 
their response. “Interferon signaling” was the most significantly enriched (p = 
2.44x10-14) with 44% of genes associated with this pathway (16 out of 36) found 
differentially expressed in response to P. falciparum infection in this volunteer (figure 
3.9). The observed effect was due to the genes; BAK1, IFI6, IFI35, IFIT1, IFIT3, 
IFITM1, IRF1, ISG15, JAK2, MX1, OAS1, PSMB8, SOCS1, STAT1, STAT2, and 
TAP1, all of which were up-regulated. Interferons (IFN) are cytokines that play a 
central role in initiating immune responses, most commonly associated with the 
antiviral response. They are divided into three classes: Type I (predominantly IFN-α, 
-β and -κ), Type II (IFN-γ) and Type III (IFN-λ1 and -λ2 also known as IL-28 and IL-
29) (Ivashkiv and Donlin 2014). The Interferon Signalling pathway is initiated upon 
binding of Type I and Type II IFNs to IFNAα1/2 and/or IFNγR2, and activation of the 
tyrosine kinases JAK1, JAK2 or TYK2 (figure 3.10). In the case of Type I IFNs, both 
STAT1 and STAT2 are required to form a heterodimer which, once phosphorylated, 
associates with IFN gene regulatory factor-9 (IRF-9) (Yan et al. 1996). The resultant 
trimeric transcription factor, ISGF3, binds to the IFN-stimulated regulatory elements 
(ISREs) to induce the expression of many IFN-α/β-regulated genes (Schneider et al. 
2014). Both STAT1 and STAT2 were found strongly up-regulated in the dataset, 
suggesting a key role of Type I IFNs in the response of the “classical” responders. 
Furthermore, increased expression of the cytosolic PRRs DDX58 (RIG-I) and IFIH1 
(MDA-5) was observed within the group of volunteers (figure 3.11 and top 100 gene 
lists). These receptors are responsible for the recognition of RNA and are highly 
associated with the induction of Type I IFNs. (McNab et al. 2015). Importantly, Type 
I IFN responses have been previously reported in a study of CHMI with P. 
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Figure 3.9 | Canonical pathways significantly enriched in volunteer 16 of the “classical” responder group. The top 20 
most significantly-enriched pathways are presented. Bars represent the –log p-value for the statistical test of the probability of 
molecules within the dataset being associated with the canonical pathway by random chance alone (Fisher’s exact right-tailed 
test). Threshold (black vertical line) indicates significance at p = 0.05 (-log p = 1.3). Bar shading represents predicted pathway 
activation (orange), pathway inhibition (blue) or an equal chance of activation or inhibition (white) based on the calculated z-score. 
The ratio of genes differentially expressed in the dataset to total number of genes associated with each pathway is shown on the 
right. (Analysis was generated through use of QIAGEN’S Ingenuity Pathway Analysis (IPA®, Qiagen, Redwood City, 
www.qiagen.com/ingenuity)) 
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test of the probability of molecules within the dataset being associated with the canonical pathway by random 
chance alone (Fisher’s ex ct right-ta led test). Threshold (black verti l line) indic es s gnificance at p = 0.05 (-log p 
= 1.3). Bar shading represents predicted pathway activation (orange), pathway inhibition (blue) or an equal chance 
of activation or inhibition (white) based on the calculated z-score. The ratio of genes differentially expressed in the 
dataset to total number of genes associated with each pathway is shown on the right. (Analysis was generated 
through use of QIAGEN’S Ingenuity Pathway Analysis (IPA®, Qiagen, Redwood City.www.qiagen.com/ingenuity)). 
 
Figure 3.10 | Interferon (IFN) Signalling Pathway. Interferon signalling pathway initiated through binding of Type I and Type II IFNs to 
IFNαR1/2 and INFγR (receptors) respectively. Red colour-shading indicates molecules that are up-regulated in the dataset, with double-
borders in purple indicating protein complexes affected by the differentially expressed genes. Pathway analysis was generated through 
the use of QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity)  
 
Figure 3.10 | Interferon (IFN) signalling pathway. Interferon signalling pathway initiated through binding of Type I 
and Type II IFNs to IFNαR1/2 and INFγR (receptors) respectively. Red colour-shading indicates molecules that are 
up-regulated in the datas t, with double-borders in purple indicat ng protein c pl xes affected by the differentially 
expressed genes. Pathway analysis was generated through the use of QIAGEN’s Ingenuity Pathway Analysis 
(IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity)). 
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Figure 3.11 | Pattern Recognition Receptors Involved in Recognition of Blood-Stage P. falciparum. Recognition of conserved microbial structures and PAMPs by membrane-
bound and cytosolic PRRs of the innate immune system, resulting in downstream proinflammatory cytokine production. Red color shading indicates genes that are upregulated in 
the dataset, with double-borders in pink indicating protein complexes affected by the differentially expressed genes. Pathway analysis was generated through the use of QIAGEN’s 





Figure 3.11 | Pattern Recognition Receptors involved in recogniti n of bl od-stage P. falciparum. Recognition of conserved microbial and PAMPs by membrane-bound and 
cytosolic PRRs of the innate immune system, resulting in downstream proinflammatory cytokine production. Red color shading indicates genes that are upregulated in the dataset, with double-
borders in pink indicating protein complexes affected by the differentially expressed genes. Pathwa  analy is was generated through the use of QIAGEN’s Ing nuity Pathway Analysis (IPA® 
QIAGEN,Redwood City, www.qiagen.com/ingenuity). 
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The Inflammasome signaling pathway was also significantly enriched (p = 3.9x10-6) 
with 35% of genes (7 out of 20) in the pathway differentially expressed (figure 3.9). 
The observed effect was due to the genes: AIM2, CASP1, CASP5, IL-1β, NOD2, 
P2RX7 and TLR4, all of which were found up-regulated. Inflammasomes are 
immune system complexes that regulate the activation of caspase-1 upon sensing 
of infectious microbes. Several families of PRRs can serve as nucleators of 
inflammasome complexes, including the absent in melanoma 2 (AIM)-like receptors, 
found up-regulated in the dataset (figure 3.12) (Latz 2010). Activation of the 
inflammasome pathway via AIM2, suggests recognition of parasite nucleic acids in 
the cytosol, consistent with the observed up-regulation of the cytosolic PRRs; RIG-I 
and MDA-5. Also found up-regulated in the dataset were three key molecules of the 
NLRP1 and NLRP3 inflammasome complexes; NOD2, caspase-1 and caspase-5. 
Upon sensing pathological stimuli, the relevant NOD-like receptor (NLR) or AIM2 
oligomerise with scaffold protein ASC, which then binds and activates pro-caspase-
1. Active caspase-1 functions to cleave the pro-inflammatory IL-1 family of cytokines 
into their bioactive forms; IL-1β and IL-18 and as a consequence, leads to 
pyroptosis (Latz 2010). Thus activation of inflammasomes has been implicated in a 
variety of inflammatory processes and disorders, including that of Plasmodium 
malaria infection (Ataide et al. 2014, Kalantari et al. 2014, Hirako et al. 2015). In line 
with this very inflammatory response, TREM-1 signalling was the third most 
significantly associated pathway in this volunteer (figure 3.9). When activated, 
triggering receptor expressed on myeloid cells 1 (TREM-1) acts to amplify neutrophil 
and monocyte-mediated inflammatory responses through the recruitment of adaptor 
proteins such as DAP-12 (Bouchon et al. 2000), thereby promoting the production of 
pro-inflammatory cytokines, as well as increased surface expression of cell 
activation markers (Charles et al. 2016). In the context of human malaria infection, 
high plasma levels of sTREM-1 have been shown to predispose patients to a 
phenotype of severe disease (Adukpo et al. 2016). Taken together, results suggest 
a model whereby cells of the innate immune system, upon detection of parasite 
nucleic acids, stimulate production of IFNs and other pro-inflammatory cytokines, 
leading to inflammation and, most likely, damaging effects to the host. However, this 
response was only observed in 8 of the 14 infected volunteers.  
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Figure 3.12 | Inflammasome Signalling Pathway. Initiation of inflammasome assembly/activation in the cytosol after sensing of pathogen-associated molecular patterns 
(PAMPs) or danger-associated molecular patterns (DAMPs). Red color shading indicates genes that are upregulated in the dataset, with double-borders in pink indicating 
protein complexes affected by the differentially expressed genes. Pathway analysis was generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA® QIAGEN, 
Redwood City, www.qiagen.com/ingenuity)  
 
Figure 3.12 | Inflammasome Signalling Pathway. Initiation of inflammasome assembly/activation in the cytosol after sensing of pathogen-associated molecular patterns (PAMPs) or danger-
associated molecular patterns (DAMPs). Red color shading indicates genes that are upregulated in the dataset, with double-borders in pink indicating protein complexes affected by the differentially 
expressed genes. Pathway analysis was generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA® QIAGEN, Redwood City, www.qiagen.com/ingenuity). 
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3.5.7.3 In the “non-classical” responder volunteer ♯19 
Pathway analysis was also performed on volunteer ♯19 of the “non-classical” 
responders. Using a fold-change cut-off of 1.5 resulted in 797 genes differentially 
expressed at diagnosis (104 up and 693 down) in this volunteer. Figure 3.13 
displays the top 20 pathways associated with their response. Interestingly, several 
of the most significantly overrepresented pathways overlapped with that of 
“classical” responder ♯16, but had opposing activity. Within the top 20 were: the 
inflammasome pathway, TREM-1 signaling, Nf-κβ and Toll-like receptor signaling, 
all of which were inhibited in response to P. falciparum blood-stage infection. 
Inhibition of inflammasome signaling was associated with the down-regulation of 
CASP1, CASP5, CASP8, NAIP and NLRP3, encompassing 25% of molecules in the 
pathway. Expression of TREM-1 was also repressed. Thus, the response in the 
“non-classical” volunteers appeared to be a highly suppressive one, in contrast to 
that of the “classical” responders. The most significantly enriched pathway in this 
volunteer was that of death receptor signaling (figure 3.13). The observed effect was 
due to 11 genes; APAF1, BIRC2, CASP8, CFLAR, NAIP, PARP8, PARP14, 
PARP15, ROCK1, TANK and TNFSF10, all of which were down-regulated. 
Apoptosis can be induced through the activation of death receptors including Fas, 
TNFαR, DR3, DR4, and DR5 by their respective ligands (figure 3.14). Death 
receptor ligands characteristically initiate signaling for the recruitment of specialised 
adaptor proteins and activation of caspase cascades. Activation of caspase-8, for 
instance, stimulates apoptosis via two parallel cascades: it can directly cleave and 
activate caspase-3, or alternatively, it can cleave Bid, a pro-apoptotic Bcl-2 family 
protein. Truncated Bid (tBid) translocates to mitochondria, leading to activation of 
caspase-9 and -3.  Activation of caspase-3 leads to downstream signaling, and 
apoptosis of cells (Kaufmann et al. 2012). Programmed cell death plays a crucial 
role in development and tissue homeostasis. It has also been shown to serve a 
protective role, by eliminating cells that are abnormal and potentially dangerous 
(Fuchs and Steller 2011). Thus, abnormal regulation of this process may prove 
detrimental to the host, but it is yet unclear what effect this may have in the context 
of P. falciparum malaria infection.  
 
It is reasonable to hypothesise that by suppressing the activity of the innate immune 
response early in infection, volunteers ♯19 and ♯22 may demonstrate a reduced 
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ability to control parasite growth in the circulation. Or vice versa, parasite growth 
kinetics may influence the type of host response produced. Thus, it was important to 
consider a potential correlation between host responder status and parasite growth 
kinetics in the blood. 
 
Figure 3.13 | Canonical pathways significantly enriched in volunteer 19 of the “non-classical” responder 
group. The top 20 most significantly-enriched pathways are presented. Bars represent the –log p-value for the 
statistical test of the probability of molecules within the dataset being associated with the canonical pathway by 
random chance alone (Fisher’s exact right-tailed test). Threshold (black vertical line) indicates significance at p 
= 0.05 (-log p = 1.3). Bar shading represents predicted pathway activation (orange), pathway inhibition (blue) or 
an equal chance of activation or inhibition (white), based on the calculated z-score. The ratio of genes 
differentially expressed in the dataset to total number of genes associated with the pathway is shown on the 
right. (Analysis was generated through use of QIAGEN’S Ingenuity Pathway Analysis (IPA ®, Qiagen, Redwood 
City, www.qiagen.com/ingenuity)) 
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Figure 3.13 | Canonical pathways significantly enriched in volunteer ♯19 of the "non-classical" responder 
group. The top 20 most significantly-enriched pathways are presented. Bars represent the –log p-value for the 
statistical test of the probability of molecules within the dataset being associated with the canonical pathway by 
random chance alone (Fisher’s exact right-tailed test). Threshold (black vertical line) indicates significance at p = 
0.05 (-log p = 1.3). Bar shading represents predicted pathway activation (orange), pathway inhibition (blue) or an 
equal chance of activation or inhibition (white), based on the calculated z-score. The ratio of genes differentially 
expressed in the dataset to total number of genes associated with the pathway is shown on the right. (Analysis was 





Figure 3.14 | Death receptor signalling pathway, triggering downstream apoptotic or survival signals. 
Green color shading indicates genes that are downregulated in the dataset, with double-borders in pink 
indicating protein complexes affected by the differentially expressed genes. Pathway analysis was 
generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA® QIAGEN, Redwood City, 
www.qiagen.com/ingenuity)  
 
Figure 3.14 | Death receptor signalling pathway. Green color shading indicates genes that are downregulated in 
the dataset, with double-borders in pink indicating protein complexes affected by the differentially expressed genes. 
Pathway analysis was generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA® QIAGEN, 




3.5.8 Relationship between host responder status and parasite growth in the 
blood 
Observations from populations of repeated malaria exposure have suggested that 
innate immunity is triggered when parasite density surpasses a predefined threshold 
(Kwiatkowski and Nowak 1991). This hypothesis is extremely difficult to investigate 
in the setting of natural infection. In studies of CHMI however, volunteers are 
monitored from as early as day 1 post-infection, allowing for detection of immune 
events at the onset. Moreover, volunteers were sampled twice daily, for 
quantification of parasites in the circulation. Figure 3.15, part A compares parasite 
densities between two volunteers; one who failed to elicit a response (volunteer 
♯18), and one of the most inflammatory volunteers in the cohort (volunteer ♯17), as 
measured at the time-point when activation of the innate immune response was first 
detected (8 days post-infection). Volunteer ♯17 initiated a detectable immune 
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response to 157 p/mL, whereas volunteer ♯18 failed to elicit a response to                  
P. falciparum at a density far greater (8,735 p/mL). Furthermore, day of diagnosis 
parasitaemias for the other three “unknown” responders; ♯12, ♯20 and ♯208, were 
higher than those observed for volunteer ♯17 at C +8 (1,645 p/mL, 15, 025 p/mL and 
1,440 p/mL respectively). Thus, results suggest that there is a parasite density 
threshold for the onset of the innate immune response, but that this threshold is 
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Figure 3.15 | Relationship between host transcriptional status and parasite growth in the blood cycle. 
Parasites/mL of blood (y-axis) as quantified by qPCR are shown against time on the x-axis. A) Parasite growth 
curves for “unknown” responder; 18 (yellow), and “classical” responder; 17 (red). Parasites/mL as measured at 8 
days post infection is shown for each. B) Parasite growth curves for all 14 infected volunteers, colour-coded 
according to parasite multiplication rate: <8 (slow/purple), 8 – 10 (intermediate/grey) and >10 (fast/green) and 
according to transcriptional response group; “unknowns” (yellow), “classical” responders (red) and “non-classical” 
responders (blue) in C. D) Parasite growth curves for volunteers 17, 18 and 19, colour-coded as per transcriptional 
response group. Day of diagnosis parasitaemias (p/mL) are shown for each. Horizontal purple line represents the 
qPCR lower limit of quantification at 20 p/mL. 
 
 
One major advantage of the blood-stage CHMI model is the ability to control for the 
dose and timing of parasites entering host circulation, allowing for more accurate 
modelling of parasite growth with each 48-hour cycle of replication in the blood 
(Douglas et al. 2013). Considering the diversity of transcriptional responses 
observed in this volunteer cohort, parasite multiplication rates (PMR) (Table 3.1) 
were used to investigate the relationship between host responder status, and 
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parasite growth in the blood. Volunteers were grouped as having either slow, 
intermediate or fast-growing parasites using arbitrary cut-offs for PMR: <8, 8 – 10, 
>10 respectively. Figure 3.15, parts B and C show parasite densities (p/mL) plotted 
against time, for the 14 volunteers. When colour-coded according to PMR (part B), a 
clear pattern is observed. This pattern, however, is completely lost when volunteers 
are re-colour-coded according to transcriptional response profile: “unknowns” in 
yellow, “classical” responders in red, and “non-classical” responders in blue (part C). 
These results suggest that there is no direct relationship between host 
transcriptional responder status, and PMR in the circulation. Given that the majority 
of all transcriptional events were recorded in the last two time-points of infection, 
parasite densities measured at day of diagnosis were compared to determine any 
influence on volunteer responder status. The parasite density measured at 
diagnosis for the “classical” responders (median = 30,309 p/mL) was found to be 
higher than that of the two other groups (“non-classical” responders = 7,899 and 
“unknowns” = 8,335) (Table 3.3), which likely reflects the longer prepatent period 
(time to thick film smear positivity) observed for these volunteers (median = 10.0 
days). However, parasite densities were highly variable between individuals within 
the same group, and were not sufficient to explain the inflammatory response of the 
“classical” responders considering that volunteers of the unresponsive “unknown” 
group had comparable parasites/mL when assessed at the individual level (figure 
3.16). Figure 3.15, part D highlights the diverse range of p/mL recorded at day of 
diagnosis, in three representative volunteers (one “classical” responder (♯17), one 
“non-classical responder (♯19) and one “unknown” volunteer (♯18)). Of these three, 
the highest parasite density was observed in the unresponsive, “unknown” volunteer 
♯18 (19,670 p/mL). Results therefore suggest that the diversity in host immune 
responses to blood-stage P. falciparum infection is not being driven by differences in 
parasite growth, or densities at time of sampling.  
 
Table 3.3 | Parasite growth parameters by host transcriptional response group 
"classical" responders "non-classical" responders "unknown" volunteers All volunteers 
Number in group 8 2 4 14
Median time to qPCR detection in days (range) 5.0 (5.0 - 6.5) 6.0 (5.0 - 7.0) 5.0 (no range) 5.0 (5.0 - 7.0)
Median Parasite Multiplication Rate (range) 9.9 (6.7 - 11.9) 8.3 (6.8 - 9.7) 12.1 (7.1 - 12.8) 9.9 (6.7 - 12.8)
Median prepatant period in days (range) 10.0 (8.5 - 10.5) 9.0 (8.5 - 10.0) 8.5 (7.5 - 9.0) 9.0  (7.5 - 10.5)
Median parasite density (p/mL) at diagnosis (range) 30,309 (9,133 - 273,247) 7,899 (6,932 - 8,865) 8,335 (1,645 - 19,670) 15,594 (1,440 - 273,247)  
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Figure 3.16 | Parasite growth curves. Graphs show number of parasites per 
mL of blood (y-axis) through time (x-axis), as measured by qPCR. Plots are 
shown for each individual in the “unknown” group (panel A), the “non-classical” 
responder group (panel B) and the “classical” responder group (panel C). The 
parasite multiplications rate (PMR) and parasitaemia at day of diagnosis 
(vertical red line) is shown for each volunteer. Dashed purple line represents 
the qPCR lower limit of quantification (20 p/mL).  













Figure 3.16 | Parasite growth curves (legend above). 
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One of the key pathological features of P. falciparum infection is that the mature 
blood stage parasites (pigmented trophozoites and schizonts) are sequestered in 
the microvasculature (Miller et al. 2002). Thus, recognising that the above analysis 
was limited to monitoring parasite numbers only in the circulation, an ELISA was set 
up to quantify levels of P. falciparum Histidine Rich protein II (PfHRPII) in volunteer 
plasma, as a more accurate read-out of total parasite burden (Dondorp et al. 2005) 
(see methods section 3.4.9). PfHRPII is a falciparum-specific antigen, produced in 
all blood-stages of the parasites life-cycle (Parra et al. 1991). A substantial amount 
of the water-soluble protein is secreted by the parasite, into the host bloodstream 
during infection, allowing for its detection and quantification. However, screening of 
PfHRPII is carried out, most commonly, by rapid diagnostic testing in populations of 
natural infection where parasite densities typically reach 2 - 3 orders of magnitude 
higher levels than those observed in studies of CHMI. Figure 3.17 displays the 12-
point standard curve of recombinant PfHRPII used for quantification in the ELISA 
(dilution range = 125 – 0.06 ng/mL, R2 = 0.993). In order to conserve precious 
samples, the ELISA was first tested on plasma collected on day of diagnosis (peak 
parasitaemia) for volunteer ♯16, demonstrating the highest observed parasite 
density within the cohort (273,247 p/mL). PfHRPII was undetectable in this sample, 
suggesting that the ELISA method is not sensitive enough to detect this parasite 
protein at the low level parasitaemias typically observed in volunteers following 
CHMI. Nevertheless, studies carried out in the field have shown a direct correlation 
between parasite numbers in the circulation as measured by qPCR, and levels of 
PfHRPII in the plasma of patients (Silamut and White 1993, Dondorp et al. 2005, 
Dobbs et al. 2017). Thus, considering that there is no association between parasite 
numbers in the circulation and host responder status in this cohort of volunteers, I 
would not expect total parasite burden to be a determinant of host responder status 
at this early stage of infection. 
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R2 = 0.993  
Figure 3.17 | Sigmoidal curve of the (log10) PfHRP2 ELISA standard 
concentrations (125 – 0.06 ng/mL range) on the x-axis against 
absorbance (O.D) on the y-axis. Interpolation was done using the 
Sigmoidal, 4PL function in GraphPad Prism. R2 value is shown in green, 
with dashed lines representing the upper and lower 95% confidence 
intervals.  
 
Figure 3.17 | Sigmoidal curve of the (log10) PfHRPII ELISA standard concentrations (125 – 0.06 ng/mL range) 
on the x-axis against absorbance (O.D) on the y-axis. Interpolation was done using the Sigmoidal, 4PL function in 
GraphPad Prism. R2 value is shown in green, with dashed lines representing the upper and lower 95% confidence 
intervals. 
 
3.5.9 Relationship between host responder status and CMV positivity 
There is evidence to suggest that microbial exposure (or past infection history) is a 
likely driver of immune variation, and a particularly robust example is that of 
cytomegalovirus (CMV), a viral infection that has marked effects on the immune 
phenotypes of humans (Sylwester et al. 2005, Brodin et al. 2015, Shmeleva et al. 
2015). The prevalence of human CMV infection varies greatly depending on 
geographic and socioeconomic backgrounds of the population, but has been 
recognised in every human population studied (Krech et al. 1971, Nankervis 1976). 
Given the observed heterogeneity in immune responses, anti-CMV IgG 
seropositivity was assessed in volunteers, to investigate a potential relationship with 
responder status. 
 
Table 3.4 displays the calculated ELISA standard units, relative to the anti-CMV IgG 
“cut-off control” (see section 3.4.12). Results show that 5 out of 14 (35%) of 
volunteers were positive for anti-CMV IgG (standard units > 11). Although 4 of the 5 
positive volunteers fall within the “classical” responder group, CMV seropositivity 
cannot be used to explain the transcriptional response groups observed, as the four 
remaining “classical” responders are negative for anti-CMV IgG. Furthermore, a 
higher proportion of volunteers in the cohort belong to the “classical” responder 
group compared to any other, thereby increasing the likelihood of finding CMV-
positive individuals within this group. Interestingly, volunteers who were positive for 
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anti-CMV IgG by ELISA (n = 5) were found to have significantly lower parasite 
multiplication rates (PMR/48 hours) when compared to volunteers that were 
negative for anti-CMV IgG (n = 9) (figure 3.18). However, this will need to be tested 
on a larger number of volunteers to determine true significance. There was no 
significant difference in the parasite densities observed at diagnosis between the 
two groups (figure 3.18).  
 
Table 3.4| Volunteer anti-CMV IgG seropositivity status 
12 2.4 N 1,645 12.8
13 33.5 Y 70,368 8.9
16 2.2 N 273,247 11.9
17 49.6 Y 16,911 6.7
18 1.6 N 19,670 11.3
19 1.8 N 6,932 9.7
20 2.2 N 15,025 12.8
22 3.0 N 8,865 6.8
24 30.03 Y 43,707 9.4
26 9.7 N 9,133 9.9
27 2.5 N 13,421 11.2
106 2.3 N 16,162 11.3
206 34.4 Y 185,576 9.9
208 33.7 Y 1,440 7.1



























































p = 0.02 (*) 
Figure 3.18 | Relationship between CMV seropositivity and parasite growth in the blood. Anti-CMV IgG seropositivity 
was assessed in each volunteer by ELISA, using baseline (C -1) plasma samples from the 14 infected volunteers. Data 
shown are the mean and standard deviations of comparisons between parasite densities (parasites/mL at diagnosis) in the 
anti-CMV IgG negative volunteers (n = 9) and anti-CMV IgG positive volunteers (n = 5) (A), and between Parasite 
Multiplication Rates (PMR/48 hours) in B. Volunteers have been colour-coded as per transcriptional response group; 
“classical” responders in red, ‘non-classical” responders in blue and “unknown” volunteers in yellow. Comparisons were 
made using unpaired non-parametric Mann-Whitney U test.  *P < 0.05. NS = Not significant.  
p = 0.30 (NS) 
 
Figure 3.18 | Relationship between CMV seropositivity and parasite growth in the blood. Anti-CMV IgG 
seropositivity was assessed in each volunteer by ELISA, using baseline (C -1) plas a samples from the 14 infected 
volunteers. Data shown are the median and standard deviations of pairwise comparisons between parasite 
densities (parasites/mL at diagnosis) in the anti-CMV IgG negative volunteers (n = 9) and anti-CMV IgG positive 
volunteers (n = 5) (A), and between Parasite Multiplication Rates (PMR/48 hours) in B. Volunteers have been 
colour-coded as per transcriptional response group; “classical” responders in red, “non-classical” responders in blue 
and “unknown” volunteers in yellow. Comparisons were made using non-parametric Mann-Whitney U test. *P < 




3.5.10 Relationship between host responder status and clinical outcome 
As is standard protocol during CHMI, volunteers were safety-assessed at each clinic 
visit, by monitoring temperature, heart rate and blood pressure. With the exception 
of fever in one “classical” responder (volunteer ♯17) on day of diagnosis (figure 
3.19), no marked changes were observed in any volunteer safety measurements 
throughout the duration of infection (see Appendix 7 for volunteer clinical data). At 
baseline, C +6 and diagnosis, volunteers were also screened for perturbations in the 
biochemical markers; sodium, potassium, urea, creatinine, bilirubin, alanine 
aminotransferase (ATL), alkaline phosphatase (ALP), albumin and haemoglobin. 
Analysis of volunteer biochemistry was performed across the groups to determine 
any associated signs of liver dysfunction. With the exception of a drop in albumin 
levels at C +6 days post-infection, in the “classical” responders, no significant 
changes in biochemistry were observed in any of the volunteers, in response to 
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Figure 3.19 | Volunteer temperatures (oC) during acute-phase P. 
falciparum infection. Graphs show volunteer temperature (y-axis) measured 
at twice-daily clinic visits, presented as days post-infection on the x-axis, for 
each individual in the “unknown” group (panel A), the “non-classical” 
responder group (panel B) and the “classical” responder group (panel C).  
Red line represents temperature indicative of fever (37.6oC). Red dot 
highlights fever in volunteer 017, at day of diagnosis.  















Figure 3.19 | Volunteer temperatures (oC) during acute-phase P. falciparum infection (see legend above)
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Table 3.5 | Table of volunteer Biochemistry 
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Angiopoietin-2 (ANG-2) is a secreted glycoprotein that plays a complex role in 
angiogenesis and inflammation. As a marker of endothelial cell activation, serum 
levels of ANG-2 in healthy individuals are normally low, whereas increased levels 
are associated with disease states that cause inflammation and vascular 
permeability (Fagiani and Christofori 2013). In the context of malaria infection, 
increased levels of ANG-2 have been widely associated with severe clinical 
outcome (Viebig et al. 2005, Yeo et al. 2008) and more recently, as a predictor of 
mortality in patients presenting with cerebral malaria (Lovegrove et al. 2009, Conroy 
et al. 2012). Therefore, to assess the relationship between host responder status 
and clinical outcome, an ELISA was used to quantify levels of ANG-2 in the plasma 
of volunteers. A mean concentration of 2,352.62 pg/mL ANG-2 was detected in 
volunteer plasma at baseline (C -1), and demonstrated little increase in response to 
P. falciparum infection (2,407.23 pg/mL at diagnosis) (figure 3.20, part A). Moreover, 
ANG-2 concentrations were comparable between the “classical” responder, “non-
classical” responder and “unknown” groups at diagnosis (figure 3.20, part B), and 
showed no significant correlation with parasitaemia (figure 3.20, part C). 
Interestingly, a 1.6-fold increase in ANG-2 levels was detected in volunteer ♯16 at 
diagnosis; the most inflammatory responder in the cohort (Table 3.6). Although only 
observed in one volunteer, it may be indicative of increased ANG-2 production in 
response to systemic inflammation, or increasing parasite sequestration, and 
endothelial cell activation. Therefore, it will be important to validate these findings in 
a larger cohort of individuals.  
 
Table 3.6 | Angiopoietin-2 levels at C -1 and diagnosis 
Volunteer I.D C -1 Diagnosis Fold change at Diagnosis 
18 1913.33 2032.08 1.06
12 3357.08 3457.08 1.03
208 1461.25 1686.25 1.15
20 1938.33 2457.08 1.27
Group Mean 2167.50 2408.13 1.11
16 3069.58 4884.17 1.61
17 1513.33 2236.25 1.48
13 3523.75 2046.67 1.35
27 2105.00 2067.50 0.98
26 2180.00 1840.42 0.84
206 2742.50 1952.92 0.71
106 2438.33 2498.75 1.02
24 3017.50 3096.67 1.03
Group Mean 2573.75 2577.92 1.00
19 1946.67 1948.75 1.00
22 1730.00 1496.67 0.87
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Figure 3.20 | Angiopoietin-2 levels during blood-stage P. falciparum malaria infection. A) Angiopoietin levels (pg/mL) as measured in volunteer 
plasma, at baseline/C -1 (open circles) and diagnosis (closed circles) for all 14 infected. The mean and standard deviation is shown. B) comparison of 
Angiopoietin levels at C -1 and diagnosis within and between groups; “unknown” volunteers 12, 18, 20 and 208 (yellow), “classical” responders 13, 16, 
17, 24, 26, 27, 106 and 206 (red) and “non-classical” responders 19 and 22 (blue). The mean and standard deviation is shown. C) Relationship 
between parasitemia at diagnosis, as measured by qPCR (parasites/mL), and levels of Angiopoietin-2 (pg/mL) at diagnosis. Spearman’s rank 
correlation coefficient (r) and p-value is shown on the graph. ELISA was performed by Diana Munoz Sandoval. NS = Not Significant. 
NS 
 
Figure 3.20 | Angiopoietin-2 levels during blood-stage P. falciparum infection. A) Angiopoietin-2 levels 
(pg/mL) as measured in volunteer plasma, at baseline/C -1 (open circles) and diagnosis (closed circles) for all 14 
infected. The mean and standard devi tion is shown. B) comparison of A giopoietin-2 levels at C -1 and diagnosis 
within a d between groups; “unknown” volunteers ♯12, ♯18, ♯20 and ♯208 (yellow), “classical” respond rs ♯13, ♯16, 
♯17, ♯24, ♯26, ♯27, ♯106 and ♯206 (red) and “non-classical” responders ♯19 and ♯22 (blue). The mean and standard 
deviation is shown. C) Relationship between parasitaemia at diagnosis, as measured by qPCR (parasites/mL), and 
levels of Angiopoietin-2 (pg/mL) at diagnosis. Spearman’s rank correlation coefficient (r) and p-value is shown on 
the graph. ELISA was performed by Diana Munoz Sandoval. NS = Not Significant. 
 
 
As a routine measure, volunteers were asked to grade any symptoms experienced 
during the CHMI follow-up period, using a severity score (see chapter 2, section 
2.1.7). Symptoms included; pyrexia, feverishness, rigor, chills, sweats, headaches, 
myalgia, arthralgia, back pain, fatigue, nausea, vomiting and diarrhoea. Volunteers 
that reported most frequent and more severe symptomology were those belonging 
to the “classical” responder group (figure 3.21), with the three most inflammatory 
volunteers (♯16, ♯17 and ♯13) reporting grade 3 severity for fatigue, headaches and 
fever. Thus, although subjective, symptomology that could be assessed during the 
CHMI follow-up period appeared to correlate with host responder status.  
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Figure 3.21 | Reported clinical events. Heatmaps of volunteer clinical events, as reported on diary cards during CHMI follow-up period. Volunteers were asked to grade symptoms (y-axis) at each 
twice-daily clinic visit post-CHMI throughout the duration of their infections (x-axis), according to the scale above: 0 = symptom absent, 1 = symptom causing mild or transient discomfort, with no 
medical intervention required, 2 = symptom causing mild to moderate limitation in activity, with minimal medical intervention required and 3 = symptom causing marked limitation in activity, 




3.6 Discussion  
The clinical outcomes associated with malaria infection are characteristically 
diverse, and appear strongly influenced by the type of immune response elicited 
early in infection. An effective response can control parasite growth without causing 
damage to the host, whereas unregulated activation of innate immune cells can 
result in the over-production of pro-inflammatory cytokines, leading to pathology 
(Gazzinelli et al. 2014). The multifactorial nature of clinical disease has greatly 
confounded efforts to define mechanisms of pathogenesis, as well as correlates of 
protection. Thus, greater investment needs to be placed in understanding the most 
basic aspects of the human response to Plasmodium falciparum.  
 
CHMI offers the opportunity to dissect host-pathogen interactions at an 
unprecedented level of detail. Over recent years, an increasing number of 
researchers have utilised this model to investigate the early host response to          
P. falciparum (see chapter 1, section 1.6.5). Where this study offers an important 
advantage over others however, is the sampling of volunteers over a time-course 
throughout infection, thus allowing each individual to be treated as their own 
experiment. Importantly, this was conducive to the assessment of inter-individual 
variability in host responses. When responses were compared across volunteers, 
distinct patterns of gene expression were evident in whole blood. 8 out of 14 
volunteers responded by up-regulation of genes associated with the innate 
inflammatory response, many of which were interferon-stimulated genes. In 
contrast, 2 volunteers had a very distinct response, suppressing genes associated 
with the inflammatory response, cell signaling and metabolism. In 4 out of 14 
volunteer (29%), no response was detected in the time frame assessed.  
 
Further validating the inter-individual variation in host immune response to               
P. falciparum, were levels of chemokines detected in the plasma of volunteers. 
CXCL10 (IP-10) and CXCL9 (MIG) were found elevated in the 8 “classical” 
responders but in none of the others, reflecting volunteer responder status as 
defined by microarray. Elevated levels of these chemokines has been associated 
with more severe disease in malaria patients (Schofield and Grau 2005, Ayimba et 
al. 2011) and thus, may be predictive of a more adverse outcome in this group of 8 
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volunteers; something otherwise impossible to assess in studies of CHMI. 
Consistent with the transcriptomics data, cytokine and chemokine analysis in the 
group of “unknown” volunteers suggest little in the way of a response to                   
P. falciparum infection within the time frame assessed. Moreover, volunteer ♯16, 
demonstrating the most marked up-regulation of innate/inflammatory response 
genes at the transcript level, displayed the biggest fold-change (from baseline) in 
levels of CCL2, CXCL10, CXCL9, INFγ, IL-10 and IL-6, all of which have been 
associated with symptomatic malaria infection (Day et al. 1999, Abrams et al. 2003, 
Lyke et al. 2004, Walther et al. 2006, Armah et al. 2007, Jain et al. 2008, Ayimba et 
al. 2011, Mirghani et al. 2011, Wilson et al. 2011). Full blood count analysis 
revealed a significant decrease in the blood proportion of lymphocytes at diagnosis 
compared to baseline, in these 8 volunteers. 3 out of the 8 in this group (volunteers 
♯16, ♯17 and ♯26) were lymphopenic (had <1x106 lymphocytes/mL of whole blood) 
by day of diagnosis. This is consistent with studies of malaria patients exhibiting 
high levels of inflammation in the natural infection setting (Hviid et al. 1997). Thus, 
based on these data it appears that increased production of CXCL9 and CXCL10 at 
the transcript and protein level, along with decreased numbers of lymphocytes in the 
blood, may serve as biomarkers of a more inflammatory, adverse clinical outcome 
during primary infection with blood-stage P. falciparum (3D7).  
 
In the “classical” responder group, pathway analysis revealed a signature consistent 
with activation of both Type II (IFNγ), and Type I (IFNα/β) signalling, as has been 
previously published in studies of CHMI (Montes de Oca et al. 2016, Gardinassi et 
al. 2018). Although well described in the context of anti-viral defense, the role of 
Type I IFNs in immunity to other pathogens is less clear. They have been 
highlighted in a regulatory capacity in models of Listeria monocytogens and 
Tuberculosis, demonstrating inhibitory effects on various innate immune cells 
including macrophages, monocytes and neutrophils, leading to higher infection 
burdens and severe pathology. (Auerbuch et al. 2004, Carrero et al. 2004, Berry et 
al. 2010, Desvignes et al. 2012, McNab et al. 2015). To date, the functional roles of 
Type I IFNs during Plasmodium infection have mainly focused on mouse models of 
lethal, experimental cerebral malaria (ECM), and evidence has been controversial. 
Disruption to Type I IFN signalling in mice lacking the IFNα/β receptor enhanced the 
survival of P. berghei-infected and P. yoelii-infected mice, and in all cases was 
 98 
accompanied by a decrease in immune cell activation, and unregulated parasite 
growth (Haque et al. 2011, Ball et al. 2013, Haque et al. 2014, Spaulding et al. 
2016, Zander et al. 2016). Yet, counterevidence form P. berghei- infected mice 
receiving daily i.p injections of recombinant IFNα suggest a protective role of Type I 
IFNs, whereby mice had better control of parasite densities, and reduced incidence 
of cerebral malaria compared to wild-type mice (Vigario et al. 2007). Limited data 
from studies of human malaria infection are also controversial. Up-regulation of the 
Type I IFN pathway has been associated with mild malaria compared to severe 
disease, in a cohort of Malawian children (Krupka et al. 2012) whereas, in the 
setting of experimentally-induced infection, Type I IFN-driven neutrophil activation 
correlated with increased levels of circulating transaminases, indicative of liver 
pathology (Rocha et al. 2015). Furthermore, a study carried out in the Gambia 
revealed that two SNPs (17470-G/G and L168V-G/G) in the gene encoding IFNαR1 
are associated with protection against severe and cerebral malaria (Aucan et al. 
2003). Thus, the capacity to which Type I IFN responses mediate 
susceptibility/protection during primary infection with P. falciparum remains to be 
defined.  
 
The erythrocytic stage of infection is characterised by a strong proinflammatory 
response, hallmarked by the production of large amounts of IFNγ (Type II IFN). 
During this phase, IFNγ is thought to play a key role in the activation of phagocytic 
cells, promoting clearance of infected red blood cells and thus controlling 
parasitaemia (Riley and Stewart 2013). The kinetics of IFNγ production during the 
earliest stages of the acute-phase of human P. falciparum infection however have 
not been well defined. In this cohort of volunteers, IFNγ was undetectable in the 
plasma at baseline and, with the exception of 3 volunteers, remained undetectable 
during the CHMI follow-up period. Interestingly, a spike in IFNγ levels was observed 
in three of the most inflammatory responders, but not until the end of their infection 
time-course (diagnosis time-point). Importantly, recent evidence suggests a 
dominant role of Type I IFNs, over that of IFNγ during the initiation of the 
inflammatory response to malaria. Data from both mouse and human models of 
Plasmodium infection have shown an ability of Type I IFNs to suppress IFNγ-driven 
cellular responses at this early stage in infection (Haque et al. 2014, Montes de Oca 
et al. 2016). Furthermore, studies suggest that this dominant Type I IFN response is 
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associated with the expression of negative regulators such PDL-1, which work to 
inhibit adaptive responses (Haque et al. 2011, Yu et al. 2016, Zander et al. 2016). 
This paradigm has also been demonstrated in the context of viral infection 
(Shaabani et al. 2016), and may be consistent with our transcriptional dataset, 
whereby volunteers displaying the strongest Type I IFN response, also had up-
regulated expression of CD274 (PDL-1), SOCS1, SOCS3, and down-regulation 
expression of CD40L.  However, given that there is substantial overlap in the genes 
they regulate, it is difficult to speculate a dominant role of either Type I or Type II 
responses in this cohort of volunteers. Furthermore, there is evidence to suggest 
that the two can work cooperatively, through the regulated expression of STAT1 
(Gough et al. 2010), although the precise mechanisms of this cross-talk have not 
been examined in the context of Plasmodium infection. Surprisingly, levels of (Type 
I) IFNα detected in the plasma did not appear to fluctuate in response to infection, 
suggesting that transcript-level interferon-stimulated responses are observed before 
an increase in circulating interferon can be detected. One possible explanation for 
this is that the initial production of IFNs, in response to P. falciparum, does not occur 
systemically, but instead is an upstream event that takes place in tissue(s). This 
hypothesis is supported by recent evidence implicating plasmacytoid dendritic cells 
(pDCs), in the bone marrow, as the main source of systemic Type I IFNs, following 
TLR7/MyD88-mediated sensing of parasites in P. yoelii-infected mice (Spaulding et 
al. 2016). Thus, the strong interferon-stimulated gene signature detected in the 
blood of these volunteers may be an effect of cells being activated by Type I IFNs 
(and/or Type II IFNs) in the bone marrow and being subsequently released into the 
circulation. It is important to note that human malaria is a multi-organ disease, 
involving a vast range of cell-types and tissues that cannot be accessed for 
investigation. Thus, only in conjunction with appropriate mouse models will we be 
able to gain a full appreciation of the mechanisms mediating protection/susceptibility 
to this parasite.  
 
In line with studies implicating the role of Type I IFNs in the initiation of deleterious 
inflammatory responses, also found activated in these volunteers were pathways for 
inflammasome and TREM1 signalling. Inflammasome signalling was associated with 
up-regulation of AIM2, CASP1 and CASP5, suggesting activation of both AIM2 and 
NLRP3 inflammasomes, in response to cytosolic sensing of parasite DNA and 
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haemozoin, respectively (Kalantari et al. 2014). Also found up-regulated were the 
cytosolic PRRs; DDX58 (RIG-I) and IFIH1 (MDA-5), responsible for the recognition 
of RNA (McNab et al. 2015). The processes by which phagocytic cells of the 
immune system are able to detect and process parasite-derived molecules via 
cytosolic PRRs, inducing Type I IFN responses, have been discussed in recent 
literature (Kalantari et al. 2014, Sisquella et al. 2017).  
 
It is difficult to predict what effect the suppressive response may mean for clinical 
outcome in the two volunteers of the “non-classical” responder group. Death 
receptors play a central role in instructive/ programmed cell death. Their activation is 
typically observed during viral infection, and in the context of malignantly-
transformed or excessively activated cells. In these settings, programmed cell death 
serves as a host defense mechanism, by eliminating cells that are potentially 
dangerous (Fuchs and Steller 2011), whilst  preventing initiation of inflammatory 
pathways (Bruchhaus et al. 2007). Abnormal regulation of this process may 
therefore prove detrimental to the host, but there is it yet unclear what effect this 
may have in the context of P. falciparum infection. Pathway analysis also revealed 
inhibition of those linked to the innate immune response, such as TREM-1 
signalling, in these “non-classical” responders. It is possible that early suppression 
of innate inflammatory responses may inhibit the overproduction of pro-inflammatory 
mediators, thus helping to reduced pathology. On the other hand, it may reflect a 
reduced ability to control parasite growth, leading to more severe disease outcome 
later in infection. Thus, it was important to consider a potential correlation between 
host responder status and parasite growth in the blood.  
 
Parasite multiplication rates, as measured over each 48-hour parasite growth cycle 
in the blood, were not influenced by host transcriptional response status, and vice 
versa. This is in line with the recent reanalysis of historical malariatherapy data, 
suggesting a host-specific influence on acquired immunity, independent of parasite 
growth kinetics during primary infection (Molineaux et al. 2002). Importantly, 
individuals who elicited a robust inflammatory response (the 8 “classical” volunteers) 
had no better control of parasite growth than those who failed to respond within the 
time assessed (the 4 “unknowns”). This contests previously published data 
associating innate inflammatory responses with enhanced parasite clearance in the 
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malaria-naïve host (Walther et al. 2005, Walther et al. 2006, Horowitz et al. 2010, 
Haque et al. 2011, Montes de Oca et al. 2016). Also interesting was the lack of 
response detected in the group of “unknowns”, as all four reached comparable- and 
in some cases higher- parasitaemias to the “classical” responders. This suggests 
that there is likely a parasite density threshold for activation of host immune 
responses, and that it is highly variable between individuals.  
 
There is evidence to suggest that microbial exposure (or past infection history) is a 
driver of immune variation, and CMV seropositivity has been shown to influence 
variability in host immune responses (Sylwester et al. 2005, Schoenfisch et al. 2011, 
Brodin et al. 2015, Shmeleva et al. 2015). The prevalence of human CMV infection 
varies greatly depending on geographic and socioeconomic backgrounds of the 
population, reaching ~30 - 80% in adults (Dollard et al. 2011). Thus, CMV IgG 
seropositivity was assessed in the volunteers, to investigate an association with host 
responder status. 35% of volunteers (5/14) tested positive for anti-CMV IgG; 4 in the 
“classical” responder group and 1 in the “unknowns”. Therefore, CMV IgG 
seropositivity does not explain the variation in host response observed in this cohort 
of volunteers, as only 50% of “classical” responders are seropositive for CMV. 
Interestingly, volunteers who were seropositive for anti-CMV IgG were found to have 
significantly lower parasite multiplication rates when compared to volunteers that 
were seronegative. However, this ELISA is designed to be semi-quantitative and 
with just 14 volunteers, this association will need to be investigated using a greater 
number of individuals before drawing any conclusions.  
 
One of the major limitations of CHMI is the early termination of volunteer infections, 
often at a time preceding any clinical symptomology. Thus, in an attempt to predict 
the clinical severity that may have eventuated had infection been allowed to 
continue without drug treatment, levels of Angiopoietin-2 (ANG-2) were quantified in 
the plasma of these individuals. The only volunteer demonstrating elevated ANG-2 
levels (>1.5 fold increase) at diagnosis was the “classical” responder ♯16. It is 
difficult to speculate a trend based on n = 1, but it may be indicative of endothelial 
cell activation in response to systemic inflammation, or upon reaching a threshold of 
parasite density (volunteer ♯16 had the highest parasite density at 273,247 p/mL). 
Overall, results may reflect too early a time-point, or parasitaemias too low for ANG-
 102 
2 production in response to CHMI with blood-stage P. falciparum, and suggest that 
activation of the endothelium is a secondary event to inflammation in this setting. 
Symptoms reported by volunteers during the CHMI follow-up period did suggest a 
relationship between host responder status and clinical outcome, however. 
Volunteers within the “classical” responder group reported more frequent and more 
severe clinical events, compared to those of the “non-classical” responders and 
“unknown” volunteers. The type of response produced following blood-stage CHMI 
thus appears to predict clinical outcome. However, it is unfortunate to have to rely 
on such subjective means for a clinical read-out in studies of CHMI.  
 
It is important to consider the other potential limitations of this study. Due to 
restrictions in blood volume/sampling of volunteers throughout the CHMI follow-up 
period, my analysis of the host transcriptional response was confined to a 48-hourly 
time course. This sampling schedule may have been too infrequent to detect certain 
immune events, and/or transient patterns of gene expression out-with the 
designated collection times. Furthermore, although the whole-blood transcriptome 
has provided a great overview of the early immune events during primary               
P. falciparum infection, this study would have benefited from a combined analysis of 
cellular subsets, to determine the key immune cells associated with the response(s). 
This will be an important consideration for future trial design. Analysis based on 
transcriptome data is also restricted in that evidence for gene expression/regulation 
does not necessary translate to protein production. Importantly, this study has 
revealed evidence for inter-individual variability in the host response to primary        
P. falciparum infection, however was limited in its statistical power due the small 
number of volunteers enrolled in control group (n = 14). I fully acknowledge that the 
results presented within this chapter are preliminary, and may be at risk of bias due 
to the small cohort of volunteers used in the study.  Interpretations of these results 
are in no way conclusive, but are intended to better inform future hypothesis-driven 
studies of the host response to P. falciparum infection. It will therefore be crucial to 
validate the observations from this study using larger cohorts of volunteers across 
more studies.  
 
In conclusion CHMI in 14 previously malaria-naïve volunteers has revealed a 
possible dichotomy in the host immune response to P. falciparum blood stage 
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infection. Responder status did not appear to be associated with parasite growth 
kinetics, but correlated with chemokine levels in the plasma. Results suggest 
important practical implications in understanding the diversity of clinical responses 
to vaccination and induction of effective anti-pathogen immunity. Thus, investment 
should be placed on understanding the contribution of host and parasite genetics, to 





























































4 P. falciparum Gene Expression in the Malaria-Naïve Host 
 
4.1 Abstract 
P. falciparum gene expression- specifically var gene expression- is predicted to 
dictate clinical outcome in the non-immune host. In particular, var genes encoding a 
restricted subset of group-A, B/A Plasmodium falciparum erythrocyte membrane 
protein 1 (PfEMP1) variant surface antigens have been associated with severe 
malaria disease, giving rise to the hypothesis that these var gene variants are 
dominantly expressed in individuals that have yet to develop an immune response 
to the parasite. However, the extent to which parasite gene expression influences 
the developing host immune response remains unclear. Herein, parasites isolated 
from the blood of 12 volunteers undergoing controlled infection with P. falciparum 
(3D7-strain) were analysed by RNA-sequencing to investigate expression of the var, 
rif and stevor multi-gene families. Moreover, parasites isolated at the end of 
volunteer infections were compared to those recovered from the inoculum used to 
infect, to investigate evidence for VSA selection in vivo. On the day of microscopic 
patency (day of diagnosis), a broad repertoire of var transcripts were detected in 
volunteer samples, and those that demonstrated highest expression were of the 
group-B subtype. Interestingly, var and rif gene profiles were almost identical across 
the 12 volunteer and 2 inoculum samples, suggesting there was little diversity within 
the cohort and that in vivo selection forces had not been activated in this setting. 
These data provide first evidence that the inter-individual variation in host immune 
responses, during primary infection with P. falciparum, is not driven by parasite 
gene expression but is instead more likely associated with factors intrinsic to the 
host.  
 
4.2 Introduction  
The virulence of Plasmodium falciparum is directly linked to the expression of 
parasite variant surface antigens (VSAs), the best characterised of which is             
P. falciparum Erythrocyte Membrane Protein 1. The expression of PfEMP1 on the 
surface of infected erythrocytes enables the parasite to adhere to a large variety of 
host receptors on microvasculature linings, in order to avoid passage through the 
spleen and subsequent clearance (Looareesuwan et al. 1987, Kyes et al. 2001). 
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This parasite survival strategy leads to the obstruction of blood flow, contributing to 
impaired perfusion in vital host organs- the main cause of pathology associated with 
infections with this species of malaria parasite (Dondorp et al. 2000, Dondorp et al. 
2004, Dondorp et al. 2008, Hanson et al. 2012). There is good evidence that 
PfEMP1, exposed on the surface of infected cells, are natural targets of the 
developing antibody response of the host (Bull et al. 1998, Chan et al. 2012). This is 
thought to impose a selection pressure on the infecting parasite population, causing 
them to switch expression between different PfEMP1 variants in order to evade the 
host immune system and establish chronic infection (Smith et al. 1995, Bull et al. 
1998, Chan et al. 2012). Allowing for this switch in PfEMP1 is the repertoire of ~60 
var genes encoding these proteins. On the basis of the full genomic sequence of the 
P. falciparum 3D7 clone, var genes have been classified into three major groups (A, 
B and C) and two intermediate groups (B/A and B/C), defined by the presence of 
one of three conserved 5′ upstream sequences (UpsA, UpsB or UpsC) and by the 
gene's position and orientation within the chromosome (summarised in table 4.1). 
(Kraemer and Smith 2003, Lavstsen et al. 2003, Kraemer et al. 2007). All group-A 
genes have a DBLα1 type N-terminal domain and a lower number of conserved 
cysteine resides compared to the group-B, B/C and C genes that have DBLα0 N-
terminal domains. Furthermore, the group-A and B/A members are larger and have 
more complex domain structures (Lavstsen et al. 2003, Robinson et al. 2003). The 
3D7 reference clone possesses 10 group-A var genes, including the inter-strain 
conserved subfamilies var1 and var3, 37 group-B members, 13 group-C genes and 
var2CSA, belonging to the conserved var2 sub-family. This group-E member is the 
dominant var gene transcribed in pregnancy-associated malaria, found expressed at 
high levels in parasites isolated from placentas (Kyes et al. 2003, Salanti et al. 
2003). Four and nine of the 3D7 clone var gene members form chimeras of group 
B/A and B/C respectively. (Lavstsen et al. 2003). The expression of var genes 
occurs in a mutually exclusive fashion, such that just one is activated by each 
parasite at any given time (Dzikowski et al. 2006, Voss et al. 2006). In a population 
of infecting parasites however, this can give rise to broad expression of up to all ~60 
members, and associated PfEMP1.  
 107 
Table 4.1 | Characteristics of P. falciparum (3D7) var gene groups 
var  subgroup Upstream Sequence Position Orientation (direction of transcription) Median transcript size (kb) No. of genes in 3D7
A UpsA Subtelomeric Telomeric 9.2 10
B/A UpsB Subtelomeric Centromeric 8.8 4
B UpsB Subtelomeric Centromeric 6.6 24
B/C UpsB Central Telomeric 6.7 9
C UpsC Central Telomeric 6.6 13
E UpsE - - 9.2 1  
In areas of high malaria transmission, immunity to severe (life-threatening) disease 
develops more rapidly than immunity to mild malaria, as children grow older 
(Langhorne et al. 2008, Goncalves et al. 2014). One popular explanation for this in 
the scientific community is that restricted subtypes of disease-causing PfEMP1 
variants are specialised for infection in malaria-naïve hosts, and upon development 
of antibodies to these PfEMP1, children are subsequently protected from severe 
infection (Bull et al. 1999, Bull et al. 2000, Nielsen et al. 2002, Staalsoe et al. 2003, 
Jensen et al. 2004, Abdi et al. 2017). Various studies have attempted to profile the 
var gene expression patterns associated with severe disease, using clinical             
P. falciparum isolates from children diagnosed with severe and mild malaria 
(Kirchgatter and Portillo Hdel 2002, Bull et al. 2005, Kaestli et al. 2006, Kyriacou et 
al. 2006, Rottmann et al. 2006, Normark et al. 2007, Falk et al. 2009, Warimwe et al. 
2009, Kalmbach et al. 2010, Lavstsen et al. 2012, Warimwe et al. 2012, Bertin et al. 
2013, Almelli et al. 2014, Abdi et al. 2015, Bertin et al. 2016, Jespersen et al. 2016, 
Mkumbaye et al. 2017, Shabani et al. 2017, Tonkin-Hill et al. 2018). However, 
results from these studies have proven inconclusive, potentially as a result of 
differences in methodologies used to measure var gene expression. The most 
common strategy uses degenerate primer pairs to target and amplify unique DBLα 
sequence tags for sequencing, and has implicated the group-A var genes 
exclusively, demonstrating that P. falciparum parasites expressing a higher 
proportion of these variants are positively associated with severe/symptomatic 
malaria disease (Kirchgatter and Portillo Hdel 2002, Bull et al. 2005, Kyriacou et al. 
2006, Falk et al. 2009, Warimwe et al. 2009, Warimwe et al. 2012). However, this 
method requires the sequencing of a large number of clones for statistical 
significance and is inherently susceptible to primer bias. Other researchers have 
utilised qPCR primers designed to quantify more directly the transcript abundance of 
group-A, B and C var genes and conserved sequence blocks of DBL-domain 
cassettes. In the majority of these studies a higher frequency of group-A, B and 
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subsets of group-A and B PfEMP1 variants containing domain cassette 13 and 8 
were detected in patients suffering with severe malaria disease, compared to those 
with mild or asymptomatic infections (Kaestli et al. 2006, Rottmann et al. 2006, 
Lavstsen et al. 2012, Abdi et al. 2015), whereas one found an association between 
increased transcripts of group-C var type and cerebral malaria (Kalmbach et al. 
2010). More recently, RNA sequencing has been used to analyse gene expression 
patterns in clinical isolates of severe and uncomplicated malaria in Papuan patients, 
confirming the up-regulation of a subset of PfEMP1 proteins (containing DBLα1 
domains) previously associated with severe malaria infections (Tonkin-Hill et al. 
2018). Despite discrepancies in these results, it has been hypothesised that a 
restricted subset of group-A and/or B/A var genes/PfEMP1 is responsible for the 
pathogenesis of severe disease. Given that severe infections are most commonly 
observed in children with limited prior exposure to the Plasmodium parasite, there is 
a need to investigate var gene expression in a representative population of malaria-
naïve individuals.  
Four previous studies have utilised the controlled human malaria infection (CHMI) 
model to assess var gene expression during primary infection in the human host, 
reporting variable findings (Peters et al. 2002, Lavstsen et al. 2005, Wang et al. 
2009, Bachmann et al. 2016). In the original study by Peters et al, var transcription 
profiles were assessed in parasites isolated from two volunteers on day 12 and 13 
following infection with P. falciparum 3D7, and they report dominant expression of 
one group-B var, comprising ~40% of the sequences cloned from each individual. 
On the other hand, Wang et al report broad-level activation of ~90% of all var genes 
at the early onset of blood-stage infection (Wang et al. 2009). However, this study 
was limited to a single volunteer from which sufficient parasite material could be 
recovered for analysis. In a more recent study, parasite populations from 18 
volunteers were found to express virtually identical transcript patterns that were 
dominated by the subtelomeric group-B var genes and, to a lesser extent, group-A 
(Bachmann et al. 2016). Unlike patients suffering with malaria following natural 
infection in the field, volunteers enrolled in studies of CHMI are only allowed to 
progress through a few cycles of parasite replication in the blood before they have 
to be treated. As a consequence, patients have very low levels of parasitaemia and 
often do not develop clinical symptoms (Sauerwein et al. 2011). Due to the reduced 
parasite material available in these volunteers, Lavstsen et al included a step for in 
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vitro culture of parasites for approximately one month prior to analysis, to ensure 
sufficient RNA material for qPCR, following isolation from the human host (Lavstsen 
et al. 2005). However, P. falciparum has been reported to switch var gene 
expression at variable rates in vitro, giving rise to potential bias in gene selection 
(Roberts et al. 1992, Horrocks et al. 2004, Peters et al. 2007, Bachmann et al. 
2011). In this instance, var gene expression profiles in the cultures at the time of 
transcriptional analysis may not reflect the expression profile at the time of blood 
collection, making it difficult to interpret results. Therefore, it is important to clarify 
these contradicting data in order to better understand parasite var gene expression 
in the naïve human host.  
In recent years, RNA sequencing (RNA-seq) has allowed many advances in the 
characterisation and quantification of transcriptomes and can now be successfully 
performed at the single cell level (Liu and Trapnell 2016, Reid et al. 2018). Providing 
that parasite samples can be prepared to sufficient purity, this method offers an 
appealing alternative to qPCR for the analysis of ex vivo parasite gene expression. 
It also holds a major advantage over var-specific qPCR, in that analysis is not 
limited to one multi-gene family. The P. falciparum genome consists of other multi-
gene families encoding VSAs with potential influence on host immunity and clinical 
outcome. These include the repetitive interspersed family (rif), encoding RIFINS and 
sub-telomeric variable open reading frame (stevor) encoding STEVORS, for which 
143 and 32 members have been found in the 3D7 genome, respectively (Kyes et al. 
1999, Lavazec et al. 2007, Joannin et al. 2008, Bachmann et al. 2012, Wahlgren et 
al. 2017). These proteins are expressed on the surface of infected erythrocytes and 
thus are thought to be important for the sequestration of parastised erythrocytes and 
the pathogenesis of severe malaria (Niang et al. 2009, Niang et al. 2014, Goel et al. 
2015, Wahlgren et al. 2017). In an important study by Bachmann et al, the 
expression dynamics of rif and stevor-encoded proteins were assessed in clinical    
P. falciparum isolates, using quantitative real-time PCR (Bachmann et al. 2012). 
Interestingly, both rif and stevor multi-gene families were found overexpressed in 
clinical isolates, relative to 3D7-strain parasites, and demonstrated a complex 
pattern of expression during clinical progression (Bachmann et al. 2012). Results 
are suggestive of diverse functional roles of the RIFIN and STEVOR proteins in 
vivo, yet little information is currently available on how they may influence disease 
progression and the developing host immune response. Having previously 
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demonstrated diversity in the host responses to controlled P. falciparum infection, I 
wanted to profile var, rif and stevor gene expression in the malaria-naïve host, and 
investigate the influence of parasite VSA expression as a driver of this inter-
individual variability.  
 
4.3 Hypothesis and specific aims 
This chapter investigates the hypotheses that a subset of group-A and/or B/A 
disease-associated var genes are dominantly expressed in the naïve human host, 
and that inter-individual variation in parasite gene expression will reflect the inter-
individual variation observed in host immune responses.  
 
 Specific aims 
 
1. To isolate parasites from the blood of volunteers during controlled human 
malaria infection, in sufficient numbers and purity for direct ex vivo RNA-
sequencing. 
2. To investigate multi-gene family (var, rif and stevor) selection in the naïve 
host, by comparing parasites isolated at time of patent infection with samples 
of parasite inoculum used to infect. 
3. To determine inter-individual variation in parasite gene expression, 
consistent with the inter-individual variation in host immune responses 




Analysis of P. falciparum gene expression in the naive host was done in 
collaboration with Dr Adam Reid, Dr Mandy Sanders and Geetha 
Sankaranarayanan, at the Wellcome Trust Sanger in Cambridge, UK. Their 
contribution has been stated in the relevant sections that follow.  
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4.4.1 List of materials 
Reagent Supplier Catalog Number
1.5 mL Eppendorf® tubes Sigma-Aldrich T9661-1000EA
50 mL Falcon tubes Becton Dickinson (BD) 352098
50 mL luer syringe Becton Dickinson (BD) 12339159
250 mL centrifuge bottles Corning Life Sciences CLS 431842
Sterile D200 ST pipette tips Gilson F171301
Sterile D1000 ST pipette tips Gilson F171501
PBS (1x) Gibco 20012-019
Leucoflex LXT filters Scottish National Blood Transfusion Service -
Saponin Sigma-Aldrich 8047-15-2
TRIzol™ Ambion (Life technologies) 115596026
0.5 mL DNA LoBind Eppendorf® tubes Eppendorf 22431005
1.5 mL DNA LoBind Eppendorf® tubes Eppendorf 22431021
UltraPure Ethanol Sigma-Aldrich 51976
Bromochloropropane Sigma-Aldrich B9673-200mL
DEPC H2O Thermo Fisher Scientific 750024
Globin-Zero® Gold kit Epicentre (Illumina) GZG1224
Linear acrylamide Ambion  (Life technologies) AM9520
Magnetic Core Kit (beads) Epicentre (Illumina) MR211124C
DynaMag™-2 Magnet Thermo Fisher Scientific 12321D
RNA 6000 Pico Chip Bioanalyzer Kit Agilent 
Sterile D10 ST pipette tips Gilson F171101
Sterile D200 ST pipette tips Gilson F171301
Sterile D1000 ST pipette tips Gilson F171501
Zymo-Spin RNA Clean and Concentrator™ -5 kit Zymo Research R1016
Agencourt Ampure XP beads Beckman Coulter A63881
Betaine (BioUltra >99.0 %) Sigma-Aldrich 61962
dNTP mix (10 mM) Fermentas R0192
DynaMag™-2 Magnet Thermo Fisher Scientific 12321D
High Sensitivity DNA Bioanalyzer kit Agilent 5067-4626
ISPCR primer (10 uM) (5′-AAGCAGTGGTATCAACGCAGAGT-3′) Biomers.net -
KAPA HiFi HotStart ReadyMix (2× KAPA) Biosystems KK2601
LNA-modified TSO (5′-AAGCAGTGGTATCAACGCAGAGTACATrGrG+G-3′) www.exiqon.com -
MgCl2 Ambion (Life technologies) AM9530G
Oligo-dT30VN (5′–AAGCAGTGGTATCAACGCAGAGTACT30VN-3′) biomers.net -
Qbit™ ds DNA high sensitivity assay kit Thermo Fisher Scientific Q32851
Recombinant RNase inhibitor Clontech 2313A
Superscript II reverse transcriptase kit* Thermo Fisher Scientific 18064-014  
 
4.4.2 Isolation of P. falciparum (3D7-strain) parasites from whole human 
blood 
Isolation of P. falciparum parasites was performed during the volunteer diagnosis 
period (ranging C +7.5 days– C +10.5 days post-CHMI). Parasites were isolated 
from 13 of the 14 infected volunteers (no sample for volunteer #22). Unless 
otherwise stated, all materials were single-use and disposable to prevent cross-
contamination between volunteers.  
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4.4.2.1 Leucodepletion  
In advance of blood collection, filtering apparatus was set up comprising a 50 mL 
capacity syringe with plunger removed (Becton Dickinson), connected to a leucoflex 
LXT filter (Scottish National Blood Transfusion Service) with 250 mL capacity 
centrifuge bottle (Corning Life Sciences) for collection of flow-through. For each 
volunteer, 50 mL blood was pooled into one 50 mL falcon tube (Becton Dickinson) 
and transferred to the syringe for passage through leucodepletion filter. To ensure 
maximal recovery of parasite-infected erythrocytes, filters were washed through with 
200 mL 1x PBS (Gibco) and left to run dry before collection of flow-through for 
centrifugation at 1,000g for 10 minutes, at room temperature. Supernatant was then 
discarded, being careful not to disturb the pellet. From this point in the protocol, all 
samples and reagents were kept at 4oC. 
 
4.4.2.2 Erythrocyte Lysis and cryopreservation of parasite pellets 
Erythrocyte pellets (containing ring-stage parasites) from the previous step were 
resuspended in 0.015% saponin (Sigma-Aldrich) in PBS, in a final volume 9x that of 
the pellet volume (varied between volunteers). Samples were incubated for 10 
minutes on ice to ensure the efficient lysis of red cells and then centrifuged at 
15,000g for 10 minutes, with the brake off. The supernatant was discarded and the 
pellets resusupend in 1 mL cold PBS, added directly to the predicted pellet location 
(marked on the centrifuge bottle prior to spin). Resuspended samples were then 
transferred to 1.5 mL Eppendorf tubes and centrifuged at 16,000g for 5 minutes, 
before removal of supernatant. Parasite pellets were resuspended in 1 mL TRIzolTM 
reagent, mixed and then incubated for 5 minutes at 37oC before being snap-frozen 
on dry ice and stored at -70oC. 
 
4.4.3 Parasite RNA Extraction and Clean-up 
Unless otherwise stated, all steps in the RNA extraction/ clean-up protocol were 




4.4.3.1 RNA Extraction and purification 
Parasites in TRIzol™ (including the two inoculum samples) were thawed at room 
temperature, before addition of 200 μl (0.2x original TRIzol™ volume) 
bromochloropropane (Sigma-Aldrich). Tubes were vortexed, incubated for 3 minutes 
at room temperature and then centrifuged at 12,000g and 4oC, for 15 minutes. ~500 
μl of aqueous phase was then transferred to a fresh 1.5 mL Eppendorf tube, and 
diluted 1:1 in 100% ethanol (Sigma-Aldrich) for purification with RNA Clean and 
Concentrator™-5 kit (Zymo Research). In brief, the aqueous phase/ethanol mix was 
added to a zymo-spin column, with collection tube, and centrifuged at 12,000g for 
30 seconds. Column flow-through was discarded and purification proceeded as 
follows: 30 second spin with 400 μl “RNA Prep Buffer”, 30 second spin with 700 μl 
“RNA Wash Buffer”, and a 2 minute spin with 400 μl “RNA Wash Buffer”. The 
column was then transferred to a fresh 1.5 mL Eppendorf tube, and 14μl 
DNAse/RNAse-free water added for incubation at RT for 5 minutes. RNA was eluted 
off the column by centrifugation at 4oC for 30 seconds. At this stage in the protocol, 
a 4 μl aliquot of the eluted sample was taken for quantification by nanodrop and/or 
the Agilent 2100 Bioanalyzer RNA 6000 Pico Chip assay for Total RNA (RNA 
concentration range of 50 pg/μl - 5,000 pg/μl).  
 
4.4.3.2 Depletion of Globin mRNA and Ribosomal RNA 
RNA was depleted of ribosomal RNA (rRNA) and globin mRNA using the Globin-
Zero® Gold kit from Illumina, as per manufacturer’s instructions. Kit specifications 
suggest a minimum starting input of ≥ 1 μg RNA. In cases where this was not 
possible, reagent volumes were adjusted (indicated by blue type) to suit lower-input 
RNA yields ranging either 100 – 250 ng RNA (‘low input 1”) or 250 – 1 μg RNA (“low 
input 2”), as per manufacturer’s guidelines below: 
 
Preparation of magnetic beads 
Magnetic beads were resuspended and aliquoted in 225 ul (90 μl) volumes per 
sample reaction, for 2x washes in 225 ul (90 μl) RNAse-free water, using the 
DynaMag™-2 Magnet (Thermo Fisher Scientific). Final resuspension of beads was 
in 65 ul (35 μl) of “resuspension solution”, with addition of 1 ul (0.5 μl) “RiboGuard 
RNAse Inhibitor”. Magnetic beads were set aside at room temperature until use.  
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Preparation of samples for magnetic bead reaction 
Kit reagents were thawed on ice before use, and combined in the order below to 
make up a 40 μl (20 μl) volume. Once combined, reagents were mixed and 
incubated at 68oC for 10 minutes and then again, for 5 minutes at room 
temperature. 
 
For RNA yields ≥1 μg; 
• 16 μl RNAse-free water 
• 4 μl Globin-Zero® Gold Reaction Buffer  
• 1 – 5 μg RNA (10 μl volume) 
• 10 μl Globin-Zero® Gold Removal Solution 
For RNA yields 250 ng – 1 μg; 
• 3 μl RNAse-free water 
• 2 μl Globin-Zero® Gold Reaction Buffer  
• 250 ng – 1 μg RNA (10 μl volume) 
• 5 μl Globin-Zero® Gold Removal Solution 
For RNA yields 100 ng – 250 ng; 
• 5.5 μl RNAse-free water 
• 2 μl Globin-Zero® Gold Reaction Buffer  
• 100 ng – 250 ng RNA (10 μl volume) 
• 2.5 μl Globin-Zero® Gold Removal Solution 
 
Magnetic bead reaction for removal of Globin mRNA and rRNA 
Treated RNA was added to the 1.5 mL Eppendorf tube containing washed magnetic 
beads, tubes vortexed and then incubated for 5 minutes at room temperature. 
Samples were mixed once again, incubated at 50oC for 5 minutes and then 
transferred to the magnetic stand. After 1 minute, supernatant (containing the RNA) 
was pipetted off and transferred to a fresh for 1.5 mL Eppendorf tube for a second 
incubation in the magnetic stand. RNA was then topped up to 180 μl volumes using 





Globin and rRNA-depleted RNA was precipitated in 600 μl ethanol (100%) and 18 μl 
3M sodium acetate, overnight at 4oC. 2 μl linear acrylamide (Ambion) served as co-
precipitant. RNA was pelleted by centrifugation at 12,000g for 20 minutes, and 
washed x2 in 75% ethanol. Samples were air-dried for 5 minutes before 
resuspension in 12  μl  DEPC H20 (Thermo Fisher Scientific) and incubation at 65oC 
for 5 minutes. RNA for use in first-strand cDNA synthesis/amplification was stored at 
-70oC until use.  
 
4.4.4 RNA quantification and QC 
To ensure the efficient depletion of ribosomal RNA, 1 μl from every sample was run 
on the Agilent 2100 bioanalyzer using the RNA 6000 Pico Chip assay (RNA 
quantification range: 50 pg/μl – 5,000 pg/μl). Following depletion of globin and 
ribosomal RNA, sample yields were too low to be quantified by nanodrop or Qbit 
fluorometer, and thus the RNA 6000 Pico Chip assay was also used for 
quantification purposes. 
 
4.4.5 Smart-seq2 for first strand synthesis and amplification of cDNA 
First strand synthesis and PCR was performed by Geetha Sankaranarayanan, at 
the Wellcome Trust Sanger institute in Cambridge. The protocol used was adapted 
from that previously published (Picelli et al. 2014), and optimised for use with low-
input (single-cell level) P. falciparum RNA (Reid et al. 2018). All steps were 
performed in clean lab areas designated exclusively for either low-input RNA, or 
low-input DNA work. DNA and RNA reagents were stored separately, in single-use 
aliquots to avoid free-thaw cycles. All plastic-wear was PCR clean, and pipettes 
RNAse/DNAse-treated before use.  
 
Master mixes for the reverse transcription reaction were prepared in 0.2 mL PCR 
strip-tubes (Eppendorf®) on ice in enough volume for all, plus one additional 
reaction. Volumes below are calculated for 10 reactions. In all cases, 2 μl of 




4.4.5.1 Reverse Transcription Reaction  
 
Master Mix 1 – (10 reactions) Master Mix 2 - (10 reactions) 
- 1 μl (100 μM) oligo-dT30VN  - 1 μl (100 μM) TSO primer 
- 10 μl (10 μM) dNTPs  - 0.6 μl MgCl2 
- 9 μl DEPC H20   - 20 μl Betaine 
   - 20 μl Superscript buffer 
   - 5 μl DTT 
   - 2. 5 μl RNAse Inhibitor 
   - 5 μl Super Script II 
   - 2.9 μl DEPC H2O 
 
2 μl of RNA was incubated with an equal volume Master Mix 1 (MM1), for 3 minutes 
at 72oC to allow the oligo-dT primer to hybridized to the poly-A tail of the mRNA 
molecules. The 3′ end of this oligonucleotide contains 'VN', where 'N' is any base 
and 'V' is either A, C or G. The two terminal nucleotides are necessary for anchoring 
the oligonucleotide to the beginning of the poly-A tail and to avoid unnecessary 
amplification of a long stretch of adenosines. The free dNTPs are added in this initial 
mix to improve the yield of the RT-PCR, likely through mechanisms that stabilize 
RNA-primer hybridizations. Samples were placed back on ice immediately following 
incubation and then 5.5 μl of Master Mix 2 (MM2) was added to obtain a final 
reaction volume of 9.5 μl. The reaction was mixed and then spun down in a minifuge 











The PCR master mix was prepared on ice, by combining the below components; 
  
PCR Mastermix - (volumes for 1 reaction) 
- 2.5 μl KAPA HiFi HotStart ReadyMix (2x) 
- 0.25 μl (10 μM) Illumina Sequencing PCR (ISPCR) primer 
- 2.75 μl DEPC H20 
 
4.4.5.2 PCR  
15 μl of PCR Master Mix was added to 10 μl of (diluted) RNA sample from the RT 
reaction, tubes vortexed and then spun down in a minifuge. PCR was performed in 
a different thermal cycler, as below:  
 
* In all cases, 25 cycles of amplification were performed 
 
The absence of DNA contamination was confirmed by the absence of amplification 
product in a reverse transcriptase (RT) negative control that was included for every 
PCR run. 
 
4.4.5.3 cDNA purification 
cDNA samples were purified with use of AMPure XP beads (Beckman Coulter), as 
per manufacturer’s guidelines. In brief, beads were equilibrated at room temperature 
and resuspended (1:1) in 25 μl volumes for incubation with 25 μl cDNA. The 
beads/cDNA mix were incubated in the DynaMag™-2 Magnet (Termo Fisher 
Scientific) for ~5 minutes and supernatant removed. Whilst still in the magnetic 
stand, beads were washed x2 in 180 μl of freshly prepared 80% ethanol by 
incubating for 30 seconds, and then ethanol discarded. Tubes were removed from 
the magnet, centrifuged for ~7 seconds at 8,500g and returned to the magnet for 
removal of any residual ethanol. Beads were air-dried for up to 5 minutes, and then 
DNA was eluted off the beads in 20 μl of DEPC H2O. Tubes were vortexed, contents 
spun down and then incubated for 5 minutes at room temperature, off the magnetic 
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stand. As a final step, tubes were placed back on the magnetic stand and incubated 
for 2 minutes before transferal of supernatant (containing the cDNA) to fresh 1.5 mL 
Eppendorf tubes.  
 
4.4.5.4 cDNA quantification and QC 
cDNA samples were quantified using the Qbit® Fluorometer 2.0 and dsDNA High 
Sensitivity assay, with quantitation range; 10 pg/μl - 100 ng/μl (Thermo Fisher 
Scientific). The Agilent 2100 Bioanalyzer, High sensitivity DNA assay (DNA size 
range; 50 – 7,000 bp) was used to assess DNA quality and sizing.  
 
4.4.6 NEB NEXTflex® for preparation of RNA-seq libraries 
cDNA libraries were prepared by Geetha Sankaranarayanan, at the Wellcome Trust 
Sanger Institute, using the NEB NEXTflex® PCR-free kit (Bioo Scientific, catalog 
number: NOVA-5144-01), as per manufacturer’s instructions.  In brief, 500 ng of 
cDNA (in 40 ul volumes DEPC H2O) was fragmented to 400 - 600 bp using a 
Covaris AFA™Ultrasonicator before incubation with NEXTflex® PCR-free End 
Repair Buffer mix and End Repair Enzyme Mix for 30 minutes at 22oC. The cDNA 
was purified using AMPure XP beads (Beckman Coulter) for size selection at 300 – 
400 bp, as per manufacturer’s instructions, prior to 3’ end adenylation using 
NEXTfelx® PCR-free Adenylation Mix and incubation at 37oC for 30 minutes. The 
index adapters were ligated to the cDNA strands by incubating at 22oC for 15 
minutes, in the presence of NEXTfelx® PCR-free Ligation Mix and DNA adaptor 
indexes. Excess adaptors were removed using AMPure XP beads (Beckman 
Coulter), according to manufacturer’s instructions. Libraries were then quality 
assessed using the Agilent Bioanalyser, High Sensitivity DNA chip and quantified by 
Qbit® 2.0 Fluorometer, under standard operating procedures.  
 
4.4.7 RNA-sequencing and data analysis 
RNA-sequencing and data analysis was performed by Dr Adam Reid at the 
Wellcome Trust Sanger institute. Samples were sequenced using the Illumina 
HiSeqv4 platform to produce 75 bp paired-end reads, which were then mapped to 
the P. falciparum v3 gene sequences as described in the GeneDB genome 
database for prokaryotic and eukaryotic pathogens (http://www.genedb.org), using 
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the Kallisto v0.42.3 quantification platform (Logan-Klumpler et al. 2012, Bray et al. 
2016). Variable sequencing depth was detected across samples and thus read 
counts were normalised by regularized logarithm transformation (rlog), using 
DESeq2 v1.16.1. This process was performed by 1) calculating the log2 value for 
each gene, in each sample 2) calculating the geometric average (average of the 
log2-transformed values) for each gene, across samples 3) subtracting the 
geometric average from the log(counts) for each gene, in each sample. This allows 
for the identification of genes that are expressed at levels significantly below or 
above the average. 4) The final “scaling factor” was then calculated for each sample 
by taking the median of all (log) gene values (within that sample) and converting this 
median value back into a “normal number”. 5) The original (raw) read counts were 
then divided by the “scaling factor” associated with each corresponding sample, to 
produce “rlog” values. (Love et al. 2014). The rlog values were used for further 
analysis. Note that only genes with ≥ 5 reads in at least one sample were included 
in this analysis. Unless otherwise stated, a corrected p-value of 0.01 was used for 
differential expression analysis. EdgeR v3.8.6 was used to determine differential 
expression across all patient samples (Robinson et al. 2010). 
 
4.5 Results 
4.5.1 Volunteer parasitaemias at day of diagnosis 
Isolation of parasites for ex vivo RNA-seq was performed on the day of volunteer 
diagnosis (positive thick film smear by microscopy), prior to initiation of treatment. 
This time point was selected to ensure peak parasitaemia, and thus the increased 
likelihood of achieving sufficient material for sequencing. Parasite isolation was 
performed on 13 of the 14 infected volunteers that underwent CHMI (volunteer ♯22 
was excluded from analysis due to a reduced blood volume available for collection 
on day of diagnosis). On average, this subset of volunteers became positive by thick 
film smear ~9 days post infection (range = 7.5 – 10.5), and thus parasites were 
predicted to be either in the 4th, 5th or 6th generation (Table 4.2). Parasitaemias 
ranged 1,440 – 273,247 parasites/mL of blood, as measured by qPCR. Excluding 
any potential loss in parasite numbers during the isolation process, this equated to a 
range of 72,000 – 13,662,350 parasites, in the 50 mL blood volumes collected. 
Percentage parasitaemia was calculated using the reference number of 
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erythrocytes/mL of whole blood for healthy adult males (5.4x109/mL) and females 
(4.8x109/mL) (https://www.nhs.uk/conditions/red-blood-count/).  
 
Table 4.2 | Volunteer infection kinetics 
Volunteer i.d Day of diagnosis Predicted parasite generation P/mL of blood Total parasites (in 50 mL of blood) % parasitemia
208 C +9.0 5th 1,440 72,000 0.00003
12 C +7.5 4th 1,645 82,250 0.00003
19 C +8.5 5th 6,932 346,600 0.0001
26 C +9.0 5th 9,133 456,650 0.0002
27 C +9.0 5th 13,421 671,050 0.0003
20 C +8.5 5th 15,025 751,250 0.0003
106 C +8.5 5th 16,162 808,100 0.0003
17 C +10.5 6th 16,911 845,550 0.0003
18 C +8.5 5th 19,670 983,500 0.0004
24 C +10.0 6th 43,707 2,185,350 0.0008
13 C +10.5 6th 70,368 3,518,400 0.001
206 C +10.0 6th 185,576 9,278,800 0.003
16 C +10.0 6th 273,247 13,662,350 0.005  
 
In addition to the 13 parasite samples isolated at day of diagnosis, two samples of 
the inoculum used to infect volunteers were also processed for analysis, as 
described in Materials and Methods section 2.2.1.4. RNA from inoculum samples 
was preserved, and processed alongside RNA from the 13 volunteer samples as 
described in section 4.4.3.1. 
 
4.5.2 Quantity and quality assessment of RNA and cDNA libraries 
One of the major issues in isolating parasites from whole human blood for RNA-seq 
analysis is the potential contamination with host material. Although samples were 
depleted of leucocytes and red cells during sample processing, it was predicted that 
the RNA extracted from the isolated parasite samples would also contain RNA from 
the host. As much as 70% of the mRNA in a (blood) total RNA sample can be globin 
mRNA, with the remaining total RNA composed of greater than 90% ribosomal RNA 
(rRNA). Neither globin mRNA nor rRNA provide valuable sequencing information 
and thus were removed from the RNA samples prior to RNA-seq. The combined 
Globin-Zero® Gold kit from Illumina was used for this purpose, as described in 
section 4.4.3.2. Bioanalyzer electropherograms were generated pre- and post-
depletion to confirm effective removal of 18S and 28S rRNA peaks (Figure 4.1).  
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Figure 4.1 | Quality control ribosomal RNA removal. Electropherograms showing fluorescence units (FU) on the y axis, versus time (s) on  the x-axis. 
A) Total RNA from isolated parasites from volunteer 16; marker (25nt), miRNA and 5s rRNA (<200nt), 18s subunit rRNA (~2000nt) and 28s subunit rRNA 
(~5000nt). B) Ribosomal depleted RNA from volunteer 16 parasite sample; marker (25 nt) and mRNA  + miRNA (100 – 2000nt). (Plots generated by the 
bioanalyzer  (Agilent Technologies)).  
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Figure 4.1 | Quality control ribosomal RNA removal. Electropherograms showing fluorescence units (FU) on the 
y-axis, versus time (s) on the x-axis. A) total RNA from isolated paraistes from volunteer 16; marker (25 nt), mRNA 
and 5s rRNA (<200 nt), 18s subunit rRNA (~2,000 nt) and 28s subunit rRNA (~5,000 nt). B) Ribosomal depleted 
RNA from volunteer 16 parasite sample; marker (25 nt) and mRNA + miRNA (100 – 2,000 nt). (Plots generated 
using the bioanalyser (Agilent Technologies)).  
 
The two main subunits of human ribosomal RNA are 18S and 28S with sizes      
1,869 nt and 5,070 nt, respectively. Post-ribosomal depletion bioanalyzer traces 
suggested complete elimination of the previously observed ribosomal peaks, which 
was a requirement for taking the samples forward for library preparation. Following 
depletion of ribosomal RNA and globin mRNA, the majority of samples were too low 
in concentration for quantification by nanodrop (quantification range 0.4 – 15,000 
ng/μl), thus samples were instead quantified using the Agilent bioanalyzer and RNA 
6000 Pico Chip assay (quantification range 50 – 5,000 pg/μl), either neat or 
following a 1:10 dilution. Table 4.3 displays the concentration and yield for each 
RNA sample recovered. Samples were quantified within the range 0.05 – 71.7 ng/μl, 
with volunteers ♯208 and ♯206 representing either end of the scale, respectively. 
RNA concentration did not correlate with parasitaemia at time of sampling, 
indicating either sensitivity issues during the quantification of such low levels, or 
host RNA contributing to the measurement. This highlights the two biggest technical 
hurdles in using CHMI for analysis of parasite gene expression; limited parasite 
material available (due to early termination of volunteer infections), and host 
contamination during parasite isolation.  
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Table 4.3 | Bioanalyzer quantification of purified RNA samples 
Total parasites Concentration Recovered yield
(in 50mL whole blood) (ng/µl) (ng)
208 72,000 0.053 0.53
12 82,250 4.840 48.4
19 346,600 0.736 36.8
26 456,650 0.158 7.88
27 671,050 0.150 7.51
20 751,250 0.394 19.7
106 808,100 0.926 46.3
17 845,550 1.964 98.2
18 983,500 5.181 259.0
24 2,185,350 0.097 4.85
13 3,518,400 0.166 8.28
206 9,278,800 71.660 716.6
16 13,662,350 0.344 3.44
Parasite Inoculum (PI1) N/A 0.281 14.05




All 15 samples (including the two from the inoculum) met the quantification 
requirements for first strand cDNA synthesis and amplification using the Smart-seq2 
protocol (10 pg – 10 ng), however, following Smart-seq2 amplification, the sample 
from volunteer ♯208 did not produce sufficient cDNA for downstream library prep 
and thus was excluded from further analysis. For all remaining samples (n = 14), the 
NEB NEXTflex® kit (requiring 500 ng cDNA) was used to produce libraries for RNA-
seq (see section 4.4.6). Libraries were quality assessed using the Agilent 
Bioanalyzer High Sensitivity DNA chip (Agilent Technologies). Figure 4.2 displays 
the electropherograms of the libraries prepared from representative samples ♯24 
(with lower-end RNA yield) and ♯18 (higher-end RNA yield). The median of cDNA 
libraries was observed, as expected, at approximately 300 bp (~500 - 600 bp with 
the inclusion of NEB NEXTflex® sequencing adapters). The NEB NEXTflex® 
libraries showed high symmetry within their distribution and high similarity across 
cDNA library samples.  
 
Figure 4.2 | Quality assessment of cDNA libraries. Electropherograms showing fluorescence units (FU) on the y- axis, against 
base-pairs (bp) on the x-axis. Plots show the cDNA libraries prepared from parasites recovered from volunteer 24 (A) and 
volunteer 18 (B), using the NEB NEXTflex® kit (Bioo Scientific). Lower (35 bp) and upper (10,380) markers are shown. (Plots 
generated by the bioanalyzer  (Agilent Technologies)).  
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Figure 4.2 | Quality assessment of cDNA libraries 
Electropherograms showing fluorescence units (FU) on the y-axis, against base-pairs (bp) on the x-axis. Plots show 
the cDNA libraries prepared from paraistes recovered from volunteer 24 (A) and volunteer 18 (B), using the NEB 
NEXTflex® kit (Bioo Scientific). Lower (36 bp) and upper (10,380 bp) markers are shown. ((Plots generated using 
the bioanalyser (Agilent Technologies)).  
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4.5.3 Read counts and coverage 
Table 4.4 displays the total read counts measured for each sample, as well as the 
total (and percentage) that mapped to either the human or P. falciparum reference 
genome. The percentage of reads mapped to the human genome ranged from 
23.05% (sample ♯13) to 94.4% (sample ♯206), with median = 89.0%, suggesting 
that RNA preparations made from the isolated parasite samples contained a high 
proportion of host material, as expected. The number of reads mapped to the         
P. falciparum genome ranged from 107,149 (sample ♯206) – 2,732,963 (sample 
♯27), with median = 884,333 and were sufficient for analysis of all samples. 
Importantly, despite the limited parasite material available, and thus low RNA inputs, 
good gene coverage was detected for all patient samples (median number of P. 
falciparum genes identified with ≥5 reads = 2,518 and range = 1,159 – 3,671). 
Furthermore, reads could be detected across the full length of genes, despite the 
high number of amplification cycles performed in the PCR, which can sometimes 
lead to a signal bias towards either the 5’ or 3’ end of transcripts (Reid et al. 2018). 
Figure 4.3 displays the read counts per nucleotide, covering the entire length of the 
most abundantly transcribed var gene in the dataset (PF3D7_1041300/ 
PF10_0406), for three representative samples (♯12, ♯17 and ♯206) with some of the 
lowest total coverage.  
 







Figure 4.3 | Read count and coverage over the var gene PF3D7_1041300, for three representative samples of low          
P. falciparum read counts; 12 (pink line), 17 (green line) and 206 (black line). Gene is composed of 2 exons and located at a 
genome region spanning 1642401 – 1649948 base pairs (bp) (total transcript length = 6.6 kbp ). Read counts per nucleotide 
is shown on the y-axis (maximum read height is shown).  Note that plot represents read counts before rlog normalisation 
and thus samples cannot be compared for differences in gene expression. Figure produced by Dr Adam Reid, Wellcome 
Trust Sanger Institute 
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Figure 4.3 | Re d count c verage over the var gene PF3D7_1041300, for three representative samples of low  
P. falciparum read counts; 12 (pink line), 17 (green line) and 206 (black line). Gene is composed of 2 exons and is 
located at a genome region spanning 1,642,401 – 1,649,948 base pairs (bp) (total transcript length = 6.6 kbp). Read 
counts per nucleotide is shown on the y-axis (maximum read height is shown). Note that plot represents read 
counts before rlog normalisation and thus samples cannot be compared for differences in gene expression. Figure 
produced by Dr Adam Reid, Wellcome Trust Sanger Institute.  
 
 
4.5.4 Differential expression analysis between parasites isolated from 
inoculum samples, and parasites recovered from infected volunteers at the 
day of patent infection  
In order to investigate evidence for VSA selection in the naive host, differential 
expression analysis was performed on parasites isolated from the two samples of 
blood-stage inoculum used to infect, and parasites recovered from the volunteers at 
the day of patent infection, following 5-6 replication cycles in the blood. Analysis 
revealed 203 differentially expressed genes (DEGs) between the two different 
sample types (Appendix 8). Of the 203 differentially expressed genes, 132 were 
found more highly expressed in the volunteer samples and mainly included genes 
encoding transcription factors, RNA binding proteins, heat-shock proteins and 
proteins involved in DNA repair and RNA processing. 37 of these 132 genes (28%) 
were conserved or hypothetical proteins of unknown function. Interestingly, the most 
differentially expressed (7.6 fold-increase in the volunteer samples) was the rif gene 
PF3D7_0401600.1/ PFD0070c. This gene encodes a group-A RIFIN protein and is 
described as strain-transcendent, having been detected in 3D7, HB3, IT and Dd2 P. 
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falciparum strains (Claessens et al. 2011). In one study, it has been found 
transcribed at high levels in parasite populations enriched for parasites that bind to 
the human endothelial receptors P-selectin, E-selectin, CD9 and CD151 (Metwally 
et al. 2017), however limited information is currently available with regards to its 
function. Of the differentially expressed genes found at lower levels in the volunteer 
samples (n = 71), five were var genes- PF3D7_0632800/ MAL6P1.1; 
PF3D7_0223500/ PFB1055c; PF3D7_1300100/ PF13_0001; PF3D7_0100100/ 
PFA0005w and PF3D7_0712000/ PF07_0049). Four of these genes encode group-
B PfEMP1, whereas PF3D7_0712000/ PF07_0049 belongs to the group-C subset. 
Reduced expression of these variants may be suggestive in vivo var gene switching 
mechanisms at play, or may simply reflect differences between the preparation of 
the inoculum and patient samples prior to analysis. For instance, whereas parasites 
in the patient samples were processed for analysis (at 4oC) within 4 hours of 
isolation from fresh blood, parasites in the inoculum samples had been previously 
cryopreserved, and then thawed and incubated at room temperature for up to 3 
hours before the addition of stabilising TRIzol reagent. Thus, it is possible that the 
viability of parasites may have been compromised during processing, and it is 
unclear if- and how- the presence of differential levels of degraded parasite RNA 
affects measurements of gene expression. Importantly, the two inoculum samples 
(PI1 and PI2), representing the only replicate samples in the dataset, were found to 
be significantly positively correlated for var and rif gene expression, as expected 
(spearman rank coefficient, r = 0.951, p= < 0.0001) (Figure 4.4). 
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Figure 4.4 | Correlation analysis of var and rif (rlog) expression in the two replicate 
inoculum samples. The pairwise Spearman’s rank correlation demonstrating a positive, 
significant correlation between the (rlog) expression values for the detectable var and rif 
transcripts in parasite inoculum replicate 1 and parasite inoculum replicate 2. The Spearman’s 
rank correlation coefficient (r) is shown, along with p. value (p<0.0001). Significance was 
defined as p = <0.05.  
 
Figure 4.4 | Correlation analysis of var and rif (rlog) expression in the tw  replicate inoculum samples 
The pairwise Spearman’s rank correlation demonstrating a positive, significant correlation between the (rlog) 
expression values for the detectable var and rif transcripts in parasite inoculum replicate 1 (x-axis) and parasite 
inoculum replicate 2 (y-axis). The Spearman’s rank correlation coefficient (r) is shown, along with p. value (p < 
0.0001). Significance was defined as p = <0.05.  
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4.5.5 Var Gene Expression in Controlled Human Plasmodium falciparum 
Infection 
There is evidence to implicate the group-A and B/A var genes/PfEMP1 proteins, in 
the pathogenesis of severe malaria infection. Given that severe disease is most 
commonly observed in children with limited prior exposure to the Plasmodium 
parasite, there is a need to investigate var gene expression in a representative 
population of malaria-naive individuals.  
Analysis of var gene profiles in 12 volunteers during CHMI revealed the detection of 
58/61 (95%) var gene variants at day of patent infection (table 4.5). Just three 
group-A var genes- (PF3D7_0533100/PFE1640w, PF3D7_1150400/PF11_0521 
and PF3D7_0600400/MAL6P1.314) were undetectable by definition of the set cut-
off (≥ 5 reads in at least one sample). Importantly, this broad-level detection of 
variants is consistent with data from three previously published studies of parasite 
var gene expression in controlled human malaria infection (Lavstsen et al. 2005, 
Wang et al. 2009, Bachmann et al. 2016). 
 
Table 4.5 | Number of each var gene subgroup detected in the dataset 
var  subgroup Upstream Sequence Position Orientation (direction of transcription) No. of genes in 3D7 No. of genes detected in volunteer cohort
A UpsA Subtelomeric Telomeric 10 7
B/A UpsB Subtelomeric Centromeric 4 4
B UpsB Subtelomeric Centromeric 24 24
B/C UpsB Central Telomeric 9 9
C UpsC Central Telomeric 13 13
E UpsE - - 1 1  
 
Interestingly, var gene expression profiles were remarkably uniform across 
volunteers (Figure 4.5). Genes demonstrating the highest levels of expression were 
largely of the group-B subclass, however also included 3 genes from the B/C 
subgroup (PF3D7_0712800/ MAL7P1.55, PF3D7_0421100/ PFD1005c and 
PF3D7_0809100/ PF08_0103), 2 from the B/A subgroup (PF3D7_0632500/ 
PFF1580c and PF3D7_1200400/ PFL0020w), 1 group-C gene (PF3D7_0421300/ 
PFD1015c) and the conserved group-E gene (PF3D7_1200600/ VAR2SCA) (table 
4.6). Across all volunteers, the highest transcript levels were detected for 
PF3D7_1041300/ PF10_0406 (rlog median = 11.07; range: 8.94 – 11.68), followed 
by PF3D7_1200100/ PFL0005w (rlog median = 9.12; range: 8.04 – 10.24), 
PF3D7_0712800/ MAL7P1.55 (rlog median = 8.02; range: 4.61 – 9.59), 
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PF3D7_0421100/ PFD1005c (rlog median = 7.88; range: 6.06 – 8.54), 
PF3D7_0421300/ PFD1015c (rlog median = 7.49; range: 6.08 – 8.21) and 
PF3D7_1100100/ PF11_0007 (rlog median = 7.22; range: 4.93 – 9.11) (figure 4.6).  
Five out of the six genes are categorised as either group-B or group-B/C var genes, 
suggesting dominant expression of the UpsB genes in vivo. This is in agreement 
with previously published data from Bachmann et al, who upon infection of 18 
volunteers with P. falciparum (N5F4), detected broad expression of var genes, and 
group-B variants as the most highly expressed (figure 4.8) (Bachmann et al. 2016). 
Conversely, members of the group A var genes, were detected at the lowest levels 




Figure 4.5 | Comparison of var gene expression across the volunteer cohort and inoculum samples 
Heatmap showing normalised (rlog) values for all detectable var transcripts. Each row represents a var gene 
(annotated on the left hand side), and each column represents a volunteer or inoculum sample (annotated along the 
bottom, and colour coded as per transcriptional response class; “classical” responders (red), “non-classical” 
responders (blue), “unknowns” (yellow), or as parasite inoculum samples (PI1 and PI2) in grey). Var type is shown 
and sample sequencing depth is indicated, as per the colour keys provided. (Heatmap generated by Dr Adam Reid, 
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Figure 4.6 | Top six var gene variants in patient samples. Graph displays the normalised (rlog) read counts for the six 
var gene variants with highest transcript levels across the 12 patient samples. Each box represents the median and 
range for one of the six genes (annotated on the x-axis). Boxes have been colour-coded as per var gene sub-group (B B/







Figure 4.6 | Top six var ge e variants in ati nts amples. Gr ph displays the normalised (rlog) read counts for 
the six var gene variants with highest transcript levels across the 12 patient samples. Each box represents the 
median and range for one of the six genes (annotated on the x-axis). Boxes have been colour-coded as per var 
gene sub-group (B, B/C or C). A colour-key is provided.   
 
 
Figure 4.7 provides a schematic representation of the PfEMP1 domain architecture 
for those encoded by the top six most highly expressed var genes in the dataset 
(PF10_0406, PFL0005w, MAL7P1.55, PFD1005c, PFD1015c and PF11_0007). All 
six represent small PfEMP1 and are similar in structure, comprising four 
extracellular domains; the semi-conserved DBLα0-CIDRα head structure (commonly 
associated with CD36 binding) (Smith et al. 2001, Robinson et al. 2003), followed by 
a DBLδ-CIDRβ/γ/δ tandem domain. DBL and CIDR domains have been further sub-
classified (denoted by numbers) according to (Rask et al. 2010). Binding of the 
CD36 receptor on host endothelial cells appears to be mediated by several CIDRα 
class domains (Baruch et al. 1995, Baruch et al. 1997, Gamain et al. 2001, Smith et 
al. 2001), but is limited to those of the B and C subgroups (Robinson et al. 2003, 
Turner et al. 2013). In contrast, group-A PfEMP1 have two distinct protein head 
structures; DBLα1-CIDRα1 and DBLα1-CIDRβ/γ/δ (Rask et al. 2010) which have 
been linked to binding activity for endothelial protein C receptor (EPCR) (Turner et 
al. 2013), and higher rates of rosetting (Russell et al. 2005, Ghumra et al. 2012), 
common in more severe infections (Carlson et al. 1990, Rowe et al. 1995). As 






Figure 4.7 | PfEMP1 domain architectures for the variants encoded by the six most highly expressed var 
genes in the dataset (PF10_0406, PFL0005w, MAL7P1.55, PFD1015c, PFD1015c and PF11_0007). PfEMP1 
proteins have multiple domains including (from N- to C-terminal): the N-terminal segment (NTS), Duffy binding-like 
(DBL) domains, Cysteine-rich inter-domain regions (CIDR), one transmembrane region (TM) and the acidic terminal 
segment (ATS). Six major classes of DBL domains have been proposed based on amino acid sequence similarity: 
DBLα, β, γ, δ, ζ, and ε, whereas CIDR domains have been divided into five major classes: CIDRα, β, γ, δ and pam. 
DBL and CIDR domains have been further sub-classified (denoted by numbers) according to Rask et al., 2010. A) 
The domain structure for each associated PfEMP1 protein has been annotated using the VarDom server                
(http://www.cbs.dtu.dk/services/VarDom/). B) summarises the PfEMP1 head-structure domains that have been 
associated with CD36 binding and non-CD36 binding PfEMP1. For each PfEMP1, the var gene i.d and associated 
group is shown.  
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Table 4.6 | Normalised (rlog) read counts for all detectable var genes in the 12 patient and 2 inoculum samples (same order as heatmap) 
transcript i.d var i.d var group v019 v026 v106 v013 v024 v016 v206 v020 v017 v027 v018 v012 median of patient samples PI1 PI2 median of inoculum samples
PF3D7_0100100 PFA0005w B 2.02 1.79 1.48 2.84 2.28 4.30 1.93 0.24 1.61 4.00 0.70 2.24 1.97 0.79 8.54 4.66
PF3D7_1373500 PF130364 B 0.89 1.04 3.04 3.07 3.31 2.85 4.24 2.90 4.02 3.08 0.94 1.27 2.97 1.00 1.70 1.35
PF3D7_0617400 MAL6P1.252 C 1.84 0.74 0.37 2.81 3.13 1.76 1.66 0.06 2.29 4.09 4.22 0.98 1.80 0.70 1.94 1.32
PF3D7_0712300 MAL7P1.50 B/C 1.51 0.94 0.61 2.89 2.38 1.44 1.80 2.60 2.63 2.15 4.34 2.10 2.12 2.73 1.60 2.16
PF3D7_1240300 PFL1950w B/C 2.81 0.36 0.05 1.57 0.75 3.98 1.28 -0.21 2.00 2.83 1.14 0.65 1.21 0.33 0.29 0.31
PF3D7_1240400 PFL1955w B/C 2.71 0.78 0.51 3.13 2.76 2.34 1.61 2.08 3.44 2.00 0.71 0.98 2.04 1.52 0.71 1.12
PF3D7_1100200 PF11_0008 A 2.30 0.69 0.39 1.04 3.57 1.55 1.55 0.53 3.42 2.20 2.16 1.87 1.71 0.66 1.84 1.25
PF3D7_1219300 PFL0935c B 0.59 0.69 0.44 1.87 2.23 2.36 2.51 1.49 2.33 1.79 2.07 1.79 1.83 0.66 1.34 1.00
PF3D7_1000100 PF10_0001 B 2.16 0.58 2.79 1.20 2.06 2.40 1.40 0.17 0.52 0.58 2.91 0.80 1.30 0.55 2.27 1.41
PF3D7_0711700 PF07_0048 C 2.92 0.72 2.51 3.06 2.48 -0.02 1.62 0.10 0.64 4.17 1.90 2.90 2.19 0.69 1.91 1.30
PF3D7_0808700 PF08_0106 B/C 0.22 1.25 3.19 2.71 3.47 0.89 1.24 -0.20 0.27 2.43 0.26 0.62 1.07 0.30 0.26 0.28
PF3D7_0712000 PF07_0049 C 0.08 0.28 0.61 1.58 0.38 -1.68 2.72 -0.81 6.62 -0.65 0.16 0.64 0.33 6.59 4.33 5.46
PF3D7_0400100 PFD0005w B 0.65 0.85 4.15 1.13 1.62 2.59 1.88 3.62 2.13 -0.03 1.59 6.03 1.75 6.09 0.73 3.41
PF3D7_0223500 PFB1055c B 1.72 2.01 3.05 3.43 2.47 4.78 3.36 2.68 4.04 2.49 1.03 1.47 2.59 6.98 1.04 4.01
PF3D7_0712900 MAL7P1.56 C 0.59 0.75 1.00 2.42 3.27 1.66 2.87 0.45 3.31 1.87 0.65 3.31 1.76 4.79 0.65 2.72
PF3D7_0100300 PFA0015c A -1.65 -1.64 -1.66 -1.63 -1.67 -1.67 -1.61 -1.67 -1.64 -1.67 -1.64 -1.63 -1.65 -1.64 -1.64 -1.64
PF3D7_0800200 PF08_0141 A -0.76 -0.70 -0.84 -0.84 -0.83 0.15 -0.39 -0.24 -0.73 -0.86 -0.74 -0.60 -0.74 -0.71 -0.74 -0.72
PF3D7_0808600 PF08_0107 C -0.57 -0.50 -0.34 0.27 -0.12 -0.41 -0.16 -0.52 -0.54 -0.65 -0.55 -0.39 -0.46 -0.52 -0.55 -0.53
PF3D7_0420900 PFD1000c C 3.84 -0.23 -0.78 -2.16 -0.09 -2.10 2.15 -1.29 -0.37 1.55 -0.38 1.35 -0.30 -0.29 5.90 2.80
PF3D7_0500100 PFE0005w B 1.51 -0.06 -0.31 1.66 0.85 0.09 0.66 -0.42 2.15 -0.39 -0.16 0.17 0.13 -0.10 -0.15 -0.12
PF3D7_1240900 PFL1970w B/C -0.08 0.05 -0.20 1.88 2.27 0.04 0.83 -0.34 2.19 1.75 -0.05 0.30 0.18 0.01 -0.05 -0.02
PF3D7_0712400 PF07_0050 B/C 0.08 0.19 -0.04 2.08 0.71 1.19 0.99 0.88 0.12 0.91 1.67 2.82 0.89 0.15 0.11 0.13
PF3D7_0412900 PFD0630c C -0.32 -0.16 -0.45 1.35 0.92 -0.70 0.59 -0.59 -0.25 1.95 -0.26 2.27 -0.20 -0.20 -0.26 -0.23
PF3D7_0800300  PF08_0140 B/A -0.29 -0.17 -0.37 1.03 -0.05 0.13 0.40 0.48 -0.24 1.54 -0.25 0.01 -0.02 -0.20 -0.25 -0.23
PF3D7_0833500 MAL7P1.212 B -0.12 0.01 1.24 1.18 -0.20 1.24 0.69 -0.30 -0.08 1.91 -0.09 1.04 0.35 -0.03 -0.08 -0.06
PF3D7_0324900 PFC1120c B 1.72 -0.09 2.45 0.67 0.41 1.05 0.67 -0.48 -0.18 -0.45 -0.19 0.15 0.28 -0.13 -0.19 -0.16
PF3D7_0413100 PFD0635c B/C 2.28 -0.40 -0.71 1.31 -0.74 0.72 0.41 -0.88 -0.50 -0.34 -0.51 -0.14 -0.37 -0.44 -0.50 -0.47
PF3D7_0700100 MAL8P1.220 B -0.17 -0.06 -0.22 0.25 1.01 0.66 0.50 1.13 -0.13 -0.26 0.46 0.12 0.18 -0.09 0.46 0.18
PF3D7_1240600 PFL1960w C -0.20 -0.05 -0.30 0.93 1.14 1.95 0.67 2.30 -0.14 -0.39 -0.15 0.18 0.06 -0.09 -0.15 -0.12
PF3D7_0900100 PFI0005w B 0.70 0.10 -0.13 1.97 2.54 -0.02 0.85 0.98 0.78 -0.22 0.01 0.34 0.52 0.06 1.22 0.64
PF3D7_1300300 PF13_0003 A 1.41 -0.07 -0.29 1.38 1.84 -0.06 0.59 -0.10 -0.16 -0.36 -0.16 0.14 -0.07 -0.11 0.54 0.22
PF3D7_0412700 PFD0625c C -0.17 -0.06 -0.23 0.64 1.38 0.76 0.54 -0.29 1.19 0.00 -0.14 0.13 0.07 -0.09 0.50 0.21
PF3D7_0937600 PFI1820w A -0.56 -0.41 -0.65 0.60 1.47 -0.38 0.26 -0.74 -0.50 -0.72 -0.50 -0.20 -0.45 -0.45 0.93 0.24
PF3D7_0400400 PFD0020c A (var3) -0.13 0.07 -0.42 1.37 3.22 1.87 1.15 1.98 -0.05 -0.75 -0.06 0.41 0.24 0.01 5.70 2.86
PF3D7_0420700  PFD0995c C 0.49 3.11 0.26 3.41 4.31 2.35 1.56 3.05 0.55 0.03 0.54 0.89 1.23 0.60 3.32 1.96
PF3D7_0115700 PFA0765c B 1.55 0.37 0.05 2.02 0.89 0.44 1.30 2.65 0.30 -0.14 0.29 3.99 0.66 2.79 1.65 2.22
PF3D7_0600200 MAL6P1.316 B/A -0.08 0.08 -0.26 -0.60 2.11 1.77 0.98 -0.04 -0.03 -0.44 -0.04 3.36 -0.03 3.00 1.40 2.20
PF3D7_0712600 PF07_0051 C 1.06 0.39 0.09 0.20 2.75 0.10 1.28 3.68 0.32 0.38 2.78 1.64 0.72 1.23 1.97 1.60
PF3D7_0425800 PFD1235w A 0.52 0.61 0.41 2.57 2.76 2.38 1.38 2.67 0.56 1.80 0.55 0.79 1.09 1.32 1.69 1.51
PF3D7_0412400 PFD0615c C 2.98 1.39 0.90 2.42 2.62 1.21 1.40 1.76 0.55 1.98 1.26 0.82 1.40 0.58 0.55 0.57
PF3D7_0426000  PFD1245c B 1.70 1.49 0.42 2.02 2.73 1.13 2.57 2.36 0.62 1.32 3.12 0.89 1.59 0.65 1.80 1.23
PF3D7_1041300 PF10_0406 B 11.23 11.44 10.65 11.40 11.68 11.40 10.33 11.30 9.84 8.94 10.91 10.79 11.07 11.47 11.53 11.50
PF3D7_1200100 PFL0005w B 9.46 10.24 8.96 9.27 9.50 9.95 8.04 8.65 8.17 9.20 9.04 8.90 9.12 8.90 10.94 9.92
PF3D7_0712800 MAL7P1.55 B/C 9.43 9.59 7.52 9.02 5.57 8.12 7.43 8.19 8.13 7.91 4.61 4.90 8.02 8.57 4.61 6.59
PF3D7_1100100 PF11_0007 B 8.16 9.11 7.33 5.82 6.79 7.34 7.56 7.40 6.76 4.93 5.64 7.12 7.22 9.57 8.25 8.91
PF3D7_0421100 PFD1005c B/C 8.07 7.36 7.75 7.91 6.43 8.54 7.43 8.02 6.06 7.84 8.04 8.07 7.88 8.57 8.33 8.45
PF3D7_0421300 PFD1015c C 8.13 7.90 6.91 7.32 6.73 7.57 6.65 7.72 6.08 7.42 8.21 7.65 7.49 8.25 8.51 8.38
PF3D7_0632500 MAL6P1.4 B/A 4.86 3.62 5.31 5.94 6.35 7.39 5.78 7.07 5.09 4.91 5.64 5.16 5.47 8.46 6.97 7.72
PF3D7_0800100 PF08_0142 B 8.05 3.07 5.21 5.05 4.72 8.00 6.70 6.12 4.53 3.92 3.97 4.72 4.89 7.38 5.84 6.61
PF3D7_0300100  PFC0005w B 8.27 5.73 5.05 6.93 6.45 6.10 6.68 6.41 6.77 4.79 5.91 5.87 6.26 7.67 8.42 8.04
PF3D7_1200600 PFL0030c E/var2CSA 6.64 8.02 5.07 6.25 7.11 8.39 6.65 5.39 6.54 5.21 5.81 5.55 6.39 7.52 5.47 6.50
PF3D7_0200100 PFB0010w B 7.42 6.14 7.96 7.33 4.41 6.83 8.34 7.34 4.16 2.71 7.37 6.06 7.08 7.01 9.51 8.26
PF3D7_0632800 MAL6P1.1 B 6.97 3.12 7.12 7.49 5.79 5.88 5.76 6.19 6.24 6.59 6.67 7.46 6.41 9.29 9.98 9.63
PF3D7_1255200 PFL2665c B 6.14 3.11 4.10 3.68 3.60 6.58 7.40 5.19 1.86 1.03 4.87 3.11 3.89 5.38 7.94 6.66
PF3D7_0733000 PF07_0139 B 2.20 1.78 1.20 4.21 1.64 3.93 4.96 5.09 4.03 5.01 3.33 6.25 3.98 6.20 8.07 7.13
PF3D7_1300100 PF13_0001 B 2.00 2.30 4.46 3.01 4.59 3.79 4.38 2.68 1.39 3.51 2.58 4.19 3.26 4.16 8.34 6.25
PF3D7_0809100 PF08_0103 B/C 4.92 8.92 7.14 4.31 3.95 6.05 4.95 6.13 2.84 3.87 7.21 5.27 5.11 5.75 3.72 4.74
PF3D7_0937800 PFI1830c B 4.84 3.77 3.82 4.62 4.44 5.00 7.34 6.05 3.30 5.30 6.32 6.60 4.92 7.62 9.07 8.34
PF3D7_1200400 PFL0020w B/A 3.09 3.40 3.95 5.33 5.08 4.83 4.95 5.79 2.28 7.47 7.34 5.59 5.02 8.24 7.91 8.08  
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4.5.5.1 Comparison of ex vivo parasite var gene profiles with previous studies 
of CHMI 
Considering the differences in methodologies used for var gene profiling, I was 
interested to compare patterns of var gene expression observed in this dataset, with 
those previously reported in studies of CHMI (Peters et al. 2002, Lavstsen et al. 
2005, Wang et al. 2009, Bachmann et al. 2016). In the original study, Peters et al 
show expression of var gene variants belonging mainly to groups A and B, with 
dominant expression coming from a single B-type PfEMP1 transcript 
(PF3D7_1100100/ PF11_0007) (Peters et al. 2002). Interestingly, this variant was 
detected among the top 6 most highly expressed var genes in my dataset (rlog 
median = 7.22; range: 4.93 – 9.11) (figure 4.6). Observations made by Peters et al, 
however, contradict the broad-level detection of almost all var gene variants (95%) 
within this study.  
 
More consistent with my results is the recent data from Bachmann et al, 
demonstrating the expression of a broad range of var gene variants, with highest 
level expression coming from the group-B subclass (Bachmann et al. 2016). Figure 
4.8 compares the expression patterns of all detectable var genes, across the 
different subgroups. The most highly expressed variant in the study by Bachmann et 
al (PF3D7_0632800/ MAL6P1.1) was found as the 8th most highly expressed within 
this cohort of volunteers. Analysis of the top 20 expressed variants across both 
studies revealed 11 shared genes (PF3D7_0632800/ MAL6P1.1; PF3D7_0937800/ 
PFI1830c; PF3D7_0800100/ PF08_0142; PF3D7_1255200/ PFL2665c; 
PF3D7_0223500/ PFB1055c; PF3D7_1373500/ PF13_0364; PF3D7_1300100/ 
PF13_0001; PF3D7_0632500/ MAL6P1.4; PF3D7_1041300/ PF10_0406; 
PF3D7_1100100/ PF11_0007 and PF3D7_1200100/ PFL0005w), 10 of which 
belong to the group-B var subclass. However, there are also some inconsistencies 
between the two datasets, which may be a result of the different methodologies 
used to measure var gene expression (qPCR vs RNA-seq) or due to the different 
models of CHMI used to infect volunteers (mosquito-bite vs blood-stage). For 
instance, in the study by Bachmann et al, the group-A variant PF3D7_0400400/ 
PFD0020c was among the top 5 most highly expressed, whereas this var gene was 
detected with some of the lowest levels across the dataset. Nevertheless, when 
considering all var gene variants, a significant positive correlation in expression was 
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observed between the two studies (figure 4.9). Interestingly, apart from slight 
differences in frequencies, the expression patterns reported by Bachmann et al, 
were almost identical to those reported in a previous study of CHMI, albeit based on 
parasites from a single volunteer (Wang et al. 2009). In this study by Wang et al, 
PF3D7_0632800/ MAL6P1.1 was also found expressed at the highest level, and all 
other var gene variants had a similar hierarchy of expression, dominated by those of 
the group-B subclass. Thus, my analysis of parasite var gene expression in 
volunteers following blood-stage CHMI demonstrates similarities with those 
previously published across different studies of mosquito-bite CHMI. However, it will 
be important to investigate parasite var gene expression by RNA-seq (as was used 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.8 | Comparison of ex vivo parasite var gene expression profiles in human volunteers to patterns observed in a previous study of mosquito-bite CHMI. A) 
RNA-seq analysis of parasite populations isolated at day of patent infection (thick film smear positivity), from 12 malaria-naïve volunteers following blood-stage CHMI with P. 
falciparum (3D7-strain). The distribution of the rlog expression (read counts) per var gene is presented as a dot plot for all volunteer samples. Each point represents a var gene 
rlog value and the median expression is marked. B) Data from Bachmann et al., 2016. qRT-PCR analysis of parasite populations isolated at day of patent infection (defined as 
thick film smear positivity)  from 18 malaria-naïve volunteers following mosquito-bite CHMI with P. falciparum (NF54). The distribution of the relative gene expression per var gene 
is shown in a dot plot for all volunteer samples. Each point represents a var gene expression value relative to the normalising gene sbp1 observed per volunteer sample and the 




Figure 4.8 | Compariso of x viv arasi e var gen  expression profiles in human volunteers. A) RNA-seq 
analysis of parasite populations isolated at day of patent infection (thick film smear positivity), from 12 malaria-naïve 
volunteers f llowing blood-stage CHMI ith P. falciparum (3D7-strain). he distribution of the rlog expression (read 
counts) per var gene is presented as a dot plot for all volunteer samples. Each point represents a var gene rlog 
value and the median expression is marked. B) Data from Bachmann et al. 2016. qRT-PCR analysis of parasite 
populations isolated at day of patent infection (defined as thick film smear positivity)  from 18 malaria-naïve 
volunteers following mosquito-bite CHMI with P. falciparum (NF54). The distribution of the relative gene expression 
per var gene is shown in a dot plot for all volunteer samples. Each point represents a var gene expression value 
relative to the normalising gene sbp1 observed per volunteer sample and the median expression per var gene is 
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marked. For both plots, var gene names and groups are indicated (var genes in grey = not detected). Note that 
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Figure 4.9 | Comparison of ex vivo parasite var gene expression profiles in human 
volunteers following blood-stage and mosquito-bite CHMI. Spearman’s rank correlation 
demonstrating a positive, significant correlation between parasite populations recovered at 
day of patent infection (defined by thick film smear positivity)  from n=12 volunteers following 
blood-stage CHMI (median rlog values on the x-axis) and from n = 18 volunteers following 
mosquito-bite CHMI (median expression values on the y-axis). The Spearman’s rank 
correlation coefficient (r) is shown, along with p. value (p = < 0.0001). Significance was 
defined as p = <0.05.   
 
Figure 4.9 | Comparison of ex vivo parasite var gene expression profiles in human volunteers following 
blood-stage and mosquito-bite CHMI. Spearman’s rank correlation demonstrating a positive, significant 
correlation between parasite populati s recovered at day of atent infection (defin d by thick film smear positivity)  
from n = 12 volunteers f llowing blood-st ge CHMI (median rlog values on the x-axi ) and from n = 18 volunteers 
following mosquito-bite CHMI (median expression values on the y-axis). The Spearman’s rank correlation coefficient 




4.5.5.2 Relationship between group A, B/A var expression and parasite growth 
in the blood  
Based on their association with severe disease, it has been predicted that PfEMP1 
of the group-A, B/A subclass confer a growth advantage in the immunologically 
naïve host through mechanisms that allow them to adhere to a more diverse range 
of endothelial cells, and thus more efficiently escape clearance from the spleen 
(Abdi et al. 2017). However, direct evidence is still needed to support an intrinsic 
growth advantage over other PfEMP1 types in the absence of antibody pressure 
(Warimwe et al. 2009, Warimwe et al. 2012). Using arbitrary cut-offs based on the 
calculated parasite multiplication rates (PMRs), volunteers in this cohort had been 
previously grouped into those having “fast” (PMR > 10), “intermediate” (PMR = 8 - 
10) and “slow” (PMR <8) growing parasites (see chapter 3, section 3.5.8 and table 
3.1). In order to investigate evidence for a growth advantage of the group-A and/or 
B/A var genes, their expression levels were compared across the parasite samples 
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of variable PMR class (figure 4.10).  It is important to note that just 1 of 3 belonging 
to the “slow” group were included in this analysis, as parasite RNA-seq was not 
performed on samples ♯22 and ♯208. For all 7 detectable group-A variants in the 
dataset, there was no trend suggestive of higher expression in parasites with “fast” 
PMR, compared to those with “intermediate” or “slow” PMR (figure 4.10, part A). 
This was also true for PF3D7_0800300/ PF08_0140, PF3D7_0600200/ 
MAL6P1.316 and PF3D7_0632500/ MAL6P1.4 of the B/A subgroup (figure 4.10, 
part B). There did look to be a trend towards higher expression of the group B/A 
variant PF3D7_1200400/ PFL0020w in those parasites with “fast” PMR compared to 
“intermediate” and slow “PMR”. However, when considering this var gene, as well 
as the two other most highly expressed variants of the group-A and B/A subclasses 
(PF3D7_0632500/ MAL6P1.4 and PF3D7_1100200/ PF11_0008), there was no 
correlation detected between expression levels and PMR (figure 4.10, parts D and 
E). It is important to note that these data are limited, however, by the small number 
of samples available in this study of CHMI. Thus, analysis of group-A and B/A var 
gene expression in parasites with variable growth rates in the naïve host will need to 






Figure 4.10 | Relationship between group-A / group-B/A var gene expression and parasite growth in the blood. Panels A and B show the rlog expression levels for the 7 and 4 detectable 
group-A and B/A var transcripts in the dataset, respectively.  Each dot represents a var gene expression value, per volunteer sample (n=12). The median expression value is marked. Volunteer 
samples have been colour-coded by Parasite Multiplication Rate (PMR); fast (PMR >10) in green; intermediate (PMR = 8-10) in grey and slow (PMR <8) in purple. Var gene names are indicated. 
Panels C, D and E show the Spearman’s rank correlation between rlog expression and PMR, for the three group-A, B/A var genes with highest expression levels; PF11_0008 (group-A); MAL6P1.4 
(group-B/A) and PFL0020w (group-B/A). Spearman’s rank correlation coefficient (r) is shown, along with p. value. Significance was defined as p = <0.05 (NS = Not significant). 
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4.5.5.3 Investigating evidence for var gene selection in the naïve human host 
The comparison of var gene expression between parasites isolated from the blood-
stage inoculum, and parasites recovered from volunteers at day of patent infection 
revealed the two to be consistently different, as is shown by the heatmap-based 
clustering (figure 4.5). Differential expression analysis revealed five var genes 
(PFF1595c/ PF3D7_0632800, PFB1055c/ PF3D7_0223500, PF13_0001/ 
PF3D7_1300100, PFA005w/ PF3D7_0100100 and PF07_0049/ PF3D7_071200) to 
be expressed at significantly lower levels in the volunteer samples compared to the 
inoculum (Appendix 8), which may represent the initial stages of var gene selection. 
Within the time frame assessed however, there was little evidence for this given that 
the majority of all variants (95%) were still detectable on the day of patent 
(microscopically-positive) infection, and the most highly expressed var gene variant 
in the volunteer samples, was also the most highly expressed in the inoculum 
samples (figure 4.5 and table 4.6). Furthermore, pairwise comparisons of var gene 
expression in parasites of the 5th generation (isolated at C +8 - C +10, n = 6 
samples) with those of the 6th generation in the blood cycle (isolated from C +10, n = 
5 samples), revealed the two to be significantly positively correlated (figure 4.10, 
part A). This was also true for the pairwise comparison between patient samples 
(median expression) and the inoculum used to infect (figure 4.10). Results suggest 
that following 5 - 6 replication cycles in the blood, var gene selection forces had not 
yet been activated in this in vivo setting. 
 
Figure 4.11 | Comparison of (rlog) var gene expression between parasites isolated at different stages in the blood cycle, and to those 
recovered from the inoculum. A) demonstrates the pairwise Spearman’s rank correlation between the median (rlog) expression values for all 
detectable var transcripts in samples from 5th generation parasites  (samples 18, 19, 20, 26, 27 and 106) and 6th generation parasites in the blood 
cycle (samples 13, 16, 17, 24 and 206). B) demonstrates the pairwise Spearman’s rank correlation between the median (rlog) expression values for 
all detectable var transcripts in the volunteer samples (n=12) vs the inoculum samples (n=2). For both plots, the Spearman’s rank correlation 
coefficient (r) is shown, along with p. value (p = < 0.0001). Significance was defined as p = <0.05. 
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Figure 4.11 | Comparison of (rlog) var gene expression between parasites isolated at different stages in the 
blood cy le, and o those recovered from the inoculum. A) demonstrates the pairwi e Sp arm n’s rank 
correlation between the median (rlog) expression values for all detectable var transcripts in samples from 5th 
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generation parasites  (samples 18, 19, 20, 26, 27 and 106) and 6th generation parasites in the blood cycle (samples 
13, 16, 17, 24 and 206). B) demonstrates the pairwise Spearman’s rank correlation between the median (rlog) 
expression values for all detectable var transcripts in the volunteer samples (n = 12) vs the inoculum samples (n = 
2). For both plots, the Spearman’s rank correlation coefficient (r) is shown, along with p. value (p = < 0.0001). 






4.5.5.4 Relationship between parasite var gene expression and the developing 
immune response in the malaria-naïve host 
Having observed inter-individual variation in the host immune response to                
P. falciparum (chapter 3), I wanted to investigate a similar variability in parasite gene 
expression, which may be indicative of a causal relationship. Furthermore, it was 
hypothesised that parasites isolated from the 8 “classical” responders (♯13, ♯16, 
♯17, ♯24, ♯26, ♯27, ♯106, and ♯206), showing a pronounced inflammatory response 
at both the transcriptional and protein level, would have a distinct var expression 
profile when compared to the rest. As is shown in figure 4.5 however, var gene 
profiles were remarkably similar across volunteers, and Principle Component 
Analysis did not reveal any divergence between the two groups, highlighting a clear 
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Figure 4.12 | Principle Component Analysis of parasite var gene expression across the 
volunteer cohort. Principle Component Analysis was performed on the detectable var transcripts in  
the 12 successfully sequenced parasite samples from the 8 “classical” responders (13, 16, 17, 24, 
26, 27, 106 and 206) in red, the “non-classical” responders (19) in blue, and 3 of the “unknown” 
volunteers (12, 18 and 20) in yellow. Data is presented in two dimensions- PC1 on the x-axis against 
PC2 on the y-axis. The variation encoded by each is presented as a percentage of the total variation 






Figure 4.12 | Principle Component Analysis of parasite var gene expression across the volunteer cohort. 
Principle Component Analysis was performed on the detectable var transcripts in the 12 successfully sequenced 
parasite samples from the 8 “classical” responders (♯13, ♯16, ♯17, ♯24, ♯26, ♯27, ♯106 and ♯206) in red, the “non-
classical” responders (♯19) in blue, and 3 of the “unknown” volunt ers (♯12, ♯18 and ♯20) in yellow. Data is 
presented in two dimensions: PC1 on the x-axis against PC2 on the y-axis. The variation encoded by each is 





When comparing the proportional distribution of var transcripts by var group 
affiliation (A, B/A, B, B/C, C and E), individuals showed remarkable similarities, 
irrespective of the host transcriptional response groupings presented in chapter 3 
(figure 4.13). As previously discussed, the group-B variants were attributed to the 
largest proportion of total var expression in all patient samples (range: 58.1% - 
87.2% and mean: 75.6%), followed by the group-B/C variants (range: 9.4% - 21.5% 
and mean: 14.0%), group-C var genes (range: 3.4% - 9.4% and mean: 5.0%), the 
group-B/A variants (range: 0.4% - 8.9% and mean: 2.6%), group-E (var2CSA) 
(range: 0.9% - 5.5% and mean: 2.5%) and then the group-A var genes (range: 0.1% 
- 0.7% and mean: 0.3%). Volunteer sample ♯27, of the “classical” host responder 
group had the most unique var group distribution, with a lower contribution of the 
group-B variants, and a higher contribution from the group-B/A, B/C and C variants 
compared to the other samples (figure 4.13). The proportional distribution of var 
gene groups in the patient samples demonstrated a slightly higher contribution of 
the B/C variants to the (mean) total expression (14.0%) compared to that of the 
inoculum samples (6.5%), but otherwise had a very similar distribution profile.  
 
Pairwise comparison of var gene expression in volunteer ♯16 (the most 
inflammatory “classical” responder in the cohort) and volunteer ♯19 (“non-classical” 
responder) revealed a significant positive correlation between the two (figure 4.14, 
part A). Positive correlations in var gene expression were also observed for group-
level comparisons between the “classical” responders (n = 8) and the “unknown” 
volunteers (n = 3) (figure 4.14, part B); the “classical” responders and the “non-
classical” responder volunteer ♯19 (figure 4.14, part C); as well as the “unknown” 
volunteers and “non-classical” responder volunteer ♯19 (figure 4.14, part D). Results 
suggest that inter-individual variation in host immune responses to P. falciparum 
during primary infection, is not driven by differences in parasite var gene expression, 





















































































































Figure 4.13 | Proportion of var gene expression by group. The distribution of var transcripts according to var group affiliation in shown as the proportion of 
total var gene expression for individual volunteer samples (A-C). Samples have been grouped according to host transcriptional response class; “non-classical” 
responder 19 (A); “unknowns“- 18, 12 and 20 (B) and “classical” responders- 16, 17, 13, 27, 26, 206, 106 and 24 (C). The proportion of var gene expression by 
group, across all patient samples (n=12) is shown in D. E) shows the proportion of var gene expression (mean) by group, for the two replicate inoculum 
samples. A var gene group colour-code is provided.  
 
Figure 4.13 | Proportion of var g ne expression by group. The distribution of var transcript  according to var 
group affiliation in shown as the proportion of total var gene expression for individual volunteer samples (A-C). 
Samples have been grouped according to host transcriptional response class; “non-classical” responder ♯19 (A); 
“unknowns“-♯18, ♯12 and ♯20 (B) and “classical” responders- ♯16, ♯17, ♯13, ♯27, ♯26, ♯206, ♯106 and ♯24 (C). The 
proportion of var gene expression by group, across all patient samples (n=12) is shown in D. E) shows the 
proportion of var gene expression (mean) by group, for the two replicate inoculum samples. A var gene group 
colour-code is provided.  
 
Figure 4.14 | Comparison of (rlog) var gene expression between parasites isolated from volunteers with variable host immune 
responses to P. falciparum infection. The pairwise Spearman’s rank correlation demonstrating a positive, significant correlation 
between the (rlog) expression values for the detectable var transcripts in parasite samples from volunteer 16 (“classical” responder) and 
19 (“non-classical” responder) in A.  Plots B - D show group-level correlations of the mean (rlog) expression values for the detectable 
var transcripts in the “unknown” volunteer group (12, 18 and 20) vs the “classical” responder group (13, 16, 17, 24, 26, 27, 106 and 206) 
in B, the “non-classical” responder volunteer (19) vs the “classical” responder group in C, and the “non-classical” responder volunteer 
(19) vs the “unknown” volunteer group samples in D. For each plot, the Spearman’s rank correlation coefficient (r) is shown, along with 
p. value (p<0.0001). Significance was defined as p = <0.05.  
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Figure 4.14 | Comparison of (rlog) var gene expression between parasites isolated from volunteers with 
variable host immune r sponses to P. f lciparum i fection. The pairwise Spea ma ’s rank correlation 
demonstrating a positive, significant correlation between the (rlog) expression values for the detectable var 
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transcripts in parasite samples from volunteer ♯16 (“classical” responder) and ♯19 (“non-classical” responder) in A.  
Plots B - D show group-level correlations of the mean (rlog) expression values for the detectable var transcripts in 
the “unknown” volunteer group (12, 18 and 20) vs the “classical” responder group (♯13, ♯16, ♯17, ♯24, ♯26, ♯27, 
♯106 and ♯206) in B, the “non-classical” responder volunteer (19) vs the “classical” responder group in C, and the 
“non-classical” responder volunteer (#19) vs the “unknown” volunteer group samples in D. For each plot, the 





4.5.5.5 Rif and stevor gene expression in Controlled Human Plasmodium 
falciparum Infection 
Whereas the var multi-gene family of P. falciparum has been well characterised, far 
less is understood about the role of rif and stevor genes in the context of severe 
malaria disease. The rif and stevor gene families encode the variant antigens         
P. falciparum repetitive interspersed families of polypeptides (RIFINs) and STEVOR, 
respectively, which can be found on the surface of parasite-infected red blood cells 
where they are thought to mediate adhesion, thus contributing to pathology 
(Wahlgren et al. 2017). RIFINs and STEVORs appear to be predominantly 
expressed by freshly isolated P. falciparum strains, and by parasites enriched for 
adhesion in vitro (Fernandez et al. 1999, Kyes et al. 1999, Blythe et al. 2008). 70% 
of all RIFINs belong to a subgroup A (A-RIFINs), and have an insertion of 25 amino 
acids at the N-terminus, that is absent in B-RIFINs. The A- and B-subgroups of 
RIFIN proteins also differ in the number of cysteine residues they contain (10 and 8, 
respectively). These proteins also localise to different compartments of infected 
erythrocytes and are predicted to have different functions. A-type RIFIN proteins are 
associated with the Maurer’s cleft, a membranous network that is involved in the 
export of proteins from the parasite cytosol to the erythrocyte surface. B-type 
RIFINs, however, appear to be mostly retained inside the parasite (Joannin et al. 
2008). STEVORs resemble B-RIFINs, in that they lack the N-terminus insertion 
sequence of the A-RIFINs (Wahlgren et al. 2017). 143 and 32 members of the rif 
and stevor gene families have been found in the 3D7 reference genome, 
respectively and their expression has been reported at various stages of the           
P. falciparum life cycle (Petter et al. 2007, Khattab et al. 2008, Claessens et al. 
2011, Khattab and Meri 2011). Interestingly, their expression patterns seem to occur 
in a highly organised, sequential manner starting with the transcription of var genes 
at the ring stage (3–18 hours post infection) (Kyes et al. 2000, Llinas et al. 2006), 
followed by the expression of rif genes (12–27 hours post infection) (Kyes et al. 
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1999, Kyes et al. 2000, Llinas et al. 2006, Wang et al. 2009), and then transcription 
of the stevor gene family (22–32 hours post infection) (Kaviratne et al. 2002, 
Lavazec et al. 2007). In most parasites, PfEMP1 proteins are not expressed alone, 
but together with RIFINs and STEVORs (Fernandez et al. 1999, Kaviratne et al. 
2002), suggesting that these proteins may be involved in key parasite-host 
interactions during primary P. falciparum infection. Therefore, in order to investigate 
the influence of parasite gene expression on the host immune response, RNA-seq 
was also used to quantify the expression of these multi-gene families during 
controlled human infection in the naïve host.  
 
Of the 32 stevor gene members in the P. falciparum (3D7) genome, just 3 were 
detected (PF3D7_0832000, PF3D7_0300900 and PF3D7_0617600), and at low 
levels across all. PF3D7_0832000 demonstrated the highest level of expression, but 
was variable between volunteers; (highest in parasites isolated from volunteer ♯24 
(rlog = 4.53), followed by volunteer ♯13 (rlog = 2.97), volunteer ♯20 (rlog = 2.09) and 
volunteer ♯16 (rlog = 0.36).  Thus, although this gene had variable expression, it did 
not follow the same trend in variability in host transcriptional responses. It is 
important to note that the stage specific expression of parasite multi-gene families 
(var genes: 3-18 hours post infection (p.i), rif genes: 12–27 hours p.i and stevor 
genes: 22–32 hours p.i) may explain the failure to detect the majority of stevor 
variants in these patient samples. Only immature ring stages of P. falciparum 
merozoites are found in the circulation of the human host, whereas the more mature 
stages (trophozoites and schizonts) are sequestered in the microvasculature (Miller 
et al. 2002), making them inaccessible during parasite isolation from whole blood. 
 
Of the 143 rif gene members present in the P. falciparum (3D7) genome, 43 were 
detected within the volunteer cohort (figure 4.15). The majority of variants were 
transcribed at very low levels however, and often in just one or two samples (table 
4.7). Across all volunteer samples, one A-type rif variant (PFD0070c/ 
PF3D7_0401600) was dominantly expressed, (rlog median = 5.96; range: 4.98 – 
7.08), followed by the B-type variant PFD1010w/ PF3D7_0421200 (rlog median = 
1.89; range: 0.71 – 3.91). Interestingly, the most highly expressed rif gene 
(PFD0070c/ PF3D7_0401600) was found to be expressed at significantly lower 
levels in the two inoculum samples (rlog median = 2.37) compared the parasites 
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recovered at day of patent infection in the volunteers (table 4.7). Given that this 
variant was the most highly expressed across all, it is unlikely to represent in vivo 
selection but instead may reflect differences in how the samples were prepared for 
sequencing, as has been previously discussed (see section 4.5.4). As with the var 
genes, the uniformity in rif variant expression across volunteers reinforces the 
concept that immune variation is not driven by parasite gene expression, 
highlighting an important gap in our understanding of the diversity in the human 





Figure 4.15 | Comparison of rif gene expression across the volunteer cohort and inoculum samples. 
Heatmap showing normalised (rlog) expression values for all detectable rif transcripts. Each row represents a rif 
gene (transcript i.d annotated on the left hand side), and each column represents a volunteer or inoculum sample 
(annotated along the bottom, and colour-coded as per transcriptional response class; “classical” responder (red), 
“non-classical” responder (blue), “unknown” (yellow), or as parasite inoculum samples (PI1 and PI2) in grey). 
Sample sequencing depth is indicated, as per the colour key provided. A colour key for rlog expression values is 
also shown.  (Heatmp generated by Dr Adam Reid, Wellcome Trust Sanger Institute). 
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 Table 4.7 | Normalised (rlog) read counts for all detectable rif genes in the 12 patient and 2 inoculum samples (same order as heatmap) 
transcript i.d v027 v106 v206 v012 v017 v019 v026 v016 v024 v013 v018 v020 median of volunteer samples PI1 PI2 median of inoculum samples
PF3D7_0401600.1 6.77 6.06 6.39 5.97 5.81 5.68 7.08 5.01 5.18 6.02 5.31 4.98 5.89 2.41 2.33 2.37
PF3D7_0421200 1.48 2.01 1.77 1.09 0.77 0.71 0.86 2.13 2.35 3.28 3.91 3.81 1.89 0.82 4.42 2.62
PF3D7_0115600 0.28 2.04 0.69 2.01 -0.13 -0.19 -0.04 1.13 -0.15 1.14 -0.14 -0.41 0.12 -0.08 -0.14 -0.11
PF3D7_0400300 0.13 1.26 0.46 0.05 0.43 -0.26 -0.14 0.01 1.53 -0.28 -0.22 0.03 0.04 -0.17 -0.21 -0.19
PF3D7_1200500 -0.17 0.74 0.82 0.33 0.75 -0.01 0.10 2.20 1.84 0.72 1.17 0.08 0.73 0.06 0.02 0.04
PF3D7_0101900 -1.58 -1.58 -1.51 -1.54 -1.56 -1.56 -1.55 -1.52 -1.59 -1.59 -1.56 -1.58 -1.56 -1.55 -1.56 -1.55
PF3D7_0324800 -1.44 -1.43 -1.31 -1.36 -1.39 -1.40 -1.39 -1.44 -1.44 -1.28 -1.40 -1.44 -1.40 -1.39 -1.39 -1.39
PF3D7_0937500 -1.44 -1.43 -1.32 -1.37 -1.40 -1.41 -1.39 -1.44 -1.32 -1.42 -1.40 -1.44 -1.40 -1.39 -1.40 -1.40
PF3D7_0937400 -1.48 -1.47 -1.36 -1.41 -1.44 -1.44 -1.43 -1.36 -1.48 -1.48 -1.44 -1.48 -1.44 -1.43 -1.44 -1.44
PF3D7_0101000 -1.52 -1.51 -1.42 -1.46 -1.49 -1.49 -1.48 -1.45 -1.52 -1.50 -1.49 -1.52 -1.49 -1.48 -1.49 -1.48
PF3D7_0617700 -1.44 -1.48 -1.39 -1.43 -1.46 -1.46 -1.45 -1.49 -1.44 -1.49 -1.46 -1.49 -1.46 -1.45 -1.46 -1.45
PF3D7_1041200 0.05 -1.26 -0.59 -0.92 -1.12 -1.17 -1.07 -1.32 -1.31 -1.32 -1.13 -1.29 -1.15 -1.09 -1.13 -1.11
PF3D7_1040500 0.23 -1.27 -0.55 -0.90 -1.12 -1.17 -1.06 -1.34 -1.34 -1.34 -1.13 -1.31 -1.15 -1.09 -1.13 -1.11
PF3D7_1101100 0.33 -1.26 -0.51 -0.87 -1.11 -1.15 -1.04 -1.34 -1.34 -1.28 -1.11 -1.31 -1.13 -1.07 -1.11 -1.09
PF3D7_0732300 0.02 -1.12 -0.70 -0.88 -1.00 -1.02 -0.97 -1.14 -1.14 -1.14 -1.00 -1.14 -1.01 -0.98 -1.00 -0.99
PF3D7_0937700 0.00 -1.04 -0.62 -0.81 -0.93 -0.95 -0.89 -0.89 -1.06 -1.06 -0.93 -1.05 -0.93 -0.91 -0.93 -0.92
PF3D7_1254200 0.22 -1.02 -0.56 -0.76 -0.90 -0.92 -0.86 -0.88 -1.01 -1.05 -0.90 -1.04 -0.90 -0.88 -0.90 -0.89
PF3D7_1479700 -1.42 -1.38 -0.68 -1.01 -1.22 -0.01 -1.16 -1.45 -1.45 -1.45 -1.22 -1.43 -1.30 -1.19 -1.22 -1.20
PF3D7_0300200 -1.06 -0.83 -0.73 -0.87 -0.96 -0.98 -0.94 -0.44 -1.06 -1.06 -0.97 -1.06 -0.97 -0.95 -0.97 -0.96
PF3D7_0833400 -1.13 -1.12 -0.82 -0.95 -1.04 -1.05 -1.01 -0.48 -1.13 -1.06 -1.04 -1.13 -1.04 -1.02 -1.04 -1.03
PF3D7_1372600 -1.12 -1.11 -0.74 -0.90 -1.01 -1.03 -0.98 -0.21 -1.09 -1.12 -1.01 -1.12 -1.02 -0.99 -1.01 -1.00
PF3D7_0300500 -1.20 -1.18 -0.92 -1.04 -1.11 -1.13 -1.09 -1.20 -1.20 -0.62 -1.11 -1.20 -1.12 -1.10 -1.11 -1.11
PF3D7_0400700 -1.28 -1.27 -1.09 -1.17 -1.22 -1.23 -1.21 -0.98 -1.25 -1.28 -1.22 -1.28 -1.23 -1.21 -1.22 -1.22
PF3D7_0101600 -1.34 -1.33 -1.17 -1.24 -1.28 -1.29 -1.27 -1.34 -1.34 -1.08 -1.29 -1.34 -1.29 -1.28 -1.29 -1.28
PF3D7_0701100 -1.30 -1.29 -1.13 -1.20 -1.25 -1.26 -1.24 -1.22 -1.31 -1.11 -1.25 -1.31 -1.25 -1.24 -1.25 -1.25
PF3D7_1040400 -1.25 -1.23 -1.02 -1.11 -1.17 -1.19 -1.16 -1.25 -0.81 -1.25 -1.18 -1.25 -1.18 -1.16 -1.17 -1.17
PF3D7_0800500 -0.93 -1.23 -1.03 -1.11 -1.17 -1.18 -1.16 -1.15 -1.24 -1.24 -1.17 -1.24 -1.17 -1.16 -1.17 -1.17
PF3D7_1040900 -0.89 -1.26 -1.06 -1.15 -1.21 -1.22 -1.19 -1.28 -1.28 -1.28 -1.21 -1.28 -1.21 -1.20 -1.21 -1.20
PF3D7_1000200 -0.54 0.73 0.12 -0.37 1.59 -0.76 -0.60 -0.13 -1.12 -1.12 -0.70 -1.02 -0.57 -0.64 -0.70 -0.67
PF3D7_0401300 -1.45 0.75 -0.48 -0.90 -1.17 -1.23 -1.10 -1.53 -1.53 -1.53 -1.18 -1.47 -1.20 -1.13 -1.18 -1.15
PF3D7_1100500 -0.98 0.99 -0.13 -0.50 -0.73 -0.78 -0.66 -1.03 -1.03 -1.03 0.87 -0.99 -0.75 -0.69 -0.73 -0.71
PF3D7_0100200 1.37 -0.15 0.21 -0.25 -0.55 -0.61 -0.47 -0.48 -0.67 1.09 -0.56 -0.79 -0.47 -0.50 -0.55 -0.53
PF3D7_1300200 1.14 -0.25 0.01 -0.32 -0.54 -0.58 -0.48 -0.70 -0.75 0.45 -0.54 -0.73 -0.51 -0.50 -0.54 -0.52
PF3D7_0732900 1.38 0.37 -0.08 -0.55 -0.86 -0.92 -0.77 -1.26 -1.26 -1.07 -0.87 -1.17 -0.86 -0.81 -0.86 -0.84
PF3D7_1149800 1.40 -1.09 -0.10 -0.57 -0.88 -0.94 -0.79 0.09 -1.28 -1.18 -0.89 -1.19 -0.88 -0.83 -0.88 -0.86
PF3D7_1255100 -0.18 -1.14 -0.06 1.50 -0.89 -0.95 -0.80 -1.39 -1.39 0.14 -0.89 -1.27 -0.89 -0.84 -0.89 -0.86
PF3D7_0732200 -1.10 -1.07 -0.34 -0.70 -0.93 -0.98 -0.87 -1.14 -1.14 -0.48 -0.94 0.45 -0.94 -0.90 -0.94 -0.92
PF3D7_0100900 -0.77 -0.75 -0.25 -0.49 -0.64 -0.67 -0.60 -0.24 0.01 -0.78 -0.64 -0.77 -0.64 -0.62 0.13 -0.24
PF3D7_0632700 0.06 -0.42 -0.26 -0.47 -0.61 -0.63 -0.57 -0.72 -0.38 -0.26 -0.61 -0.71 -0.52 -0.59 -0.61 -0.60
PF3D7_0100600 0.35 -0.92 -0.41 -0.64 -0.79 -0.82 -0.75 -0.95 -0.95 -0.95 -0.79 -0.43 -0.79 -0.77 -0.79 -0.78
PF3D7_0800400 0.39 -0.78 -0.29 -0.52 -0.67 -0.70 -0.63 -0.46 -0.81 -0.50 -0.67 -0.65 -0.64 -0.64 -0.67 -0.66
PF3D7_1200200 0.71 -0.45 -0.16 -0.54 -0.79 -0.84 -0.72 -0.48 -1.00 -0.71 -0.79 -0.97 -0.71 -0.75 -0.79 -0.77
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4.6 Discussion  
The inter- and intra-clonal variability of P. falciparum var genes have hampered 
attempts to investigate the roles of the encoded PfEMP1 proteins in the 
pathogenesis of malaria in the field. To date, the most popular strategy has involved 
the use of degenerate primers, and qPCR approaches to quantify var gene 
transcripts found in patient isolates of variable clinical outcome. Using this method, 
numerous studies have implicated a subset of group-A, B/A var gene variants in 
severe disease outcome following infection with P. falciparum (Kirchgatter and 
Portillo Hdel 2002, Bull et al. 2005, Kaestli et al. 2006, Kyriacou et al. 2006, 
Rottmann et al. 2006, Normark et al. 2007, Falk et al. 2009, Warimwe et al. 2009, 
Kalmbach et al. 2010, Lavstsen et al. 2012, Warimwe et al. 2012, Bertin et al. 2013, 
Almelli et al. 2014, Abdi et al. 2015, Bernabeu et al. 2016, Bertin et al. 2016, 
Jespersen et al. 2016, Mkumbaye et al. 2017, Shabani et al. 2017, Tonkin-Hill et al. 
2018). Given that severe disease is most commonly observed in young children 
having had limited exposure to the Plasmodium parasite, it has been hypothesised 
that group-A and/or B/A variants are dominantly expressed in the malaria-naïve.  
In this study, parasites isolated from the blood of 12 volunteers undergoing CHMI 
with P. falciparum (3D7-strain) were analysed by RNA-seq, to characterise 
expression of var gene variants in the naïve host. All volunteers received direct 
blood-stage challenge of ~690 parasitised erythrocytes. At day of patent infection 
(7.5 - 10.5 days later), 95% of the 3D7 var gene variants were detected across the 
cohort. Moreover, those with highest levels of expression belonged to the group-B 
subclass. This was in agreement with three previous studies of CHMI showing 
similar broad expression of group-B var gene variants following mosquito-bite 
challenge (Lavstsen et al. 2005, Wang et al. 2009, Bachmann et al. 2016), although 
contradicts data from another (Peters et al. 2002). In the original study by Peters et 
al, var expression was analysed using semi-quantitative RT-PCR followed by 
sequencing of a large number of clones, revealing the dominant expression of a 
single B-group variant (PF3D7_1100100/ PF11_0007). One possible explanation for 
this divergent observation is that the semi-quantitative RT-PCR method used is 
susceptible to primer and cloning bias, which can result in the overestimation of 
transcript frequencies. Furthermore, this study was limited to just two volunteers. 
Using a different method Wang et al, detected much broader expression of variants 
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but report a different group-B var gene as being dominantly transcribed 
(PF3D7_0632800/ MAL6P1.1). This study however, was limited by low 
parasitaemias, meaning that just one blood sample, from one volunteer, gave 
sufficient mRNA for quantitative analysis of NF54-expressed var genes.  
 
Despite the limitations of these studies, two models of in vivo var gene selection 
have been proposed. The first suggests that switching of var genes comes about via 
an ordered hierarchical program, meaning that most parasites express a single var 
type in the first generation after egress from the liver. In subsequent replication 
cycles the parasite switches to other variants, determined by the intrinsic rate for 
each gene to be turned on or off. This model would allow for efficient evasion of the 
host immune system, without exposing the remaining PfEMP1 variants to the 
immune system (Peters et al. 2002, Bachmann et al. 2011). The second model 
proposes that the parasite population released from the liver express all var genes 
and later on, immune pressures force selection of parasites expressing certain 
PfEMP1 variants with optimal adhesion properties, for which the human host has no 
pre-existing variant-specific immunity (Wang et al. 2009).  
 
Results from this study correlate well with Bachmann et al in support of the second 
model whereby, at the earliest stages of infection in the naïve host, parasites 
express a broad repertoire of var gene variants with no single one being dominantly 
transcribed (Bachmann et al. 2016). This concept supports the early exploration of 
the suitability of available host sequestration receptors, at a time when specific 
antibody-mediated immune responses are unlikely to be controlling the first waves 
of parasite growth. With use of the blood-stage challenge model, my study was able 
to expand on this analysis, offering a direct comparison between transcript patterns 
of parasites in the inoculum and parasites recovered from patient samples, to 
investigate evidence for var gene selection in vivo. The most highly expressed 
variant at day of patent infection in the volunteers (following ~5 parasite replication 
cycles in the blood) was also the most highly expressed in the inoculum used to 
infect, suggesting that var gene selection forces had not been activated in this 
infection setting. Interestingly, parasites had a mean parasite multiplication rate of 
10.0 (range 6.7 – 12.8) consistent with other studies of CHMI, and thus were able to 
successfully establish infection, and multiply in the human host without selection of 
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specific var gene variants predicted to have a growth advantage and enhanced 
abilities to sequester and escape splenic clearance (Warimwe et al. 2009, Warimwe 
et al. 2012, Abdi et al. 2017). Moreover, based on data from historical malaria-
therapy studies, it can be speculated that an estimated 50% (likely more) of 
volunteers in this cohort, if left un-treated, would have gone on to develop symptoms 
of malaria disease following just a few more cycles of parasite replication in the 
blood (Glynn et al. 1995). Yet, the disease-associated var gene variants were not 
amongst those dominantly expressed in these individuals. This finding therefore 
challenges some key concepts in the field and raises some questions with regards 
to the importance of PfEMP1 proteins for the growth and survival of parasites in 
vivo, and their association with disease severity during primary infection.  
 
Having observed diversity in the host immune response to P. falciparum, I wanted to 
investigate the relationship between host and parasite gene expression using 
parasites isolated from the same cohort of volunteers. Interestingly, var and rif gene 
expression was found to be remarkably uniform across all volunteer samples. 
Pairwise comparisons between the different host transcriptional groups revealed 
parasite var gene expression to be significantly positively correlated across all. 
Furthermore, the percentage distribution of var genes by var gene group was highly 
consistent irrespective of immune response class. Results suggest that the host 
immune response is not directed by parasite gene expression, and vice versa; the 
type of host immune response elicited has little influence of parasite VSA 
expression early in infection. Instead, it is likely that host genetics and/or 
environmental factors are the cause of variability in immune responses. In recent 
years, this has been researched in great depth, offering up some interesting insights 
into the drivers of immune variation during the host response to pathogen insult 
(Brodin et al. 2015, Chen et al. 2016, Nedelec et al. 2016, Oosting et al. 2016, 
Schirmer et al. 2016, Ter Horst et al. 2016). 
 
One of the key pathological features of P. falciparum malaria infection is that the 
mature blood stage parasites (pigmented trophozoites and schizonts) are 
sequestered in the microvasculature (Miller et al. 2002). Therefore, a potential 
limitation of studies such as these is the restricted access to parasites found in 
circulation, which may not accurately represent the sequestered population. It is 
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also important to note that volunteers in this study were infected using the direct 
blood-stage challenge model of CHMI, which does not rely on vector transmission 
and thus bypasses the skin and liver infectious stages in the human host. 
Interestingly, there is evidence to suggest that mosquito transmission modifies 
parasite virulence by re-setting expression of virulence genes (Spence et al. 2013, 
Bachmann et al. 2016). For the rodent malaria parasite Plasmodium chabaudi, this 
has been shown to correlate with altered expression of the cir (chabaudi 
interspersed repeats) multi-gene family. In the study by Spence et al, mosquito-
transmission resulted in a broader expression of these cir genes, and attenuated 
symptoms of disease when compared to parasites that had been serially blood-
passaged (Spence et al. 2013), albeit following a much higher number of blood 
passages than was applied to the inoculum used in this study of CHMI (figure 4.16) 
(Cheng et al. 1997, Payne et al. 2016). Although my results appear to correlate well 
with previous studies of parasite var gene expression following mosquito-bite CHMI 
(Wang et al. 2009, Bachmann et al. 2016), it will therefore be important to compare 




It is also important to consider the potential limitations with use of the RNA-seq 
protocol for the measurement of parasite var gene expression. In the Smart-Seq2 
protocol, designed for low input RNA yields (see section 4.4.5), only full-length 
transcripts are targeted for amplification in the PCR reaction, which may introduce a 
potential amplification bias towards the genes of shorter length. This may be 
particularly relevant for the analysis of var gene expression levels, as many 
(specifically, the group-A var genes) are larger in size compared to genes of the 
other subclasses (table 4.1). Importantly, in a recent study of single-cell RNA-seq 
using P. falciparum (trophozoite, schizont and gametocyte stages), Reid et al 
demonstrate the ability to detect the expression of longer length P. falciparum genes 
with use of the same Smart-seq2 protocol (Reid et al. 2018). This is thought to be 
due to internal poly-A priming by the Oligo-dT primer, resulting in the reverse 
transcription of fragments of long genes; a phenomenon commonly reported with its 
use (Nam et al. 2002). Giving confidence to my dataset was the detection of the 
group-B/A var gene; PF3D7_0632500/ PFF1580c, as one of the longest of the var 
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genes variants (11.9 kb), and one of the most abundantly expressed (top 11) across 
all in the cohort. Nevertheless, optimisation of the protocol to reduce the number of 
amplification cycles performed prior to transcript fragmentation may help to limit the 
potential bias towards smaller length genes, and thus will be considered for future 
experiment design.  
 
It is important to acknowledge that results presented within this chapter may be at 
risk of bias due to the small number of parasite samples available for assessment in 
this study. This is especially relevant when considering the comparison of parasite 
gene expression between previously stratified volunteer groups, as is discussed in 
chapter 3. My interpretations of the results presented in this chapter are not 
intended to be conclusive, but observational.  
 
In summary, parasites isolated at the early stages of infection in the naive host 
appear to transcribe a broad repertoire of var gene variants, with those of the group-
B subclass having highest levels of expression. Moreover, var gene selection forces 
do not appear active during the first 5 - 6 replication cycles in the blood. These data 
contest the popular hypothesis that group-A and or B/A var genes actively dominate 
infection in the naïve host. Furthermore, parasite virulence gene expression does 
not influence the developing host immune response during primary infection, 
considering that var and rif profiles were uniform across volunteers. This highlights a 
need to better understand the host genetic and environmental factors giving rise to 
variability in immune responses during P. falciparum malaria infection. Importantly, I 
have shown for the first time that RNA-sequencing can be successfully applied for 
ex vivo analysis of P. falciparum gene expression during CHMI. In this study 
however, analysis was restricted to parasites recovered at day of patent infection 
(peak parasitaemia), following direct blood-stage inoculation. These data would be 
complimented by a study conducive to the assessment of parasite gene expression 
at earlier time-points in infection, as well as a comparison of parasite VSA 
expression following vector transmission. As a next step, my protocol for ex vivo 
parasite RNA-seq will therefore need to be optimised for use with the much lower 
parasite densities predicted at the onset of blood-stage infection following mosquito 
bite CHMI, which may prove more challenging.  
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(Payne et al., 2016) 
(n = 14) 
Blood-stage challenge 
using inoculum from volunteer 1 above 
 (Cheng et al., 1997)	
day 0 
(inoculum dose = 
690 iRBCs) 
C) D) 
day of diagnosis range = 7.5 – 10.5 days post infection 
(~4-6 parasite replication cycles in the blood) 
 
Figure 4.16 | History of the parasite inoculum used for blood-stage CHMI. A) Laboratory-reared Anopheles stephensi mosquitoes infected with P. falciparum clone 3D7A were used to infect 2 
volunteers at the Queensland institute of Medical research (QIMR) (Cheng et al., 1997). On day 0, volunteer 1 (orange) was exposed to the bites of 22 mosquitoes (7 of which were found positive for 
P. f 3D7 sporozoites (SPZs)), and two days later was exposed to the bites of another 3 mosquitoes (2 of which were found positive for P. f 3D7 SPZs). On day 0, volunteer 2 (blue) was exposed to 
the bites of 25 mosquitoes (3 of which were found positive for P. f 3D7 sporozoites (SPZs)), and two days later was exposed to the bites of another 8 mosquitoes (6 of which were found positive for 
P. f 3D7 SPZs). From day 4 following mosquito-bite infection, parasite densities were monitored by both PCR and microscopy in the two volunteers. B) Schematic showing the course of parasite 
growth in the two volunteers. Parasites could be detected in the blood from ~ 7 days post mosquito-bite (after egress from the liver), and continued to grow for ~ 3-4 cycles of replication in the 
circulation, until treatment was administered at 13 days post infection (volunteer 1), and at 14 days post infection (volunteer 2). Before the administration of drug treatment, a unit of blood (500 mL) 
was collected from each volunteer for preparation of the blood-stage inoculum to be used in subsequent blood-stage CHMI trials. C) Schematic diagram to indicate use of blood-stage inoculum 
(prepared from blood of volunteer 1 in Cheng at al., 1997), in my study (Payne et al., 2016). 14 malaria-naïve volunteers were infected upon injection with ~690 parasitised erythrocytes (iRBCs) and 
parasite density was monitored by qPCR at twice-daily time-points, until diagnosis and administration of drug treatment. D) Graph displays the number of parasites/mL of blood as measured by 
qPCR (y-axis), through time (x-axis) for each of the 14 volunteers. Day of diagnosis ranged 7.5 – 10.5 days post infection (after ~4-6 parasite replication cycles in the blood). Dashed vertical lines 
denote day of diagnosis (or range of diagnosis). Dashed horizontal line indicates the lower limit of detection by qPCR (20 p/mL). 
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Chapter 5: Optimising a Protocol for ex vivo Parasite RNA-seq 




























The expression of parasite var genes is thought to be influenced by the developing 
host immune response, yet current knowledge of var gene switching parameters is 
limited to studies based on in vitro cultured parasites in the absence of immune 
pressure. Moreover, despite clear associations between group-A, B/A PfEMP1s and 
severe disease, var gene expression has not yet been assessed at the very onset of 
infection, which limits our understanding of their influence on host clinical outcome. 
Having previously demonstrated the successful application of ex vivo parasite RNA-
seq in a blood-stage model of controlled human malaria infection, I wanted to extend 
my analysis of var gene expression to the blood stages following immediate egress 
from the liver. Herein, optimisation was performed on various steps of the RNA-seq 
protocol with the aim to recover sufficient P. falciparum ring-stages at the onset, and at 
subsequent time points following mosquito-transmission in the naïve host. At days 9 
and 10 post-infection (~cycle 2 in the blood), a good number of P. falciparum genes 
could be detected in parasites isolated from 5 volunteers. However, the detection of 
VSA genes was markedly reduced when compared to parasites isolated on day 11 
post-challenge. Hence, low parasite densities and host contamination restrict the 
application of this protocol, precluding the assessment of var gene expression at these 
early time-points. Profiling of var genes on day 11 post mosquito-bite challenge (~cycle 
3 in the blood) revealed broad level detection of variants, this time inclusive of the 
group-A subclass. Interestingly, var gene expression patterns were more variable 
across volunteers, compared to observations from the previous blood-stage challenge. 
Results suggest that diversity in var gene expression may be dictated by events 
occurring in either the mosquito vector or liver stages, before entering the blood-phase. 
However, it will be important to assess var gene expression in the first blood cycle, 
using a more appropriate method for parasite isolation and/or gene expression analysis 




5.2 Introduction  
The mutually exclusive switching between var gene variants affords the P. falciparum 
parasite an immune evasion strategy, and a means to exploit different host tissues 
(Roberts et al. 1992, Smith et al. 1995). In non-immune individuals, this parasite 
survival strategy can have fatal consequences by leading to the obstruction of blood 
flow, and contributing to impaired perfusion in vital host organs (Dondorp et al. 2000, 
Dondorp et al. 2008, Warimwe et al. 2009, Hanson et al. 2012, Warimwe et al. 2013). 
Although a restricted subset of group-A, B/A PfEMP1 variants has been associated 
with severe clinical outcomes (Jensen et al. 2004, Bull et al. 2005, Kaestli et al. 2006, 
Rottmann et al. 2006, Warimwe et al. 2009), little is known about var gene expression 
at the onset of infection and our current understanding of var gene switching 
parameters is largely restricted to studies based on in vitro cultured parasites (Kyes et 
al. 2003, Horrocks et al. 2004, Horrocks et al. 2004, Peters et al. 2007, Recker et al. 
2011, Zhang et al. 2011, Noble et al. 2013). In this setting, it has been speculated that 
rates at which var genes become activated and deactivated is non-random, and is 
dependent on chromosomal position. For instance, genes occupying subtelomeric loci 
(group-A and B types) tended to switch off faster than those positioned more centrally 
in the chromosome (Frank et al. 2007). This concept is supported by the more recent 
findings of Noble et al, who, with use of a diverse set of clonal parasite cultures, 
revealed a global hierarchy in var gene activation, favouring those in central 
chromosomal locations (Noble et al. 2013). However, most studies of this nature have 
been limited due to restrictions in the number of variants considered, as well as time 
points at which gene transcription levels were measured. Moreover, the diversity and 
order of PfEMP1 variants in the human host is thought to be influenced by the 
developing immune response (Kyriacou et al. 2006), which is something that cannot be 
assessed in these experiments.  
In the previous chapter, I demonstrated the application of ex vivo parasite RNA-seq 
during a study of blood-stage CHMI, for the assessment of var, rif and stevor 
expression in the naïve host. RNA-sequencing at day of patent infection (positive thick 
film microscopy) revealed broad level detection of var gene variants, with the group-B 
subclass demonstrating highest levels of expression. Moreover, parasites recovered 
after ~5 - 6 replication cycles in the blood had similar expression profiles to that of 
parasites isolated from the inoculum used to infect. This suggested that var gene 
selection forces were not yet activate in this infection setting. These two observations 
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contradict the hypothesis that group-A and/or B/A PfEMP1s are actively selected 
during the blood-phase of infection in the malaria-naïve host. However, the blood-stage 
challenge model is not conducive to the assessment of var gene expression 
immediately following liver egress. Thus, it was important to extend my analysis to 
earlier stages of infection, and to compare patterns of parasite gene expression 
following direct blood challenge, to those observed following vector transmission.  
In continued collaboration with Professor Adrian Hill and Dr Simon Draper at the 
Jenner institute in Oxford, I was granted access to blood samples from 5 (unvaccinated 
control) volunteers undergoing mosquito-bite CHMI at the CCVTM, in January 2017 
(Clinical/ Trails.gov i.d: NCT02905019). Sampling for my sub-study was designed to 
allow for the assessment of parasite var gene expression from C +7 (predicted onset of 
blood-phase infection), and at subsequent daily time points until the termination of 
volunteer infections (at first microscopic detection). Based on data from previous 
mosquito-bite trials carried at the CCVTM (Roestenberg et al. 2012), parasite densities 
were predicted to be extremely low, particularly during the first and second replication 
cycles in blood; ~40 – 50 p/mL and 400 – 500 p/mL, respectively (table 5.1). This 
highlights the major limitation of the CHMI model for the analysis of parasite gene 
expression, as has been previously discussed (Peters et al. 2002, Lavstsen et al. 2005, 
Wang et al. 2009, Bachmann et al. 2016). For RNA-sequencing of parasites that have 
been isolated from whole human blood, it is also important to consider the potential 
host contaminants, which may act to dwarf the valuable sequencing information 
coming from the parasite. Thus, in order to ensure maximal recovery and purity of       
P. falciparum rings stages in this study, it was important to optimise the protocol used 
for parasite isolation and ex vivo RNA-seq. 
Table 5.1 | Comparison of parasitological data from CHMI trials 
(table modified from Roestenberg et al., 2012) 
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5.3 Chapter aims  
This chapter provides details of the work carried out to optimise the protocol used for 
ex vivo parasite RNA-seq, and demonstrates its application to the mosquito-bite 
challenge model for assessment of parasite VSA expression early in the naïve host.  
 Specific aims 
 
1. To improve the recovery and purity of P. falciparum ring-stages from whole 
human blood, using numbers representative of those predicted immediately 
following liver egress after mosquito-bite challenge. 
2. To determine how early in infection (and thus the lower limit of parasites/mL) 
this protocol can be successfully applied. 
3. To investigate parasite var and rif gene expression early following mosquito-
transmission in the naïve human host. 
 
5.4 Methods 
The optimisation of ex vivo parasite RNA-seq required readily available samples of in 
vitro cultured P. falciparum (3D7-strain). Provided below are details of the in vitro         
P. falciparum culture. A description of the methods used for each optimisation step is 
provided in the relevant sections that follow.  
 
5.4.1 P. falciparum culture 
All work with P. falciparum was carried out in a biosafety level 3 laboratory and where 
possible, in a Class II biological safety cabinet under sterile conditions. All materials 
and reagents used for culturing were sterile and the solutions warmed to 37°C for use.  
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5.4.1.1 List of Materials 
Reagent Supplier Catalog Number
Absolute Methanol Fisher Scientific 10516279
AlbuMAX® II Lipid-Rich BSA Termo Fisher Scientific 11021
D-sorbitol Sigma-Aldrich S-3889
Gentamicin Sulfate Lonza 17-518Z
Giemsa TCS Biosciences HS295
Glucose Scientific Laboratory Supplies CHE1806
Glycerol Thermo Fisher Scientific 4392215
HEPES Lonza 17-737F
Human Serum Scottish National Blood Transfusion Service -
L-glutamine Thermo Fisher Scientific 25030
NaOH Fisher Scientific 10675692
O+ erythrocytes Scottish National Blood Transfusion Service -
PBS tablets Merk 109468
Roswell Park Memorial (RPMI) 1640 medium Lonza BE12-167F
Leucoflex LXT filters Macopharma -  
 
Incomplete RPMI medium    Complete RPMI medium 
RPMI 1640 medium    RPMI 1640 medium 
25 mM Hepes     25 mM Hepes 
20 mM glucose    20 mM glucose 
2 mM L-glutamine    2 mM L-glutamine 
25 μg/mL gentamicin    25 μg/mL gentamicin 
      0.25% AlbuMAX® II 
      5% pooled human serum 
 
Freezing medium (glycerolyte)   Synchronising medium   
57% glycerol     5% D-sorbitol 
0.14 M sodium lactate   dH2O 
4 mM potassium chloride 
24 mM sodium phosphate  
 
5.4.1.2 General 
P. falciparum (3D7A) parasites were cultured in O+ erythrocytes (Scottish National 
Blood Transfusion Service) in RPMI 1640 media (Lonza), adjusted to pH 7.2 – 7.3 
using 1M NaOH (Fisher Scientific), and supplemented with 25 mM Hepes (Lonza), 20 
mM glucose (Scientific Laboratory Supplies), 2 mM L-glutamine (Thermo Fisher 
Scientific), 25 g/mL gentamicin sulfate (Lonza), 0.25% AlbuMAX® II Lipid-Rich BSA 
(Thermo Fisher Scientific) and 5% pooled human serum (Scottish National Blood 
Transfusion Service), comprising “Complete RPMI medium”. Cultures were incubated 
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at 37oC in 1% O2, 3% CO2 and 96% N gas (BOC gases). On a daily basis (or every two 
days in some cases), smears were made from ~250 ul of culture and stained with 
Giemsa (TCS Biosciences) for assessment of parasitaemia. Parasites were diluted in 
O+ erythrocytes when necessary, to allow for reinvasion and for maintenance of desired 
parasitaemia. 
 
5.4.1.3 Giemsa staining for determination of parasitaemia 
250 μl volumes of parasite culture were centrifuged at 8,500g for ~7 seconds, and 
pellets reconstituted in approximately 30 μl of the supernatant to achieve a 30 - 50% 
haematocrit for smearing. 10 μl volumes of resuspension were smeared at an angle of 
about 45o on clean glass slides. Smears were air dried, fixed with absolute methanol 
(Fisher Scientific) and air-dried again, before flooding with filtered 10% v/v Giemsa in 
Giemsa buffer made up of PBS pH 7.2 (Merck). Stain was left for 15 - 25 minutes 
before being washed off with water, and air-dried. The smears were viewed under oil 
with the 100X objective on a light microscope (Leica Microsystems, Leica DM1000). 
Parasitaemia was determined by counting the number of infected erythrocytes (IEs) 
and uninfected erythrocytes per field, until a minimum of 500 cells had been counted in 
at least 3 different fields.  
 
5.4.1.4 Washing of erythrocytes for culture 
Blood used for parasite cultures was obtained weekly, from donors at the Scottish 
National blood Transfusion Service. In preparation for use, whole blood was first 
filtered of leucocytes by passing through a Leucoflex LXT filter (Macopharma). 
Recovered erythrocytes were then centrifuged 2,400g for 15 minutes, and pelleted 
cells washed x2 at 20 - 30% haematocrit in “incomplete RMPI medium” at 2,400g for 
15 minutes. Erythrocytes were resuspended at a final haematocrit of 50% in 
“incomplete RPMI medium”, and stored at 4oC for a maximum of 1 week.  
 
5.4.1.5 Synchronising parasites with Sorbitol 
For experiments requiring synchronous ring-stage merozoites only (representative of 
the stages found in human circulation), the more mature parasite forms (> 20 hours 
post-invasions) were lysed using 5% sorbitol in dH2O. Cultures to be treated were 
centrifuged at 800g for 4 minutes, the supernatant removed and pelleted cells 
 157 
resuspended in 7 mL 5% sorbitol. Cells were then incubated at 37oC for 15 minutes. 
Suspensions were centrifuged at 800g for removal of supernatant, and then washed 
twice in 13 mL “incomplete RPMI”. Final suspensions were at 2% haematocrit in 
“complete RPMI medium”, for returning to culture prior to use in experiments. After 
every sorbitol treatment, an aliquot of culture was used to make a smear for 
confirmation of lysis of the mature-stage IEs. 
 
5.4.1.6 Cryopreservation of IEs 
Cultures were centrifuged at 800g for 4 minutes, and supernatant removed prior to the 
gradual addition of glyercerolyte (57% glycerol, 0.14 M sodium lactate, 4 mM 
potassium chloride, 24 mM sodium phosphate at pH 6.8) as follows: Glycerolyte, 0.33 
times the packed cell volume (pcv) of the pellet, was added to the cells slowly and 
drop-wise, with constant agitation to ensure uniform mixing. The suspension was then 
left to stand for 5 minutes before addition of the next volume of glycerolyte; 1.33 times 
the pcv this time, added as before. The suspension was aliquoted into cryovials and 
stored at -70oC for 24 hours before transferring to liquid nitrogen for longer-term 
storage.  
 
5.4.1.7 Thawing of IEs 
Cryopreserved IEs (1 mL aliquots) were thawed at 37oC and transferred to 50 mL 
falcon tubes before addition of 200 μl 12% NaCl, slowly and drop-wise. With each drop, 
tubes were agitated to ensure uniform mixing of suspension. After 5 minutes rest, a 10 
mL volume of 1.8% NaCl was added, slowly and drop-wise as above, followed by a 10 
mL volume of 0.9% NaCl/0.2% glucose. Suspensions were centrifuged at 800g for 4 
minutes, and the pelleted cells washed in 20 mL “incomplete RPMI medium”. Cells 
were resuspended at 2% haematocrit in “complete RPMI medium” for culture, and an 
aliquot taken to make a smear for determination of parasitaemia. Cultures were then 
gassed with a mixture of 1% O2, 3% CO2 and 96% N, and incubated at 37oC. 
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5.5 Protocol Optimisation 
5.5.1 List of materials 
Reagent Supplier Catalog Number
Leucoflex LXT filters Macopharma -
0.5 mL DNA LoBind Eppendorf® tubes Eppendorf 22431005
1.5 mL DNA LoBind Eppendorf® tubes Eppendorf 22431021
1x PBS Gibco 20012-019
250 mL centrifuge bottles Corning Life Sciences CLS 431842
anti-human CD45-FITC (HI30) eBioscience 11-0459-42
EDTA Invitrogen AM9260G
FCS Gibco 16080-044
Multispot slides Hendley-Essex PH001
Saponin Sigma-Aldrich 8047-15-2
Zymo-Spin RNA Clean and Concentrator™ -5 kit Zymo Research R1016
Globin-Zero® Gold kit Epicentre (Illumina) GZG1224
RNA 6000 Pico Chip Bioanalyzer Kit Agilent 5067-1513
Ultrapure DEPC H20 Thermo Fisher Scientific 750024
0.2 mL Eppendorf® PCR strip tubes Eppendorf 951010022
Agencourt Ampure XP beads Beckman Coulter A63881
Betaine (BioUltra >99.0 %) Sigma-Aldrich 61962
DEPC H2O Thermo Fisher Scientific 750024
dNTP mix (10 mM) Fermentas R0192
DynaMag™-2 Magnet Thermo Fisher Scientific 12321D
High Sensitivity DNA Bioanalyzer kit Agilent 5067-4626
ISPCR primer (10 uM) (5′-AAGCAGTGGTATCAACGCAGAGT-3′) Biomers.net -
KAPA HiFi HotStart ReadyMix (2× KAPA) Biosystems KK2601
LNA-modified TSO (5′-AAGCAGTGGTATCAACGCAGAGTACATrGrG+G-3′) www.exiqon.com -
MgCl2 Ambion (Life technologies) AM9530G
Oligo-dT30VN (5′–AAGCAGTGGTATCAACGCAGAGTACT30VN-3′) biomers.net -
Qbit™ ds DNA high sensitivity assay kit Thermo Fisher Scientific Q32851
Recombinant RNase inhibitor Clontech 2313A
Superscript II reverse transcriptase kit* Thermo Fisher Scientific 18064-014
UltraPure Ethanol Sigma-Aldrich 51976  
 
 
5.5.2 Isolation of parasites from whole human blood 
One of the major concerns with direct ex vivo parasite RNA-seq is contamination with 
host material. The constituents of human peripheral blood include 93 - 96% 
erythrocytes (3,800 – 6,200 x106/mL), 4 - 7% platelets  (140 – 450 x106/mL) and 0.1-
0.2% leucocytes (4.1 – 10.9 x106/mL). In the first and second blood cycles following 
mosquito-bite challenge, parasitaemias are predicted to be as low as 40 p/mL and 400 
p/mL, respectively (Roestenberg et al. 2012). Therefore, to maximise the likelihood that 
a sufficient number of sequenced reads would map to the P. falciparum genome 
without being dwarfed by those mapping to the human genome, parasite samples 
needed to be purified. Mature erythrocytes, although anucleated, contain large 
quantities of polyadenylated globin, which is a contaminating factor for down-stream 
RNA-seq. Furthermore, these cells make up 93 - 96% of whole blood. Thus, a crucial 
step during the purification process was to remove red cells, along with leucocytes, 




Leucocyte depletion was to be performed as per the previous blood-stage CHMI trial 
(chapter 4, section 4.4.2.1), using Leucoflex LXT filters (Macopharma). These filters 
are designed for use in blood-transfusion services and thus were predicted to be highly 
efficient for the removal of leucocytes from whole blood. In order to test their efficiency 
before application in the mosquito-bite CHMI, an experiment was set up to quantify the 
percentage of leucocytes in blood samples post-filtration, using CD45 as a marker for 
white blood cells. For each experiment run, a 10 μl sample of fresh whole blood 
(predicted to contain ~4.0x107 RBCs and ~4.0x104 leucocytes) served as the “pre-
filtration” positive control, and a duplicate sample of unstained blood served as the 
negative control. Filter efficiency was tested using 20 mL volumes of whole blood 
(representative of the volume to be collected from volunteers in the trial) and then 
staining 3x 10 μl (replicate samples) of filter flow-though. Staining was performed using 
5 μl (0.25 μg/test) of anti-human CD45-FITC (eBioscience), in a 100 μl volume of FACs 
buffer (PBS with 2% FCS and 5mM EDTA), for 20 minutes whilst protected from light. 
After staining, cells were washed x3 with 1 mL FACs buffer and then acquired using 
the BD™ LSR-II and FACSDiva™ software. For each experiment run, 3x106 events 
were acquired.  
 
Figure 5.1 displays the gating strategy used for calculating the percentage of CD45+ 
leucocytes in the pre- and post-filtered samples of blood in representative experiment 1 
of 5.  In the positive control stain (unfiltered blood), percentage CD45+ cells were 
within the expected range for the population of leucocytes in whole human blood (0.1 – 
0.2%). Gating on the CD45+ population in the post-filtered samples consistently 
revealed percentage levels below that of the negative unstained control, confirming the 
highly efficient depletion of leucocytes with use of these filters. Table 5.2 displays the 
percentage of CD45+ cells calculated pre- and post-filtration for each replicate, in each 
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Figure 5.1 | Gating strategy used for the assessment of CD45+ cells in samples of whole-blood. The percentage 
(%) of CD45+ leucocytes was assessed in samples of whole blood pre- (B) and post- (C) filtration following staining with 
anti-CD45-FITC.  Unstained blood served as the negative control (A). 1) Psuedo-colour plots showing FSC-A on the x-
axis vs SSC-A on the y-axis, for gating on whole-blood cell populations (erythrocytes, platelets and leucocytes). 2) Plots 
showing FSC-A on the x-axis vs FSC-H on the y-axis for gating on single cells (singlets) and exclusion of doublets. 3) 
anti-CD4-FITC vs FSC-H for distinction of CD45- and CD45+ cell populations following each condition tested (% CD45+ 
cells are shown in red). 
 161 
 
Table 5.2 | Percentage of CD45+ cells pre- and post-filtration of whole blood 
 
 
5.5.2.2 Red cell lysis and recovery of ring-stage parasites 
Saponin works to lyse red blood cells by making the lipid bilayer permeable to 
macromolecules. During this process, the Plasmodium parasite is left intact with its 
parasite membrane and parasitophorous vacuole (Cordery et al. 2007, Kyes et al. 
2007, Lemieux et al. 2013). 0.015% saponin in PBS was shown to successfully lyse 
red cells following isolation from the human host in the previous trial, however this 
protocol step had not been optimised and there was a concern that using too high a 
concentration may result in the unnecessary loss of ring-stage parasites. Given the 
extremely low parasitaemias predicted at the early stages following mosquito-bite 
challenge, it was thus important to establish the concentration at which optimal 
recovery of ring-stage parasites would be achieved, without compromising the 
efficiency of red cell lysis. 
 
So as to represent the P. falciparum stages present in the circulation of the human 
host, all experiments were performed using in vitro (3D7-strain) cultured parasites that 
had been synchronised at the ring stage (see section 5.1.3.4). Percentage 
parasitaemia was determined on the morning of each experiment (see section 5.1.3.2) 
and the number of RBCs/mL counted by haemocytometer. Samples were prepared by 
centrifugation of culture at 800g for 4 minutes, to pellet the red cells. The volume of 
packed red cells (typically ~300 – 500 μl) was then split equally between the number of 
tubes/concentrations to be tested to ensure each sample contained the same starting 
number of ring-stage parasites. Red cell lysis was performed by incubation with 
saponin (Sigma-Aldrich) at 0.0015%, 0.0025%, 0.00375% 0.005%, 0.0075%, 0.01%, 
0.015% or 0.03%, using a ratio of 1:9 (packed red cells: saponin), for 10 minutes on 
ice. After incubation, samples were centrifuged at 12,000g for 5 minutes at 4oC and 
then washed x2 in 1 mL PBS. 2 μl of each pellet was then diluted 1:2 in human serum 
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(Scottish National Blood Transfusion Service) for addition to a well of a multispot slide 
(Hendley-Essex) for fixing with methanol and staining with 10% Giemsa for 1 hour. 
Slide preparations were viewed under oil with the 100x objective on a light microscope 
(Leica Microsystems, Leica DM1000) and the ratio of ring-stage parasites: RBCs were 
counted in 40 random fields.  
 
In an initial experiment, saponin concentrations of 0.0015%, 0.0025% and 0.00375% 
were found to insufficiently lyse red cells. When incubation times were extended to 1 
hour, no visual indication of red cell lysis was observed and thus these concentrations 
were excluded from further analysis. Table 5.3 displays the counts for the samples of 
ring-stage parasites and RBCs following saponin lysis at 0.03%, 0.015%, 0.01%, 
0.0075% and 0.005% saponin in PBS. Results suggested an inverse correlation 
between increasing concentrations of saponin and the number of RBCs in the parasite 
prep, as expected. However, with increasing concentrations of saponin, a decreased 
number of ring-stage parasites was also observed (0.0075% mean = 4,079; 0.01% 
mean = 3,804; 0.015% mean = 2,599; and 0.03% = 2,487). Although these differences 
are minimal, the trend was consistent across all independent experiments suggesting 
that ring-stage parasites may be sensitive to subtle differences in the saponin 
concentration used for red cell lysis. At the lowest concentration of 0.005%, the ratio of 
rings:RBCs was estimated at 6:1. Compared to the (93:1) ratio that was observed with 
the 0.015% concentration used in the first trial, this was considered too high a drop in 
red cell lysis efficiency. The difference in ring counts between 0.015% and 0.0075% 
concentrations (1.6-fold) suggested that this 2-fold dilution would give optimal recovery 
of rings, while maintaining an acceptable efficiency of red cell lysis for use in the 
mosquito-bite CHMI. When tested on 20 mL volumes of leucodepleted blood 
(representative of the volume to be collected during the mosquito-bite CHMI), 0.0075% 
saponin worked to successfully lyse the ~8 mL volume of packed red cells (40% 
haematocrit in whole human blood). Figure 5.2 shows representative images of smears 
made following red cell lysis with 0.015%, 0.01% and 0.0075% saponin.  
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Table 5.3 | Ring-stage parasites and RBC counts following Saponin lysis 
 
 




red blood cell 
red blood cell 
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Figure 5.2 | Quantifying P. f (3D7) ring-stage recovery following saponin-lysis of RBCs. Giemsa-stained smears of in vitro parasite 
preparations following red blood cell lysis with saponin at 0.015% (A), 0.01% (B) 0.0075% (C). Images represent one field of view, taken 
under 100x objective (LEICA DM LB2 microscope and Yencam HD camera (Yenway microscopes)).  P. falciparum (3D7) ring-stage parasites, 
red blood cells and red cell membrane “ghosts” are indicated. 
 
Figure 5.2 | Qua tifying P. falciparum (3D7) ring-stage recovery following saponin-lysis of RBCs. Gi msa-
stain d smears of in vitro parasite preparations following red blood cell l sis with saponin t 0.015% (A , 0.01% (B) nd 
0.0075% (C). Images repr sent one field of view, taken under 100x objective (LEICA DM LB2 microscope and Yencam 
HD camera (Yenway microscopes)). P. falciparum (3D7) ring-stage parasites, red blood cells and red cell membrane 
“ghosts” are indicated. 
 
 
Following red cell lysis, samples were to be centrifuged to pellet the parasite ring 
stages and dispose of the supernatant. In the previous trial, centrifugation was 
performed at 15,000g, for 10 minutes (see chapter 4, section 4.4.2.2). However, in an 
experiment set up to optimise centrifugation speed and duration, some parasite ring-
stages were found present in the supernatant using these settings. This centrifugation 
step was therefore adjusted to 18,000g, for 20 minutes to ensure optimal recovery of 
parasites during the mosquito-bite CHMI. Furthermore, an additional step was included 
to wash parasite pellets of any free globin that may have resulted following the lysis of 
red cells, as described below.  
 
Washing of parasite pellets 
Samples were centrifuged at 16,000g for 5 minutes and then, to ensure maximal 
recovery of isolated parasites, the supernatants from each tube were collected into 
fresh 1.5 mL Eppendorfs labelled “S1”, and pellets stored on ice. “S1” tubes were 
centrifuged at 16,000g for 5 minutes to pellet any residual parasite material, and as 
before, supernatants from “S1” tubes were then transferred into fresh 1.5 mL 
Eppendorfs, labelled “S2”. “S2” supernatants were centrifuged, and the supernatant 
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transferred into tubes labelled “S3” for a final spin at 16,000g for 5 minutes. The 
recovered parasite pellets from each supernatant spin were then pooled back into the 
tube containing the original parasite pellet by resuspending in 1 mL cold PBS.  Pellets 
were then washed x3 by centrifugation at 16,000g for 5 minutes, again collecting the 
supernatants from each pellet wash (to be centrifuged at the end, before pooling 
together with the original). Washed pellets were resuspended in 1 mL TRIzol™ 
reagent, then mixed by pipetting before incubation at 37oC for 5 minutes. Pellets were 
snap-frozen on dry-ice and transferred to -70oC for storage until RNA extraction.  
 
5.5.3 RNA extraction and quantification 
RNA extraction was to be performed, with inclusion of globin and rRNA-removal, as 
had been optimised for the previous trial (see chapter 4, section 4.4.3). However, at 
such low levels of RNA out-put (picogram quantities), it becomes difficult to accurately 
quantify samples. This can be an issue for the downstream application of the Smart-
seq2 protocol, specifically, for directing the number of PCR amplification cycles to be 
performed following first strand cDNA synthesis. For the previous trial, quantification of 
RNA (after globin and rRNA removal) relied on the use the Agilent Bioanalyzer and 
RNA 6000 Pico Chip assay (quantification range 50 - 5,000 pg/μl). As is shown in 
chapter 4, figure 4.1 (part B), a proportion of the estimated concentration was being 
attributed to the presence of small RNAs (< 200 nt), which was likely to have caused 
an over-estimation in the measurement coming from the larger (> 200 nt) message 
(mRNA) of interest. For this reason, it was decided that exclusion of small RNAs would 
be necessary for more accurate quantification and more efficient amplification in 
downstream steps.  
 
 
The exclusion of small RNAs (< 200 nt) was to be performed using the ZymoSpin RNA 
Clean and Concentrator Kit™- 5 (Zymo Research), as per manufacturer’s guidelines. 
Before application to the trial samples, the protocol was first optimised using RNA that 
had been extracted from mock samples containing (~1x107) in vitro (3D7-strain) ring-
stage parasites, lysed of RBCs. After the removal of globin mRNA and rRNA (see 
chapter 4, section 4.4.3), samples were resuspended in a volume of 50 μl DEPC H2O 
(Thermo Fisher scientific), for immediate mixing with 100 μl of “RNA binding buffer” (50 
μl ethanol + 50 μl buffer). Samples were transferred to a zymo spin column with 
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collection tube and centrifuged at 12,000g for 30 seconds, at 4oC. At this stage, flow 
through (containing small RNAs < 200 nt) was kept aside for assessment of kit 
efficiency. 400 μl of “RNA prep buffer” was then added to the column (containing RNAs 
> 200 nt), centrifuged at 12,000g, at 4 oC for 30 seconds, and flow-through discarded. 
RNA was then washed x2 in 700 μl, then 400 μl “RNA wash buffer” before transferal to 
a fresh 1.5 mL eppendorf tube. 10 μl of DEPC H2O was then added to the column 
matrix, which was centrifuged for 30 seconds at 4oC for elution of RNA. Samples were 
run on the Agilent bioanalyzer RNA 6000 Pico Chip assay to ensure efficient depletion 
of RNAs < 200 nt.  
 
Samples treated with the ZymoSpin RNA Clean and Concentrator kit™-5 
demonstrated a partial reduction in the presence small RNAs (representative Figure 
5.3). By comparing the same samples before and after exclusion, results across 3 
independent experiments suggested that the small RNA fraction (miRNA and 5s rRNA 
<200 nt) contributes to ~80% of the ribosomal-depleted RNA concentration (table 5.4). 
Thus, although the kit did not remove 100% of the small RNA fraction, this step was 
considered important to include in order to accurately quantify samples for downstream 
Smart-seq2.  
 
Figure 5.3 | Depletion of small RNAs (<200 nt) using Zymo Spin RNA Clean and Concentrator Kit™- 5.  Fuorescence units (FU) are shown 
on the y axis, versus nucleotide length (nt) on the x-axis. Plot shows ribosomal-depleted RNA before small RNA exclusion in A, ribosomal-
depleted RNA after small RNA exclusion in B, and the flow-through from step one of protocol (containing the excluded small RNAs) in C. Peaks 
have been annotated, and measured concentrations (pg/µl) are shown in red. (Plots generated by the bioanalyzer  (Agilent Technologies)).  
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Figur  5.3 | Depletion of small RNAs (<200 nt) using Zymo Spin RNA Clean and C cent ator KitTM- 5. .  
Fuorescence units (FU) are shown on the y axis, versus nucleotide length (nt) on the x-axis. Plot shows ribosomal-
depleted RNA before small RNA exclusion in A, ribosomal-depleted RNA after small RNA exclusion in B, and the flow-
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through from step one of protocol (containing the excluded small RNAs) in C. Peaks have been annotated, and 
measured concentrations (pg/μl) are shown in red. Note that scales are different between plots (Plots generated by the 
bioanalyzer  (Agilent Technologies)).  
 
 
Table 5.4 | RNA concentrations before and after exclusion of small (<200 nt) RNA, across three independent 
experiments 
rRNA-depleted RNA rRNA-depleted RNA Column flow-through
(before exlusion of small RNA <200 nt) (after exlusion of small RNA <200 nt) (containing small RNA <200 nt)
Experiment 1 2,013 pg/µl 350 pg/µl 680 pg/µl
Experiment 2 5,957 pg/µl 654 pg/µl 1,345 pg/µl
Experiment 3  2,571 pg/µl 419 pg/µl 952 pg/µl  
 
5.5.4 Smart-seq2 for first strand cDNA synthesis and amplification 
The Smart-seq2 protocol for first-strand cDNA synthesis and amplification has been 
specifically designed for use with low-input quantities of RNA (10 pg – 10 ng range), 
and has been shown to give the greatest coverage of genes in mammalian cells at the 
single-cell level (Picelli et al. 2013, Picelli et al. 2014, Reid et al. 2018). This makes it 
ideal for use in ex vivo parasite RNA-seq during studies of CHMI, where RNA material 
is extremely limited (Reid et al. 2018). Smart-seq2, as performed by Geetha 
Sankaranarayanan during the previous trial, has been described in full in chapter 4, 
section 4.4.5. Figure 5.4 below outlines the key steps. 
 
 
Figure 5.4 | Smart-Seq2 for first strand synthesis and amplification. Flowchart highlighting the key protocol steps. 
1) Incubation of purified Poly(A)+ RNA with dNTPs and Oligo (dT) for priming of samples for reverse transcription.         
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2) Reverse transcription using a Template Switching Oligomer (TSO) carrying two riboguanosines in the third- and 
second-last positions, and a modified guanosine to produce a locked nucleic acid (LNA) as the last base at the 3’ end, 
for template switching (3).  4) Amplification of cDNA by PCR (~10-12 cycles recommended). Poly(A)+ = polyadenylated, 
dNTPs = deoxyribonucleic triphosphates, RT = Reverse Transcription, IS PCR = Illumina Sequencing PCR primers. 
Figure modified from Picelli et al. 201 
 
 
1) Priming for the RT reaction- Samples are primed for the RT-reaction upon 
incubation with free dNTPs and tailed oligo-dT oligonucleotides (30-nt poly-dT 
stretch and a 25-nt universal 5’ anchor sequence). The free dNTPs are added 
in this initial step to improve the yield of RT-PCRs, likely through mechanisms 
that stabilise RNA-primer hybridisations.  
 
2) Reverse Transcription- as described using the original Smart-seq protocol is 
normally performed at 42oC for 90 minutes (the optimal conditions for 
Superscript IITM, according to the manufacturer). However, with the inclusion of 
betaine (1M) to increase protein thermal-stability during the RT reaction in the 
Smart-seq2 protocol, the temperature is allowed to reach to 50oC for 2 minute 
intervals, to promote the unfolding of any secondary RNA structures, thus 
helping to maximize enzyme efficiency and cDNA yield. 
 
3) Template Switching- relies on 2 - 5 un-templated nucleotides being added to 
the cDNA 3’ end when the reverse transcriptase reaches the 5’ end of the RNA. 
To achieve this, Smart-seq2 uses a template switching oligomer (TSO) carrying 
two riboguanosines in the third- and second-last positions, and a modified 
guanosine to produce a locked nucleic acid (LNA) as the last base. Upon 
reaching the 5’ end of the RNA transcript, the Superscript II™ enzyme is able 
switch template and synthesise a complementary sequence to the TSO, 
meaning that every full-length cDNA carries the entire 5’ end of the transcript, 
and an additional artificial sequence, which in this case is the same as the one 
located at the 5’ end of the Oligo-dT primer. This makes it possible to perform 
the subsequent PCR using a single primer.  
 
4) PCR amplification- is performed using a limited number of cycles 
(recommended 10 - 12), or just as many as needed to produce enough material 
for going into library prep (usually ~1 - 2 nanograms is sufficient). Following 
 168 
amplification, samples were to be purified with use of Agencourt Ampure XP 
beads, as per manufacturer’s guidelines (see chapter 4, section 4.4.5.3). 
 
During the processing of samples from the previous trial, the recommended number of 
PCR cycles (10 - 12) did not give sufficient cDNA material for library prep using the 
NEB NEXTflex® kit (Bioo Scientific). For this reason, all samples were put through an 
arbitrary 25 cycles of PCR. This step in the protocol had not be optimsied for variable 
quantities of starting RNA input however, and over-amplification risks inefficiency in the 
RT reaction, and the introduction of technical variability due to amplification bias 
(Oshlack and Wakefield 2009, Stegle et al. 2015). Importantly, the Smart-seq2 protocol 
uses template switching technology, resulting in a bias towards genes that are reverse 
transcribed in full during the RT reaction (full length genes). This may be particularly 
relevant for var gene profiling as many of the genes (particularly those of the A and B/A 
groups) are large in size, at ~ 10 - 12 kb in length (see table 4.1). Thus, reducing the 
number of amplification cycles performed at this stage may help to limit the bias 
towards genes of shorter length. It was therefore decided that for use in the mosquito-
bite CHMI, it would be important to first optimise the number of PCR cycles to be 
applied to samples, based on a predicted range of RNA concentrations following 
parasite isolation from the human host.  
 
Based on the RNA yields recovered from parasites at day of patent infection in the 
blood-stage CHMI (see chapter 4, table 4.3), it was predicted that parasites isolated (at 
more frequent, and earlier time-points) during the mosquito-bite CHMI would produce 
yields between 10 pg - 1 ng of mRNA. The number of PCR cycles was thus optimised 
using RNA samples that had been depleted of globin mRNA, ribosomal RNA and small 
RNAs (< 200 nt) following extraction from in vitro cultured (ring-stage) 3D7 parasites, 
and then diluted as appropriate to give 10 pg, 50 pg, 100 pg, 500 pg or 1 ng in 2 μl 
volumes (required for the initial RT reaction). The RT reaction was performed exactly 
as described previously (see section 4.4.5.1). Based on the commercial Smart-seq 
(version 4) guidelines, the optimal PCR cycle number was determined as that resulting 
in a target cDNA yield of ~3 - 17 ng, when measured by Qbit™ fluorometer and dsDNA 
High Sensitivity kit (Thermo-Fisher Scientifc). Furthermore, quality assessment by 
Agilent 2100 bioanalyzer and High Sensitivity DNA Kit (Agilent Technologies) was used 
confirm the presence of a clean cDNA product spanning 300 – 10,000 base-pairs (bp), 
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as is shown in Figure 5.5. Each experiment run included three replicates, and a Minus 
Reverse Transcriptase (-RT) control to ensure the absence of DNA contamination. 
 
 
Figure 5.5 | Example electropherogram from SMART-seq ® v4 low-input RNA Kit user manual. Plot shows fluorescence units (FU) on the y-axis versus 
base-pairs (bp) along the x-axis, for a cDNA sample following synthesis and 17 cycles of PCR amplification using Smart-seq v4. Lower and upper marker 
peaks are displayed at 35 bp and 10,380 bp, respectively. Amplified cDNA product spans 300 bp – 10,000 bp (region 1), with a clean peak at ~2,500 bp as is 
indicative of a successful reaction.  
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Figure 5.5 | Example electropherogram from SMART-seq® v4 low-input RNA kit user manual. Plot shows 
fluorescenc  units (FU) on the y-axis versus base-pairs (bp) along the x-axis, for a cDNA sample following synthesis 
and 17 cycles of PCR amplification using Smart-seq v4. Lower and upper marker peaks are displayed at 35 bp and 
10,380 bp, respectively. Amplified cDNA product spans 300 bp – 10,000 bp (region 1), with a clean peak at ~2,500 bp 
as is indicative of a successful reaction. 
 
 
cDNA yields, as measured for each replicate sample across all experiments, are 
provided in Appendix 9. Table 5.5 displays the mean yield (ng) of the replicate samples 
for each condition tested.  
 
Table 5.5 | Optimising Smart-seq2 PCR cycle number based on cDNA yield   
13  cycles 14 cycles 15 cycles 16 cycles 17 cycles 18 cycles 19 cycles 20 cycles 21 cycles 22 cycles 25 cycles
10 pg RNA 5.65a 9.05b 11.7b 36.1b 53.2b 1499.3b
50 pg RNA 7.4a 13.2a 20.6b
100 pg RNA 3.2a 9.9a 19.6a 52.5b 134.5b
500 pg RNA 12.5a 21.3a 34.2a
1 ng RNA 7.5a 13.7a 48.7b 72.9b
a mean of 6 replicates, across 2 independent experiemt runs
b mean of 3 replicates, from 1 experiment
cDNA yield (ng)
PCR cycle number not assessed
 
 
Results suggested that the number of PCR cycles required to give ~3 – 17 ng cDNA, 
was variable depending on the starting RNA amount (10 pg, 50 pg, 100 pg, 500 pg or 1 
ng), as expected. When 25 cycles of PCR was applied to 10 pg starting mRNA, the 
recovered yield (1,499.3 ng) far exceeded the amount required for going into 
downstream library prep (few nanograms). When starting with 10 pg of RNA, 20 cycles 
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of PCR resulted in a mean yield of 11.7 ng cDNA, within the predicted size range (300 
– 10,000 bp) when quality assessed by bioanalyzer (Figure 5.6, part A). 18 and 19 
cycles of PCR also produced cDNA yields within the target range. With increasing 
concentrations of RNA, decreasing numbers of PCR amplification cycles were required 
(table 5.5). Figure 5.6 (B - E) shows representative electropherograms of cDNA 
amplification product following 18, 17, 16 and 13 cycles of PCR for 50 pg, 100 pg, 500 
pg and 1 ng starting amounts of mRNA, respectively. Based on these experiments, an 
optimal number of PCR cycles was proposed for each amount of input mRNA 
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Figure 5.6 | Electropherograms of cDNA product following amplification using an optimsed number of PCR cycles. RNA samples were prepared 
from in vitro cultured P. falciparum (3D7) ring-stage parasites, and reverse transcribed using Smart-seq2. Plots show fluorescence units (FU) on the y-axis 
against base-pairs (bp) along the x-axis for the cDNA produced from 10 pg (A), 50 pg (B), 100 pg (C), 500 pg (D) and 1 ng (E) starting RNA input. The 
number of PCR cycles applied to each sample is shown. (F) shows a plot of negative amplification for a representative sample processed without the 
reverse transcriptase enzyme (-RT control). Peaks at 35 bp and 10,380 bp represent the lower and upper markers of the Agilent 2100 HS DNA Chip, 
respectively. Region 1 highlights the predicted region for the cDNA amplification product (300 bp – 10,000 bp). (Plots generated by the Agilent 2100 
bioanalyzer (Agilent Technologies)). 
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Figure 5.6 | Electropherograms of cDNA product following amplification using an optimised number of PCR 
cycles. RNA samples were prepared from in vitro cultured P. falciparum (3D7) ring-stage parasites, and reverse 
transcribed using Smart-seq2. Pl ts show fluorescence units (FU) on the y-axis against base-pa rs (bp) along the x-axis 
for the cDNA produced from 10 pg (A), 50 pg (B), 100 pg (C), 500 pg (D) and 1 ng (E) starting RNA input. The number 
of PCR cycles applied to each sample is shown. (F) shows a plot of negative amplification for a representative sample 
processed without the reverse transcriptase enzyme (-RT control). Peaks at 35 bp and 10,380 bp represent the lower 
and upper markers of the Agilent 2100 HS DNA Chip, respectively. Region 1 highlights the predicted region for the 





Table 5.6 | Proposed PCR cycle number for the predicted amounts of input RNA 
Input Amount of RNA Number of PCR cycles to apply
1 ng 13 - 14
500 pg 15 - 16
100 pg 16 - 17
50 pg 17 - 18
10 pg  18 - 20  
 
 
5.5.5 Library prep and RNA-seq 
Library prep was to be performed by Geetha Sankaranarayanan at the Wellcome Trust 
Sanger Institute, as with the previous trial. In this instance however, it was decided that 
the Nextera XT library prep kit (Illumina) would be best suited, having been optimised 
for low-input (1 ng) DNA, therefore allowing for a reduced number of amplification 
cycles during the Smart-seq2 protocol. The success of this kit is dependent on the 
accurate quantification of cDNA, thus before shipment, samples were to be quantified 
using the Qbit fluorometer 2.0 and dsDNA High Sensitivity kit (Thermo Fisher 
Scientific).  
 
Library prep was to be performed as per manufacturer’s instructions. In brief, 1 ng of 
cDNA (0.2 ng/μl, in 5 μl volumes) is incubated with 10 μl of Nextera XT “Tagment 
Buffer” and 5 μl of “Amplicon Tagment Mix” in a well of 96-well, PCR plate. DNA is then 
tagmented (fragmented and tagged with adaptor sequences) by incubating at 55oC for 
5 minutes, using a thermal cycler with heated lid. Following incubation, 5 μl of 
“Neutralize Tagment Buffer” is added to the well, and plate is centrifuged at 280g and 
20oC for 1 minute, prior to incubation at room temperature for 5 minutes. 5 μl of each 
index adapter (Index I (i7) and Index 2 (i5)), along with 15 μl of “Nextera XT PCR 
Master Mix” is then added to the 25 μl of tagmented DNA for amplification using a 
limited-cycle PCR program (table 5.7). After amplification, library DNA is treated with 
AMPure XP (Beckman Coulter) beads to purify, and then 1 μl of undiluted library is run 




Table 5.7 | Nextera XT PCR program 
Cycle Temperature Duration
cycle 1 72oC 3 minutes
cycle 2 95oC 30 seconds
cycle 3 - 15 95oC 10 seconds
55oC 30 seconds
72oC 30 seconds
cycle 16 72oC 5 minutes
cycle 17 4oC Hold  
 
RNA-sequencing of samples was to be performed by Dr Adam Reid (Wellcome Trust 
Sanger Institute), as described previously (see chapter 4 section 4.4.7).  
 
5.5.6 Summary of protocol amendments 
The protocol used for ex vivo parasite RNA-seq during the original (blood-stage) CHMI 
trial is described in full, in chapter 4 methods. Table 5.8 summarises the amendments 
made to the protocol for use in the mosquito-bite CHMI, based on the optimisation 
experiments discussed in this chapter. 
 
Table 5.8 | Summary of protocol amendments for use in mosquito-bite CHMI 
 
Procedure used in Original *Amendment(s)* made for follow-up
(blood-stage) CHMI trial mosquito-bite CHMI trial
Leucodepletion Leucodepletion by filtration
(LEUCOFLEX LXT filters, Macopharma)
Red cell lysis and 0.015% saponin in PBS 0.0075% saponin in PBS 0.0075% saponin gives better recovery of rings.
recovery of rings 10 minute incubation at 4oC 10 minute incubation at 4oC Faster and longer centrifugation to recover rings
Centrifugation at 15,000g for 10 minutes Centrifugation at 18,000g for 20 minutes otherwise lost in the supernatant
RNA extraction and quantification Depletion of globin mRNA and rRNA, Depletion of globin mRNA, rRNA and small RNAs More accurate quantification 
Quantification by Bioanalyzer (Pico Chip) Quantification by Bioanalyzer (Pico Chip)  for downstream Smart-seq2
Smart-seq2 for first strand Reverse transcription, Reverse transcription, Reduced risk of over-amplification / 
cDNA synthesis and amplification 25 cycles of PCR optimised number of PCR cycles (input-dependent) bias towards genes of shorter length
Library prep NEB NEXTflex® kit (Bioo Scientific) Nextera™ XT kit (Illumina) Optimised for use with lower input DNA (1 ng)
RNA-seq Illumina sequecning (paired-end, HiSeqv4) - -





5.5.7 Test run using in vitro “mock” samples 
In order to test run the fully optimised protocol before application during the mosquito-
bite CHMI, two samples of in vitro cultured (3D7) parasites were prepared and run 
through the protocol, for subsequent RNA-seq analysis. I was interested to know 
whether it would be possible to detect expression of parasite genes in the earliest 
stages of infection, after just one or two cycles following parasite egress from the liver. 
To explore this, samples were prepared using representative numbers of ring-stage 
 173 
parasites (~40 p/mL and ~400 p/mL respectively), based on previous data from 
mosquito-bite challenges performed at the CCVTM, Oxford (Roestenberg et al. 2012). 
Samples were controlled for the total blood volumes that had originally been allocated 
during the challenge follow-up period, such that the “cycle 1 mock” contained 2,000 
parasites in 50 mL of whole blood, and “cycle 2 mock” contained 8,000 parasites in 20 
mL of whole blood. Parasites were purified, RNA extracted and cDNA amplified as per 
the protocol amendments summarised above. Library prep and RNA-sequencing was 
performed by collaborators at the Wellcome Trust Sanger Institute), as previously 
described in chapter 4, sections 4.4.6 and 4.4.7.  
 
RNA-sequencing results showed the ability to detect the expression of P. falciparum  
genes in these samples (table 5.9). For “cycle 1 mock” and “cycle 2 mock”, 658 and 
786 genes were found with at ≥ 5 reads mapping to the reference genome, 
respectively. Although this was an encouraging result, it is important to note that the 
number of genes observed for each represents a small proportion of the > 5,000 genes 
present in the P. falciparum (3D7) reference genome (Gardner et al. 2002). Moreover, 
just four (PF3D7_1200100/ PFL0005w, PF3D7_1200600/ PFL0030c, 
PF3D7_0412900/ PFD0630c and PF3D7_1041300/ PF10_0406) and six 
(PF3D7_0712800/ MAL7P1.55, PF3D7_0800100/ PF08_0142, PF3D7_0421300/ 
PFD1015c, PF3D7_1200600/ PFL0030c, PF3D7_1200100/ PFL0005w and 
PF3D7_1041300/ PF10_0406) var gene variants were detected (with ≥ 5 reads) in the 
“cycle 1 mock” and “cycle 2 mock” samples, respectively. It has been shown previously 
that parasites adapted to long-term culture (as with the parasites used for mock sample 
preparation here), tend to transcribe a reduced number of var gene variants (Peters et 
al. 2007, Zhang et al. 2011), which may partly explain this observation. However, 
considering the overall reduction in the number of detectable genes in these samples 
(mean = 722), compared to that in samples isolated at day of patent infection in the 
previous trial (see chapter 4, table 4.4), results suggest that the low parasite densities 
expected at the onset of infection may limit the number of genes that can be 
successfully detected using this protocol.  
 
Table 5.9| Number of detectable genes in "cycle 1 mock" and "cycle 2 mock" samples 
RNA concentration RNA yield Number of P. falciprum genes Number of P. falciprum genes 
(ng/µl (ng) identified (≥ 5 reads) identified (≥ 10 reads)
"cycle 1 mock" 2,000 0.20 1.99 658 426
"cycle 2 mock" 8,000 8.33 8.33 786 428
Sample I.D Number of parasites in sample 
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5.5.8 Application of optimised protocol to mosquito-bite CHMI 
The protocol described within was applied to a mosquito-bite CHMI study that took 
place at the CCVTM in Oxford, in January 2017 (Clinical/ Trails.gov i.d: 
NCT02905019). Sampling for my sub-study was designed to test how early in infection 
parasites could be isolated for successful RNA-sequencing, following liver egress at   
~6 - 7 days post-infection. Parasites (in 20 mL volumes of blood) were isolated from 5 
(unvaccinated) control volunteers on day 7 post-infection (C +7) and at subsequent 24 
hour time-points, until the termination of volunteer infections at first microscopic 
detection (ranging C +11 - C +12). 
 
5.5.8.1 Parasite densities following mosquito-bite CHMI 
As is routine practice for studies of CHMI, qPCR was used to monitor parasite density 
at twice-daily time points throughout the duration of the challenge follow-up period. 
Figure 5.7 displays the parasite growth curves for the 5 volunteers; ♯1037, ♯1068, 
♯1073, ♯1074 and ♯1076, and the parasite densities (p/mL) as measured at day of 
diagnosis for each. Compared to the previous blood-stage challenge trial, parasite 
densities following mosquito-bite CHMI were consistently lower (mean; 4,658 p/mL and 
range; 1,453 – 10,466 p/mL versus mean; 48,722 p/mL and range; 1,440 – 273,247 
p/mL). In this study, just one of five volunteers (20%) was diagnosed at a parasite 
density ≥ 10,000 parasites/mL, compared to the 9/14 (64%) as was observed following 
blood-stage CHMI. Based on these data, it was decided that parasites isolated at the  
C +7 and C +8 time points, where densities were below or just above the lower limit of 
qPCR detection (20 p/mL), would be too low in numbers to give sufficient RNA material 
for successful RNA-seq considering the likely host contamination in these samples. 
Thus, focus was placed on the parasites recovered at the three time-points; C +9,        
C +10 and C +11, by which time parasitaemias (in 20 mL volumes of blood) were in the 
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Figure 5.7 | Parasite growth through time following mosquito-bite CHMI. Graph shows the number of parasites per 
mL of blood (y-axis) through time (x-axis), as measured by qPCR. A colour key is provided for each of the 5 volunteers, 
along with the parasite density (p/mL) as measured at day of diagnosis for each. Dashed purple line represents the 
qPCR lower limit of quantification (20 p/mL). Red arrows denote the sampling time-points at which isolated parasites 












Figure 5.7 | Parasite growth following mosquito-bite CHMI. Graph shows the number of parasites per mL of blood 
(y-axis) through time (x-axis), as measured by qPCR. A colour key is provided for each of the 5 volunteers, along with 
the parasite density (p/mL) as measured at day of diagnosis for each. Dashed purple line represents the qPCR lower 




5.5.8.2 Number of P. falciparum genes detected at 9, 10 and 11 days post 
mosquito-bite CHMI 
In order to compare the number of genes detected in these samples to that of the 
“cycle 1 mock, “cycle 2 mock” and the 12 patient samples from the blood-stage 
challenge trial, only genes that had ≥ 5 reads (in at least one sample) were considered 
for analysis. As expected, parasite samples isolated at C +11 (from volunteers ♯1037, 
♯1068 and ♯1074) gave the best coverage of genes (1,285, 1,915 and 2,323, 
respectively), most likely reflecting the higher parasitaemias in these volunteers, at this 
time-point (table 5.10). On the other hand, parasite samples from volunteers ♯1073 and 
♯1076 demonstrated best coverage at C +10, when parasite densities had not yet 
reached their peak. Parasites from volunteer ♯1074 gave the best coverage of genes 
(2,323), representing 44% of the 5,268 genes belonging to the P. falciparum genome 
(Gardner et al. 2002). When compared to the 12 patient samples from the blood-stage 
challenge (day of diagnosis mean: 2,518 and range: 1,159 – 3,671), coverage in these 
samples was slightly lower overall (C +11 mean: 1,235 and range: 221 – 2,323). 
However, for volunteers ♯1037, ♯1068 and ♯1074, where parasite densities reached 
>3,000 p/mL (~60,000 total), the number of genes that could be detected was highly 
comparable to that observed for the majority of volunteers in the previous trial (see 
section 4.5.3, table 4.4).  
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The total parasite numbers predicted (in 20 mL) at C +9 (mean: 4,444 and range: 2,600 
– 10,220) were within a similar range to those used to create the “cycle 1 mock” and 
“cycle 2” mock samples, and demonstrated a similar number of detectable genes 
(median: 414 genes and range: 219 - 570). This observation was also true of the C +10 
samples (mean coverage: 596 genes and range: 348 - 904). Importantly, the detection 
of var, and rif genes was markedly reduced in these earlier samples, for volunteers 
♯1037, ♯1068 and ♯1074 (table 5.10). No stevor genes were detected in any volunteer, 
at any time-point. As previously noted, maximal gene coverage (including the VSAs of 
interest) was taken as C +10 for volunteers ♯1073 and ♯1076. However, detection was 
lowest overall in these individuals. A full list of the var and rif genes detected for each 
volunteer, is provided in Appendix 10.   
 
Thus, despite optimisation, the protocol for ex vivo RNA-seq described within appears 
restricted by the low parasite densities in the first two blood cycles and/or host 
contamination, precluding the ability to assess var gene expression at the onset of 
infection. The gene coverage detected at C +11, for volunteers ♯1037, ♯1068 and 
♯1074, and C +10, for volunteers ♯1073 and ♯1076 was considered sufficient to make 
some preliminary observations of var gene expression following mosquito-bite CHMI.  
 
 
Table 5.10 | Number of P. falciparum genes detected in parasites isolated at 9, 10 and 11 days post mosquito-
bite CHMI 
Volunteer i.d/ time-point Parasites/mL Total parasites (in 20 mL) No. of genes detetced (≥ 5 reads) No. of var genes detected No. of rif genes detected No. of stevor genes detected
 1037 C +9 511 10,220 570 2 0 0
C +10 131 2,620 619 8 0 0
C +11 10,466 209,320 1,285 29 1 0
1068 C +9 180 3,600 432 1 0 0
C +10 171 3,420 422 2 1 0
C +11 6,489 129,780 1,915 31 3 0
1074 C +9 176 3,520 558 3 0 0
C +10 68 1,360 348 0 1 0
C +11 3,166 63,320 2,323 33 2 0
1073 C +9 114 2,280 290 1 0 0
C +10 119 2,380 686 17 0 0
C +11 1,714 34,280 429 2 0 0
1076 C +9 130 2,600 219 1 0 0
C +10 44 880 904 10 1 0
C +11 1,453 29,060 221 0 0 0  
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5.5.8.3 Parasite var gene expression following mosquito transmission in the 
naïve host 
Figure 5.8 displays the read counts for all detectable var genes at either C +11 (for 
volunteers ♯1037, ♯1068 and ♯1074) or at C +10 (for volunteers ♯1073 and ♯1076). 
Consistent with observations from the blood-stage challenge trial, a high proportion of 
var gene variants (38/61, 62%) were detected with reads ≥ 5 reads (in at least one 
sample). In parasite samples from volunteers ♯1074, ♯1068 and ♯1037, showing the 
greatest coverage of genes, 55%, 51% and 48% of all variants were detected, 
respectively (figure 5.8). These 3 individuals had shared expression of 23 var genes, 
including variants from the group-A, B/A, B, B/C subclasses, and var2csa (group-E). 
However, read count hierarchies for these common genes were variable between 
volunteer samples. When considering the entire cohort (n = 5), just two variants were 
shared across all (PF3D7_0632800/ MAL6P1.1 and PF3D7_0400100/ PFD0005w). 
MAL6P1.1 was found with the highest number of associated read counts in volunteer 
♯1074, and was within the top ten genes with highest read counts for volunteers ♯1037 
(3rd), ♯1068 (9th), ♯1076 (9th) (figure 5.8). A similar observation was made for 
PFD0005w, which was detected among the top ten for volunteers ♯1073 (1st), ♯1074 
(6th), ♯1037 (7th) and ♯1076 (8th). Interestingly, these group-B var genes have been 
reported as the most highly expressed in two previous studied of mosquito-bite CHMI 
(Wang et al. 2009, Bachmann et al. 2016), showing consistency between the three 
datasets. MAL6P1.1 was also found expressed at high levels in the 12 volunteers that 
received the blood-stage challenge. Yet, PFD0005w was among the variants detected 
at some of the lowest levels (see chapter 4, table 4.6 and figure 4.5).  
 
In contrast to what was observed in the blood-stage trial, group-A genes were reported 
with some of the highest associated read counts in these 5 volunteers, although at 
variable levels across the 5 volunteers (figure 5.8). For instance, PF3D7_0400400/ 
PFD0020c was found among the top four in volunteers ♯1074 (read count = 795), 
♯1068 (read count = 176) and ♯1073 (read count = 299) (similar to previous reports) 
(Wang et al. 2009, Bachmann et al. 2016), but was detected with a low read count in 
volunteer ♯1037 (read count = 5), and not at all in volunteer ♯1076 (figure 5.8).  Other 
group-A var genes found shared between volunteers included PF3D7_0425800/ 
PFD1235w (in volunteers ♯1037, ♯1068, ♯1074 and ♯1076), PF3D7_1100200/ 
PF11_0008 (in volunteers ♯1068, ♯1074 and ♯1076) and PF3D7_1300300/ PF13_0003 
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(in volunteers ♯1068 and ♯1075). Of the top six most highly expressed variants 
detected following blood-stage CHMI (chapter 4, figure 4.6), four (PF3D7_1041300/ 
PF10_0406, PF3D7_1200100/ PFL0005W, PF3D7_0421100/ PFD1005c, and 
PF3D7_1100100/ PF11_0007) were detected in the 3 volunteers with best gene 
coverage in this trial (figure 5.8).  
 
 
var transcript I.D read count var transcript I.D read count var transcript I.D read count var transcript I.D read count var transcript I.D read count
1 PF3D7_0632800 1,660 1 PF3D7_0937800 287 1 PF3D7_1255200 137 1 PF3D7_0400100 544 1 PF3D7_1373500 41
2 PF3D7_0426000 946 2 PF3D7_1255200 277 2 PF3D7_0300100 81 2 PF3D7_1255200 390 2 PF3D7_0600200 33
3 PF3D7_1255200 880 3 PF3D7_0300100 211 3 PF3D7_0632800 81 3 PF3D7_0400400 299 3 PF3D7_0833500 31
4 PF3D7_0400400 795 4 PF3D7_0400400 176 4 PF3D7_0223500 64 4 PF3D7_1300100 190 4 PF3D7_0425800 26
5 PF3D7_0632500 766 5 PF3D7_0632500 141 5 PF3D7_0800100 50 5 PF3D7_0200100 172 5 PF3D7_0800300 22
6 PF3D7_0400100 739 6 PF3D7_1100200 136 6 PF3D7_0937800 45 6 PF3D7_0426000 172 6 PF3D7_1100200 21
7 PF3D7_0223500 734 7 PF3D7_1100100 120 7 PF3D7_0400100 44 7 PF3D7_0712800 112 7 PF3D7_0712300 14
8 PF3D7_0425800 683 8 PF3D7_1041300 117 8 PF3D7_0733000 40 8 PF3D7_0833500 103 8 PF3D7_0400100 12
9 PF3D7_1300100 611 9 PF3D7_0632800 115 9 PF3D7_1373500 39 9 PF3D7_0711700 82 9 PF3D7_0632800 8
10 PF3D7_0733000 509 10 PF3D7_0800100 111 10 PF3D7_1041300 33 10 PF3D7_0617400 75 10 PF3D7_0115700 5
11 PF3D7_1373500 475 11 PF3D7_1373500 100 11 PF3D7_0632500 32 11 PF3D7_1200600 70
12 PF3D7_0937800 456 12 PF3D7_1200400 96 12 PF3D7_0200100 30 12 PF3D7_1041300 42
13 PF3D7_1100200 422 13 PF3D7_1300300 89 13 PF3D7_1200400 30 13 PF3D7_0632500 29
14 PF3D7_1041300 418 14 PF3D7_1240400 88 14 PF3D7_0426000 27 14 PF3D7_0600200 20
15 PF3D7_0115700 413 15 PF3D7_0400100 82 15 PF3D7_1240600 24 15 PF3D7_1100100 20
16 PF3D7_1100100 406 16 PF3D7_1200100 82 16 PF3D7_1200600 22 16 PF3D7_0632800 13
17 PF3D7_1200400 387 17 PF3D7_0733000 80 17 PF3D7_0421100 20 17 PF3D7_0733000 12
18 PF3D7_0100100 315 18 PF3D7_0100100 79 18 PF3D7_1100100 19
19 PF3D7_1200600 252 19 PF3D7_1200600 75 19 PF3D7_0115700 18
20 PF3D7_0800100 236 20 PF3D7_0421100 62 20 PF3D7_1200100 17
21 PF3D7_0200100 191 21 PF3D7_0600200 54 21 PF3D7_1300100 15
22 PF3D7_0300100 147 22 PF3D7_0426000 53 22 PF3D7_0100100 14
23 PF3D7_1200100 145 23 PF3D7_0324900 43 23 PF3D7_0712300 12
24 PF3D7_0421100 119 24 PF3D7_0712400 34 24 PF3D7_0425800 11
25 PF3D7_1240400 105 25 PF3D7_0712800 23 25 PF3D7_0712400 11
26 PF3D7_0809100 94 26 PF3D7_0425800 21 26 PF3D7_0412700 8
27 PF3D7_0800300 87 27 PF3D7_0420900 19 27 PF3D7_0809100 8
28 PF3D7_1240600 74 28 PF3D7_0712300 16 28 PF3D7_0324900 7
29 PF3D7_0712400 64 29 PF3D7_1300100 12 29 PF3D7_0400400 5
30 PF3D7_0712000 17 30 PF3D7_0617400 6
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Figure 5.8 | List of detectable var genes (and associated read counts) following mosquito-bite CHMI in 5 
volunteers. Figure displays the full list of var genes and associated read counts, as detected by ex vivo RNA-seq at 10 
days post mosquito-bite challenge (C +10) for volunteers 1073 and 1076, and at 11 days post mosquito-bite challenge 
(C +11) for volunteers 1037, 1068 and 1074. Note that data is not normalised (rlog converted) thus read count values 
are not directly comparable between volunteers. A colour key for var group affiliation is provided.  
 
I was interested to assess the proportional distribution of parasite var transcripts by var 
group affiliation (A, B/A, B, B/C, C and E) in these 5 volunteers (figure 5.9). Consistent 
with observations from the previous blood-stage challenge, the group-B variants were 
attributed to the largest proportion of total var expression in all patient samples (range: 
45.5% - 81.0% and mean: 66.1%). However, in this study, the group-A variants were 
attributed to a second highest proportion of total read counts (range: 2.0% – 22.1% and 
mean: 13.27%), followed by those of the B/A group (range: 2.1%  - 25.8% and mean: 
10.9%), the B/C variants (range: 2.9% - 7.9% and mean: 5.3%), the group-C var genes 
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(range: 0% - 6.7% and mean: 2.4%) and then var2csa (range: 0% - 3% and mean: 
2.0%). Interestingly, the proportional distribution of each var gene group appeared to 
be more variable following mosquito-bite CHMI, compared to the patterns observed 
following blood-stage challenge (see chapter 4, figure 4.13). Parasites from volunteers 
♯1074 and ♯1068, demonstrating the best coverage of genes at C +11, had remarkably 
similar var group distribution profiles (figure 5.9). However, this pattern was not 
observed in parasites from volunteer ♯1037 (demonstrating a similar number of 
detectable genes). This volunteer had reduced contribution from the group-A variants, 
and a larger proportion of group-B and C variants attributed to their total var read 
counts. Volunteer ♯1076 displayed the most unique var group distribution pattern within 
the cohort (figure 5.9), however this parasite sample had the poorest coverage of var 
genes (n = 10), which is likely skewing the distribution profile towards those select few 
with high read counts, and hence may be misrepresentative of its expression pattern 
had a broader range of variants been detected.   
 
Nevertheless, var gene expression profiles appear to be more variable across 
volunteers following mosquito-transmission, albeit based on this small cohort of n = 5. 
It is possible that this variability may be an effect of ectopic var gene recombination 
events that take place during meiosis in the mosquito-vector (Freitas-Junior et al. 2000, 
Taylor et al. 2000, Claessens et al. 2014), and hence why it was not observed following 
direct blood-stage inoculation in the previous trial. Based on these preliminary 
observations of the read count data, it will be therefore be important to next compare 
the normalised (rlog) var gene expression levels between volunteers, and between 


















































































Figure 5.9 | Percentage distribution of var transcripts by var gene group. The distribution of var transcripts 
according to var group affiliation in shown as the proportion of total var gene read counts, for individual volunteer 
samples as measured at either C +11 (1074, 1068 and 1037) or C +10 (1073 and 1076). A var gene group colour-code 
is provided.  
 
 
5.5.8.4 Parasite rif gene expression following mosquito transmission in the naïve 
host 
Of the 143 rif gene members in the P. falciparum (3D7) genome, just 3 
(PF3D7_0401600, PF3D7_0400500 and PF3D7_1200500) were detected following 
mosquito-bite CHMI in this study, and only in certain volunteers (Appendix 10).  Of the 
3, the most widely detected (and displaying highest read counts) was 
PF3D7_0401600, encoding a group-A RIFIN. This variant was found expressed in 
parasites isolated from the three volunteers demonstrating the best gene coverage 
(♯1074, ♯1068 and ♯1037), and at both C +10 and C +11 time points in two of these 
three individuals (♯1074 and ♯1068). Interestingly, this rif gene variant was also found 
dominantly expressed in volunteer samples from the previous blood-stage CHMI study 
(chapter 4, figure 4.15). There is currently limited information with regards to the 
function of this protein, although it has been found transcribed at high levels in parasite 
populations enriched for parasites that bind to the human endothelial receptors            
P-selectin, E-selectin, CD9 and CD151 (Metwally et al. 2017), It will therefore be 
important to investigate the adhesive properties of this RIFIN further, to determine its 





The switching between hyper-variable var genes affords P. falciparum parasites a 
means to evade the developing host immune response and establish chronic infection 
(Roberts et al. 1992, Smith et al. 1995). This is thought to explain, in part, the delay to 
naturally acquired immunity, which coincides with a transition from acute and severe 
infection in young infants, to asymptomatic carriage in older individuals (Marsh and 
Snow 1997). The severe disease associated with young children (< 5 years) has been 
linked specifically to a subset of group-A, B/A var genes/PfEMP1, suggesting that 
these variants confer a fitness advantage in the immunologically naïve host (Jensen et 
al. 2004, Bull et al. 2005, Kaestli et al. 2006, Rottmann et al. 2006). This, in turn, has 
given rise to the hypothesis that var gene expression (and the acquisition of anti-
PfEMP1 immunity) follows an ordered pattern, with group-A variants being the first to 
be recognised by the developing host immune response (Warimwe et al. 2009, Cham 
et al. 2010, Abdi et al. 2016). Contradictory to this hypothesis however, is data from 
studies of CHMI (including those discussed in the previous chapter of this thesis), 
which demonstrates activation of all, or the majority of var gene variants upon infection 
in the naïve host (Lavstsen et al. 2005, Wang et al. 2009, Bachmann et al. 2016). 
These studies propose a model whereby, at the onset of infection (and in the absence 
of antibody-specific immune selection forces), parasites express a broad repertoire of 
var gene variants for the early exploration of host sequestration receptors. This is in 
line with results reported in the previous chapter of this thesis, showing consistent 
patterns of var gene expression between parasites isolated from the 3rd blood cycle 
(inoculum sample) and parasites recovered after a further 5 - 6 cycles in the blood 
(volunteer samples). In this setting, var gene switching was not observed. Furthermore, 
the disease-associated group-A, B/A var gene variants were detected at some of the 
lowest levels in these non-immune individuals. However, this analysis was restricted to 
a short time-window, and was not conducive to the assessment of var gene expression 
immediately following liver egress (cycles 1 and 2 in the blood).  
 
In order to better understand the parameters of var gene selection in vivo, and hence 
their influence on host clinical outcome, we need to investigate var gene expression 
patterns from the very onset of infection in the human host. Having previously 
demonstrated the successful application of ex vivo parasite RNA-seq during a study of 
blood-stage CHMI, I aimed to optimise my protocol for application to parasitaemias as 
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low as those expected in the first 1 - 2 blood cycles following liver egress (~40 p/mL). 
Moreover, I wanted to ensure the efficient depletion of all (irrelevant) host contaminants 
(blood cells and RNA), as is necessary for successful RNA-sequencing. With use of in 
vitro cultured parasites (P. falciparum 3D7-strain), I was able to show improved 
recovery of parasite ring stages from whole human blood, by reducing the 
concentration of saponin used for red blood cell lysis from 0.015% to 0.0075%. 
Furthermore, by adjusting centrifugation speeds and duration, I was able to prevent the 
loss of parasites that had previously been discarded along with the supernatant. A step 
to wash parasite pellets of residual free globin was also included to improve the purity 
of final parasite preparations before freezing in TRIzol™ reagent. During the RNA-
extraction protocol, I added a step to exclude the presence of small RNAs (< 200 nt in 
length), for the more accurate quantification and estimation of the PCR cycle number 
required in the Smart-seq2 protocol. Importantly, I optimised the number of 
amplification cycles required for the predicted range of parasite RNA yields expected 
during the mosquito-bite CHMI trial, thereby helping to reduce the risk of technical 
variation due to amplification bias. This was also afforded by the switching of protocols 
used for library prep, to a kit designed for use with low-input cDNA yields (1 ng).  
 
RNA-sequencing results from “cycle 1” and “cycle 2” mock samples (consisting of 
2,000 and 8,000 ring-stage parasites, respectively) confirmed the ability to detect 
parasite gene expression from parasite densities representative of those expected after 
immediate liver egress (~40 – 50 p/mL), and in the subsequent blood cycle (~400 – 
500 p/mL). However, it is important to note that a limited number of genes were 
detectable in these samples (“cycle 1 mock” = 658 and “cycle 2 mock” = 786), 
considering the > 5,000 genes that make up the 3D7 reference genome.  Furthermore, 
a reduced number of var gene variants were detected (4 - 6) compared to parasites 
isolated on the day of patent infection (positive thick film by microscopy) in the previous 
blood-stage CHMI trial (58). This may be explained, in part, by the tendency for long-
term cultured parasites to have reduced transcription of var gene variants; a well 
described phenomenon (Peters et al. 2007, Zhang et al. 2011). Therefore, it was 
important to determine the coverage of P. falciparum VSA genes that could be 
achieved using this protocol, when applied early following mosquito-transmission in the 
naïve host.  
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In this study of mosquito-bite CHMI, parasite densities were lower compared to those 
observed during the blood-stage challenge, albeit based on a small cohort of 5 
volunteers. As a consequence, the parasite material recovered at C +7 and C +8 days 
was presumed to be insufficient for sequencing. At 9 days post infection (mean 
parasite density: 222 p/mL/ 4,444 parasites total), a good number of P. falciparum 
genes (mean: 414) could be detected using my protocol for ex vivo RNA-seq, however 
coverage was far reduced when compared to the number of genes detectable at C +11 
(mean: 1,285). In two volunteers, optimal gene coverage was observed at C +10, when 
parasite densities had not yet reached their peak. This observation suggests that, as 
well as low parasitaemias, contaminating host material is likely to have affected the 
success of this protocol. Thus, despite optimisation, this method for ex vivo RNA-seq 
appears restricted to the 3rd blood cycle onwards. Furthermore, observations from this 
trial and the previous blood-stage challenge trial imply a parasite density threshold (of 
~2,000 p/mL / ~50,000 total) for the sufficient coverage of parasite genes. Interestingly, 
a recent study using the same Smart-seq2 technology for parasite RNA-sequencing 
has demonstrated the ability to detect a large proportion of P. falciparum genes in the 
single-cell transcriptomes of parasites at either the asexual trophozoite stage (mean 
coverage = 1,712 genes) or sexual gametocyte stage (mean coverage = 2,090 genes) 
(Reid et al. 2018). Hence, a similar level of coverage that required ~3,000 p/mL in the 
CHMI model, but in transcriptomes from a single parasite. However, it is important to 
note that later stage trophozoites and gametocytes contain larger quantities of RNA 
material than the ring-stages found in the blood, which may have aided sequencing 
efficiency. Moreover, single cell preparations made from in vitro cultures, are unlikely to 
contain contaminating host material, which may have otherwise reduced the number of 
reads mapped to the P. falciparum genome. It may be that Fluorescence Activated Cell 
Sorting (FACS) could offer an alternative approach for the assessment of parasite 
gene expression at the onset of infection in the human host. Single cell sorting of ring 
stage-infected erythrocytes would likely reduce the risk of contamination. Furthermore, 
based on the number of genes detected in single parasite transcriptomes, by Reid et 
al, it is presumed that sorting of just a few ring stage-infected erythrocytes (~10 – 20) 
would provide sufficient material for sequencing. However, this method may not be 
appropriate in a setting where the desired cell population is at such low frequencies in 
the blood (predicted < 0.0003% at the earlier time-points). Moreover, it is difficult to 
distinguish between ring-stage infected and uninfected erythrocytes without the use of 
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intracellular DNA dyes and it is not clear what affect these dyes may have on parasite 
viability and/or gene expression.  
 
Analysis of parasite var gene expression in samples isolated at C +10 (for two 
volunteers, and C +11 (for the remaining three volunteers) revealed the broad 
expression of variants, consistent with observations from the blood-stage CHMI. 
Furthermore, variants associated with all subgroups (A, B/A, B, B/C, C and E) were 
detected across the cohort. Var genes detected with highest associated read counts 
were largely of the group-B and group-A subclasses following mosquito-bite challenge, 
but demonstrated a variable hierarchy across volunteers. Interestingly, the only two 
variants detected in all 5 individuals (MAL6P1.1 and PFD0005w) have been reported 
as the most abundantly expressed variants in two previous studies of mosquito-bite 
CHMI (Wang et al. 2009, Bachmann et al. 2016). Moreover, the group-A var gene; 
PFD0020c, detected with some of the highest read counts in 3/5 volunteers in this 
study, was reported as the 4th and 5th most highly expressed by Wang et al and 
Bachmann et al, respectively (Wang et al. 2009, Bachmann et al. 2016), demonstrating 
consistency between the three datasets. Interestingly, this group-A var gene variant 
encodes a PEMP1 protein with an N-terminal region containing DBLα1.7 and 
CIRDα1.4 (domain cassette13) (Rask et al. 2010), and has been linked to severe 
malaria disease (CM) through its capacity to bind human brain endothelial cells 
(Claessens et al. 2012, Lavstsen et al. 2012, Bertin et al. 2013, Turner et al. 2013, 
Almelli et al. 2014). Based on results from the previous blood-stage CHMI study, 
parasite var gene/PfEMP1 expression is not predicted to influence host immune 
responses at this early stage of infection.  However, it will be interesting to assess host 
immune responses in these volunteers, given the differing var gene expression profiles 
between these individuals and those following mosquito-bite challenge. Samples of 
whole blood were collected for transcriptional analysis of the host response in this trial, 
but results are yet to be analysed.  
 
Despite overlapping expression of var gene variants across this cohort, expression 
hierarchies varied between volunteers. This was reflected in the proportional 
distribution of var gene read counts, by var gene group. When compared to the 
(almost) identical patterns of var gene expression observed in volunteers following 
direct blood inoculation (blood-stage challenge), this observation suggests that var 
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gene recombination events that occur in the mosquito-vector may be driving variability 
in var gene expression profiles before entry to the blood-phase. However, this study 
was limited to the analysis of var gene expression in parasites recovered from the third 
blood cycle in these volunteers, and it may be that switching events occur during the 
first two cycles in the blood. This will be important to investigate in future studies, 
assuming an appropriate method becomes available.  This study was also limited by 
the small cohort, and by the reduced gene coverage in 2 of the 5 volunteers. 
Therefore, it will be important to validate these findings with use of a much larger 
cohort, and ideally at more time points during infection. It is also important to consider 
that all CHMI studies of P. falciparum gene expression to date have been done using 
the 3D7 or the parental NF54 laboratory strain of the parasite (Peters et al. 2002, 
Lavstsen et al. 2005, Wang et al. 2009, Bachmann et al. 2016). It is therefore essential 
that other strains of the P. falciparum species be tested in studies of CHMI, for 




















































6 General discussion and Future Directions 
In order to reduce the burden associated with malaria disease, focus needs to be 
placed on understanding what drives pathogenesis in those at greatest risk. Most 
observations of human malaria are based on studies conducted at a time when the 
infection has already led to disease, making it difficult to identify the initiating immune 
events that may be driving severe disease outcome. Furthermore, the expression of 
Plasmodium falciparum erythrocyte membrane 1 (PfEMP1), along with other variant 
surface antigens (VSAs), is thought to influence clinical outcome, by mediating the 
parasite-host interactions that contribute to the obstruction of blood flow and organ 
dysfunction. However, despite clear associations between group-A, B/A PfEMP1 and 
severe disease in patients presenting to the clinic, little is known about their expression 
at the onset of infection. Importantly, not all individuals exposed to P. falciparum for the 
first time develop severe disease and evidence from studies of experimental human 
malaria infection support marked inter-individual variability in host responses (Walther 
et al. 2006, Burel et al. 2017). Yet, out-with the well-described red cell polymorphisms 
associated with protection, factors influencing diversity in the host response to              
P. falciparum have not been well defined. Therefore, to better understand what drives 
severe malaria disease, we need to investigate the early parasite-host interactions that 
are predicted to dictate outcome of infection in the non-immune host. 
 
The aim of this thesis was to investigate patterns of host and parasite gene expression 
early during infection in the malaria-naïve and to determine the influence of parasite 
VSA expression on the developing host immune response, and vice versa. This 
chapter seeks to provide a general overview of findings, limitations of this project and 
recommendations for future studies. Discussed first will be the host response to           
P. falciparum infection, followed by our analysis of parasite gene expression in the 
malaria naive host.  
 
6.1 The early host response to primary P. falciparum infection 
It is increasingly evident that individuals produce diverse responses to P. falciparum, 
yet few studies have been designed in a way that is conducive to the assessment of 
inter-individual variation. By sampling volunteers over a time-course throughout 
infection, this study allowed each volunteer to be treated as their own experiment. 
Furthermore, with use of the blood-stage CHMI model, variables such as liver to blood 
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inoculum load, and the timing of parasites entering the host circulation (as is expected 
with use of the mosquito-bite challenge model), could be excluded. This study was 
therefore uniquely designed to assess inter-individual variation in host immune 
responses during primary P. falciparum infection, and to allow us to investigate the 
earliest of immune events.  
 
In chapter 3, our analysis of the host (whole blood) transcriptome response to              
P. falciparum infection is presented. These data were complemented by the 
quantification of cytokines and chemokines in host plasma and parasite growth in the 
blood, the assessment of haematological perturbations (full blood counts) and the 
monitoring of clinical adverse events. 
 
6.1.1 Overview of key findings 
6.1.1.1 Activation of the immune response and inter-individual variation  
An important observation from this study was that 4 volunteers (29% of the cohort) did 
not produce a detectable transcriptional response, despite having parasite densities 
comparable to (or exceeding) those who demonstrated marked differential expression 
of genes in response to P. falciparum. This suggests that the parasite density threshold 
required for activation of the immune response is variable between individuals, 
something which has only before been suggested in historical studies of malaria-
therapy (Glynn and Bradley 1995, Molineaux et al. 2002, Dietz et al. 2006). In those 
that did react, a dichotomous pattern of gene expression was detected, confirming 
inter-individual variability in the early host response. Surprisingly, 2 volunteers 
demonstrated down-regulation of genes associated with inflammation, cell signaling 
and metabolism. Moreover, IPA predicted the inhibition of pathways such as interferon 
signalling and TREM-1 signalling in this group of volunteers. To our knowledge, this 
study is the first to document this “non-classical” type of response, whereby 
inflammation is actively suppressed during primary P. falciparum infection. On the 
other hand, 8 volunteers demonstrated up-regulation of genes that were classically 





6.1.1.2 The early host inflammatory response  
6.1.1.2.1 Cytosolic sensing of P. falciparum 
Studies in vitro, murine models and human infection have implicated a range of 
parasite associated molecular patters (PAMPs) and host pattern recognition receptors 
(PRRs) in initiating the inflammatory response to Plasmodium, as has been previously 
reviewed (Gazzinelli and Denkers 2006, Liehl and Mota 2012, Gazzinelli et al. 2014, 
Liehl et al. 2014, Oviedo-Boyso et al. 2014). However, evidence has been largely 
context and species dependent. In the 8 individuals that demonstrated an inflammatory 
transcriptional signature in this study, among the most up-regulated genes were 
DDX58 (RIG-I), IFIH1 (MDA5) and TLR7. All three of these cytosolic PRRs are 
responsible for the detection of RNA (Akira et al. 2006, Goubau et al. 2013, McNab et 
al. 2015). Interestingly, there is evidence to suggest that RIG-1 and MDA5 may also 
recognise certain AT-rich DNA motifs, although this is controversial (Goubau et al. 
2013). Another cytosolic PRR found to be up-regulated in the dataset was AIM2, which 
recognises double-stranded DNA. This protein has been shown to serve as a potent 
activator of the inflammasome complex, by initiating the recruitment of caspase-1 
precursor and processing of interleukin-1 beta and interleukin-18 (Latz 2010). Genes 
associated with the NLRP3 inflammasome, including PR2X7 and CASP1, were also 
expressed. Evidence for dual activation of the AIM2 and NLRP3 inflammasomes has 
been previously reported in a study of P. berghei ANKA infection whereby parasite-
produced haemozoin and DNA were thought to be the key inducers of the systemic 
inflammation (Kalantari et al. 2014). As P. falciparum infects red blood cells and not 
leukocytes, it is unclear how parasite nucleic acids come into contact with host 
cytosolic sensors. However, recent evidence suggests this process may occur though 
the internalisation of parasite secreted extracellular vesicles (EVs), containing parasitic 
small RNA and/or genomic DNA (Sisquella et al. 2017). In this study by Sisquella et al, 
human monocytes were shown capable of this interaction, via expression of the 
Stimulator of Interferon genes (STING) cytosolic DNA sensor, resulting in downstream 
activation immune genes including Type I IFNs. 
 
6.1.1.2.2 Interferon-signalling 
Pathway analysis revealed “interferon signaling” to be the most significantly enriched 
pathway in the response of the 8 inflammatory volunteers. Consistently, both RIG-I and 
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MDA5 (discussed above) have been widely associated with the induction of Type I 
IFNs (Yoneyama and Fujita 2004, Kawai et al. 2005, Gitlin et al. 2006, Kawai and Akira 
2006, Besch et al. 2009, Broquet et al. 2011, McNab et al. 2015, Ho et al. 2016, Maria 
et al. 2017), suggesting a key role for these cytokines in the early response to              
P. falciparum. This observation is in line with previously reported results from studies in 
both mouse models of Plasmodium infection (Rocha et al. 2015, Spaulding et al. 2016, 
Yu et al. 2016, Zander et al. 2016) and CHMI (Montes de Oca et al. 2016, Gardinassi 
et al. 2018), suggesting a “classical” type response from these 8 volunteers. 
Interestingly, data from both mouse and human models of Plasmodium infection have 
shown an ability of Type I IFNs to suppress IFNγ-driven cellular responses at the early 
stages of Plasmodium infection (Haque et al. 2014, Montes de Oca et al. 2016). Yet, 
data from this study suggest that both Type I (IFNα/β) and Type II IFNs (IFNγ) are 
important mediators in the early response to P. falciparum, as CXCL9 and CXCL10 
(both induced by IFNγ) were found elevated at the transcript and protein level in these 
8 individuals. Importantly, there is substantial overlap in the genes that Type I and 
Type II IFNs regulate, making it is difficult to interpret whether one type may dominate 
over the other in this infection setting. Furthermore, there is evidence to suggest that 
the two can work cooperatively, through the regulated expression of STAT1 (Gough et 
al. 2010), although the mechanisms of this crosstalk have not been defined in the 
context of Plasmodium infection. Surprisingly, IFNγ was not found elevated in host 
plasma until C +10 (48 hours after the first transcriptional responses could be 
detected), and only in the 3 most inflammatory volunteers. Furthermore, no detectable 
increase in circulating IFNα (Type I IFN) was observed throughout. This was another 
important observation, as it suggests that the initial IFN-signalling event may be 
occurring in host tissue(s), out-with the blood. In line with this hypothesis, there is 
evidence to suggest that during severe P. yoelli infection in mice, Type I IFNs are 
largely produced by plasmacytoid DCs in the bone marrow (Spaulding et al. 2016).  
 
6.1.1.2.3 Evidence for a role of myeloid cells 
Activation of the inflammasome signaling pathway was predicted among the top ten 
pathways significantly enriched within the group of the 8 inflammatory volunteers, 
suggesting a key role for myeloid cells in their response. In line with this, TREM-1 
(Triggering Receptor Expressed on Myeloid Cells 1)-signalling was also predicted with 
high significance. This protein is expressed on monocytes, macrophages and 
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neutrophils (Bouchon et al. 2000, Zanzinger et al. 2009). Interestingly, full blood count 
analysis did not reveal any fluctuations in circulating monocytes and neutrophils 
throughout the course of infection, contradictory to what has been reported in previous 
studies of CHMI (Antonelli et al. 2014, Teirlinck et al. 2015), and in studies of infection 
in the field (Chimma et al. 2009, Ogonda et al. 2010, Ataide et al. 2014, Dobbs et al. 
2017, Patel et al. 2017). However, CXCL10 (produced in large quantities by 
monocytes), was among the top 10 most up-regulated genes in this group, and was 
found significantly elevated in the plasma of these volunteers. This protein serves as a 
chemoattractant for monocytes/macrophages, as well as other cell types including T 
cells, NK cells and dendritic cells. Interestingly, the response of these 8 volunteers was 
associated with a significant drop in circulating lymphocytes. Furthermore, CXCL10 
was detected in plasma before IL-8 (the chemoattractant for neutrophils) could be 
observed. Thus, given their capacity to phagocytose and their location in the blood, it is 
reasonable to speculate that monocytes are among the earliest of cell types 
responding to P. falciparum infection. Evidence from in vitro studies has demonstrated 
an ability of these cells to phagocytose PEs and parasite-secreted EVs, independently 
of malaria-specific antibodies (Su et al. 2002, Sisquella et al. 2017). There is also 
evidence to suggest that ring-stage PEs can be opsonised by complement proteins 
and natural IgG, and thus targeted for destruction via complement and Fc receptor-
dependent pathways (Turrini et al. 1992, Ayi et al. 2004). Interestingly, the gene 
encoding FCγR1 (high affinity IgG Fc receptor) was among the top 10 most up-
regulated for all 8 volunteers in this group. A recent study has highlighted an ability of 
monocytes, via expression of a cytosolic DNA sensor, to interact with parasite nucleic 
acids through phagocytosis of P. falciparum-secreted EVs, resulting in downstream 
activation of Type I IFN responses (Sisquella et al. 2017). If the cytosolic receptors 
found up-regulated in our dataset (RIG-I, MDA5, TLR7 and AIM2) are also capable of 
this interaction, data presented by Sisquella et al may provide the link between the host 
transcriptional responses reported in our volunteer cohort. 
 
Overall, observations from our study of the early host response to blood-stage             
P. falciparum (3D7) suggest that onset of inflammation likely involves cytosolic host 
PRRs such as RIG-I, MDA5, AIM2 and TLR7 for the detection of parasite nucleic acids. 
Activation of these PRRs may lead to the production of Type I IFNs (via RIG-I and 
MDA5), engagement of the AIM2 and NLRP3 inflammasome complexes in myeloid 
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cells, the recruitment of immune cells via IFNγ-induced CXCL9 and CXL10, Fc 
receptor-dependent phagocytosis of PEs by monocytes/macrophages, and the 
production of pro-inflammatory cytokines, which may be amplified by TREM-1 
expression. However, the resulting outcome of the response is difficult to predict. 
 
6.1.1.3 Predicting clinical outcome in the non-immune host 
The ethical necessity to treat volunteers before the onset of clinical symptoms in CHMI, 
precludes our ability to determine disease severity in these 8 inflammatory volunteers. 
Within the most up-regulated genes expressed by this group, however, were those 
encoding the chemokines CXCL9 and CXCL10, both of which are considered robust 
biomarkers of severe malaria disease (Schofield and Grau 2005, Jain et al. 2008, 
Ayimba et al. 2011, Wilson et al. 2011). Moreover, their transcriptional response 
coincided with a significant drop in lymphocytes (lymphopenia in three volunteers), 
which has been reported in malaria patients exhibiting high levels of inflammation in 
the natural infection setting (Hviid et al. 1997). Individuals in this group also reported 
more frequent and more adverse symptoms, compared to volunteers that did not share 
this inflammatory transcriptional response. These data thus highlight CXCL9, CXCL10 
and lymphopenia as potential biomarkers of disease for use with the CHMI model, 
something currently lacking. Interestingly, levels of angiopoietin-2 (ANG-2) were found 
elevated in the most inflammatory volunteer in this group. In the context of malaria 
infection, increased levels of ANG-2 have been widely associated with severe clinical 
outcome (Viebig et al. 2005, Yeo et al. 2008) and more recently, as a predictor of 
mortality in patients presenting with cerebral malaria (Lovegrove et al. 2009, Conroy et 
al. 2012).  
 
In mouse and human models documenting the early production of Type I IFNs during 
Plasmodium infection, this response has been predominantly associated with impaired 
immune cell responses, unregulated parasite growth and poor host outcome (Haque et 
al. 2014, Rocha et al. 2015, Montes de Oca et al. 2016, Spaulding et al. 2016, Zander 
et al. 2016). In other disease models such as Listeria monocytogenes (in mice) and 
Tuberculosis (mouse and human infection), Type I IFNs have been shown to exert 
inhibitory effects on immune cells, leading to higher infection burdens and disease 
(Auerbuch et al. 2004, Carrero et al. 2004, Berry et al. 2010, Desvignes et al. 2012, 
McNab et al. 2015). However, their protective role during the host response to viral 
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infections has been well described (Isaacs and Lindenmann 1957, Muller et al. 1994, 
Schneider et al. 2014). Hence, the extent to which Type I IFNs mediate either 
pathology or protection during primary infection remains to be defined. Also predicted 
to be activated in these volunteers was the inflammasome pathway and TREM-1 
signalling. In mice infected with P. chabuadi AS, caspase-1 activation via the NLRP3 
inflammasome results in high-level production of IL-1β, and lethal outcome (Ataide et 
al. 2014). Furthermore, a significant increase in the frequency of circulating 
CD14+CD16−Caspase-1+ and CD14dimCD16+Caspase-1+ monocytes has been reported 
in the peripheral blood mononuclear cells from febrile patients (Ataide et al. 2014). In 
the broader context of human disease, inflammasome signaling has been implicated in 
a variety of inflammatory processes and disorders, as has been reviewed (Strowig et 
al. 2012). TREM-1 signalling has been causally implicated in rodent models of 
inflammatory pathologies, including sepsis (Charles et al. 2016), and this is 
consistently linked to elevated monocyte TREM-1 and plasma sTREM-1 in the 
corresponding human condition. In malaria infection, TREM-1 has been found at 
elevated levels on monocytes, and in plasma (sTREM-1) of patients with severe 
disease (Adukpo et al. 2016). Thus, it is plausible to speculate that the 8 volunteers 
would have gone on to develop severe malaria disease if left untreated. However, the 
inflammatory response has also been implicated in a protective capacity, in the early 
control of parasite growth. For instance, the phagocytosis of parasitised erythrocytes 
(PEs) and merozoites, by myeloid cells, is thought to be important for controlling 
parasite growth in non-immune individuals based on evidence that this can occur in the 
absence of malaria-specific antibodies (Trubowitz and Masek 1968, Su et al. 2002). 
Furthermore, in malaria infected humans and mice, haemozoin-laden myeloid cells are 
found abundant in the blood and particularly the spleen- the primary site of PE 
clearance (Coban et al. 2010). Therefore, it was important to consider the relationship 
between host immune responses and parasite growth in the blood.  
 
 
6.1.1.4 Relationship between early host immune responses and parasite growth 
in the blood 
Parasite multiplication rates (PMRs) in this cohort of individuals were similar to those 
reported in other studies of CHMI with P. falciparum (mean: 10 and range: 6.7 – 12.8) 
(Roestenberg et al. 2012, Sheehy et al. 2012, Sheehy et al. 2013). Importantly, 
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parasite densities at time of diagnosis were not sufficient to explain the inflammatory 
response of the 8 “classical” responders. Furthermore, there was no evidence to 
suggest that the rate of parasite growth in the blood influenced the host transcriptional 
response, or vice versa. Thus, the 8 volunteers who elicited an early inflammatory 
response had no better control of parasite growth in the circulation than those who 
failed to respond. Results from this study thus contest evidence that suggest a key role 
for the innate immune response in controlling parasite growth early during infection in 
the non-immune host (Trubowitz and Masek 1968, Clark et al. 1987, Taverne et al. 
1987, Turrini et al. 1992, Tsutsui and Kamiyama 1999, McGilvray et al. 2000, Su et al. 
2002, Omer et al. 2003, Ayi et al. 2004, Walther et al. 2005, Walther et al. 2006, 
Robinson et al. 2009, Coban et al. 2010, Horowitz et al. 2010, Willcocks et al. 2010). It 
is important to consider that this evidence has largely been derived from studies 
carried out in vitro, or in mouse models whereby parasite growth kinetics are highly 
variable between species, and are not necessarily representative of those observed in 
human Plasmodium infections. Importantly, recent reanalysis of data from studies of 
malaria-therapy suggest that the acquisition of clinical immunity, following repeated re-
exposure to Plasmodium, is not associated with a reduction in parasite density during 
the first few infections (Molineaux et al. 2002). The same observation has more 
recently been reported in a large cohort of Tanzanian children (Goncalves et al. 2014), 
highlighting disconnect between the animal models and human infection studies used 
to investigate the innate immune response during Plasmodium infection in the naïve 
host.  
 
6.1.2 Study limitations 
Results from our study of the early host immune response, in conjunction with parasite 
growth kinetics raise some important questions. For example, is there really a 
protective function of the innate immune response early during primary infection? 
Although we saw no evidence for reduced parasite growth during the first ~5 - 6 
replication cycles in the blood, we need to consider what effect it may have on 
sequestered parasites- something that was not assessed in his study. Hence, are we 
missing evidence for this protective function because it’s happening in the tissues? 
There is convincing data to show that myeloid cells are able to phagocytose PEs in the 
spleen, for instance, as haemozoin-laden macrophages have been found abundant in 
this tissue during human malaria-infection (Coban et al. 2010). Yet, whether this is a 
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feature associated with the early response during primary infection remains unclear. 
Furthermore, results from this study suggest that initial immune signalling events 
during the host response to primary P. falciparum infection may involve cells located in 
tissue(s), outwith the blood. This highlights an important limitation of CHMI, and human 
studies of Plasmodium infection more generally, in that current ethical constraints limit 
our analysis to immune events occurring in host circulation. Malaria is a multi-organ 
disease involving tissues such as the liver, bone marrow and spleen (Del Portillo et al. 
2012, Joice et al. 2014, Punsawadl et al. 2014, Viriyavejakul et al. 2014, Obaldia et al. 
2018) and there are likely important parasite-host interactions occurring at these sites. 
A central, protective role of the spleen, for instance, has been well described 
(Chotivanich et al. 2002, Engwerda et al. 2005, Del Portillo et al. 2012). Although many 
crucial insights into the immune response during Plasmodium infection have been 
gained with use of murine models (Wykes and Good 2009), none fully recapitulate 
malaria infection in the human host. Therefore, it is likely that future studies of the early 
host immune response would benefit from continued use of non-human primate 
models (Cox-Singh et al. 2010, Langhorne et al. 2011) and/or access to human tissue 
biopsies, assuming the necessary ethical approvals can be granted.  
 
By selecting to analyse the whole blood response to P. falciparum, we have been able 
to provide an overview of the early transcriptional events. Yet, this study was limited in 
its ability to dissect the function of specific immune cell subsets in the early host 
response. Furthermore, it is important to consider that our analysis of the host 
transcriptional response may not necessarily translate at the protein level.  Although 
we were able to validate the up-regulated expression of certain genes by screening for 
their corresponding proteins in the plasma, it was not feasible to screen for everything 
we found differentially expressed.  
 
A key finding reported in this work was the inter-individual variation in host immune 
responses. However, we were unable to correlate these immune response variables 
with disease outcome, due to the stringent diagnosis cut-offs used in CHMI. This 
represents the major limitation of this study. Switching to a higher parasite density cut-
off for diagnosis would likely benefit future studies, although may not be feasible due to 
ethical concerns. An important consideration with use of the CHMI model for studying 
the host immune response is that volunteers are of adult age (>18 years), and there 
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are some well-characterised differences between the immune systems of adults and 
children (Elahi et al. 2013, Krow-Lucal et al. 2014, Levy and Wynn 2014, Kollmann et 
al. 2017). Furthermore, age-dependent characteristics of clinical outcome in malaria 
(Baird 1998, Baird et al. 1998, Dondorp et al. 2008) suggest that progression to severe 
disease may occur through distinct mechanisms in children. Therefore, findings 
presented here may not be fully representative of the early immune events occurring 
during natural P. falciparum infection in children <5 years of age- i.e. those at greatest 
risk of severe disease.  
 
Nevertheless, this study provides important insight into the diversity in early host 
immune responses to primary P. falciparum infection, and highlights an important gap 
in our understanding of how differing immune responses, at the onset of infection, may 
contribute to the diversity in clinical outcomes observed at the later stages of disease.  
 
6.1.3 Future considerations 
A key finding reported in this work was the inter-individual variation in host immune 
responses. However, this study is limited in statistical power due to the small number 
of volunteers (n = 14), of which only 2 produced the “non-classical” type response.  It is 
therefore crucial to test the reproducibility of this observation, using a much larger 
cohort of individuals, over repeated studies of CHMI. It will also be important to do this 
using both mosquito-bite and blood-stage challenge models, to explore any differences 
between the two infection routes. Importantly, our analysis of the host response 
excluded non-coding transcripts, such as micro RNAs (miRNAs). Yet, microRNAs are 
important regulators of the immune response, and there is recent evidence to suggest 
that inter-individual variability during P. falciparum infection is also reflected in this non-
coding fraction of the host transcriptome (Burel et al. 2017). Future analysis should 
therefore be extended to non-coding, as well as coding transcripts.  
 
Our data give evidence for a transcriptional signature of myeloid cells in the whole 
blood transcriptional response to P. falciparum. These cells are likely important 
mediators of the response to P. falciparum, given their ability to phagocytose and to 
produce large quantities of inflammatory cytokines. However, their role in protection 
and/or pathogenesis during primary infection remains to be defined (Serghides et al. 
2003, Silver et al. 2010, Chua et al. 2013, Weinberg et al. 2016, Dobbs et al. 2017). 
 197 
Thus, future work should consider a focused analysis of monocytes and neutrophils, to 
determine their activation status during primary P. falciparum infection, as well as their 
contribution to the diversity in host responses. A time-course analysis of these cells 
would likely give insight into the order and timing of key transcriptional events. 
Furthermore, experiments designed to test the functional capacity of these cells would 
also be of interest. For instance, incubating monocytes with parasite-infected RBCs to 
monitor phagocytic uptake or by re-stimulating these cells ex vivo, using P. falciparum 




6.2 Parasite gene expression in the naïve host  
There is substantial evidence for an association between the expression of                  
P. falciparum variant surface antigens, in particular group-A and/or group-B/A PfEMP1, 
and severe clinical outcome (Kirchgatter and Portillo Hdel 2002, Bull et al. 2005, 
Kaestli et al. 2006, Kyriacou et al. 2006, Rottmann et al. 2006, Normark et al. 2007, 
Falk et al. 2009, Warimwe et al. 2009, Kalmbach et al. 2010, Lavstsen et al. 2012, 
Warimwe et al. 2012, Bertin et al. 2013, Almelli et al. 2014, Abdi et al. 2015, Bertin et 
al. 2016, Jespersen et al. 2016, Mkumbaye et al. 2017, Shabani et al. 2017, Tonkin-Hill 
et al. 2018). However, the extent to which these variants actually drive pathology has 
been difficult to assess as little is known about their expression at the onset of 
infection. Hence, their influence on the developing host immune response, and disease 
severity, remains elusive. This is also true for the other parasite VSAs with predicted 
disease-causing characteristics, such as the RIFINSs and STEVORs. Given that 
severe disease is almost exclusively associated with the very young, having had little 
or no previous exposure to the Plasmodium parasite, our cohort of malaria-naïve 
volunteers represented an opportunity to assess parasite (var, rif and stevor) 
expression during the volunteers’ first infection.  
 
6.2.1 Overview of key findings 
6.2.1.1 Rif and stevor gene expression in the malaria-naïve host 
In most parasites, RIFIN and STEVOR proteins (encoded by the rif and stevor multi-
gene families) are found expressed along with PfEMP1 (Fernandez et al. 1999, Kyes et 
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al. 1999, Kaviratne et al. 2002), suggesting that they may be involved in key parasite-
host interactions during primary P. falciparum infection. Furthermore, RIFINS have 
been implicated in severe malaria given their ability to form rosettes upon binding to 
uninfected red cells (Goel et al. 2015). In this study the majority of detectable rif 
variants were transcribed at very low levels, whereas one A-type rif variant (PFD0070c/ 
PF3D7_0401600) was dominantly expressed in all. Although there is limited 
information available with regards to its function, this RIFIN protein appears to be 
strain-transcendent, having been detected in 3D7, HB3, IT and Dd2 P. falciparum 
strains (Claessens et al. 2011). Interestingly, this rif gene variant was also found 
dominantly expressed in volunteers following mosquito-bite CHMI. It is thus of 
considerable interest to better characterise the function of this protein, and its 
interactions with host cell receptors.  
 
Just 3 (of 32) stevor variants were detected in this dataset (PF3D7_0832000, 
PF3D7_0300900 and PF3D7_0617600), and all at very low levels. This is likely due to 
the late stage expression of the stevor multi-gene family (22–32 hours post infection) 
(Kaviratne et al. 2002, Lavazec et al. 2007), on more mature stages (trophozoites and 
schizonts) that are sequestered in the microvasculature (Miller et al. 2002). Parasites 
isolated from the blood are thus not suitable for investigating expression patterns of 
this multi-gene family during infection in the human host. 
 
6.2.1.2 Var gene expression in the malaria-naive host 
Group-A, B/A disease-associated var gene/PfEMP1 variants are predicted to dominate 
expression in the non-immune host. Furthermore, these variants are thought to confer 
a growth advantage over others in this infection setting, through mechanisms that 
afford them promiscuity in host cell receptor binding (Abdi et al. 2017). Results from 
this study contradict these hypotheses, showing broad-level detection of variants (95% 
of the total var gene repertoire), with highest expression coming from the group-B 
subclass. Importantly, these results were consistent with two other studies of parasite 
var gene expression during CHMI (Wang et al. 2009, Bachmann et al. 2016). The 6 
most highly expressed var genes in our study (PF10_0406, PFL0005w, MAL7P1.55, 
PFD1005c, PFD1015c and PF11_0007) were small group-B and C PfEMP1, with 
structures comprising the semi-conserved DBLα0-CIDRα head structure commonly 
associated with CD36 binding) (Smith et al. 2001, Robinson et al. 2003). The 
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relationship between CD36 binding and pathogenesis has not been well defined, with 
alternative lines of evidence supporting contradictory models (Newbold et al. 1997, 
Rogerson et al. 1999, Aitman et al. 2000, Pain et al. 2001, Mackintosh et al. 2004). 
Clumping of PEs has been associated with severe disease, and appears to be 
predominantly mediated by CD36 expressed on platelets (Pain et al. 2001). Yet, 
parasites from children with cerebral malaria tend to have relatively lower CD36 
binding (Newbold et al. 1997, Rogerson et al. 1999) and in more recent studies have 
been linked to the EPCR-binding (group-A, B/A PfEMP1) variants containing domain 
cassettes 8 and 13 (Jensen et al. 2004, Kyriacou et al. 2006, Bertin et al. 2013, Almelli 
et al. 2014, Almelli et al. 2014).  These group-A, B/A variants were detected at some of 
the lowest levels in this blood-stage challenge trial, and we found no evidence for the 
group-A, B/A PfEMP1s having a growth advantage upon comparison of rlog expression 
values across parasite populations with high, intermediate or slow PMRs.  
 
It is reasonable to speculate that in the absence of anti-PfEMP1 specific antibodies (as 
would be expected during primary infection in the naïve host), var gene switching 
mechanisms are not required. Instead, parasite survival strategies might favour the 
broad expression of all (or most variants), for sampling the availability of host cell 
receptors upon entry into a new host. In the limited number of studies that have 
investigated var gene expression in this in vivo setting, the majority support this 
hypothesis, by showing broad-level detection of var genes in non-immune volunteers 
(Lavstsen et al. 2005, Wang et al. 2009, Bachmann et al. 2016). Offering further 
support to this hypothesis are results presented in chapter 4 of this thesis. With use of 
the blood-stage challenge model we have been able to directly compare var gene 
expression profiles of parasites isolated from the inoculum used to infect (day 0) and 
parasites recovered following a further 5 - 6 cycles, in the same infection (volunteer 
diagnosis samples). Importantly, var gene expression patterns between these different 
stages of infection were found to be significantly positively correlated, as the 
dominantly expressed variant in the inoculum on day 0 was still the most dominantly 
expressed in cycles 5 and 6. This suggested that var gene switching had not occurred 
within this time-window. Moreover, parasites isolated from each of the 12 volunteers 
(for which RNA-seq was successful), demonstrated remarkably similar expression 
profiles. This was another important observation from our study, as it gives first 
evidence that factors driving inter-individual variability in host responses to                   
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P. falciparum, during primary infection, appear independent of parasite var gene 
expression, and vice versa; the type of early host immune response elicited has little 
influence of parasite var gene expression.  
 
Although based on a small cohort of n = 5, var gene expression profiles measured at   
C +11 post mosquito-bite CHMI appeared to be more variable between volunteers 
(chapter 5, figures 5.8 and 5.9), compared to those following blood-stage challenge 
(chapter 4, figure 4.13). These results, combined with observations from the blood-
stage CHMI, suggest that var gene/PfEMP1 expression may be randomly selected in 
the mosquito vector, or liver stages, and upon entry into the circulation remains random 
(and unchanged) until activation of host antibody responses, when immune pressures 
may then force selection of specific variants. However, it is presumed that the first 
signs of malaria disease are apparent before this time. As was shown in the blood-
stage challenge, some volunteers had started to develop symptoms of malaria within 
the time-frame we were able to assess, yet none of the group-A disease-associated 
variants were found to be expressed in their infecting parasite populations. 
Furthermore, parasite gene expression had no apparent influence on the inter-
individual variability in immune responses observed in this cohort. Although we cannot 
be sure of the severity of outcome in the volunteers, these findings challenge some key 
concepts in the field. For instance, expression of group-A, B/A PfEMP1 is not driving, 
nor is required for disease outcome in the malaria-naive. Moreover, var gene 
expression does not influence the host immune response during primary exposure, and 
vice versa.  
 
6.2.2 Study limitations 
A key finding of this study was that var gene switching does not appear to take place 
during the first 5 - 6 blood cycles in the malaria-naïve host. However, this study was 
not able to examine var gene expression upon immediate egress from the liver, and it 
may be that switching events occur during these early time points. Therefore, it was 
important to try and extend our analysis to earlier stages of infection, to determine any 
influence of parasite var gene expression at the onset of host immune responses. In 
chapter 5 of this thesis, a protocol for the ex vivo RNA sequencing of parasites was 
optimised for application to parasite densities of ~40 – 400 p/mL, as expected 
immediately following liver egress (cycles 1 and 2). However, in parasites isolated at     
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C +9 and C +10 post mosquito-bite CHMI (~ cycle 2 in the blood of these volunteers), a 
markedly reduced number of P. falciparum genes (including VSAs) could be detected 
compared to the later time-point of C +11, and to the diagnosis time-point range (C 
+7.5 – C +10.5) in the previous blood-stage challenge trial. Results suggested that this 
was due to a combination of low parasite densities at these time-points but also host 
contamination, highlighting the two biggest technical challenges in using the CHMI 
model for this type of analysis. Hence, despite efforts, our method for parasite isolation 
and RNA-seq appears restricted to cycle 3 onwards, thereby precluding our ability to 
assess parasite VSA expression any earlier during infection in the naïve host. Only 
with improved sensitivity of currently available sequencing technologies and more 
efficient methods for parasite isolation, will this analysis be possible. It is also important 
to consider that all CHMI studies of P. falciparum gene expression to date, have been 
done using the 3D7 or the parental NF54 laboratory strain of the parasite (Peters et al. 
2002, Lavstsen et al. 2005, Wang et al. 2009, Bachmann et al. 2016). It is therefore 
essential that other strains of the P. falciparum species be tested in studies of CHMI, 
for validation of findings.  
 
6.2.3 Future considerations 
A key novel finding from our analysis of P. falciparum gene expression in the naive 
host, was that parasite VSA expression (var and rif) had no apparent influence on the 
diversity of immune responses observed in the volunteer cohort. This raises an 
important question: what drives inter-individual variation in the host response to             
P. falciparum? The immune system is thought to be shaped by many different factors 
such as host genetics, environmental stimuli, the gut microbiome and the various 
different microbes that an individual encounters in their life time. In recent years, great 
effort has been made to better understand the factors that determine variability of host 
immune responses.  Key studies, including those performed as part of the Human 
Functional Genomics Project, have provided some crucial insight (Brodin et al. 2015, Li 
et al. 2016, Oosting et al. 2016, Schirmer et al. 2016, Ter Horst et al. 2016, Piasecka et 
al. 2018). In one study, 700 healthy individuals were genotyped in order to assess the 
impact of genetic heritability on the cytokine production capacity of isolated cells, 
following stimulation with pathogenic stimuli. Results, when analysed alongside the 
~8.0 million detected SNPs, revealed a strong influence of host genetics on inter-
individual variation. Furthermore, researchers identified 17 novel eQTLs (genetic 
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variants that impact transcript abundance for immune genes), most of which were 
found enriched within monocyte-specific enhancer regions (Li et al. 2016). Non-genetic 
factors, such as age and gender, have also been shown to influence cytokine 
production. For instance, older age is associated with defects in the production of T-
helper cell cytokine responses including IL-22 and IFNγ, whereas the production of 
monocyte-derived cytokines does not appear to be affected (Ter Horst et al. 2016). In 
another study, the affect of age was found to be stimulus-specific, with 40% of genes 
presenting age-dependent expression in only one or two conditions tested (E.coli, 
BCG, SEB, C.albicans, Influenza-A virus). Moreover, the mapping of expression 
quantitative trait loci (eQTLs) revealed that genetic factors had a stronger effect on 
variable immune gene regulation than age (Piasecka et al. 2018). In addition to host 
factors, the immune responses of an individual are also likely to be influenced by the 
environment. Interestingly, environmental factors such as body mass index (BMI) and 
use of the contraceptive pill were shown to affect circulatory levels of inflammatory 
mediators including IL-6, IL-18 and IL-1Rα, C-reactive protein and VEGF (Ter Horst et 
al. 2016). The gut microbiome is also thought to be crucial for shaping and modulating 
immune system responses, as gut microbial dysbioses are commonly linked to 
aberrant cytokine responses in auto-immune and immune mediated disease 
(Kosiewicz et al. 2011, Gevers et al. 2014, Paun et al. 2016). As part of the Human 
Functional Genomics Project, differences in the composition and function of gut 
microbial communities were assessed to determine how they might contribute to inter-
individual variation in the cytokine responses of 500 healthy humans (Schirmer et al. 
2016). Importantly, between-subject variation in microbial composition was found to be 
substantial, and was predicted to account for ~5 - 10% of variation in host cell cytokine 
responses. Interestingly, the most pronounced effect of microbial variation was 
observed for the production of TNFα, in response to stimulation with C. albicans 
(Schirmer et al. 2016). Although the majority of studies discussed here have focused 
on responses to viral and/or bacterial stimulus, it is likely that host-intrinsic and/or 






Overall, this study provides important insight into the early host response to                   
P. falciparum infection in the non-immune host. Our combined analysis of parasite and 
host gene expression suggest that early decisions of the innate immune response are 
what determine disease outcome in the malaria-naïve, and that host-intrinsic and/or 
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Appendix 1: Volunteer Inclusion and Exclusion Criteria 
Inclusion Criteria 
 
• Healthy, male or non-pregnant female adult aged 18 - 45 years. 
• Subject willing and able to give written informed consent for participation in the 
study. 
• Resident in or near Oxford for the duration of the CHMI part of the study. Or for 
volunteers not living in Oxford: agreement to stay in arranged accommodation 
close to the trial centre during a part of the study (from the day before CHMI 
until anti-malarial treatment is completed). 
• Female subjects of child bearing potential willing to practice continuous 
effective contraception for the duration of the study. 
• Able (in the Investigator’s opinion) and willing to comply with all study 
requirements. 
• Willing to allow his or her General Practitioner and consultant, if appropriate, to 
be notified of participation in the study. 
• Agreement to permanently refrain from blood donation, as per current UK Blood 
Transfusion and Tissue Transplantation Services guidelines  
• Reachable (24 hours a day) by mobile phone during the period between CHMI 
and completion of antimalarial treatment. 
• Willingness to take a curative anti-malaria regimen following CHMI. 




• History of clinical malaria (any species). 
• Travel to a malaria endemic region during the study period or within the 
preceding six months with significant risk of malaria exposure. 
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• Use of systemic antibiotics with known antimalarial activity within 30 days of 
CHMI (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, 
clindamycin, erythromycin, fluoroquinolones and azithromycin). 
• Prior receipt of an investigational malaria vaccine or any other investigational 
vaccine likely to impact on interpretation of the trial data.  
• Receipt of an investigational product in the 30 days preceding enrolment, or 
planned receipt during the study period. 
• History of sickle cell anaemia, sickle cell trait, thalassaemia or thalassaemia 
trait or any haematological condition that could affect susceptibility to malaria 
infection. 
• Any confirmed or suspected immunosuppressive or immunodeficient state, 
including HIV infection; asplenia; recurrent, severe infections and chronic (more 
than 14 days) immunosuppressant medication within the past 6 months (inhaled 
and topical steroids are allowed). 
• Use of immunoglobulins or blood products within 3 months prior to enrolment or 
previous severe adverse reaction to a blood transfusion.  
• History of allergic disease or reactions likely to be exacerbated by any 
component of the vaccine (or malaria infection). 
• Any history of anaphylaxis post vaccination. 
• Pregnancy, lactation or intention to become pregnant during the study. 
• Use of medications known to cause prolongation of the QT interval and existing 
contraindication to the use of Malarone. 
• Use of medications known to have a potentially clinically significant interaction 
with Riamet and Malarone. 
• Contraindications to the use of all three proposed anti-malarial medications; 
Riamet, Malarone and Chloroquine. 
• Any clinical condition known to prolong the QT interval. 
• Family history of congenital QT prolongation or sudden death. 
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• Positive family history in 1st and 2nd degree relatives < 50 years old for cardiac 
disease. 
• History of cardiac arrhythmia, including clinically relevant bradycardia. 
• An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated 
by the Systematic Coronary Risk Evaluation (SCORE) system  
• Any clinically significant abnormal finding on biochemistry or haematology blood 
tests, urinalysis or clinical examination. In the event of abnormal test results, 
confirmatory repeat tests may be requested at the discretion of the Investigator. 
Absolute values for exclusion for confirmed abnormal results are shown in 
Appendix A. 
• History of cancer (except basal cell carcinoma of the skin and cervical 
carcinoma in situ). 
• History of serious psychiatric condition that may affect participation in the study. 
• Any other serious chronic illness requiring hospital specialist supervision. 
• Suspected or known current alcohol abuse as defined by an alcohol intake of 
greater than 42 standard UK units every week. 
• Suspected or known injecting drug abuse in the 5 years preceding enrolment. 
• Seropositive for hepatitis B surface antigen (HBsAg). 
• Seropositive for hepatitis C virus (antibodies to HCV) at screening. 
• Any other significant disease, disorder, or finding which may significantly 
increase the risk to the volunteer because of participation in the study, affect the 
ability of the volunteer to participate in the study or impair interpretation of the 
study data. 
• Volunteers unable to be closely followed for social, geographic or psychological 
reasons. 
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Appendix 2: Post-challenge qPCR data (p/mL) 
Volunteer ID Day of Diagnosis C +1 C +2 C +2.5 C +3 C +3.5 C +4 C +4.5 C +5 C +5.5 C +6 C +6.5 C +7 C +7.5 C +8 C +8.5 C +9 C +9.5 C +10 C +10.5
012 C +7.5 N N N N 13 19 N 76 146 72 97 5268 1645
013 C +10.5 N N N N N N N 25 9 12 5 334 147.018356 595 1722 2091 1740 23346 70368
016 C +10 N N N N 8 13 5 105 91 4 202 1179 610 3026 14951 12105 3636 273247
017 C +10.5 N 3 N N 1 N N 6 16 2 26 65 46 157 518 798 347 4858 16911
018 C +8.5 N 1 5 N 5 5 N 84 69 3 195 452 536 8735 19670
019 C +8.5 N N N N 13 N N 21 35 9 115 332 540 1846 6932
020 C +8.5 N N N N 11 12 N 67 127 17 195 1578 641 3405 15025
022 C +10 N 16 10 N 12 N N 18 9 N 15 76 84 263 425 756 310 8865
024 C +10 N 14 N N N N N 25 64 N 98 737 361 994 4814 4604 1288 43707
026 C +9 N 13 23 N 14 N N 63 72 40 88 822 785 1455 4817 9133
027 C +9 N N N N N 18 N 45 49 17 102 1246 642 2160 16625 13421
104 C +9 N 8 10 N 7 17 31 170 291 14 357 2971 3589 4788 16899 54085
106 C +8.5 N 10 N N N N 19 89 99 77 138 1145 1084 2137 16162 14395
206 C +10 N N N N 8 2 N 39 65 19 13 889 736 360 7115 18143 4062 185576
208 C +9 N 17 N N N N N 15 30 11 21 238 208 197 1169 1440
 = diagnosed (no further samples)
 = low level positive PCR <20 p/mL in at least one replicate and below minimum positive reporting criteria (early indication of likely positivity - all here have ultimately gone reliably positive)
red  = 2/3 replicates with significant differences but mean >20
 = point of diagnosis
 = values altered following QC process (no substantial changes)




Appendix 2: raw qPCR data. Parasite qPCR was performed on C +1 (1 day after inoculum challenge) and twice daily from C +2. 150 μl volumes of leucocyte-depleted blood were run in triplicate, 
using TaqManTM probe (5′ FAM-AAC AAT TGG AGG GCA AG-NFQ-MGB 3′) to amplify the P. falciparum 18s ribosomal region. Values below 20 p/mL (lower limit of quantification), or with only one 







Appendix 3: Top 100 (most variable) gene lists (“classical” responders) 
Interferon-stimulated genes (ISGs) are indicated by green type 
Top 25 genes, for which top 25th percentile variation was calculated, are boxed in pink 
 
Top 16 Variance factor 17 Variance factor 13 Variance factor 27 Variance factor 
1 CXCL10 7.57 ANKRD22 5.29 CXCL10 4.68 CXCL10 4.52
2 ANKRD22 7.05 IFI44L 4.20 ANKRD22 3.29 ANKRD22 3.50
3 FCGR1A 5.11 SERPING1 3.85 FCGR1A 2.49 SERPING1 2.96
4 IFI44L 5.00 CXCL10 3.84 FCGR1B 2.33 IFI44L 2.83
5 FCGR1B 4.69 RSAD2 3.36 PDL1 1.97 RSAD2 2.21
6 PDL1 4.24 FCGR1A 3.36 SERPING1 1.95 FCGR1A 1.88
7 RSAD2 4.12 PDL1 3.21 GBP1 1.74 TNFAIP6 1.80
8 SERPING1 4.11 P2RY14 3.19 GBP5 1.71 GBP5 1.65
9 IDO1 3.67 CARD17 3.18 IFI44L 1.65 PDL1 1.62
10 TNFAIP6 3.34 FCGR1B 2.88 P2RY14 1.60 FCGR1B 1.61
11 IFI44 3.33 IFI44 2.64 RSAD2 1.43 P2RY14 1.50
12 P2RY14 3.27 TNFAIP6 2.32 MYOF 1.40 CXCL9 1.46
13 CARD17 3.03 GBP5 2.30 GBP4 1.35 IFI44 1.44
14 GBP1 2.66 GBP1 2.06 TNFAIP6 1.33 CARD17 1.40
15 GBP5 2.65 IFIT1 2.01 CXCL9 1.22 GBP1 1.40
16 IFIT3 2.51 IDO1 1.95 LAP3 1.20 IFIT3 1.27
17 IFIT1 2.46 IFIT3 1.89 IFIT3 1.14 GBP4 1.26
18 PDCD1LG2 2.29 PDCD1LG2 1.68 IFI44 0.99 IFIT1 1.19
19 GBP4 2.13 LAP3 1.64 IFIT1 0.90 OAS3 1.18
20 HERC5 1.97 IFI6 1.48 IDO1 0.89 PDCD1LG2 1.16
21 EPSTI1 1.86 GBP4 1.48 EPSTI1 0.87 MYOF 1.15
22 CEACAM1 1.84 OAS3 1.47 STAT1 0.80 EPSTI1 1.13
23 MYOF 1.75 GBP6 1.42 CARD17 0.78 IFI6 1.10
24 IFI6 1.74 HERC5 1.42 IFI6 0.77 HERC5 1.03
25 PLSCR1 1.73 PRRG4 1.39 SAMD9L 0.75 PRRG4 0.95
26 OAS3 1.66 AIM2 1.28 WARS 0.74 IDO1 0.89
27 PSTPIP2 1.60 EPSTI1 1.28 GBP2 0.73 GCH1 0.85
28 LAMP3 1.53 CEACAM1 1.17 IFIT2 0.71 IFIH1 0.76
29 LAP3 1.51 ETV7 1.14 PARP14 0.70 LAP3 0.71
30 CXCL9 1.49 PSTPIP2 1.12 HERC5 0.69 DHRS9 0.70
31 WARS 1.49 SLAMF8 1.12 PLSCR1 0.69 TIFA 0.70
32 SLAMF8 1.45 MYOF 1.08 GBP3 0.69 STAT1 0.69
33 GK 1.45 DHRS9 1.05 GK 0.63 PARP14 0.68
34 SAMD9L 1.41 PLSCR1 1.00 GCH1 0.63 GBP6 0.66
35 ANXA3 1.38 RTP4 0.99 PARP9 0.63 WARS 0.66
36 GBP6 1.38 WARS 0.99 CEACAM1 0.62 PSME2 0.65
37 PARP14 1.31 PARP14 0.97 PSTPIP2 0.61 LAMP3 0.64
38 XAF1 1.30 FRMD3 0.96 SLAMF8 0.61 AIM2 0.63
39 AIM2 1.28 XAF1 0.94 KLRF1 0.60 SAMD9L 0.62
40 PARP9 1.27 CXCL9 0.93 STAT2 0.57 OAS2 0.61
41 IFIT2 1.24 IFIT2 0.88 TIFA 0.56 FRMD3 0.61
42 GPR84 1.22 IFIH1 0.87 OAS3 0.55 ETV7 0.60
43 EFCAB2 1.20 PARP9 0.86 GBP6 0.54 DDX60 0.60
44 GCH1 1.18 OAS1 0.86 IFIH1 0.53 OAS1 0.59
45 KCNJ2 1.17 STAT2 0.84 XAF1 0.52 OASL 0.58
46 IFIH1 1.17 SAMD9L 0.83 ETV7 0.50 GBP3 0.54
47 BMX 1.13 GCH1 0.82 ANXA3 0.49 CEACAM1 0.53
48 TIFA 1.11 CLEC5A 0.82 CASP5 0.49 GRAMD1B 0.52
49 STAT1 1.10 GBP3 0.82 PDCD1LG2 0.48 PSTPIP2 0.52
50 OAS1 1.09 DOCK4 0.80 PRRG4 0.47 XAF1 0.52
51 RTP4 1.08 SEPT4 0.79 LPCAT2 0.45 ALDH1A1 0.51
52 GBP3 1.06 STAT1 0.79 DDX60 0.45 GBP2 0.51
53 GBP2 1.05 TIFA 0.71 TNFSF10 0.45 PARP9 0.49
54 RIG-I 1.05 RIG-I 0.71 AIM2 0.44 TLR7 0.48
55 PRRG4 1.03 GK 0.68 CASP5 0.44 DOCK4 0.46
56 DDX60 1.03 GBP2 0.68 RIG-I 0.43 PLSCR1 0.46
57 ETV7 1.02 DDX60 0.65 DHRS9 0.41 STAT2 0.45
58 DHRS9 1.02 BMX 0.64 TRAFD1 0.41 APOL3 0.45
59 KCNJ15 1.01 KCNJ2 0.64 HCAR2 0.39 SLAMF8 0.45
60 FRMD3 1.01 HSPH1 0.63 TLR7 0.39 IFIT2 0.43
61 CASP5 1.01 HSPA1B 0.62 HCAR3 0.39 IFIT5 0.41
62 SEPT4 1.01 OAS2 0.61 P2RX7 0.38 TNFSF10 0.41
63 STAT2 0.99 HSPA1B 0.61 IFI35 0.38 CD38 0.40
64 CASP5 0.99 IFIT5 0.61 TAP1 0.38 GPR84 0.39
65 HCAR2 0.98 HSPA1B 0.61 TNFSF10 0.38 RIG-I 0.39
66 KLRF1 0.95 OASL 0.60 TAP1 0.38 CLC 0.38
67 DOCK4 0.95 HSPA1B 0.60 TAP1 0.38 P2RX7 0.38
68 LPCAT2 0.95 CMPK2 0.60 TAP1 0.38 SLAMF7 0.37
69 ERLIN1 0.88 TAP1 0.60 TAP1 0.38 EIF2AK2 0.37
70 HCAR3 0.81 TAP1 0.60 TAP1 0.38 UBE2L6 0.37
71 TNFSF10 0.79 TAP1 0.60 TAP1 0.38 MTHFD2 0.36
72 OAS2 0.76 TAP1 0.60 TAP1 0.38 SORT1 0.36
73 IFI35 0.76 TAP1 0.60 KLRD1 0.37 MX1 0.35
74 FAS 0.76 TAP1 0.60 JAK2 0.37 RTP4 0.35
75 TNFSF10 0.75 TAP1 0.60 APOL2 0.36 RIPK2 0.35
76 TAP1 0.75 TAP1 0.60 KCNJ2 0.36 DTX3L 0.35
77 CMPK2 0.75 MX1 0.59 APOL6 0.36 KCNJ2 0.34
78 APOL2 0.75 CASP5 0.58 RTP4 0.36 JAK2 0.34
79 MX1 0.74 EIF2AK2 0.58 PSME2 0.35 EFCAB2 0.34
80 TAP1 0.74 PSME2 0.58 OAS1 0.35 MT2A 0.34
81 TAP1 0.74 IFI35 0.55 LACTB 0.35 TAP1 0.34
82 TAP1 0.74 WDFY1 0.54 SECTM1 0.35 TAP1 0.34
83 FFAR2 0.74 EFCAB2 0.54 OR56B1 0.34 ALOX15 0.34
84 EIF2AK2 0.74 CASP5 0.54 STX11 0.34 SUCNR1 0.33
85 TAP1 0.74 ALPL 0.53 IRF1 0.33 TAP1 0.33
86 TAP1 0.74 UBE2L6 0.52 DTX3L 0.33 TAP1 0.33
87 STEAP4 0.73 APOL2 0.52 UBE2L6 0.33 TAP1 0.33
88 TAP1 0.73 APOL1 0.52 KCNJ15 0.32 TAP1 0.33
89 TAP1 0.73 HIST2H2BF 0.51 APOL1 0.32 TAP1 0.33
90 STX11 0.72 TFEC 0.51 APOL3 0.31 TAP1 0.33
91 OASL 0.70 TNFSF10 0.50 SORT1 0.31 IFI35 0.33
92 TFEC 0.69 KREMEN1 0.50 IL1B 0.31 NBN 0.32
93 CLEC6A 0.67 GPR84 0.48 KREMEN1 0.31 IL5RA 0.32
94 APOL1 0.67 OR56B1 0.48 EIF2AK2 0.30 BST2 0.32
95 DDX60L 0.66 TMEM140 0.47 P2RX7 0.30 WDFY1 0.31
96 CD38 0.66 MT2A 0.47 LAMP3 0.30 KLRB1 0.31
97 IFIT5 0.65 SECTM1 0.46 SLAMF7 0.30 FGL2 0.31
98 RIPK2 0.64 LAMP3 0.46 IL15 0.30 TFEC 0.31
99 TRAFD1 0.63 RIPK2 0.46 FAS 0.29 HCAR3 0.31
100 SLC26A8 0.63 HCAR3 0.46 TNFSF13B 0.29 TNFSF10 0.31  
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Appendix 3: Top 100 (most variable) gene lists (“classical” responders) 
Interferon-stimulated genes (ISGs) are indicated by green type 
Top 25 genes, for which top 25th percentile variation was calculated, are boxed in pink 
 
Top 26 Variance factor 206 Variance factor 106 Variance factor 24 Variance factor 
1 CXCL10 4.70 CXCL10 3.53 ANKRD22 2.90 CXCL10 3.27
2 ANKRD22 3.14 ANKRD22 2.86 CXCL10 2.77 FCGR1A 1.30
3 SERPING1 2.38 SERPING1 1.89 FCGR1A 1.50 FCGR1B 1.29
4 FCGR1A 2.05 IFI44L 1.86 FCGR1B 1.35 ANKRD22 1.25
5 FCGR1B 2.03 TNFAIP6 1.80 SERPING1 1.31 GBP1 1.16
6 GBP1 1.39 P2RY14 1.77 GBP1 1.15 GBP5 1.11
7 TNFAIP6 1.23 FCGR1A 1.61 PDL1 1.14 SERPING1 1.08
8 GBP5 1.23 FCGR1B 1.45 P2RY14 1.10 GBP4 0.95
9 IGJ 1.15 PDL1 1.42 GBP4 1.10 CXCL9 0.74
10 IFI44L 1.15 CXCL9 1.32 GBP5 1.10 PDL1 0.70
11 GBP4 1.13 GBP1 1.22 MYOF 1.00 STAT1 0.63
12 PDL1 1.13 IFIT3 1.15 SLAMF8 0.81 LAP3 0.59
13 CXCL9 1.08 GBP5 1.04 IFI44L 0.80 IFI44L 0.50
14 SLAMF8 0.88 RSAD2 0.97 RSAD2 0.69 WARS 0.46
15 RSAD2 0.86 LAP3 0.97 EPSTI1 0.66 IFIT3 0.44
16 IFIT3 0.73 CARD17 0.96 LAP3 0.64 EPSTI1 0.43
17 MYOF 0.72 GBP4 0.84 IDO1 0.63 GBP2 0.43
18 PDCD1LG2 0.69 IFI44 0.83 IFIT3 0.62 MYOF 0.38
19 SECTM1 0.63 IFI6 0.74 IGJ 0.60 GBP3 0.37
20 LAP3 0.61 EPSTI1 0.68 PSTPIP2 0.58 PARP14 0.37
21 P2RY14 0.61 MYOF 0.67 TNFAIP6 0.56 SAMD9L 0.36
22 WARS 0.60 STAT1 0.65 STAT1 0.56 PARP9 0.35
23 CARD17 0.57 IFIT1 0.62 WARS 0.55 IFI6 0.34
24 IFI6 0.57 WARS 0.62 TLR7 0.54 GCH1 0.32
25 STAT1 0.57 IDO1 0.59 PARP14 0.54 TNFAIP6 0.30
26 ETV7 0.56 CASP5 0.58 IFI44 0.53 KLRC3 0.30
27 TXNDC5 0.56 PARP14 0.57 GCH1 0.53 KLRC2 0.30
28 GBP2 0.55 SAMD9L 0.56 TXNDC5 0.52 STAT2 0.27
29 OAS3 0.51 PSTPIP2 0.52 GBP3 0.50 ETV7 0.27
30 IL1RL1 0.50 PDCD1LG2 0.51 ALDH1A1 0.50 RSAD2 0.27
31 GBP6 0.50 PARP9 0.50 CXCL9 0.48 KLRF1 0.27
32 GPR84 0.50 PLSCR1 0.49 TIFA 0.47 ALDH1A1 0.26
33 KLRF1 0.49 OAS3 0.49 IFIH1 0.45 IFIT1 0.26
34 UBE2L6 0.49 CEACAM1 0.47 PDCD1LG2 0.40 IFI44 0.25
35 PSME2 0.49 XAF1 0.45 STAT2 0.39 IFIH1 0.25
36 EPSTI1 0.49 GCH1 0.45 SAMD9L 0.38 IFIT2 0.24
37 IL5RA 0.49 GK 0.44 CARD17 0.37 PSTPIP2 0.24
38 SAMD9L 0.47 IL1B 0.44 IFI6 0.37 SLAMF8 0.24
39 GCH1 0.47 IFIT2 0.43 GBP2 0.36 PLSCR1 0.23
40 TNFSF10 0.45 SLAMF8 0.43 HERC5 0.36 SECTM1 0.23
41 UGT2B11 0.45 HERC5 0.42 CD38 0.36 STX11 0.23
42 PRRG4 0.44 PRRG4 0.41 DDX60 0.36 PSME2 0.22
43 PARP9 0.43 KCNJ2 0.40 LACTB 0.35 TLR7 0.22
44 TLR7 0.42 GBP2 0.40 APOL6 0.35 IFIT5 0.22
45 ANKRD36 0.42 TIFA 0.40 ETV7 0.35 UBE2L6 0.22
46 IFI44 0.42 IFIH1 0.39 PSME2 0.35 KIR3DS1 0.20
47 GBP3 0.41 AIM2 0.38 PRRG4 0.35 XAF1 0.20
48 IFIT1 0.40 CLEC4D 0.38 IFIT1 0.34 TAS2R19 0.20
49 ALDH1A1 0.40 GBP3 0.38 SORT1 0.34 DTX3L 0.19
50 MT2A 0.40 OAS1 0.38 PLSCR1 0.33 GZMB 0.19
51 IFIT2 0.39 CASP5 0.38 PARP9 0.33 MYBL1 0.19
52 IDO1 0.38 PLA2G7 0.37 OAS3 0.33 KIR3DL2 0.18
53 AIM2 0.37 TNFSF10 0.37 RIPK2 0.32 TAP1 0.18
54 STX11 0.37 ANXA3 0.36 CCR2 0.31 TAP1 0.18
55 ARL17A 0.37 STAT2 0.36 ICAM1 0.31 TAP1 0.18
56 IFI35 0.36 LPCAT2 0.36 STX11 0.30 TAS2R20 0.18
57 ANKRD36B 0.36 FFAR2 0.35 UBE2L6 0.30 GZMH 0.18
58 PARP14 0.36 GPR84 0.35 CYBB 0.29 TAP1 0.18
59 CCL2 0.36 HCAR2 0.34 APOL3 0.29 TAS2R50 0.18
60 KLRD1 0.34 ETV7 0.34 SECTM1 0.28 RTP4 0.18
61 TAS2R20 0.34 TLR7 0.34 DTX3L 0.28 TAP1 0.18
62 RTP4 0.34 CD38 0.33 TRAFD1 0.28 TAP1 0.18
63 ICAM1 0.33 PSME2 0.33 OAS2 0.28 TAP1 0.18
64 TAS2R31 0.33 TNFSF10 0.32 IFI35 0.27 TAP1 0.18
65 KLRC3 0.33 P2RX7 0.32 CNTNAP3 0.27 APOL6 0.18
66 APOL3 0.33 TFEC 0.32 HLA-DRB4 0.27 APOL3 0.18
67 STAT2 0.33 SORT1 0.32 AIM2 0.27 DTHD1 0.17
68 HERC5 0.32 HCAR3 0.31 CD86 0.26 KIR2DL2 0.17
69 ABCA5 0.32 FPR2 0.31 FRMD3 0.26 OR5A2 0.17
70 SLAMF7 0.31 FGL2 0.30 CCR1 0.26 PRRG4 0.17
71 FRMD3 0.31 ALDH1A1 0.30 ARG1 0.25 NFE2L2 0.17
72 CLC 0.30 APOL3 0.29 P2RX7 0.25 GPR52 0.17
73 HCAR3 0.30 STX11 0.29 PLA2G7 0.25 ANKRD36 0.17
74 CEACAM1 0.30 IFI35 0.29 C3AR1 0.25 OAS2 0.17
75 P2RX7 0.30 LRRK2 0.29 KMO 0.24 GK5 0.16
76 CD209 0.30 FLVCR2 0.29 CEACAM1 0.24 TNFSF10 0.16
77 TIFA 0.28 CLEC6A 0.29 GBP6 0.24 KLRD1 0.16
78 LGALS3BP 0.28 DHRS9 0.29 HIST1H2BM 0.24 ICAM1 0.16
79 PDK4 0.28 SLAMF7 0.29 GK 0.24 IFI35 0.16
80 KREMEN1 0.28 C3AR1 0.28 TNFSF10 0.24 P2RY14 0.16
81 TAS2R46 0.27 KIAA1598 0.28 KCTD12 0.23 DHRS9 0.16
82 KLRC1 0.27 FRMD3 0.28 GLDC 0.23 IRS2 0.15
83 SYNE1 0.27 UBE2L6 0.27 FAM198B 0.23 MAK 0.15
84 XAF1 0.27 CASP1 0.27 DRAM1 0.23 TAS2R31 0.15
85 ALOX15 0.27 GBP6 0.27 GM2A 0.23 APOL1 0.15
86 GOLGA8B 0.27 TNFSF13B 0.26 GBP7 0.22 ANKRD36B 0.15
87 APOL1 0.27 APOBEC3A 0.26 LY86 0.22 OAS3 0.15
88 APOL6 0.27 DRAM1 0.26 IFIT5 0.22 OR56B1 0.15
89 PSTPIP2 0.26 EIF2AK2 0.26 BST2 0.22 FGL2 0.15
90 GOLGA8A 0.26 JAK2 0.26 IRF4 0.21 CASP5 0.14
91 HCAR2 0.26 TAP1 0.26 DEFA1B 0.21 HERC5 0.14
92 OAS2 0.26 CARD16 0.26 LPCAT2 0.21 SH2D1B 0.14
93 TAS2R43 0.26 TAP1 0.26 HSP90B1 0.21 IRF1 0.14
94 KLRC2 0.26 TAP1 0.26 HLA-DMA 0.21 PTGDR 0.14
95 GPR52 0.26 TAP1 0.26 NETO2 0.21 DEFA1B 0.14
96 GOLGA8A 0.26 TAP1 0.25 GPR15 0.21 CARD17 0.13
97 CCR3 0.26 TAP1 0.25 MTHFD2 0.21 DDX60 0.13
98 TAS2R50 0.26 TAP1 0.25 PSMA4 0.21 TRIM21 0.13
99 P2RY13 0.26 TAP1 0.25 OR5V1 0.20 HLA-DMA 0.13
100 CLK1 0.26 ACSL1 0.25 HLA-DRB1 0.20 LGALS9 0.13  
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Appendix 3: Top 100 (most variable) gene lists (“unknowns”) 
Interferon-stimulated genes (ISGs) are indicated by green type 
Top 25 genes, for which top 25th percentile variation was calculated, are boxed in pink 
 
 
Top 18 Variance factor 12 Variance factor 208 Variance factor 20 Variance factor 
1 IFIT1 0.57 TAS2R19 0.36 KIR2DL5B 0.34 CXCL10 1.07
2 PTPLAD1 0.36 IFIT1B 0.33 KIR3DS1 0.32 ANKRD22 0.51
3 IFI44L 0.35 AHSP 0.32 KIR3DL1 0.27 FCGR1A 0.48
4 KLRF1 0.33 PI3 0.31 KIR2DS2 0.25 FCGR1B 0.45
5 IFI44 0.32 ARHGEF12 0.30 ZMAT1 0.24 GBP5 0.39
6 SH2D1B 0.31 GMPR 0.29 KIR2DS1 0.23 SERPING1 0.38
7 FGFBP2 0.30 CLEC4E 0.29 KIR2DS4 0.23 GBP1 0.34
8 HERC5 0.28 TESC 0.29 KIR3DL2 0.22 GBP4 0.33
9 RSAD2 0.27 TAS2R13 0.26 KIR2DL3 0.22 TAS2R13 0.21
10 KLRD1 0.27 CLC 0.26 KIR2DS3 0.21 CXCL9 0.20
11 KIR3DS1 0.26 KLRF1 0.26 KIR2DL2 0.20 PDL1 0.20
12 GZMA 0.26 USP12 0.25 AHSP 0.19 TAS2R20 0.20
13 KIR2DL5B 0.26 EPB42 0.24 FGFBP2 0.19 KLRF1 0.19
14 IFIT3 0.25 DEFA1B 0.24 NKG7 0.18 TLR7 0.18
15 NKG7 0.23 IL1R2 0.24 TAS2R19 0.18 PDK4 0.18
16 KIR2DL2 0.22 PPBP 0.24 KIR2DL1 0.18 IL1R2 0.17
17 IL1RL1 0.22 RPIA 0.23 ADAM20 0.18 GRAMD1C 0.16
18 PDK4 0.22 SLC4A1 0.23 GZMH 0.17 OR1G1 0.16
19 HIST1H1E 0.21 GYPA 0.23 HCST 0.17 WARS 0.16
20 CD180 0.21 TAS2R50 0.22 CNTNAP3 0.17 CD180 0.16
21 CX3CR1 0.20 SLC14A1 0.22 CCDC88A 0.16 OR5V1 0.16
22 KIR2DL3 0.19 IL5RA 0.22 ALG3 0.16 TAS2R16 0.15
23 CTSW 0.19 EIF1AY 0.22 PDK4 0.16 CLEC12B 0.15
24 IFIT2 0.18 DEFA1B 0.21 PTPLAD1 0.16 ZMAT1 0.14
25 IFI6 0.18 ALAS2 0.21 PRF1 0.16 OCLM 0.14
26 FCGR1B 0.18 ENKUR 0.20 CTSW 0.16 MYOF 0.14
27 KIR2DL1 0.18 MS4A14 0.20 CCDC18 0.15 KLRC2 0.14
28 TGFBR3 0.17 OR2W3 0.20 COX8A 0.15 TAS2R40 0.14
29 GBP5 0.17 MMD 0.19 NFE2L2 0.15 STAT1 0.13
30 MX1 0.17 CD180 0.19 GCNT4 0.15 GBP2 0.13
31 PRF1 0.16 TBCEL 0.19 BAZ2B 0.14 PI3 0.13
32 KIR2DS4 0.16 MBOAT2 0.19 HLA-DRB5 0.14 KLRD1 0.13
33 TAS2R19 0.16 IGF2BP2 0.19 LY96 0.14 CARD17 0.13
34 GNLY 0.16 GRAMD1C 0.19 OR2T3 0.14 KLRC1 0.13
35 CD160 0.16 DEFA1B 0.19 COPE 0.14 SRRM5 0.13
36 OR6X1 0.16 SLC6A8 0.18 DMXL2 0.14 CLK1 0.13
37 ADAM20 0.16 ODC1 0.18 PBOV1 0.14 MMP8 0.13
38 SLAMF7 0.16 RNF10 0.18 OR10T2 0.14 LY6G5B 0.12
39 FCGR1A 0.16 SDPR 0.18 MYOF 0.14 LY6G5B 0.12
40 TOX 0.15 FCER2 0.18 LRRK2 0.13 LY6G5B 0.12
41 SLAMF6 0.15 OR52K2 0.18 SPN 0.13 LY6G5B 0.12
42 KLRB1 0.15 PPM1A 0.17 PMCH 0.13 LY6G5B 0.12
43 CD79A 0.15 KIF27 0.17 TGFBR3 0.13 LY6G5B 0.12
44 OR2AT4 0.15 TMOD1 0.17 SLCO4C1 0.13 SPANXN3 0.12
45 CD40LG 0.15 SFRP2 0.17 TTC14 0.13 KLRC3 0.12
46 GBP1 0.15 TSPAN5 0.17 CNTNAP3B 0.13 CLK4 0.12
47 TMEM14E 0.15 RGS18 0.17 IFNG 0.13 RSRP1 0.12
48 SERPING1 0.15 CCDC176 0.17 OR51A4 0.13 CLK1 0.12
49 UGT2B11 0.15 MYL4 0.17 CNTLN 0.13 LAP3 0.12
50 PHGR1 0.14 CCR3 0.17 GZMB 0.12 IL18RAP 0.12
51 HCST 0.14 SCLT1 0.16 GBP4 0.12 GBP3 0.12
52 KIR2DS3 0.14 FAM210B 0.16 TIMM22 0.12 PLGLB1 0.11
53 KIR3DL1 0.14 FECH 0.16 KIR3DL3 0.12 EPSTI1 0.11
54 KIR2DS2 0.14 ANKRD36 0.16 UGT2B11 0.12 TAS2R50 0.11
55 DEFB128 0.14 IRS2 0.16 HIST1H1B 0.12 GNLY 0.11
56 GIMAP7 0.13 SH3BGRL2 0.16 HIST1H2BM 0.12 GCH1 0.11
57 ZMAT1 0.13 PDK4 0.16 KIAA0825 0.12 ARL17A 0.11
58 IL5RA 0.13 ANK1 0.16 C6orf163 0.12 VNN3 0.11
59 HLA-DQA2 0.13 RAB2B 0.16 GPR56 0.12 TIFA 0.10
60 ICOS 0.13 CCDC18 0.16 KLRD1 0.12 APOL3 0.10
61 IL2RB 0.13 TESC 0.16 TNF 0.12 PLGLB1 0.10
62 GPR18 0.13 OR8A1 0.15 TNF 0.12 SCP2D1 0.10
63 TARP 0.13 GYPB 0.15 TNF 0.12 TNFSF10 0.10
64 KLRG1 0.13 UBXN6 0.15 TNF 0.12 ERV3-1 0.10
65 CD3G 0.13 CPEB4 0.15 TNF 0.12 TMEM14E 0.10
66 CD28 0.13 RAB2B 0.15 TNF 0.12 LOC100130705 0.10
67 SLCO4C1 0.13 GPR52 0.15 TNF 0.12 FGFBP2 0.10
68 HIST1H4C 0.13 TMEM63B 0.15 TNF 0.12 ABCA5 0.10
69 IGJ 0.13 OCLM 0.15 CX3CR1 0.12 DUSP1 0.10
70 GPR174 0.13 CA1 0.15 SEPTIN1 0.12 OR52K2 0.10
71 MANEA 0.12 VNN3 0.15 MS4A14 0.12 GZMB 0.10
72 GZMH 0.12 IL1RAP 0.15 GPR52 0.12 IFI44L 0.10
73 KLRC4 0.12 THBS1 0.15 CDK2AP2 0.12 NFE2L2 0.10
74 KIR2DS1 0.12 KIF14 0.15 GZMA 0.12 ADAM20P1 0.10
75 SYT11 0.12 TAS2R46 0.15 LOC643802 0.12 CXorf65 0.10
76 USP28 0.12 TFDP1 0.15 OR10A7 0.12 OR4K5 0.10
77 IFNG 0.12 DEFB133 0.15 LDHAL6B 0.11 OR4C11 0.10
78 GPR183 0.12 DCUN1D1 0.15 TLR6 0.11 RNF182 0.10
79 RBMXL3 0.12 ALS2CR12 0.15 CBWD2 0.11 LIPN 0.10
80 FCRL6 0.12 CAPRIN2 0.15 MME 0.11 VNN3 0.10
81 RPS5 0.12 ITGB3 0.15 LUC7L3 0.11 SLAMF8 0.10
82 PARP14 0.12 C6orf163 0.14 EIF5AL1 0.11 RPIA 0.10
83 KLRC2 0.12 HIST1H3H 0.14 TAS2R31 0.11 HLA-DQA2 0.10
84 FOXR2 0.12 YOD1 0.14 MGAM 0.11 TRPM6 0.10
85 CHRM4 0.12 ADAM20 0.14 GPR148 0.11 CCR3 0.10
86 GPR56 0.11 IL1RL1 0.14 RPS18 0.11 TTC14 0.10
87 KLRC3 0.11 MICALCL 0.14 VCPKMT 0.11 P2RY14 0.10
88 HSPH1 0.11 MXI1 0.14 CD86 0.11 SPANXN2 0.10
89 FAIM3 0.11 CLU 0.14 CD180 0.11 LOC643802 0.10
90 NDRG3 0.11 CD22 0.14 NLRC4 0.11 OR10A2 0.10
91 LMAN1 0.11 SLPI 0.14 PRKACG 0.11 STAT2 0.10
92 TAS2R20 0.11 MICAL2 0.14 CBWD5 0.11 ETV7 0.10
93 DOCK4 0.11 PITHD1 0.14 WDFY3 0.11 TAS2R19 0.10
94 EIF2AK2 0.11 BIRC2 0.14 SPRR2F 0.11 FLJ45513 0.10
95 OR5D18 0.11 PRKAR2B 0.13 KATNBL1 0.11 SLITRK1 0.10
96 CD96 0.11 TCF7 0.13 FAM105A 0.11 FAM157B 0.10
97 RSL1D1 0.11 GZMB 0.13 PGBD4 0.11 GPR52 0.10
98 TAS2R46 0.11 FOXO3 0.13 ATP2B1 0.11 CCR7 0.10
99 SDAD1 0.11 YBX3 0.13 TAS2R41 0.11 TAS2R46 0.10
100 KRTAP24-1 0.11 FAM104A 0.13 C7orf62 0.11 TNF 0.10  
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Appendix 3: Top 100 (most variable) gene lists (“non-classical” responders) 
Interferon-stimulated genes (ISGs) are indicated by green type 
Top 25 genes, for which top 25th percentile variation was calculated, are boxed in pink 
 
 
Top 19 Variance factor 22 Variance factor 
1 RGS18 0.53 ALAS2 1.09
2 CLEC4E 0.51 CLC 0.99
3 USP12 0.46 IFIT1B 0.80
4 IFIT1B 0.44 PPBP 0.71
5 ANKRD36 0.43 IGJ 0.71
6 CLK1 0.42 SLC4A1 0.69
7 GYPA 0.41 TXNDC5 0.55
8 USP15 0.41 CXCR2 0.53
9 CLK1 0.38 OR2W3 0.53
10 ANKRD36B 0.37 SLC25A39 0.52
11 NABP1 0.36 AQP9 0.52
12 LRRK2 0.36 CXCR1 0.52
13 ERV3-1 0.35 STRADB 0.51
14 BIRC2 0.35 SLC25A37 0.51
15 CMAS 0.34 GYPA 0.49
16 VNN3 0.33 GMPR 0.48
17 CCDC18 0.33 PHOSPHO1 0.48
18 CLEC7A 0.33 PF4 0.46
19 MBOAT2 0.33 SNCA 0.45
20 VNN3 0.33 DCAF12 0.45
21 GPCPD1 0.32 FAM46C 0.44
22 RSRP1 0.32 CA1 0.43
23 KIF14 0.32 PI3 0.41
24 IL5RA 0.31 FFAR2 0.40
25 VCPKMT 0.31 IFIT1 0.40
26 ARHGEF12 0.31 VNN3 0.39
27 NAMPT 0.29 YBX3 0.38
28 TTC14 0.29 SH3BGRL2 0.38
29 CCR3 0.29 EPB42 0.38
30 CD58 0.28 FECH 0.37
31 EIF1AY 0.28 HEMGN 0.35
32 PKN2 0.28 STEAP4 0.34
33 SPOPL 0.28 AHSP 0.33
34 CD46 0.28 MME 0.33
35 SWT1 0.28 PROK2 0.33
36 BAZ2B 0.28 CHI3L1 0.32
37 SCLT1 0.28 RGS18 0.32
38 CCNL1 0.28 MXD1 0.32
39 SAT1 0.27 HIST1H4H 0.31
40 PPBP 0.27 RGS2 0.30
41 CLK4 0.27 TMEM56 0.30
42 CYB5R4 0.26 HIST1H3B 0.30
43 OR6X1 0.26 TNFAIP6 0.29
44 KATNBL1 0.26 R3HDM4 0.29
45 DOCK5 0.26 NAMPT 0.29
46 CCNH 0.26 BPGM 0.29
47 SMCHD1 0.26 PF4V1 0.28
48 RGS2 0.26 SLC14A1 0.28
49 VPS8 0.26 MYL4 0.28
50 RIOK3 0.26 KCNJ15 0.28
51 PELI1 0.25 MPP1 0.27
52 SH3BGRL2 0.25 ALPL 0.26
53 ABCA5 0.25 SLC6A8 0.26
54 NKTR 0.25 MARCH8 0.26
55 TLR2 0.25 VNN3 0.25
56 KIAA1551 0.25 CLEC4E 0.25
57 FAM185A 0.25 MGAM 0.25
58 KIF27 0.25 MBNL3 0.25
59 TIA1 0.25 HIST1H2BM 0.25
60 OR10H2 0.25 IFIT2 0.25
61 CLC 0.25 RIOK3 0.25
62 PTGS2 0.24 TMOD1 0.25
63 CAPRIN2 0.24 TSPAN5 0.24
64 PIGB 0.24 VNN2 0.24
65 MS4A14 0.24 RAB2B 0.24
66 UBE2B 0.24 RSAD2 0.23
67 RPIA 0.24 MBOAT2 0.23
68 FCHO2 0.24 GPR97 0.23
69 LUC7L3 0.24 FPR1 0.23
70 GK 0.24 SOD2 0.23
71 TAS2R13 0.24 TBCEL 0.23
72 RPS6KA5 0.24 ALS2CR12 0.22
73 TANK 0.24 VNN2 0.22
74 PDK4 0.23 HIST1H3H 0.22
75 RBM39 0.23 TREM1 0.22
76 TBCEL 0.23 GYPC 0.22
77 PITHD1 0.23 FKBP8 0.21
78 NFXL1 0.22 RAB2B 0.21
79 TLR1 0.22 IGF2BP2 0.21
80 CLEC4D 0.22 CCR3 0.21
81 CBWD5 0.22 EMR3 0.21
82 TXNDC16 0.22 USP12 0.20
83 FGFR1OP2 0.22 SDPR 0.20
84 VPS13A 0.22 GYPB 0.20
85 IL1R2 0.22 MANSC1 0.20
86 DCUN1D1 0.22 HIST1H1E 0.20
87 USP32 0.22 TESC 0.20
88 TSPAN5 0.22 HBZ 0.19
89 CBWD3 0.22 IL1R2 0.19
90 CDC27 0.22 CYP4F3 0.19
91 STXBP3 0.22 MXI1 0.19
92 ATAD5 0.22 FAM157B 0.19
93 CHPT1 0.22 LY6G5B 0.19
94 NT5C3A 0.22 IFIT3 0.19
95 RNASE8 0.22 KLHL14 0.19
96 ZFYVE16 0.22 FBXO7 0.19
97 TAS2R19 0.22 CSF3R 0.19
98 VRK1 0.22 PADI2 0.19
99 ZMAT1 0.21 FAM210B 0.19







Appendix 3: Top 100 (most variable) gene lists (“Baseline controls”) 
Interferon-stimulated genes (ISGs) are indicated by green type 
Top 25 genes, for which top 25th percentile variation was calculated, are boxed in pink 
 
Top BC.1 Variance factor BC.2 Variance factor BC.3 Variance factor BC.4 Variance factor 
1 CASP5 0.30 PI3 0.21 IGJ 0.62 IFI44L 1.53
2 SLPI 0.29 KCNJ15 0.18 TXNDC5 0.25 SERPING1 1.28
3 PDK4 0.28 HCAR3 0.15 PDK4 0.17 IFIT1 1.22
4 PI3 0.26 PROK2 0.14 TMEM81 0.15 RSAD2 1.14
5 ALPL 0.22 ALPL 0.13 HCAR2 0.13 CXCL10 0.90
6 PROK2 0.22 MME 0.13 FCGR1B 0.13 IFI44 0.88
7 SH2D1B 0.21 HCAR2 0.13 OR1G1 0.13 FCGR1A 0.85
8 ANXA3 0.20 IL1R2 0.13 LIPT2 0.13 FCGR1B 0.80
9 CASP5 0.20 CHI3L1 0.13 FCGR1A 0.13 IFIT3 0.71
10 KLRF1 0.19 C4BPA 0.12 KLRF1 0.12 IFI6 0.67
11 ACSL1 0.18 PDK4 0.12 IFNK 0.12 ANKRD22 0.63
12 KIR2DL5B 0.18 DEFA1B 0.11 FFAR2 0.12 HERC5 0.60
13 OR4K5 0.17 PHOSPHO1 0.11 OR1L6 0.11 EPSTI1 0.57
14 KIR2DL3 0.16 OR7G2 0.11 VNN2 0.11 GBP1 0.54
15 OR14J1 0.14 IFNA7 0.11 ACSL1 0.10 OAS3 0.54
16 KIR2DL1 0.14 TNFAIP6 0.11 HCAR3 0.10 IFIT2 0.39
17 FGFBP2 0.13 DEFA1B 0.11 SRRM5 0.10 GBP5 0.39
18 GZMB 0.13 KIR2DL5B 0.10 OR1N2 0.10 PPBP 0.37
19 FFAR2 0.13 CXCR1 0.10 LY96 0.10 ALAS2 0.35
20 OR51A4 0.13 DEFA1B 0.10 AQP9 0.10 CLC 0.35
21 KIR2DL2 0.13 ACSL1 0.10 FPR2 0.10 GBP4 0.34
22 TAS2R40 0.13 CPLX4 0.10 GK 0.10 LAP3 0.32
23 HCAR3 0.13 TAS2R13 0.10 OR7G2 0.10 MYOF 0.32
24 HIST1H1E 0.13 ANXA3 0.10 OR10J1 0.10 MX1 0.31
25 GK 0.12 BCL6 0.10 MME 0.09 PARP14 0.30
26 IL18RAP 0.12 AQP9 0.09 OR10AG1 0.09 TNFAIP6 0.29
27 KIR3DS1 0.12 TREM1 0.09 ZMAT1 0.09 CAPRIN2 0.29
28 MGAM 0.12 ALAS2 0.09 CXorf51A 0.09 PARP9 0.28
29 FPR2 0.12 TAS2R19 0.09 KIR2DL5B 0.09 EPB42 0.28
30 AQP9 0.12 MXD1 0.09 RGS2 0.09 XAF1 0.28
31 KIR2DS3 0.12 FAM157B 0.09 OR51B2 0.09 OAS1 0.28
32 CDR1 0.11 CEACAM8 0.09 STEAP4 0.09 STAT1 0.27
33 HCAR2 0.11 TIGD2 0.09 PROK2 0.09 ALS2CR12 0.26
34 CCL4 0.11 P2RY13 0.09 NAMPT 0.08 MMD 0.26
35 KIR2DS4 0.11 VNN3 0.09 LRRK2 0.08 GMPR 0.26
36 KCNJ15 0.11 OR51A4 0.09 TREM1 0.08 OAS2 0.25
37 FAM129A 0.11 OR5A1 0.09 PCDHB1 0.08 FCHO2 0.25
38 OR5V1 0.11 CPT1A 0.09 VNN2 0.08 AHSP 0.24
39 CLC 0.11 MGAM 0.09 OR51T1 0.08 WARS 0.24
40 KCNJ2 0.10 OR2Y1 0.08 OR5H15 0.08 TESC 0.24
41 PRF1 0.10 CD1C 0.08 TAS2R40 0.08 STAT2 0.24
42 TMEM133 0.10 C5AR2 0.08 TAS2R20 0.08 PSME2 0.23
43 SPRR2F 0.10 VNN3 0.08 HIST1H1B 0.08 FAXDC2 0.23
44 OR2A25 0.10 OR11H1 0.08 PRRG4 0.08 SLC4A1 0.23
45 TAS2R41 0.10 TREML2 0.08 OR8A1 0.08 DDX60 0.22
46 GZMH 0.10 IFI44L 0.08 NFE2L2 0.08 CAPRIN2 0.22
47 DEFA1B 0.10 GK 0.08 OR2B3 0.08 ZMAT1 0.22
48 KIR2DS1 0.10 OR13G1 0.08 OR9A2 0.08 ANKRD36 0.22
49 ERVV-2 0.10 MMP25 0.08 OR14C36 0.08 PHOSPHO1 0.21
50 IFIT1B 0.10 KIR2DL4 0.08 CPLX4 0.08 MYL4 0.21
51 KIR2DS2 0.10 CXCR2 0.08 DNAJB7 0.08 SECTM1 0.21
52 TGFBR3 0.10 RBMXL2 0.08 OR56A5 0.08 PLSCR1 0.21
53 IL1R2 0.09 STEAP4 0.08 SPATA45 0.08 SAMD9L 0.21
54 FPR3 0.09 C18orf54 0.08 TNFAIP6 0.08 KIF14 0.20
55 SPDYE6 0.09 GZMK 0.08 OR6K2 0.08 IFIT1B 0.20
56 NAMPT 0.09 IFIT1B 0.08 DCAF8L2 0.08 OASL 0.20
57 BCL6 0.09 TMEM133 0.08 PAPOLB 0.07 SIGLEC1 0.20
58 KLRD1 0.09 NAMPT 0.08 MGAM 0.07 SH3BGRL2 0.20
59 FCGR1A 0.09 PTGS2 0.07 OR1L8 0.07 CCL2 0.20
60 OR5D14 0.09 OR2L8 0.07 SSMEM1 0.07 EIF2AK2 0.20
61 ACTBL2 0.09 TRHR 0.07 IFIT1 0.07 SLAMF8 0.20
62 FCGR1B 0.09 CYP4F3 0.07 OR2T10 0.07 PDL1 0.20
63 STEAP4 0.09 KCNJ2 0.07 OR8B12 0.07 GYPC 0.19
64 ST20 0.09 NCF4 0.07 ANXA3 0.07 SWT1 0.19
65 KIR3DL1 0.08 SLPI 0.07 KCNJ15 0.07 ANKRD36B 0.19
66 LRRC10 0.08 GNPDA2 0.07 PI3 0.07 CCDC18 0.18
67 AKR1C3 0.08 KIR2DS3 0.07 OR4C16 0.07 IGF2BP2 0.18
68 KREMEN1 0.08 OR10A7 0.07 OR1M1 0.07 IFI35 0.18
69 TRAPPC13 0.08 ESF1 0.07 WDFY3 0.07 PF4 0.18
70 SPATA45 0.08 FAM157A 0.07 TIFAB 0.07 SLC6A8 0.18
71 CXCR1 0.08 BIRC3 0.07 VNN3 0.07 VRK1 0.17
72 OR5V1 0.08 MRGPRX2 0.07 OR2AT4 0.07 TLR7 0.17
73 MAK 0.08 CYP51A1 0.07 MAS1 0.07 STIL 0.17
74 DEFA1B 0.08 CSF2RB 0.07 OR2T34 0.07 UBXN6 0.17
75 CCL4L2 0.08 RGS2 0.07 THRSP 0.07 IFIH1 0.17
76 VNN3 0.08 CSTF2T 0.07 VNN3 0.07 LY6E 0.17
77 CCR3 0.08 TAS2R39 0.07 IFNA7 0.07 GBP2 0.17
78 TAS2R10 0.08 HIST1H1E 0.07 OR5V1 0.07 FKBP8 0.17
79 OR4P4 0.08 OR14A16 0.07 DEFB121 0.07 RGS2 0.17
80 CHI3L1 0.08 RPS18 0.07 CXCR1 0.07 CHI3L1 0.17
81 CNTNAP3 0.08 ST6GALNAC2 0.07 POU3F4 0.07 STEAP4 0.16
82 HRH2 0.08 MMP8 0.07 OR5AC2 0.07 GRAMD1C 0.16
83 IFNG 0.08 MRPL50 0.07 CXorf51A 0.07 LOC643802 0.16
84 MBOAT2 0.08 DNAAF2 0.07 OR5I1 0.07 CCR1 0.16
85 LIMK2 0.08 OR4C16 0.07 TAS2R3 0.07 DMTN 0.16
86 ALPK1 0.08 OCLM 0.07 TNFRSF17 0.07 RGS18 0.16
87 IFI44L 0.08 ANPEP 0.07 GCA 0.07 MT2A 0.16
88 CNTNAP3B 0.07 HIST1H1C 0.07 H1FX 0.07 PF4V1 0.15
89 GCA 0.07 ZIC4 0.07 SDPR 0.07 APOBEC3A 0.15
90 OR52E4 0.07 GPR97 0.07 OR8K3 0.07 ASCC2 0.15
91 WDFY3 0.07 ERV3-1 0.07 C4orf19 0.07 SLC25A39 0.15
92 HIST1H1C 0.07 VNN2 0.07 PRR32 0.07 CMPK2 0.15
93 OR6C4 0.07 SAMD5 0.06 KRTAP25-1 0.07 OR4K5 0.15
94 TAS2R16 0.07 OR52M1 0.06 CLEC4D 0.07 CCNA2 0.15
95 TAAR1 0.07 OR8B8 0.06 TLR2 0.07 EMR3 0.15
96 XCL2 0.07 KRTAP4-6 0.06 TLR6 0.06 HCAR2 0.15
97 SPDYE2 0.07 SPRR2F 0.06 CLEC2B 0.06 CASP5 0.15
98 OR51A2 0.07 CEACAM3 0.06 C3orf79 0.06 KLRF1 0.15
99 GNLY 0.07 HRH2 0.06 FCGR3B 0.06 GYPA 0.15
100 OR51B6 0.07 OR7G3 0.06 IQCF2 0.06 CCR3 0.15
 266 
Appendix 5: Dichotomy in the host transcriptional response to blood-stage      
P. falciparum (list of the 517 genes used in the global gene set analysis).  
 
Table shows the 517 genes (gene I.Ds), ordered as per displayed in the heatmap in figure 3.3 
(top to bottom). Up-regulated gene clusters observed in the group of “classical” responders are 
shown in red. Down-regulated gene clusters observed in the “non-classical” responders are 
shown in blue.  
 
Up-regulated gene clusters Down-regulated gene clusters
in the "classical" volunteers in the "non-classical" volunteers
1 TOX thymocyte selection-associated high mobility group box
2 TGFBR3 transforming growth factor, beta receptor III
3 TNF tumor necrosis factor
4 PTPLAD1 protein tyrosine phosphatase-like A domain containing 1
5 CD40LG CD40 ligand
6 SCLT1 sodium channel and clathrin linker 1
7 CCNL1 cyclin L1
8 NKTR natural killer cell triggering receptor
9 IL18RAP interleukin 18 receptor accessory protein
10 HIST1H4H histone cluster 1, H4h
11 RIPK2 receptor-interacting serine-threonine kinase 2
12 GM2A GM2 ganglioside activator
13 CCR2 chemokine (C-C motif) receptor 2
14 WDFY3 WD repeat and FYVE domain containing 3
15 SPOPL speckle-type POZ protein-like
16 TLR1 toll-like receptor 1
17 CYB5R4 cytochrome b5 reductase 4
18 MANSC1 MANSC domain containing 1
19 STXBP3 syntaxin binding protein 3
20 LUC7L3 LUC7-like 3 (S. cerevisiae)
21 ERV3-1 endogenous retrovirus group 3, member 1
22 SYNE1 spectrin repeat containing, nuclear envelope 1
23 LY6G5B lymphocyte antigen 6 complex, locus G5B
24 ANKRD36B ankyrin repeat domain 36B
25 TNFSF13B tumor necrosis factor (ligand) superfamily, member 13b
26 NBN nibrin
27 PSMA4 proteasome (prosome, macropain) subunit, alpha type, 4
28 APOL3 apolipoprotein L, 3
29 IFI35 interferon-induced protein 35
30 BST2 bone marrow stromal cell antigen 2
31 TRAFD1 TRAF-type zinc finger domain containing 1
32 CARD16 caspase recruitment domain family, member 16
33 SORT1 sortilin 1
34 SLAMF7 SLAM family member 7
35 HSPH1 heat shock 105kDa/110kDa protein 1
36 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa
37 MX1 MX dynamin-like GTPase 1
38 PSTPIP2 proline-serine-threonine phosphatase interacting protein 2
39 CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1
40 GBP3 guanylate binding protein 3
41 UBE2B ubiquitin-conjugating enzyme E2B
42 FCHO2 FCH domain only 2
43 FGFR1OP2 FGFR1 oncogene partner 2
44 CMAS cytidine monophosphate N-acetylneuraminic acid synthetase
45 VRK1 vaccinia related kinase 1
46 YOD1 YOD1 deubiquitinase
47 CA1 carbonic anhydrase I
48 TMEM56 transmembrane protein 56
49 CHPT1 choline phosphotransferase 1
50 CAPRIN2 caprin family member 2
51 SLC14A1 solute carrier family 14 (urea transporter), member 1 
52 MYL4 myosin, light chain 4, alkali; atrial, embryonic
53 IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2
54 ANK1 ankyrin 1, erythrocytic
55 TSPAN5 tetraspanin 5
56 WDFY1 WD repeat and FYVE domain containing 1
57 APOL6 apolipoprotein L, 6
58 OR56B1 olfactory receptor, family 56, subfamily B, member 1
59 JAK2 Janus kinase 2
60 ICAM1 intercellular adhesion molecule 1
61 APOL2 apolipoprotein L, 2
62 XAF1 XIAP associated factor 1
63 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
64 TRIM21 tripartite motif containing 21
65 IRF1 interferon regulatory factor 1
66 PSME2 proteasome (prosome, macropain) activator subunit 2 (PA28 beta)
67 SAT1 spermidine/spermine N1-acetyltransferase 1
68 DMXL2 Dmx-like 2
69 CASP1 caspase 1, apoptosis-related cysteine peptidase





71 LMAN1 lectin, mannose-binding, 1
72 LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein
73 HLA-DMA major histocompatibility complex, class II, DM alpha
74 CDK2AP2 cyclin-dependent kinase 2 associated protein 2
75 CCR1 chemokine (C-C motif) receptor 1
76 SDPR serum deprivation response
77 MMD monocyte to macrophage differentiation-associated
78 THBS1 thrombospondin 1
79 SH3BGRL2 SH3 domain binding glutamate-rich protein like 2
80 TLR6 toll-like receptor 6
81 BAZ2B bromodomain adjacent to zinc finger domain, 2B
82 MME membrane metallo-endopeptidase
83 KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2
84 GK glycerol kinase
85 IL1B interleukin 1, beta
86 FPR2 formyl peptide receptor 2
87 KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15
88 TCF7 transcription factor 7 (T-cell specific, HMG-box)
89 SDAD1 SDA1 domain containing 1
90 CD180 CD180 molecule
91 TIMM22 translocase of inner mitochondrial membrane 22 homolog (yeast)
92 IRF4 interferon regulatory factor 4
93 TXNDC5 thioredoxin domain containing 5 (endoplasmic reticulum)
94 KIR2DS3 killer cell immunoglobulin-like receptor
95 KIR2DS1 killer cell immunoglobulin-like receptor
96 KIR2DS2 killer cell immunoglobulin-like receptor
97 PPM1A protein phosphatase, Mg2+/Mn2+ dependent, 1A
98 CPEB4 cytoplasmic polyadenylation element binding protein 4
99 HIST1H3H histone cluster 1, H3h
100 CLU clusterin
101 BPGM 2,3-bisphosphoglycerate mutase
102 GOLGA8B golgin A8 family, member B
103 GOLGA8A golgin A8 family, member A
104 CLK1 CDC-like kinase 1
105 ANKRD36 ankyrin repeat domain 36
106 KIR3DS1 killer cell immunoglobulin-like receptor
107 KIR3DL2 killer cell immunoglobulin-like receptor
108 KIR2DL5B killer cell immunoglobulin-like receptor
109 KIR3DL1 killer cell immunoglobulin-like receptor
110 PTGDR prostaglandin D2 receptor (DP)
111 MYBL1 v-myb avian myeloblastosis viral oncogene homolog-like 1
112 KLRF1 killer cell lectin-like receptor subfamily F, member 1
113 TARP TCR gamma alternate reading frame protein
114 KLRG1 killer cell lectin-like receptor subfamily G, member 1
115 KLRD1 killer cell lectin-like receptor subfamily D, member 1
116 GZMH granzyme H (cathepsin G-like 2, protein h-CCPX)
117 FCRL6 Fc receptor-like 6
118 USP28 ubiquitin specific peptidase 28
119 KIR3DL3 killer cell immunoglobulin-like receptor
120 HIST2H2BF histone cluster 2, H2bf
121 ALG3 ALG3, alpha-1,3- mannosyltransferase
122 CD86 CD86 molecule
123 CCDC88A coiled-coil domain containing 88A
124 IRS2 insulin receptor substrate 2
125 KIR2DL2 killer cell immunoglobulin-like receptor
126 KIR2DL1 killer cell immunoglobulin-like receptor
127 KIR2DL3 killer cell immunoglobulin-like receptor
128 KIR2DS4 killer cell immunoglobulin-like receptor
129 RNF182 ring finger protein 182
130 TNFAIP6 tumor necrosis factor, alpha-induced protein 6
131 P2RY14 purinergic receptor P2Y, G-protein coupled, 14
132 SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1
133 FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64)
134 PARP9 poly (ADP-ribose) polymerase family, member 9
135 EPSTI1 epithelial stromal interaction 1 (breast)
136 IFIT3 interferon-induced protein with tetratricopeptide repeats 3
137 FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64)
138 TANK TRAF family member-associated NFKB activator
139 NT5C3A 5'-nucleotidase, cytosolic IIIA
140 TTC14 tetratricopeptide repeat domain 14
141 CBWD3 COBW domain containing 3
142 VNN3 vanin 3
143 PTGS2 prostaglandin-endoperoxide synthase 2 
144 OR52K2 olfactory receptor, family 52, subfamily K, member 2
145 VPS8 vacuolar protein sorting 8 homolog (S. cerevisiae)
146 CCNH cyclin H
147 N4BP2L2 NEDD4 binding protein 2-like 2
148 CD58 CD58 molecule
149 RPS6KA5 ribosomal protein S6 kinase, 90kDa, polypeptide 5
150 PIGB phosphatidylinositol glycan anchor biosynthesis, class B  
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151 PF4V1 platelet factor 4 variant 1
152 SLPI secretory leukocyte peptidase inhibitor
153 SWT1 SWT1 RNA endoribonuclease homolog (S. cerevisiae)
154 MBOAT2 membrane bound O-acyltransferase domain containing 2
155 ALS2CR12 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 12
156 GYPB glycophorin B (MNS blood group)
157 GYPA glycophorin A (MNS blood group)
158 MICALCL MICAL C-terminal like
159 PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)
160 KIAA1598 KIAA1598
161 NLRC4 NLR family, CARD domain containing 4
162 FAM105A family with sequence similarity 105, member A
163 C3AR1 complement component 3a receptor 1
164 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane)
165 KREMEN1 kringle containing transmembrane protein 1
166 ANXA3 annexin A3
167 LAP3 leucine aminopeptidase 3
168 GCH1 GTP cyclohydrolase 1
169 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa
170 DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60
171 MYOF myoferlin
172 P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7
173 LACTB lactamase, beta
174 CD38 CD38 molecule
175 IFIT5 interferon-induced protein with tetratricopeptide repeats 5
176 IFIH1 interferon induced with helicase C domain 1
177 OASL 2'-5'-oligoadenylate synthetase-like
178 APOL1 apolipoprotein L, 1
179 IFIT2 interferon-induced protein with tetratricopeptide repeats 2
180 TIA1 TIA1 cytotoxic granule-associated RNA binding protein
181 CLK4 CDC-like kinase 4
182 VPS13A vacuolar protein sorting 13 homolog A (S. cerevisiae)
183 ZFYVE16 zinc finger, FYVE domain containing 16
184 CBWD5 COBW domain containing 5
185 CBWD2 COBW domain containing 2
186 IL1RAP interleukin 1 receptor accessory protein
187 MS4A14 membrane-spanning 4-domains, subfamily A, member 14
188 KLRC3 killer cell lectin-like receptor subfamily C, member 3
189 SH2D1B SH2 domain containing 1B
190 PDK4 pyruvate dehydrogenase kinase, isozyme 4
191 ICOS inducible T-cell co-stimulator
192 GPR18 G protein-coupled receptor 18
193 GCNT4 glucosaminyl (N-acetyl) transferase 4, core 2
194 SYT11 synaptotagmin XI
195 CD160 CD160 molecule
196 MANEA mannosidase, endo-alpha
197 HIST1H2BM histone cluster 1, H2bm
198 HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2
199 NFXL1 nuclear transcription factor, X-box binding-like 1
200 KATNBL1 katanin p80 subunit B-like 1
201 IL1R2 interleukin 1 receptor, type II
202 CNTNAP3 contactin associated protein-like 3
203 HBZ hemoglobin, zeta
204 TIFA TRAF-interacting protein with forkhead-associated domain
205 SLAMF8 SLAM family member 8
206 PLSCR1 phospholipid scramblase 1
207 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
208 TLR7 toll-like receptor 7
209 ALDH1A1 aldehyde dehydrogenase 1 family, member A1
210 MTHFD2 methylenetetrahydrofolate dehydrogenase 
211 FLVCR2 feline leukemia virus subgroup C cellular receptor family, member 2
212 ERLIN1 ER lipid raft associated 1
213 CLEC4D C-type lectin domain family 4, member D
214 RTP4 receptor (chemosensory) transporter protein 4
215 AIM2 absent in melanoma 2
216 GRAMD1B GRAM domain containing 1B
217 CD209 CD209 molecule
218 DRAM1 DNA-damage regulated autophagy modulator 1
219 SFRP2 secreted frizzled-related protein 2
220 CCDC18 coiled-coil domain containing 18
221 CCDC176 coiled-coil domain containing 176
222 IFIT1B interferon-induced protein with tetratricopeptide repeats 1B
223 AHSP alpha hemoglobin stabilizing protein
224 IL5RA interleukin 5 receptor, alpha
225 ALOX15 arachidonate 15-lipoxygenase
226 CCR3 chemokine (C-C motif) receptor 3
227 EIF1AY eukaryotic translation initiation factor 1A, Y-linked
228 VCPKMT valosin containing protein lysine (K) methyltransferase
229 LOC643802 u3 small nucleolar ribonucleoprotein protein MPP10-like




231 KIF27 kinesin family member 27
232 TMEM14E transmembrane protein 14E
233 TXNDC16 thioredoxin domain containing 16
234 ATAD5 ATPase family, AAA domain containing 5
235 ZMAT1 zinc finger, matrin-type 1
236 FAM185A family with sequence similarity 185, member A
237 FLJ45513 uncharacterized LOC729220
238 CXorf65 chromosome X open reading frame 65
239 PLGLB1 plasminogen-like B1
240 GPR15 G protein-coupled receptor 15
241 Sep-04 septin 4
242 EFCAB2 EF-hand calcium binding domain 2
243 CHRM4 cholinergic receptor, muscarinic 4
244 OR2T3 olfactory receptor, family 2, subfamily T, member 3
245 NETO2 neuropilin (NRP) and tolloid (TLL)-like 2
246 FAM198B family with sequence similarity 198, member B
247 LIPN lipase, family member N
248 LAMP3 lysosomal-associated membrane protein 3
249 ETV7 ets variant 7
250 DOCK4 dedicator of cytokinesis 4
251 DHRS9 dehydrogenase/reductase (SDR family) member 9
252 CASP5 caspase 5, apoptosis-related cysteine peptidase
253 TAS2R31 taste receptor, type 2, member 31
254 GPR52 G protein-coupled receptor 52
255 NFE2L2 nuclear factor, erythroid 2-like 2
256 KIAA0825 KIAA0825
257 MAK male germ cell-associated kinase
258 ENKUR enkurin, TRPC channel interacting protein
259 KLRC2 killer cell lectin-like receptor subfamily C, member 2
260 DTHD1 death domain containing 1
261 KLRC1 killer cell lectin-like receptor subfamily C, member 1
262 GRAMD1C GRAM domain containing 1C
263 RBMXL3 RNA binding motif protein, X-linked-like 3
264 PHGR1 proline/histidine/glycine-rich 1
265 SRRM5 serine/arginine repetitive matrix 5
266 KLHL14 kelch-like family member 14
267 HIST1H3B histone cluster 1, H3b
268 TAS2R43 taste receptor, type 2, member 43
269 GK5 glycerol kinase 5 (putative)
270 ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5
271 C6orf163 chromosome 6 open reading frame 163
272 SLC26A8 solute carrier family 26 (anion exchanger), member 8
273 LY96 lymphocyte antigen 96
274 KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)
275 FRMD3 FERM domain containing 3
276 TFEC transcription factor EC
277 GBP7 guanylate binding protein 7
278 CLEC5A C-type lectin domain family 5, member A
279 IDO1 indoleamine 2,3-dioxygenase 1
280 PDCD1LG2 programmed cell death 1 ligand 2
281 GBP6 guanylate binding protein family, member 6
282 BMX BMX non-receptor tyrosine kinase
283 OR5A2 olfactory receptor, family 5, subfamily A, member 2
284 CLEC6A C-type lectin domain family 6, member A
285 CCL2 chemokine (C-C motif) ligand 2
286 PGBD4 piggyBac transposable element derived 4
287 LOC100130705 uncharacterized LOC100130705
288 GLDC glycine dehydrogenase (decarboxylating)
289 PRKACG protein kinase, cAMP-dependent, catalytic, gamma
290 TAS2R41 taste receptor, type 2, member 41
291 KIF14 kinesin family member 14
292 CNTLN centlein, centrosomal protein
293 ARG1 arginase 1
294 IL1RL1 interleukin 1 receptor-like 1
295 CLEC12B C-type lectin domain family 12, member B
296 SLITRK1 SLIT and NTRK-like family, member 1
297 RNASE8 ribonuclease, RNase A family, 8
298 DEFB128 defensin, beta 128
299 OR10H2 olfactory receptor, family 10, subfamily H, member 2
300 EIF5AL1 eukaryotic translation initiation factor 5A-like 1
301 IL15 interleukin 15
302 IFNG interferon, gamma
303 GPR84 G protein-coupled receptor 84
304 MMP8 matrix metallopeptidase 8 (neutrophil collagenase)
305 IFI44 interferon-induced protein 44
306 HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5
307 RSAD2 radical S-adenosyl methionine domain containing 2
308 IFIT1 interferon-induced protein with tetratricopeptide repeats 1
309 IFI44L interferon-induced protein 44-like




311 CARD17 caspase recruitment domain family, member 17
312 CXCL10 chemokine (C-X-C motif) ligand 10
313 ANKRD22 ankyrin repeat domain 22
314 SPANXN2 SPANX family, member N2
315 KRTAP24-1 keratin associated protein 24-1
316 TAS2R40 taste receptor, type 2, member 40
317 SPANXN3 SPANX family, member N3
318 OR10T2 olfactory receptor, family 10, subfamily T, member 2
319 OR4K5 olfactory receptor, family 4, subfamily K, member 5
320 OR51A4 olfactory receptor, family 51, subfamily A, member 4
321 SUCNR1 succinate receptor 1
322 TAS2R16 taste receptor, type 2, member 16
323 OR5D18 olfactory receptor, family 5, subfamily D, member 18
324 OR8A1 olfactory receptor, family 8, subfamily A, member 1
325 C7orf62 chromosome 7 open reading frame 62
326 OR2AT4 olfactory receptor, family 2, subfamily AT, member 4
327 SCP2D1 SCP2 sterol-binding domain containing 1
328 PBOV1 prostate and breast cancer overexpressed 1
329 OR4C11 olfactory receptor, family 4, subfamily C, member 11
330 OR6X1 olfactory receptor, family 6, subfamily X, member 1
331 PMCH pro-melanin-concentrating hormone
332 OR10A2 olfactory receptor, family 10, subfamily A, member 2
333 OR1G1 olfactory receptor, family 1, subfamily G, member 1
334 LDHAL6B lactate dehydrogenase A-like 6B
335 DEFB133 defensin, beta 133
336 OR10A7 olfactory receptor, family 10, subfamily A, member 7
337 GPR148 G protein-coupled receptor 148
338 SPRR2F small proline-rich protein 2F
339 OR5V1 olfactory receptor, family 5, subfamily V, member 1
340 FOXR2 forkhead box R2
341 HIST1H1B histone cluster 1, H1b
342 UGT2B11 UDP glucuronosyltransferase 2 family, polypeptide B11
343 TAS2R46 taste receptor, type 2, member 46
344 TAS2R20 taste receptor, type 2, member 20
345 TAS2R19 taste receptor, type 2, member 19
346 TAS2R50 taste receptor, type 2, member 50
347 ADAM20P1 ADAM metallopeptidase domain 20 pseudogene 1
348 TAS2R13 taste receptor, type 2, member 13
349 OCLM oculomedin
350 ADAM20 ADAM metallopeptidase domain 20
351 CXCL9 chemokine (C-X-C motif) ligand 9
352 TMEM63B transmembrane protein 63B
353 TESC tescalcin
354 TMOD1 tropomodulin 1
355 TFDP1 transcription factor Dp-1
356 BIRC2 baculoviral IAP repeat containing 2
357 FAM104A family with sequence similarity 104, member A
358 PITHD1 PITH (C-terminal proteasome-interacting domain of thioredoxin-like) domain containing 1
359 GMPR guanosine monophosphate reductase
360 EPB42 erythrocyte membrane protein band 4.2
361 ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12
362 RAB2B RAB2B, member RAS oncogene family
363 MPP1 membrane protein, palmitoylated 1, 55kDa
364 TBCEL tubulin folding cofactor E-like
365 RPIA ribose 5-phosphate isomerase A
366 ODC1 ornithine decarboxylase 1
367 CDC27 cell division cycle 27
368 PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta
369 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
370 PELI1 pellino E3 ubiquitin protein ligase 1
371 CD46 CD46 molecule, complement regulatory protein
372 NABP1 nucleic acid binding protein 1
373 RSRP1 arginine/serine-rich protein 1
374 TLR2 toll-like receptor 2
375 PROK2 prokineticin 2
376 CYP4F3 cytochrome P450, family 4, subfamily F, polypeptide 3
377 ARL17A ADP-ribosylation factor-like 17A
378 RBM39 RNA binding motif protein 39
379 PKN2 protein kinase N2
380 GPCPD1 glycerophosphocholine phosphodiesterase GDE1 homolog (S. cerevisiae)
381 ATP2B1 ATPase, Ca++ transporting, plasma membrane 1
382 SLCO4C1 solute carrier organic anion transporter family, member 4C1
383 HCAR3 hydroxycarboxylic acid receptor 3
384 HCAR2 hydroxycarboxylic acid receptor 2
385 FFAR2 free fatty acid receptor 2
386 STEAP4 STEAP family member 4
387 PADI2 peptidyl arginine deiminase, type II
388 CLC Charcot-Leyden crystal galectin
389 USP32 ubiquitin specific peptidase 32
390 RGS18 regulator of G-protein signaling 18  
 
 271 
391 PF4 platelet factor 4
392 TREM1 triggering receptor expressed on myeloid cells 1
393 CLEC7A C-type lectin domain family 7, member A
394 EMR3 egf-like module containing, mucin-like, hormone receptor-like 3
395 NAMPT nicotinamide phosphoribosyltransferase
396 ACSL1 acyl-CoA synthetase long-chain family member 1
397 LRRK2 leucine-rich repeat kinase 2
398 APOBEC3A apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A
399 CLEC4E C-type lectin domain family 4, member E
400 MGAM maltase-glucoamylase (alpha-glucosidase)
401 DOCK5 dedicator of cytokinesis 5
402 GPR97 G protein-coupled receptor 97
403 FPR1 formyl peptide receptor 1
404 DUSP1 dual specificity phosphatase 1
405 ALPL alkaline phosphatase, liver/bone/kidney
406 PI3 peptidase inhibitor 3, skin-derived
407 RPS18 ribosomal protein S18
408 GPR174 G protein-coupled receptor 174
409 HIST1H4C histone cluster 1, H4c
410 NDRG3 NDRG family member 3
411 CD28 CD28 molecule
412 GPR56 G protein-coupled receptor 56
413 FGFBP2 fibroblast growth factor binding protein 2
414 GZMA granzyme A
415 KLRC4 killer cell lectin-like receptor subfamily C, member 4
416 KLRB1 killer cell lectin-like receptor subfamily B, member 1
417 GZMB granzyme B 
418 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23)
419 CD22 CD22 molecule
420 IGJ immunoglobulin J polypeptide
421 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)
422 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10
423 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
424 FAS Fas cell surface death receptor
425 TMEM140 transmembrane protein 140
426 UBE2L6 ubiquitin-conjugating enzyme E2L 6
427 SECTM1 secreted and transmembrane 1
428 LPCAT2 lysophosphatidylcholine acyltransferase 2
429 LGALS9 lectin, galactoside-binding, soluble, 9
430 KCTD12 potassium channel tetramerization domain containing 12
431 HSPA1B heat shock 70kDa protein 1B
432 STAT2 signal transducer and activator of transcription 2, 113kDa
433 DTX3L deltex 3 like, E3 ubiquitin ligase
434 PARP14 poly (ADP-ribose) polymerase family, member 14
435 WARS tryptophanyl-tRNA synthetase
436 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa
437 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2
438 GBP4 guanylate binding protein 4
439 GBP1 guanylate binding protein 1, interferon-inducible
440 STAT1 signal transducer and activator of transcription 1, 91kDa
441 GBP2 guanylate binding protein 2, interferon-inducible
442 STX11 syntaxin 11
443 SAMD9L sterile alpha motif domain containing 9-like
444 GBP5 guanylate binding protein 5
445 DEFA1B defensin, alpha 1B
446 SEPTIN1 septin 1
447 CD3G CD3g molecule, gamma (CD3-TCR complex)
448 CX3CR1 chemokine (C-X3-C motif) receptor 1
449 HIST1H1E histone cluster 1, H1e
450 RPS5 ribosomal protein S5
451 CCR7 chemokine (C-C motif) receptor 7
452 FAIM3 Fas apoptotic inhibitory molecule 3
453 CD79A CD79a molecule, immunoglobulin-associated alpha
454 USP15 ubiquitin specific peptidase 15
455 KIAA1551 KIAA1551
456 SPN sialophorin
457 IL2RB interleukin 2 receptor, beta
458 CD96 CD96 molecule
459 SLAMF6 SLAM family member 6
460 RSL1D1 ribosomal L1 domain containing 1
461 HCST hematopoietic cell signal transducer
462 COPE coatomer protein complex, subunit epsilon
463 GNLY granulysin
464 MXI1 MAX interactor 1, dimerization protein
465 MICAL2 microtubule associated monooxygenase, calponin and LIM domain containing 2
466 FAM210B family with sequence similarity 210, member B
467 SLC6A8 solute carrier family 6 (neurotransmitter transporter), member 8
468 USP12 ubiquitin specific peptidase 12
469 UBXN6 UBX domain protein 6




471 OR2W3 olfactory receptor, family 2, subfamily W, member 3
472 HEMGN hemogen
473 DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 1
474 HLA-DRB5 major histocompatibility complex, class II, DR beta 5
475 SOD2 superoxide dismutase 2, mitochondrial
476 SMCHD1 structural maintenance of chromosomes flexible hinge domain containing 1
477 MXD1 MAX dimerization protein 1
478 FAM157B family with sequence similarity 157, member B
479 CXCR2 chemokine (C-X-C motif) receptor 2
480 VNN2 vanin 2
481 CXCR1 chemokine (C-X-C motif) receptor 1
482 AQP9 aquaporin 9
483 RGS2 regulator of G-protein signaling 2
484 PHOSPHO1 phosphatase, orphan 1
485 FOXO3 forkhead box O3
486 FECH ferrochelatase
487 SLC4A1 solute carrier family 4 (anion exchanger), member 1 (Diego blood group)
488 PRF1 perforin 1 (pore forming protein)
489 NKG7 natural killer cell granule protein 7
490 CTSW cathepsin W
491 MT2A metallothionein 2A
492 HSP90B1 heat shock protein 90kDa beta (Grp94), member 1
493 COX8A cytochrome c oxidase subunit VIIIA (ubiquitous)
494 HLA-DRB1 major histocompatibility complex, class II, DR beta 1
495 GIMAP7 GTPase, IMAP family member 7
496 HLA-DRB4 major histocompatibility complex, class II, DR beta 4
497 SLC25A37 solute carrier family 25 (mitochondrial iron transporter), member 37
498 RIOK3 RIO kinase 3
499 R3HDM4 R3H domain containing 4
500 FBXO7 F-box protein 7
501 YBX3 Y box binding protein 3
502 STRADB STE20-related kinase adaptor beta
503 P2RY13 purinergic receptor P2Y, G-protein coupled, 13
504 CSF3R colony stimulating factor 3 receptor (granulocyte)
505 PPBP pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
506 MARCH8 membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase
507 FKBP8 FK506 binding protein 8, 38kDa
508 SNCA synuclein, alpha (non A4 component of amyloid precursor)
509 RNF10 ring finger protein 10
510 FGL2 fibrinogen-like 2
511 CYBB cytochrome b-245, beta polypeptide
512 IFI6 interferon, alpha-inducible protein 6
513 MBNL3 muscleblind-like splicing regulator 3
514 FAM46C family with sequence similarity 46, member C
515 DCAF12 DDB1 and CUL4 associated factor 12
516 ALAS2 aminolevulinate, delta-, synthase 2
517 SLC25A39 solute carrier family 25, member 39  
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Appendix 5: Within-volunteer “distance travelled” 
 
Appendix 5 | Within-volunteer "distance travelled" was calculated by assessing within-volunteer variation by Principle Component Analysis. By plotting each time point in the volunteer’s time 
course on a 2D scale (as PC1 vs PC2), the “distance travelled” between each point could be calculated using “Pythagoras’ Theorem” (a2 + b2 = c2). “Total distance” was taken as the sum of each 
sequential distance travelled (a – b – c - d), and “final distance”, calculated by drawing a direct line between the first time-point and the last (a – d). Table shows a break-down of the measurements, 
for each of the 14 infected and 4 uninfected (baseline) controls through time. “Unknowns” = yellow, “non-classical” responders  = blue, “classical” responders = red and “baseline controls” = black. 
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Appendix 6: Concentrations (pg/mL) of Cytokines and Chemokines in Volunteer Plasma  
volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD
12 76.53 25.045 58.5 41 58.99 12 261.47 207.11 203.29 222.16 196.04 12 1431.14 810.635 1163.45 965.53 1407.01 12 198.585 121.165 177.88 176.345 197.25
13 70.75 104.9 47.86 54.2 44.07 158.4 157.88 13 251.43 290.53 254.08 199.83 263.82 645.02 991.39 13 919.85 1693.21 993.19 1143.65 854.92 1390.8 13 262.11 342.915 187.49 249.725 223.265 311.83 285.01
16 96.98 60.82 91.84 42.51 405.04 3722.61 16 289.47 444.66 322.35 270.9 1241.4 10,144.18 16 1325.46 1072.83 1307.22 1085.02 2567.33 7,752.66 16 259.785 176.975 194.43 142.765 220.305 439.86
17 70.56 37.01 88.81 46.69 128 555.67 914.4 17 158.07 173.38 171.86 153.54 355.1 1711.75 2523.1 17 1743.86 1160.05 1683.55 1523.47 1550.02 2710.17 17 263.73 208.34 313.265 259.525 329.765 339.785 503.885
18 94.23 56.74 42.1 89.85 95.69 43.9 18 257.49 283.71 263.91 265.79 305.41 197.5 18 1039.4 868.9 956.86 683.875 898.985 742.635 18 209.68 179.81 204.135 163.42 197.505 139.58
19 56.57 96.66 39.83 85.04 53.24 76.42 19 338.53 314.89 231.28 297.22 265.99 240.95 19 889.93 1419.1 896.705 1407.52 1009.52 1134.83 19 168.145 220.035 155.51 253.98 162.475 249.745
22 43.21 43.63 97.84 57.1 80.57 40.15 22 227.42 283.95 364.87 267.45 305.17 288.54 22 851.435 729.715 1171.92 794.175 985.005 1125.67 22 174.94 157.28 266.225 153.975 194.23 147.37
24 53.42 57.13 32.68 81.1 40 120.19 24 279.61 179.84 284.79 213.57 336.42 506.57 24 695.095 577.765 883.335 762.55 928.37 1099.15 24 251.095 199.525 258.96 276.43 302.89 340.72
26 177.63 84.31 140.1 76.1 124.86 184.8 26 313.54 283.28 278.24 256.67 310.99 822.56 26 1224.65 808.41 1140.05 889.87 943.505 1162.16 26 223.825 177.93 201.65 147.955 189.98 175.11
27 39.63 67.97 43.39 62.49 128.18 717.21 27 181.87 133.11 182.82 185.97 382.87 1918.48 27 1177.79 1071.26 1725.68 1461.56 1021.62 3671.01 27 107.515 180.87 127.54 136.065 88.065 141.235
106 72.74 18.31 55.64 43.89 58.6 79.2 106 184.93 179.46 214.21 230.64 205.61 644.28 106 771.305 657.9 798.205 820.805 715.34 1051.02 106 431.41 280.71 261.23 326.765 244.75 330.02
206 39.11 19.46 37.05 13.46 44.1 217.62 206 267.18 303.51 286.92 286.57 285.29 1436.72 206 927.23 985.99 1044.5 862.04 967.575 1829.07 206 315.605 218.3 277.65 176.64 212.475 220.445
208 38.82 101.87 43.91 110.91 30.24 79 208 204.68 261.47 256.8 316.08 212.73 214.16 208 1096.89 1161.85 1126.4 1231.74 901.105 1354.25 208 113.39 238.74 135.33 235.71 126.015 187.625
volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD
12 481.585 219.83 403.905 132.715 342.32 12 16.32 13.935 13.6 12 19.66 16.2 17.33 12
13 29.24 68.43 67.685 37.615 34.17 15.43 13 18.75 39.4 27.235 20.97 13 23.005 27.85 24.36 22.07 13 85.45
16 35.625 22.595 42.315 16 16 30.72 22.54 23.615 16 1,325.14
17 17 17 13.745 16.23 15.365 17.345 17 36.775 258.63
18 117.835 25.8 66.25 28.095 84.14 18 37.11 19.525 20.65 18 16.79 18
19 125.505 193.52 188.48 180.32 84.58 166.745 19 19.55 18.49 19 29.11 26.785 16.155 22.685 19
22 65.315 25.325 140.45 53.175 98.555 55.82 22 19.565 37.905 86.115 54.905 67.41 60.88 22 17.62 74.705 40.02 39.315 45.51 22
24 9.945 36.95 18.295 51.245 27.635 60.435 24 18.805 19.035 49.785 24 17.335 25.505 24
26 80.375 28.625 77.7 28.495 74.415 43.46 26 26 15.09 14.82 26
27 21.91 52.82 49.695 39.06 27 27 20.56 18.78 19.365 27
106 46.17 46.005 33.37 106 106 3567.1 3165.28 3105.59 3631.08 2755.62 3265.72 106
206 16.95 206 206 14.015 206
208 25.935 16.465 28.105 25.195 208 115.76 242.565 102.065 162.41 65.9 77.965 208 14.28 16.54 15.645 208
volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD volunteer i.d C -1 C +2 C +4 C +6 C +8 C +10 DoD
12 49.565 41.445 39.15 12 18.81 12 12 11.91 10.025 9.03
13 32.73 21.83 20.305 13 13 21.285 14.145 15.855 6.855 13 4.775 19.56 2.53 14.515 3.37 14.51 4.12
16 16 31.33 16 77.73 16 9.405 12.55 183.20
17 17 16.415 17 36.775 17 31.985
18 18 79.765 50.06 18 17.945 18 10.88 11.755 11.835
19 25.295 19.845 20.83 19 19 21.75 15.06 16.265 19 13.885 2 13.275 9.87
22 79.225 30.205 52.745 35.67 22 22 21.17 77.535 34.645 49.01 45.49 22 11.43 2 10.5
24 16.69 24 24 17.915 24 2 10.335 9.715
26 26 26 26 9.71 9.335
27 27 27 27 21.2
106 106 106 106
206 206 206 6.51 206
208 16.425 15.935 15.09 208 208 208 9.03 9.635
Concentrations of IL-18 (pg/mL)
Concentrations of IFNγ (pg/mL)
Concentrations of IL-10 (pg/mL)
 = Analyte undetectable 
 = Time-point subsequent to volunteer diagnosis (and treatment), therefore no available sample
Concentrations of IL-1β (pg/mL) Concentrations of IL-8 (pg/mL) Concentrations of IL-6 (pg/mL)
Concentrations of CXCL9 (pg/mL) Concentrations of CXCL10 (pg/mL) Concentrations of CCL2 (pg/mL)
Concentrations of INFα (pg/mL) Concentrations of IL-17 (pg/mL) Concentrations of TNFα (pg/mL)
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Appendix 7: Volunteer Safety Data (temperature (oC) and heart rate (BPM)) 
 
Temperature (oC)
volunteer i.d C -1 C +2.0 C +2.5 C +3.0 C +3.5 C +4.0 C +4.5 C +5.0 C +5.5 C +6.0 C +6.5 C +7.0 C +7.5 C +8.0 C +8.5 C +9.0 C +9.5 C +10.0 C +10.5
18 36.9 36.9 36.7 36.8 37.2 36.2 37.4 36.4 36.1 36.9 36.7 36.8 36.7 36.6 37.4
12 36.2 36.6 36.1 36.1 36.8 35.5 36.7 36 36.1 35.9 36.3 36.1 36.2
208 36.2 36.5 37.1 36.6 36.6 36.2 36.4 36.4 36.6 36.3 36.8 37.1 36.1 37.1 36.9 36.9
20 36.2 36.1 36 36 36 36.3 36 36.5 36.1 36.1 36 35.7 35.8 36.2 36.9
Group Mean 36.4 36.5 36.5 36.4 36.7 36.1 36.4 36.3 36.2 36.3 36.4 36.4 36.0 36.6 37.1 36.9
16 36.2 36.1 36.4 36.1 36.2 36.2 36.2 36.3 36.4 36 36 36.1 36.5 36.2 36.8 36.6 36.9 37.3
17 36.2 36 36.1 36.8 36.3 36.2 36.1 36.1 35.9 36.8 36.1 36.6 35.9 36.7 35.7 36.8 37.6 36.2 38.2
13 36.7 36.1 36.6 36.4 36.5 36.7 36.5 36.1 36.3 36.6 37.5 36.3 36.2 36.5 36.1 36.3 37.1 36.2 37.0
27 36.7 35.8 35.8 37.1 36.3 36.1 36.7 36.4 36 36.3 36.8 36.5 36 36.2 36.4 36.8
26 36.9 36.2 36.1 36.6 36.3 36.9 36.4 36.8 36.9 36.8 36.4 36.5 37 36.6 37.3 37.1
206 36.4 36.4 36.3 36 36.4 36.2 35.6 36.1 36.7 36.1 36.6 35.9 36.9 36.3 36.7 36.8 37 36.8
106 37.1 36.9 37.2 36.8 36.9 36.6 36.8 37.2 37.1 37.1 36.7 36.9 36.2 36.8 37.1
24 36.4 36.2 36.2 36.7 36 36.3 36.2 36.2 36.2 35.9 36 36.1 36.2 36.1 36.6 35.8 37.1 36.0
Group Mean 36.6 36.2 36.3 36.6 36.4 36.4 36.3 36.4 36.4 36.4 36.5 36.4 36.4 36.4 36.6 36.6 37.14 36.5 37.6
22 36.2 36.8 36.3 36.7 37.1 36.5 37.1 36.7 36.7 36.3 37.1 36.7 36.8 36.7 37.2 36.1 36.8 36.1
19 36.8 36.1 36.2 36.2 35.8 36.4 36.2 36.1 36.1 36.3 36.2 36.2 36.7 36.1 36.7
Group Mean 36.5 36.4 36.3 36.5 36.4 36.4 36.7 36.4 36.4 36.3 36.7 36.5 36.8 36.4 36.95 36.1 36.8 36.1
Heart Rate (BPM)
volunteer i.d C -1 C +2.0 C +2.5 C +3.0 C +3.5 C +4.0 C +4.5 C +5.0 C +5.5 C +6.0 C +6.5 C +7.0 C +7.5 C +8.0 C +8.5 C +9.0 C +9.5 C +10.0 C +10.5
18 91 78 87 83 78 98 90 79 72 78 82 82 82 78 91
12 68 65 74 103 68 63 75 64 83 68 84 86 64
208 66 64 74 62 67 72 60 67 70 77 56 63 73 77 69 77
20 58 64 55 90 57 70 47 76 53 78 55 67 N/A 55 87
Group Mean 71 68 73 85 68 76 68 72 70 75 69 75 73 70 82 77
16 72 49 60 102 89 57 64 57 78 65 59 54 53 65 67 76 73 93
17 81 82 94 82 88 69 97 84 83 71 88 93 84 84 88 91 82 94 83
13 62 83 73 90 71 89 67 86 55 82 84 75 65 69 91 62 87 55 97
27 94 88 83 96 68 90 83 73 74 73 84 76 103 84 99 98
26 79 65 90 86 71 75 67 73 79 84 67 77 66 77 88 73
206 54 74 60 71 58 64 56 65 61 63 66 56 59 66 55 62 62 76
106 88 93 79 86 103 89 80 65 95 93 80 94 80 96 79
24 61 60 77 78 72 69 78 62 68 77 68 61 66 63 67 82 84 84
Group Mean 74 74 77 86 78 75 74 71 74 76 75 73 72 76 79 78 78 80 90
22 74 68 70 66 71 67 68 72 68 74 67 59 58 69 77 63 68 63
19 81 84 92 87 86 89 75 83 99 87 73 80 86 74 93
Group Mean 78 76 81 77 79 78 72 78 84 81 70 70 72 72 85 63 68 63





Appendix 7 Continued: Volunteer safety data (blood pressure (BP)) 
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Appendix 8: List of (203) Differentially Expressed Genes Between Parasites 
Isolated From Volunteers at Day of Patent Infection and Parasites Recovered from 
Blood-stage Inoculum 
 
transcript id log2FoldChange adjusted p.value description  transcript id log2FoldChange adjusted p.value description
PF3D7_0401600.1 7.589696519 0.000162813 rifin PIR protein PF3D7_1446900 3.157589548 0.008674698 glutaminyl-peptide cyclotransferase, putative
PF3D7_1222600 7.056450524 0.004128576 transcription factor with AP2 domain(s) PF3D7_1011600 3.152572994 0.006681229 conserved Plasmodium protein, unknown function
PF3D7_1004400 6.885845263 0.001193024 RNA-binding protein, putative PF3D7_0217600 3.151321263 0.006415943 conserved Plasmodium protein, unknown function
PF3D7_0621000 6.371605844 0.004967138 conserved Plasmodium protein, unknown function PF3D7_1210400 3.134049237 0.002689235 general transcription factor 3C polypeptide 5, putative
PF3D7_0212300 6.316650195 0.001860276 peptide chain release factor subunit 1, putative PF3D7_0919100 3.133070031 0.003920393 DnaJ protein, putative
PF3D7_1307600 6.261076569 0.008576355 DNA-directed RNA polymerase alpha chain, putative PF3D7_1122300 3.127968389 0.001562525 conserved Plasmodium protein, unknown function
PF3D7_1021900 6.258342957 0.008554609 conserved Plasmodium protein (10b antigen), unknown function PF3D7_1408400 3.120851274 0.001082668 DNA repair helicase, putative
PF3D7_1368200 6.210902227 0.005477977 RNAse L inhibitor protein, putative PF3D7_0731600 3.117483393 0.006859746 acyl-CoA synthetase
PF3D7_1135900 5.869392045 0.005020867 3-oxo-5-alpha-steroid 4-dehydrogenase, putative PF3D7_1205400 3.090476908 0.002409188 conserved Plasmodium protein, unknown function
PF3D7_0310400 5.816774187 0.005900786 parasite-infected erythrocyte surface protein PF3D7_1450600 3.073778817 0.002779141 conserved Plasmodium protein, unknown function
PF3D7_1008900 5.777594785 0.008646082 adenylate kinase PF3D7_1421400 3.067637897 0.000203053 DNA-directed RNA polymerase III subunit C, putative
PF3D7_0621700 5.595624295 0.007865631 conserved Plasmodium protein, unknown function PF3D7_0923900 3.03115755 0.000508993 RNA-binding protein, putative
PF3D7_1215100 5.147264846 0.002093246 conserved Plasmodium protein, unknown function PF3D7_1225500 3.009777073 0.007018203 small subunit rRNA processing factor, putative
PF3D7_0608800 4.852681574 0.000253703 ornithine aminotransferase PF3D7_0725300 3.006568515 0.005142894 conserved Plasmodium protein, unknown function
PF3D7_1035800 4.639032499 0.00661158 probable protein, unknown function PF3D7_1038100 3.004726701 0.000508993 GDP dissociation inhibitor, putative
PF3D7_0313100 4.585079665 0.00098878 ubiquitin-protein ligase, putative PF3D7_1323500 2.996151746 0.000578771 plasmepsin V PEXEL protease
PF3D7_1017900 4.397342279 0.000483826 26S proteasome regulatory subunit p55, putative PF3D7_0506800 2.977551073 0.002203153 transcription factor 25, putative
PF3D7_1329100 4.325649942 0.002409188 myosin C PF3D7_1134000 2.959348321 0.00183968 heat shock protein 70
PF3D7_1402800 4.256969419 1.21145E-05 conserved Plasmodium protein, unknown function PF3D7_0821700 2.953313306 0.000167765 60S ribosomal protein L22, putative
PF3D7_0601900 4.169424174 0.000121686 conserved Plasmodium protein, unknown function PF3D7_0630600 2.920112228 0.003739123 conserved Plasmodium protein, unknown function
PF3D7_1030300 4.141242261 0.004128576 conserved Plasmodium protein, unknown function PF3D7_1434300 2.919079953 3.74857E-06 Hsp70/Hsp90 organizing protein
PF3D7_1354200 4.131329319 0.002270942 inositol-polyphosphate 5-phosphatase, putative PF3D7_0730900 2.899633149 0.003749965 EMP1-trafficking protein
PF3D7_1307800 4.058050673 0.000299532 fork head domain protein, putative PF3D7_1220100 2.890700194 0.008266248 pre-mRNA splicing factor, putative
PF3D7_1323800 4.026533135 0.006341894 vacuolar protein sorting-associated protein 52, putative PF3D7_0807900 2.878566748 0.002111257 tyrosine--tRNA ligase
PF3D7_1415600 3.978823292 0.007018203 conserved Plasmodium protein, unknown function PF3D7_1102500 2.87155595 0.006721578 Plasmodium exported protein (PHISTb), unknown function
PF3D7_0913700 3.961248452 0.006681229 conserved Plasmodium protein, unknown function PF3D7_1117800 2.867525797 0.005834226 DNA mismatch repair protein MLH
PF3D7_1306400 3.909001017 0.000230448 26S protease regulatory subunit 10B, putative PF3D7_1307700 2.859846433 0.000208979 conserved Plasmodium protein, unknown function
PF3D7_1407300 3.896194195 0.000845152 pre-mRNA splicing factor, putative PF3D7_0920900 2.851240596 0.003635992 U4/U6 snRNA-associated-splicing factor, putative
PF3D7_1208900 3.874977254 0.002409188 conserved Plasmodium protein, unknown function PF3D7_1317000 2.804908929 0.006197414 U4/U6.U5 tri-snRNP-associated protein 2, putative
PF3D7_0717400 3.87078768 0.000177985 queuine tRNA-ribosyltransferase, putative PF3D7_1478600 2.770861538 0.003350396 EMP1-trafficking protein
PF3D7_0802000 3.867459151 0.000202375 glutamate dehydrogenase, putative PF3D7_1231600 2.761053926 0.000320171 pre-mRNA-splicing factor ATP-dependent RNA helicase PRP2, putative
PF3D7_1113600 3.842159963 0.004677872 Rpr2, RNAse P, putative PF3D7_1439100 2.739988871 0.000716273 DEAD/DEAH box helicase, putative
PF3D7_1366600 3.837084867 0.002203153 signal recognition particle receptor alpha subunit PF3D7_0211800 2.730267399 5.08668E-05 asparagine--tRNA ligase
PF3D7_1139300 3.816201815 2.21864E-06 transcription factor with AP2 domain(s) PF3D7_1207600 2.726138975 0.007509846 tRNA delta(2)-isopentenylpyrophosphate transferase, putative
PF3D7_1473200 3.806113656 0.000665293 DnaJ protein, putative PF3D7_1005600 2.680673175 4.51981E-05 DnaJ protein, putative
PF3D7_1021700 3.797870093 0.009692009 conserved Plasmodium membrane protein, unknown function PF3D7_1242800 2.667853101 0.004576557 rab specific GDP dissociation inhibitor
PF3D7_1004200 3.73798755 0.000371194 conserved Plasmodium membrane protein, unknown function PF3D7_0610100 2.663432925 3.29865E-05 pre-mRNA-splicing factor SLU7, putative
PF3D7_1306900 3.698760882 0.000310495 U1 small nuclear ribonucleoprotein a, putative PF3D7_1343700 2.654159529 0.006415943 kelch protein K13, putative
PF3D7_0415000 3.650658437 0.00857253 arsenical pump-driving ATPase, putative PF3D7_0925200 2.6314443 0.000664728 rRNA processing and telomere maintaining methyltransferase, putative
PF3D7_1422800 3.642101843 0.004659408 actin-related protein, putative PF3D7_0912900 2.625869565 6.1697E-05 26S proteasome regulatory subunit RPN8, putative
PF3D7_0902200 3.634861136 0.0026505 serine/threonine protein kinase, FIKK family PF3D7_1455500 2.620644125 0.009980309 AP-1 complex subunit gamma, putative
PF3D7_1309000 3.613586507 2.97416E-06 conserved Plasmodium protein, unknown function PF3D7_1237600 2.606180959 0.008576355 rRNA processing WD-repeat protein, putative
PF3D7_0801700 3.596528781 0.008843903 sentrin-specific protease 2, putative PF3D7_1135100 2.597667236 0.000821409 protein phosphatase 2C, putative
PF3D7_1107800 3.57798007 0.000845152 transcription factor with AP2 domain(s) PF3D7_1249300 2.591251287 0.008674698 protein phosphatase, putative
PF3D7_0201500 3.559010391 0.009508445 Plasmodium exported protein (hyp9), unknown function PF3D7_1339300 2.483464709 1.36143E-05 conserved Plasmodium protein, unknown function
PF3D7_0410000 3.520026739 0.00471645 conserved Plasmodium protein, unknown function PF3D7_1224400 2.40845892 0.000295317 conserved Plasmodium protein, unknown function
PF3D7_0409400 3.510609487 0.000650811 heat shock protein 40 PF3D7_0929200 2.397921949 1.95153E-05 RNA-binding protein, putative
PF3D7_0506700 3.504809849 0.004508475 GTPase-activating protein, putative PF3D7_0411000 2.391703614 2.64352E-05 conserved Plasmodium protein, unknown function
PF3D7_0316700 3.465973839 0.007050907 HVA22/TB2/DP1 family protein, putative PF3D7_1353000 2.310334837 0.000162813 tryptophan-rich antigen, pseudogene
PF3D7_1410000 3.462820348 0.004234528 tetratricopeptide repeat family protein, putative PF3D7_1466400 2.308592188 2.96614E-09 transcription factor with AP2 domain(s)
PF3D7_0514900 3.441394338 0.001494755 conserved Plasmodium protein, unknown function PF3D7_0813900 2.292206969 0.002270205 40S ribosomal protein S16, putative
PF3D7_0811400 3.431857847 0.000483826 conserved protein, unknown function PF3D7_0802300 2.28234867 0.002108594 rRNA processing WD-repeat protein, putative
PF3D7_0404600 3.41529078 5.10477E-05 conserved Plasmodium membrane protein, unknown function PF3D7_1119300 2.26879073 0.000967908 U2 snRNP auxiliary factor, small subunit, putative
PF3D7_0409100 3.41089642 0.000144259 U4/U6 small nuclear ribonucleoprotein PRP31, putative PF3D7_0501000 2.255275362 0.007235025 Plasmodium exported protein, unknown function
PF3D7_0724200 3.406504374 0.004128576 type 2A phosphatase-associated protein 42, putative PF3D7_1340600 2.254006078 0.008576355 RNA lariat debranching enzyme, putative
PF3D7_0410900 3.399687981 0.000211196 conserved Plasmodium protein, unknown function PF3D7_0615600 2.091958312 0.000202375 conserved Plasmodium protein, unknown function
PF3D7_1472400 3.390692792 0.000665293 M1-family alanyl aminopeptidase, putative PF3D7_0904000 2.020687425 4.07114E-05 GTPase-activating protein, putative
PF3D7_0310500 3.38324818 0.001287094 DEAD box helicase, putative PF3D7_0716800 1.969573584 0.003237866 eukaryotic translation initiation factor 3 37.28 kDa subunit, putative
PF3D7_0806500 3.381134406 0.001077071 DnaJ protein, putative PF3D7_1353400 1.8645978 0.008373671 Ran-binding protein, putative
PF3D7_0821600 3.319163249 0.00077128 clp1-related protein, putative PF3D7_1450100 1.842473303 1.95153E-05 signal recognition particle subunit SRP54
PF3D7_1472300 3.295635351 0.006189479 conserved Plasmodium membrane protein, unknown function PF3D7_0720700 1.815932955 0.002409188 phosphoinositide-binding protein, putative
PF3D7_0711500 3.291725131 0.002409188 regulator of chromosome condensation, putative PF3D7_0206000 1.791970021 0.007923738 DNA repair endonuclease, putative
PF3D7_0625600 3.270147309 6.3738E-05 poly(A) polymerase PAP, putative PF3D7_1309700 1.747188261 0.00093173 vacuolar protein sorting-associated protein 18, putative
PF3D7_0215500 3.242430561 0.005562389 conserved Plasmodium protein, unknown function PF3D7_1350500 1.596525609 0.009744215 conserved Plasmodium protein, unknown function
PF3D7_1316600 3.221833194 0.003789631 choline-phosphate cytidylyltransferase PF3D7_1227800 1.566859513 0.000162301 histone S-adenosyl methyltransferase, putative
PF3D7_0323500 3.202768768 0.000477372 survival motor neuron-like protein PF3D7_1470600 3.160090769 0.002409188 RAP protein, putative
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Appendix 8 continued: List of (203) Differentially Expressed Genes Between 
Parasites Isolated From Volunteers at Day of Patent Infection and Parasites 
Recovered from Blood-stage Inoculum 
 
transcript id log2FoldChange adjusted p.value description
PF3D7_0719900 -0.978419593 0.005668415 conserved Plasmodium membrane protein, unknown function
PF3D7_1349200 -1.250190149 0.000211196 glutamate--tRNA ligase, putative
PF3D7_0819000 -1.276686744 0.007018203 conserved Plasmodium protein, unknown function
PF3D7_1341200 -1.305171203 0.00471645 60S ribosomal protein L18, putative
PF3D7_0106700 -1.327991758 0.002474345 small ribosomal subunit assembling AARP2 protein
PF3D7_0801800 -1.413621719 0.00553724 mannose-6-phosphate isomerase, putative
PF3D7_0617900 -1.460222023 0.005811386 histone H3 variant, putative
PF3D7_0321800 -1.466029802 3.66904E-07 conserved Plasmodium protein, unknown function
PF3D7_1408700 -1.471323798 0.002354089 conserved Plasmodium protein, unknown function
PF3D7_0820000 -1.533245901 4.98854E-06 Snf2-related CBP activator, putative
PF3D7_0518500 -1.542409885 0.008554609 ATP-dependent RNA helicase DDX23, putative
PF3D7_1349500 -1.581279415 0.008373671 conserved Plasmodium protein, unknown function
PF3D7_1248700 -1.827383977 0.007050907 conserved Plasmodium protein, unknown function
PF3D7_1407100 -1.936893935 0.003749965 fibrillarin, putative
PF3D7_0628200 -1.987880431 0.000330297 protein kinase PK4 eukaryotic translation initiation factor 2-alpha kinase
PF3D7_1003800 -2.047587809 0.000162813 U5 small nuclear ribonuclear protein, putative
PF3D7_1427100 -2.112371598 0.002270205 lipase, putative
PF3D7_0206500 -2.118661143 0.001195824 conserved Plasmodium protein, unknown function
PF3D7_1142400 -2.144827789 4.51131E-07 coproporphyrinogen-III oxidase
PF3D7_0922600 -2.186275798 0.006197414 glutamine synthetase, putative
PF3D7_1123100 -2.218855177 0.001000142 calcium-dependent protein kinase 7
PF3D7_0409800 -2.342523298 0.000125273 zinc finger protein, putative
PF3D7_0918700 -2.350466897 0.001644286 conserved Plasmodium protein, unknown function
PF3D7_0922500 -2.460567397 0.000243325 phosphoglycerate kinase
PF3D7_0309500 -2.504671843 0.008744462 asparagine synthetase, putative
PF3D7_1202600 -2.516073357 0.003724837 conserved protein, unknown function
PF3D7_0505700 -2.627650403 0.000719992 conserved Plasmodium membrane protein, unknown function
PF3D7_0621900 -2.676647384 0.004128576 signal recognition particle subunit SRP68, putative
PF3D7_1228900 -2.918995136 0.000377563 conserved Plasmodium protein, unknown function
PF3D7_1001800 -3.000665691 0.002530902 Plasmodium exported protein (PHISTc), unknown function
PF3D7_1459200 -3.01436934 0.002270205 conserved Plasmodium protein, unknown function
PF3D7_1209000 -3.038602704 0.000693761 conserved Plasmodium protein, unknown function
PF3D7_1034000 -3.054691395 0.000719992 Sec1 family protein, putative
PF3D7_0610800 -3.111696467 0.002029505 transketolase
PF3D7_0804300 -3.128554613 0.001136993 conserved Plasmodium protein, unknown function
PF3D7_1352400 -3.156730331 0.000766316 conserved Plasmodium protein, unknown function
PF3D7_0526500 -3.17122799 1.09742E-12 conserved Plasmodium protein, unknown function
PF3D7_0622100 -3.182788596 0.002530902 conserved Plasmodium protein, unknown function
PF3D7_0309800 -3.187445029 0.000283252 YTH domain-containing protein, putative
PF3D7_1113300 -3.338219552 0.00153738 UDP-galactose transporter, putative
PF3D7_1407600 -3.42414992 0.007150283 conserved Plasmodium protein, unknown function
PF3D7_0304300 -3.458913235 0.002401704 conserved Plasmodium protein, unknown function
PF3D7_0405300 -3.603500019 0.000115301 liver specific protein 2, putative 6-cysteine protein
PF3D7_1302500 -3.647871616 2.97416E-06 conserved Plasmodium protein, unknown function
PF3D7_0632800 -3.738616926 0.000729613 erythrocyte membrane protein 1, PfEMP1
PF3D7_1120300 -3.995245692 4.07114E-05 metal ion channel - Mg2+, Co2+ and Ni2+
PF3D7_0112000 -4.018303524 6.00944E-07 TatD-like deoxyribonuclease, putative
PF3D7_1251100 -4.121413205 6.1697E-05 conserved Plasmodium protein, unknown function
PF3D7_0217900 -4.210780603 0.006873667 conserved Plasmodium protein, unknown function
PF3D7_0912200 -4.216400356 4.93262E-06 conserved Plasmodium membrane protein, unknown function
PF3D7_0223500 -4.265234687 0.009355964 erythrocyte membrane protein 1, PfEMP1
PF3D7_0511600 -4.615520172 0.002401704 apical rhoptry neck protein
PF3D7_0604600 -4.667514797 0.003237866 DNA helicase, putative
PF3D7_0209600 -4.683750805 0.000162301 transporter, putative
PF3D7_1406300 -4.690373539 0.009592626 glycerophosphodiester phosphodiesterase
PF3D7_1300100 -4.840764226 0.000508993 erythrocyte membrane protein 1, PfEMP1
PF3D7_0315200 -4.914366545 0.004127674 circumsporozoite- and TRAP-related protein
PF3D7_0415500 -4.916812243 0.00072182 nuclear cap-binding protein, putative
PF3D7_0111900 -5.21421173 1.95153E-05 conserved Plasmodium protein, unknown function
PF3D7_1117500 -5.217339031 0.000211196 tyrosine--tRNA ligase
PF3D7_1011300 -5.651434127 0.00054578 conserved Plasmodium membrane protein, unknown function
PF3D7_1411400 -5.740537929 0.001692076 plastid replication-repair enzyme
PF3D7_1039100 -6.072440815 0.00553724 DnaJ protein, putative, pseudogene
PF3D7_1136000 -6.413824044 0.004226415 conserved Plasmodium protein, unknown function
PF3D7_0916000 -6.597749567 0.001562525 sugar transporter, putative
PF3D7_1217600 -6.716201129 0.007453375 anaphase promoting complex subunit 10, putative
PF3D7_0100100 -6.840804674 0.000115301 erythrocyte membrane protein 1, PfEMP1
PF3D7_0712000 -6.858380099 0.000663224 erythrocyte membrane protein 1, PfEMP1
PF3D7_1033400 -6.875761214 0.000240065 haloacid dehalogenase-like hydrolase, putative
PF3D7_0730800.2 -28.87174117 2.96614E-09 Plasmodium exported protein, unknown function
PF3D7_1235600 -29.02807788 2.96614E-09 serine hydroxymethyltransferase










Appendix 9: Optimising the PCR cycle number for use with Smart-seq2 
 
 
Appendix 9 | Optimising the PCR cycle number for use with Smart-seq2. Smart-seq2. PCR cycle number was 
optimised using variable starting quantities of RNA,   (10 pg, 50 pg, 100 pg, 500 pg and 1 ng), to cover the predicted 
range for parasite preparations following isolation from the human host during mosquito-bite CHMI. Each 
experiment included three replicate samples (means shown in red), and a Minus Reverse Transcriptase control (-
RT control). 
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Appendix 10: List of detectable var and rif genes following mosquito-bite CHMI 
P. f (3D7) transcript I.D var/ rif group read count P. f (3D7) transcript I.D var/ rif group read count P. f (3D7) transcript I.D var/ rif group read count P. f (3D7) transcript I.D var/ rif group read count P. f (3D7) transcript I.D var/ rif group read count
PF3D7_0426000 B (var) 66 PF3D7_0800300 B/A (var) 16 PF3D7_1200600 var2csa (E) 33 PF3D7_0711700 C (var) 88 PF3D7_0100100 B (var) 145
PF3D7_1300100 B (var) 15 PF3D7_0733000 B (var) 15
PF3D7_0223500 B (var) 6 PF3D7_1255200 B (var) 46 PF3D7_0400100 B (var) 544 PF3D7_1373500 B (var) 41
PF3D7_0400100 B (var) 40 PF3D7_0712800 B/C (var) 55 PF3D7_1255200 B (var) 390 PF3D7_0600200 B/A (var) 33
PF3D7_0401600 A (rif) 12 PF3D7_0401600 A (rif) 14 PF3D7_0115700 B (var) 34 PF3D7_0400400 A (var) 299 PF3D7_0833500 B (var) 31
PF3D7_0425800 A (var) 29 PF3D7_1300100 B (var) 190 PF3D7_0425800 A (var) 26
PF3D7_0632800 B (var) 1,660 PF3D7_0937800 B (var) 287 PF3D7_0833500 B (var) 28 PF3D7_0200100 B (var) 172 PF3D7_0800300 B/A (var) 22
PF3D7_0426000 B (var) 946 PF3D7_1255200 B (var) 277 PF3D7_1200100 B (var) 22 PF3D7_0426000 B (var) 172 PF3D7_1100200 A (var) 21
PF3D7_1255200 B (var) 880 PF3D7_0300100 B (var) 211 PF3D7_1200600 var2csa (E) 20 PF3D7_0712800 B/C (var) 112 PF3D7_0712300 B/C (var) 14
PF3D7_0400400 A (var) 795 PF3D7_0400400 A (var) 176 PF3D7_0937800 B (var) 19 PF3D7_0833500 B (var) 103 PF3D7_0400100 B (var) 12
PF3D7_0632500 B/A (var) 766 PF3D7_0632500 B/A (var) 141 PF3D7_0632800 B (var) 13 PF3D7_0711700 C (var) 82 PF3D7_0632800 B (var) 8
PF3D7_0400100 B (var) 739 PF3D7_1100200 A (var) 136 PF3D7_0617400 C (var) 75 PF3D7_0115700 B (var) 5
PF3D7_0223500 B (var) 734 PF3D7_1100100 B (var) 120 PF3D7_1255200 B (var) 137 PF3D7_1200600 var2csa (E) 70 PF3D7_1200500 A (rif) 5
PF3D7_0425800 A (var) 683 PF3D7_1041300 B (var) 117 PF3D7_0300100 B (var) 81 PF3D7_1041300 B (var) 42
PF3D7_1300100 B (var) 611 PF3D7_0632800 B (var) 115 PF3D7_0632800 B (var) 81 PF3D7_0632500 B/A (var) 29
PF3D7_0733000 B (var) 509 PF3D7_0800100 B (var) 111 PF3D7_0223500 B (var) 64 PF3D7_0600200 B/A (var) 20
PF3D7_1373500 B (var) 475 PF3D7_1373500 B (var) 100 PF3D7_0401600 A (rif) 53 PF3D7_1100100 B (var) 20
PF3D7_0937800 B (var) 456 PF3D7_1200400 B/A (var) 96 PF3D7_0800100 B (var) 50 PF3D7_0632800 B (var) 13
PF3D7_1100200 A (var) 422 PF3D7_1300300 A (var) 89 PF3D7_0937800 B (var) 45 PF3D7_0733000 B (var) 12
PF3D7_1041300 B (var) 418 PF3D7_1240400 B/C (var) 88 PF3D7_0400100 B (var) 44
PF3D7_0115700 B (var) 413 PF3D7_0401600 A (rif) 86 PF3D7_0733000 B (var) 40 PF3D7_1041300 B (var) 854
PF3D7_1100100 B (var) 406 PF3D7_0400100 B (var) 82 PF3D7_1373500 B (var) 39 PF3D7_0400100 B (var) 381
PF3D7_1200400 B/A (var) 387 PF3D7_1200100 B (var) 82 PF3D7_1041300 B (var) 33
PF3D7_0401600 A (rif) 344 PF3D7_0733000 B (var) 80 PF3D7_0632500 B/A (var) 32
PF3D7_0100100 B (var) 315 PF3D7_0100100 B (var) 79 PF3D7_0200100 B (var) 30
PF3D7_1200600 var2csa (E) 252 PF3D7_1200600 var2csa (E) 75 PF3D7_1200400 B/A (var) 30
PF3D7_0800100 B (var) 236 PF3D7_0421100 B/C (var) 62 PF3D7_0426000 B (var) 27
PF3D7_0200100 B (var) 191 PF3D7_0600200 B/A (var) 54 PF3D7_1240600 C (var) 24
PF3D7_0300100 B (var) 147 PF3D7_0426000 B (var) 53 PF3D7_1200600 var2csa (E) 22
PF3D7_1200100 B (var) 145 PF3D7_0324900 B (var) 43 PF3D7_0421100 B/C (var) 20
PF3D7_0421100 B/C (var) 119 PF3D7_0400500 A (rif) 34 PF3D7_1100100 B (var) 19
PF3D7_1240400 B/C (var) 105 PF3D7_0712400 B/C (var) 34 PF3D7_0115700 B (var) 18
PF3D7_0809100 B/C (var) 94 PF3D7_0712800 B/C (var) 23 PF3D7_1200100 B (var) 17
PF3D7_0400500 A (rif) 90 PF3D7_0425800 A (var) 21 PF3D7_1300100 B (var) 15
PF3D7_0800300 B/A (var) 87 PF3D7_0420900 C (var) 19 PF3D7_0100100 B (var) 14
PF3D7_1240600 C (var) 74 PF3D7_0712300 B/C (var) 16 PF3D7_0712300 B/C (var) 12
PF3D7_0712400 B/C (var) 64 PF3D7_1300100 B (var) 12 PF3D7_0425800 A (var) 11
PF3D7_0712000 C (var) 17 PF3D7_1200500 A (rif) 6 PF3D7_0712400 B/C (var) 11
PF3D7_0420900 C (var) 9 PF3D7_0617400 C (var) 6 PF3D7_0412700 C (var) 8
PF3D7_0412700 C (var) 8 PF3D7_1240600 C (var) 5 PF3D7_0809100 B/C (var) 8
PF3D7_1300300 A (var) 6 PF3D7_0324900 B (var) 7





















Appendix 10 | List of detectable var and rif genes (with associated read counts) following mosquito-bite CHMI (n = 5 volunteers). Tables show the P. falciparum transcript i.d 
and associated reads counts for the var and rif genes detected at each of the 3 time points for which parasite samples were sequenced (C +9, C +10 and C +11), for each of the 5  
volunteers (1074, 1068, 1037, 1073 and 1076).  For each time point, genes have been ordered by read count (highest to lowest). Var genes have been colour coded according to group 
(A, B/A, B, B/C, C, and E), and rif genes are highlighted in yellow. Note that data are not normalised and hence read counts are not directly comparable between volunteers.  
  
